0001552781-24-00048810-Q SWK Holdings Corp 20240814202408141623371623371623371 0 0001552781-24-000488 10-Q 73 20240630 20240814 20240814 SWK Holdings Corp 0001089907 6159 770435679 DE 1231 10-Q 34 001-39184 241208377 5956 SHERRY LANE SUITE 650 DALLAS TX 75225 2142177253 5956 SHERRY LANE SUITE 650 DALLAS TX 75225 KANA SOFTWARE INC 20011114 KANA COMMUNICATIONS INC 19990702 10-Q 1 e24328_swkh-10q.htm SWKH 10-Q false --12-31 2024 Q2 0001089907 P10Y P10Y P10Y P10Y P10Y P2Y4M24D P5Y3M18D P1Y2M12D P5Y9M18D P4Y2M12D P4Y6M P3Y4M24D P4Y4M24D 0001089907 2024-01-01 2024-06-30 0001089907 swkh:CommonStockParValue0.001PerShareMember 2024-01-01 2024-06-30 0001089907 swkh:Sec9.00SeniorNotesDue2027Member 2024-01-01 2024-06-30 0001089907 2024-08-08 0001089907 2024-06-30 0001089907 2023-12-31 0001089907 2024-04-01 2024-06-30 0001089907 2023-04-01 2023-06-30 0001089907 2023-01-01 2023-06-30 0001089907 us-gaap:CommonStockMember 2023-12-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001089907 us-gaap:RetainedEarningsMember 2023-12-31 0001089907 us-gaap:CommonStockMember 2022-12-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001089907 us-gaap:RetainedEarningsMember 2022-12-31 0001089907 2022-12-31 0001089907 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001089907 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001089907 2024-01-01 2024-03-31 0001089907 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001089907 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001089907 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001089907 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001089907 2023-01-01 2023-03-31 0001089907 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001089907 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001089907 us-gaap:CommonStockMember 2024-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001089907 us-gaap:RetainedEarningsMember 2024-03-31 0001089907 2024-03-31 0001089907 us-gaap:CommonStockMember 2024-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001089907 us-gaap:RetainedEarningsMember 2024-06-30 0001089907 us-gaap:CommonStockMember 2023-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001089907 us-gaap:RetainedEarningsMember 2023-03-31 0001089907 2023-03-31 0001089907 us-gaap:CommonStockMember 2023-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001089907 us-gaap:RetainedEarningsMember 2023-06-30 0001089907 2023-06-30 0001089907 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-03-31 0001089907 srt:RestatementAdjustmentMember 2024-01-01 2024-03-31 0001089907 srt:ScenarioPreviouslyReportedMember 2024-03-31 0001089907 srt:RestatementAdjustmentMember 2024-03-31 0001089907 swkh:LifeScienceTermLoansMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember 2022-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2022-12-31 0001089907 swkh:LifeScienceTermLoansMember 2023-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-06-30 0001089907 swkh:LifeScienceTermLoansMember 2024-01-01 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2024-01-01 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember 2023-01-01 2023-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-01-01 2023-06-30 0001089907 us-gaap:NonperformingFinancingReceivableMember swkh:LifeScienceTermLoansMember 2024-06-30 0001089907 us-gaap:PerformingFinancingReceivableMember swkh:LifeScienceTermLoansMember 2024-06-30 0001089907 us-gaap:NonperformingFinancingReceivableMember swkh:LifeScienceTermLoansMember 2023-12-31 0001089907 us-gaap:PerformingFinancingReceivableMember swkh:LifeScienceTermLoansMember 2023-12-31 0001089907 us-gaap:NonperformingFinancingReceivableMember swkh:LifeScienceRoyaltyPurchasesMember 2024-06-30 0001089907 us-gaap:PerformingFinancingReceivableMember swkh:LifeScienceRoyaltyPurchasesMember 2024-06-30 0001089907 us-gaap:NonperformingFinancingReceivableMember swkh:LifeScienceRoyaltyPurchasesMember 2023-12-31 0001089907 us-gaap:PerformingFinancingReceivableMember swkh:LifeScienceRoyaltyPurchasesMember 2023-12-31 0001089907 us-gaap:NonperformingFinancingReceivableMember 2024-06-30 0001089907 us-gaap:PerformingFinancingReceivableMember 2024-06-30 0001089907 us-gaap:NonperformingFinancingReceivableMember 2023-12-31 0001089907 us-gaap:PerformingFinancingReceivableMember 2023-12-31 0001089907 swkh:TrioHealthcareLtdMember 2024-06-30 0001089907 swkh:ExeevoIncMember 2024-06-30 0001089907 swkh:FlowonixMedicalIncMember 2024-06-30 0001089907 swkh:BestRoyaltyMember 2024-06-30 0001089907 swkh:IdealImplantIncMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PassMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SpecialMentionMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SubstandardMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:DoubtfulMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:UnlikelyToBeCollectedFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PassMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SpecialMentionMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SubstandardMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PassMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SpecialMentionMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SubstandardMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:DoubtfulMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:UnlikelyToBeCollectedFinancingReceivableMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PassMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SpecialMentionMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SubstandardMember 2023-12-31 0001089907 us-gaap:TrademarksAndTradeNamesMember 2024-06-30 0001089907 us-gaap:CustomerRelationshipsMember 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-12-31 0001089907 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001089907 us-gaap:CustomerRelationshipsMember 2023-12-31 0001089907 2023-06-28 0001089907 2023-10-10 0001089907 us-gaap:LineOfCreditMember 2024-04-01 2024-06-30 0001089907 us-gaap:LineOfCreditMember 2023-04-01 2023-06-30 0001089907 us-gaap:LineOfCreditMember 2024-01-01 2024-06-30 0001089907 us-gaap:LineOfCreditMember 2023-01-01 2023-06-30 0001089907 swkh:DallasTexasOfficeMember 2024-01-01 2024-06-30 0001089907 swkh:DallasTexasOfficeMember 2023-01-01 2023-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001089907 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 us-gaap:WarrantMember srt:MinimumMember 2024-01-01 2024-06-30 0001089907 us-gaap:WarrantMember srt:MaximumMember 2024-01-01 2024-06-30 0001089907 us-gaap:WarrantMember srt:MinimumMember 2023-01-01 2023-12-31 0001089907 us-gaap:WarrantMember srt:MaximumMember 2023-01-01 2023-12-31 0001089907 us-gaap:WarrantMember srt:WeightedAverageMember 2024-01-01 2024-06-30 0001089907 us-gaap:WarrantMember srt:MedianMember 2024-01-01 2024-06-30 0001089907 us-gaap:WarrantMember srt:WeightedAverageMember 2023-01-01 2023-12-31 0001089907 us-gaap:WarrantMember srt:MedianMember 2023-01-01 2023-12-31 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel1Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001089907 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001089907 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001089907 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001089907 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001089907 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001089907 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001089907 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001089907 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001089907 us-gaap:LicensingAgreementsMember 2024-04-01 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-04-01 2023-06-30 0001089907 us-gaap:LicensingAgreementsMember 2024-01-01 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-01-01 2023-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2024-04-01 2024-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2023-04-01 2023-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2024-01-01 2024-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2023-01-01 2023-06-30 0001089907 us-gaap:FinanceReceivablesMember 2024-04-01 2024-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2024-04-01 2024-06-30 0001089907 us-gaap:FinanceReceivablesMember 2023-04-01 2023-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2023-04-01 2023-06-30 0001089907 us-gaap:FinanceReceivablesMember 2024-01-01 2024-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2024-01-01 2024-06-30 0001089907 us-gaap:FinanceReceivablesMember 2023-01-01 2023-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2023-01-01 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure swkh:Number Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q â˜’Â Â Â QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR â˜Â Â Â TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39184 Â SWK Holdings Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 77-0435679 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Â Â 5956 Sherry Lane, Suite 650 Â Dallas, TX 75225 (Address of Principal Executive Offices) (Zip Code) Â (Registrantâ€™s Telephone Number, Including Area Code): (972) 687-7250 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Â Trading Symbol(s) Â Name of Each Exchange on Which Registered Â Â Â Â Â Common Stock, par value $0.001 per share Â SWKH Â The Nasdaq Stock Market LLC 9.00% Senior Notes due 2027 Â SWKHL Â The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days. â˜’Â Â Â YesÂ Â Â Â Â â˜Â NO Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). â˜’Â Â Â YesÂ Â Â Â â˜Â NO Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act: Large Accelerated FilerÂ Â â˜ Accelerated FilerÂ Â â˜ Â Non-Accelerated FilerÂ Â â˜’ Â SmallerÂ Reporting CompanyÂ â˜’ Â Emerging Growth CompanyÂ Â â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â Â Â â˜Â Â Â YESÂ Â Â Â Â â˜’Â Â Â NO As of AugustÂ 8, 2024, there were 12,361,850 shares of the registrantâ€™s Common Stock, $0.001 par value per share, outstanding. Â Â SWK Holdings Corporation Form 10-Q Quarter Ended June 30, 2024 Table of Contents PART I. FINANCIAL INFORMATION Â Â Â Â Â Â ItemÂ 1. Financial Statements Â 1 Â Â Â Â Â Unaudited Condensed Consolidated Balance Sheetsâ€"June 30, 2024 and December 31, 2023 Â 1 Â Â Â Â Â Unaudited Condensed Consolidated Statements of Incomeâ€"Three and Six Months Ended June 30, 2024 and 2023 Â 2 Â Â Â Â Â Unaudited Condensed Consolidated Statements of Stockholdersâ€™ Equityâ€"Three and Six Months Ended June 30, 2024 and 2023 Â 3 Â Â Â Â Â Unaudited Condensed Consolidated Statements of Cash Flowsâ€"Six Months Ended June 30, 2024 and 2023 Â 4 Â Â Â Â Â Notes to the Unaudited Condensed Consolidated Financial Statements Â 5 Â Â Â Â ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 29 Â Â Â Â ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk Â 38 Â Â Â Â ItemÂ 4 Controls and Procedures Â 38 Â Â Â PART II. OTHER INFORMATION Â Â Â Â Â Â ItemÂ 1. Legal Proceedings Â 39 Â Â Â Â Item 1A. Risk Factors Â 39 Â Â Â Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Â 39 Â Â Â Â ItemÂ 3. Defaults Upon Senior Securities Â 39 Â Â Â Â ItemÂ 4. Mine Safety Disclosures Â 39 Â Â Â Â ItemÂ 5. Other Information Â 39 Â Â Â Â ItemÂ 6. Exhibits Â 40 Â Â Â Â Â Signatures Â 41 Â Â FORWARD-LOOKING STATEMENTS In addition to historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. From time to time, we may also provide oral or written forward-looking statements in other materials we release to the public. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. The forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections about our business and industry, and our beliefs and assumptions, and include, but are not limited to, statements under the heading â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ Words such as â€œanticipate,â€ â€œbelieve,â€ â€œcould,â€ â€œestimate,â€ â€œexpects,â€ â€œintend,â€ â€œmay,â€ â€œplan,â€ â€œshould,â€ â€œwillâ€ and variations of these words and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, are difficult to predict and could cause actual results to differ materially (both favorably and unfavorably) from those expressed or forecasted in the forward-looking statements. Â These risks and uncertainties include, but are not limited to, those described in Item 1A, â€œRisk Factors,â€ and elsewhere in this report. Forward-looking statements that were believed to be true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Â Â PART I. FINANCIAL INFORMATION ITEM 1.Â Â Â Â Â FINANCIAL STATEMENTS SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value and share data) Â Â June 30, 2024Â Â December 31, 2023Â Assets:Â Â Â Â Â Â Â Current assets:Â Â Â Â Â Â Â Cash and cash equivalentsÂ $5,549Â Â $4,503Â Restricted cashÂ Â â€"Â Â Â 733Â Interest, accounts receivable and other receivables, netÂ Â 7,384Â Â Â 4,729Â Other current assetsÂ Â 1,859Â Â Â 1,904Â Total current assetsÂ Â 14,792Â Â Â 11,869Â Â Â Â Â Â Â Â Finance receivables, net of allowance for credit losses of $13,083 and $13,901 as of June 30, 2024 and DecemberÂ 31, 2023, respectivelyÂ Â 265,470Â Â Â 274,504Â Collateral on foreign currency forward contractÂ Â 2,750Â Â Â 2,750Â Marketable investmentsÂ Â 731Â Â Â 48Â Deferred tax assets, netÂ Â 27,052Â Â Â 28,290Â Warrant assetsÂ Â 835Â Â Â 1,759Â Intangible assets, netÂ Â 232Â Â Â 6,487Â Property and equipment, netÂ Â 5,008Â Â Â 5,438Â Other non-current assetsÂ Â 4,504Â Â Â 3,109Â Total assetsÂ $321,374Â Â $334,254Â Â Â Â Â Â Â Â Liabilities and Stockholdersâ€™ Equity: Â Â Â Â Â Â Â Current liabilities:Â Â Â Â Â Â Â Accounts payable and accrued liabilitiesÂ $3,310Â Â $3,935Â Deferred incomeÂ Â 2,216Â Â Â 9Â Total current liabilitiesÂ Â 5,526Â Â Â 3,944Â Â Â Â Â Â Â Â Contingent consideration payableÂ Â â€"Â Â Â 4,900Â Unsecured senior notes, netÂ Â 31,078Â Â Â 30,781Â Revolving credit facilityÂ Â â€"Â Â Â 12,350Â Other non-current liabilitiesÂ Â 1,566Â Â Â 1,964Â Total liabilitiesÂ Â 38,170Â Â Â 53,939Â Â Â Â Â Â Â Â Commitments and contingencies (Note 6)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstandingÂ Â â€"Â Â Â â€"Â Common stock, $0.001 par value; 250,000,000 shares authorized; 12,447,195 and 12,497,770 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectivelyÂ Â 12Â Â Â 12Â Additional paid-in capitalÂ Â 4,423,472Â Â Â 4,425,104Â Accumulated deficitÂ Â (4,140,280)Â Â (4,144,801) Total stockholdersâ€™ equityÂ Â 283,204Â Â Â 280,315Â Total

liabilities and stockholdersâ€™ equityÂ $321,374Â Â Â $334,254Â Â Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 1 Â SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in thousands, except per share data) Â Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivable interest income, including feesÂ $10,680Â Â $9,278Â Â $21,399Â Â $18,538Â Pharmaceutical developmentÂ Â 804Â Â Â 183Â Â Â 1,083Â Â Â 301Â OtherÂ Â 57Â Â Â 36Â Â Â 103Â Â Â 69Â Total revenuesÂ Â 11,541Â Â Â 9,497Â Â Â 22,585Â Â Â 18,908Â Costs and expenses:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Provision (benefit) for credit lossesÂ Â 4,074Â Â Â (682)Â Â 9,397Â Â Â (682) Loss on impairment of intangibles assetsÂ Â 5,771Â Â Â â€”Â Â Â 5,771Â Â Â â€”Â Interest expenseÂ Â 1,119Â Â Â 363Â Â Â 2,375Â Â Â 545Â Pharmaceutical manufacturing, research and development expenseÂ Â 520Â Â Â 1,509Â Â Â 1,050Â Â Â 2,228Â Change in fair value of acquisition-related contingent considerationÂ Â (4,900)Â Â â€”Â Â Â (4,900)Â Â â€”Â Depreciation and amortization expenseÂ Â 421Â Â Â 637Â Â Â 935Â Â Â 1,285Â General and administrative expenseÂ Â 2,923Â Â Â 2,997Â Â Â 5,607Â Â Â 5,537Â Income from operationsÂ Â 1,613Â Â Â 4,673Â Â Â 2,350Â Â Â 9,995Â Other income (expense), netÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Unrealized net gain (loss) on warrantsÂ Â 226Â Â Â 399Â Â Â 131Â Â Â (583) Net realized gain on sale of marketable investmentsÂ Â 656Â Â Â â€”Â Â Â 513Â Â Â â€”Â Realized gain (loss) on sale of assetsÂ Â 3Â Â Â â€”Â Â Â (228)Â Â â€”Â Gain on revaluation of finance receivableÂ Â 2,495Â Â Â â€”Â Â Â 2,495Â Â Â â€”Â Realized and unrealized foreign currency transaction gainsÂ Â 437Â Â Â 316Â Â Â 524Â Â Â 502Â Income before income tax expenseÂ Â 5,430Â Â Â 5,388Â Â Â 5,785Â Â Â 9,914Â Income tax expenseÂ Â 1,035Â Â Â 1,454Â Â Â 1,264Â Â Â 1,345Â Net incomeÂ $4,395Â Â $3,934Â Â $4,521Â Â $8,569Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net income per shareÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â BasicÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â DilutedÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Weighted average shares outstandingÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â BasicÂ Â 12,457Â Â Â 12,741Â Â Â 12,466Â Â Â 12,787Â DilutedÂ Â 12,528Â Â Â 12,785Â Â Â 12,534Â Â Â 12,830Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 2 Â SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (in thousands, except share data) Â Â Six Months Ended June 30, 2024Â Â Â Â Â Â Â Â Â Â Â Â TotalÂ Â Â Common StockÂ Â Additional Paid-Â Â AccumulatedÂ Â Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â EquityÂ Balances at December 31, 2023Â Â 12,497,770Â Â $12Â Â $4,425,104Â Â $(4,144,801)Â $280,315Â Stock-based compensationÂ Â â€”Â Â Â â€”Â Â Â 111Â Â Â â€”Â Â Â 111Â Forfeiture of unvested restricted stockÂ Â (6,446)Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Issuance of common stock upon vesting of restricted stockÂ Â 48,918Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Repurchases of common stock in open marketÂ Â (58,298)Â Â â€”Â Â Â (999)Â Â â€”Â Â Â (999) Net incomeÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 126Â Â Â 126Â Balances at March 31, 2024Â Â 12,481,944Â Â Â 12Â Â Â 4,424,216Â Â Â (4,144,675)Â Â 279,553Â Stock-based compensationÂ Â â€”Â Â Â â€”Â Â Â 249Â Â Â â€”Â Â Â 249Â Issuance of common stock upon vesting of restricted stockÂ Â 17,323Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Repurchases of common stock in open marketÂ Â (54,667)Â Â â€”Â Â Â (950)Â Â â€”Â Â Â (950) Net settlement for employee taxes on stock optionsÂ Â â€”Â Â Â â€”Â Â Â (43)Â Â â€”Â Â Â (43) Stock options exercised, netÂ Â 2,595Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Net incomeÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 4,395Â Â Â 4,395Â Balances at June 30, 2024Â Â 12,447,195Â Â $12Â Â $4,423,472Â Â $(4,140,280)Â $283,204Â Â Â Â Â Â Â Six Months Ended June 30, 2023Â Â Â Â Â Â Â Â Â Â Â Â TotalÂ Â Â Common StockÂ Â Additional Paid-Â Â AccumulatedÂ Â Stockholdersâ€™Â Â Â SharesÂ Â AmountÂ Â In CapitalÂ Â DeficitÂ Â EquityÂ Balances at December 31, 2022Â Â 12,843,157Â Â $12Â Â $4,430,922Â Â $(4,151,005)Â $279,929Â Stock-based compensationÂ Â â€”Â Â Â â€”Â Â Â 35Â Â Â â€”Â Â Â 35Â Effect of adoption of ASU 2016-13Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (9,683)Â Â (9,683) Issuance of common stock upon vesting of restricted stockÂ Â 16,008Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Repurchases of common stock in open marketÂ Â (28,766)Â Â â€”Â Â Â (531)Â Â â€”Â Â Â (531) Net incomeÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 4,635Â Â Â 4,635Â Balances at March 31, 2023Â Â 12,830,399Â Â Â 12Â Â Â 4,430,426Â Â Â (4,156,053)Â Â 274,385Â Stock-based compensationÂ Â â€”Â Â Â â€”Â Â Â 164Â Â Â â€”Â Â Â 164Â Issuance of common stock upon vesting of restricted stockÂ Â 8,612Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Repurchase of common stock in open marketÂ Â (272,492)Â Â â€”Â Â Â (4,599)Â Â â€”Â Â Â (4,599) Net incomeÂ Â â€”Â Â Â â€”Â Â Â 3,934Â Â Â 3,934Â Balances at June 30, 2023Â Â 12,566,519Â Â $12Â Â $4,425,991Â Â $(4,152,119)Â $273,884Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 3 Â SWK HOLDINGS CORPORATION UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Cash flows from operating activities:Â Â Â Â Â Â Â Net incomeÂ $4,521Â Â $8,569Â Adjustments to reconcile net income to net cash provided by operating activities:Â Â Â Â Â Â Â Provision (benefit) for credit lossesÂ Â 9,397Â Â Â (682) Loss on impairment of intangible assetsÂ Â 5,771Â Â Â â€”Â Right-of-use amortization and cease use costsÂ Â 261Â Â Â 156Â Amortization of debt issuance costsÂ Â 491Â Â Â 168Â Deferred income taxes, netÂ Â 1,239Â Â Â 1,316Â Net change in fair value of warrant assetsÂ Â (131)Â Â 583Â Net realized gain on exercise of warrantsÂ Â (513)Â Â â€”Â Realized loss from sale of assetsÂ Â 228Â Â Â â€”Â Change in fair value of acquisition-related contingent considerationÂ Â (4,900)Â Â â€”Â Gain on revaluation of finance receivableÂ Â (2,495)Â Â â€”Â Foreign currency transaction gainÂ Â (327)Â Â (516) Loan discount amortization and fee accretionÂ Â (2,592)Â Â (2,297) Interest paid-in-kindÂ Â (904)Â Â (957) Stock-based compensationÂ Â 360Â Â Â 199Â Depreciation and amortization expenseÂ Â 935Â Â Â 1,285Â Changes in operating assets and liabilities:Â Â Â Â Â Â Â Interest, accounts receivable and other receivablesÂ Â (2,655)Â Â (1,287) Other assetsÂ Â (150)Â Â (792) Accounts payable, accrued expenses, and other non-current liabilitiesÂ Â (900)Â Â (354) Deferred incomeÂ Â 2,207Â Â Â (3) Net cash provided by operating activitiesÂ Â 9,843Â Â Â 5,388Â Â Â Â Â Â Â Â Cash flows from investing activities:Â Â Â Â Â Â Â Sale of finance receivablesÂ Â â€”Â Â Â 13,942Â Sale of marketable investmentsÂ Â 574Â Â Â â€”Â Investment in finance receivablesÂ Â (7,446)Â Â (13,101) Repayment of finance receivablesÂ Â 11,693Â Â Â 3,041Â Corporate debt securities principal paymentsÂ Â 13Â Â Â 17Â Purchases of property and equipmentÂ Â (21)Â Â (191) Net cash provided by investing activitiesÂ Â 4,813Â Â Â 3,708Â Â Â Â Â Â Â Â Cash flows from financing activities:Â Â Â Â Â Â Â Net settlement for employee taxes on stock optionsÂ Â (43)Â Â â€”Â Net payments on credit facilityÂ Â (12,350)Â Â (2,445) Payments for financing costsÂ Â â€”Â Â Â (872) Repurchases of common stock, including fees and expensesÂ Â (1,950)Â Â (5,130) Net cash used in financing activitiesÂ Â (14,343)Â Â (8,447) Â Â Â Â Â Â Â Net increase in cash, cash equivalents, and restricted cashÂ Â 313Â Â Â 649Â Cash, cash equivalents, and restricted cash at beginning of periodÂ Â 5,236Â Â Â 6,156Â Cash, cash equivalents, and restricted cash at end of periodÂ $5,549Â Â $6,805Â Â Â Â Â Â Â Supplemental non-cash investing and financing activities:Â Â Â Â Â Â Â Derecognition of right-of-use assets and operating lease liabilities upon termination of leaseÂ $82Â Â $â€”Â Â See accompanying notes to the unaudited condensed consolidated financial statements. 4 Â SWK HOLDINGS CORPORATION Â NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Â Note 1. SWK Holdings Corporation and Summary of Significant Accounting PoliciesÂ Nature of Operations Â SWK Holdings Corporation (the â€œCompany,â€ â€œwe,â€ or â€œusâ€) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: â€œFinance Receivablesâ€ and â€œPharmaceutical Development.â€ We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, â€œlife sciencesâ€). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of June 30, 2024, the Company had 22 full-time employees. The Company has net operating loss carryforwards (â€œNOLsâ€) and believes that the ability to utilize these NOLs is an important and substantial asset. As of AugustÂ 8, 2024, the Company and its partners have executed transactions with 56 different parties under its specialty finance strategy, funding an aggregate of $779.8 million in various financial products across the life science sector. The Companyâ€™s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. Â During 2019, we commenced our Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. (â€œEnterisâ€). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform. We seek to generate income by providing customers pharmaceutical development, formulation and manufacturing services as well as licensing its internally developed intellectual property. With an effective date of April 21, 2023 we entered into a collaboration agreement with a strategic partner under which we would be the exclusive provider of certain contract development and manufacturing organization (â€œCDMOâ€) services to its customers. Fee revenue generated as a result of this agreement is presented as pharmaceutical development revenue on the unaudited condensed consolidated statement of income and is accounted for in accordance with our revenue recognition policy as described under Revenue Recognition below. With an effective date of January 1, 2024, we entered into an Option and Asset Purchase Agreement with the same strategic partner on March 14, 2024, which granted the partner an exclusive option to acquire certain of Enterisâ€™ assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The partner must exercise the option by or before January 1, 2026. Basis of Presentation and Principles of ConsolidationÂ The Companyâ€™s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (â€œVIEâ€) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. 5 Â The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control. Even though the Companyâ€™s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Companyâ€™s consolidated financial statements, it would have no effect on its operations and/or total stockholdersâ€™ equity attributable to the Company. Â Unaudited Interim Financial InformationÂ The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (â€œSECâ€). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024. Use of EstimatesÂ The preparation of the Companyâ€™s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Companyâ€™s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. Â The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Companyâ€™s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Companyâ€™s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Â Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies (â€œFinance Receivable segmentâ€), and its business offering CDMO services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform (â€œPharmaceutical Development segmentâ€). 6 Â Revenue Recognition Â The Companyâ€™s Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Â Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets. Â Correction of an Error in Previously Issued Unaudited Condensed Financial Statements Â During the quarter ended June 30, 2024, the Company identified an error related to the recognition of a holdback liability for a royalty which was incorrectly recorded into revenue. This error affected the consolidated financial statements for the quarter ended March 31, 2024 and was determined to be immaterial to the prior periodâ€™s unaudited condensed consolidated financial statements and did not warrant restatement and reissuance of the previously issued unaudited condensed consolidated financial statements. However, the Company recorded a correction to the prior quarter ended March 31, 2024 and the financial statements will be revised the next time they are presented as comparative information in future filings. The Company based their qualitative and quantitative analysis on SEC Staffâ€™s Accounting Bulletins Topic 1.M, â€œMateriality and Topic 1.N, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements.â€ Â The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands): Â Schedule of Revisions to the line items of our previously issued financial statements Three Months Ended March 31, 2024Â As ReportedÂ AdjustmentÂ As Revised Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivable interest income, including feesÂ $11,454Â Â $(735)Â $10,719Â Pharmaceutical developmentÂ Â 279Â Â Â â€”Â Â Â 279Â OtherÂ Â 46Â Â Â â€”Â Â Â 46Â Total revenuesÂ Â 11,779Â Â Â (735)Â Â 11,044Â Net incomeÂ $861Â Â $(735)Â $126Â Basic net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Diluted net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, net of allowance for credit Â Â 261,285Â Â Â (13)Â Â 261,272Â Total assetsÂ $322,350Â Â $(13)Â $322,337Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Â Â Â Â Â Accumulated deficitÂ Â (4,143,940)Â Â (735)Â Â (4,144,675) Total stockholdersâ€™ equityÂ $280,288Â Â $(735)Â $279,553Â Â Â Â Â Research and Development Â Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the unaudited condensed consolidated statements of income. 7 Â Recent Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) 2020-04, â€œReference Rate Reform (Topic 848),â€ which provides optional guidance for a limited period of time to ease the potential burden in

accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference London Inter-Bank Offered Rate (â€œLIBORâ€) and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Companyâ€™s consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires public entities to disclose information about their reportable segmentsâ€™ significant expenses on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Public entities are required to adopt the changes retrospectively, recasting each prior-period disclosure for which a comparative income statement is presented in the period of adoption. The Company is currently evaluating the impact of this ASU on the Companyâ€™s consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ The standard is intended to provide greater transparency in various income tax components that affect the rate reconciliation based on the applicable taxing jurisdictions, as well as the qualitative and quantitative aspects of those components. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures. 8 Â Note 2. Net Income per Share Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method. Â The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Â Schedule of Basic and Diluted Earning per Share Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Numerator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net incomeÂ $4,395Â Â $3,934Â Â $4,521Â Â $8,569Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Denominator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstandingÂ Â 12,457Â Â Â 12,741Â Â Â 12,466Â Â Â 12,787Â Effect of dilutive securitiesÂ Â 71Â Â Â 44Â Â Â 68Â Â Â 43Â Weighted-average diluted sharesÂ Â 12,528Â Â Â 12,785Â Â Â 12,534Â Â Â 12,830Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Diluted net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Â For the three months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 159,000 and 118,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. For the six months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 161,000 and 119,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. 9 Â Note 3. Finance Receivables Â Finance receivables are reported at their determined principal balances net of any unearned income, cumulative write offs charged against the allowance for credit losses, and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method. The carrying values of finance receivables were as follows (in thousands): Â Schedule of carrying value of finance receivables Â Â June 30, 2024Â Â December 31, 2023Â Term loansÂ $213,683Â Â $221,145Â Royalty purchasesÂ Â 64,870Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 278,553Â Â Â 288,405Â Allowance for credit lossesÂ Â (13,083)Â Â (13,901) Total carrying valueÂ $265,470Â Â $274,504Â Â Allowance for Credit Losses The allowance for credit loss (â€œACLâ€) is managementâ€™s estimate of the amount of expected credit losses over the life of the loan portfolio, or the amount of amortized cost basis not expected to be collected, at the balance sheet date. This estimate encompasses information about historical events, current conditions and reasonable and supportable economic forecasts. Determining the amount of the ACL is complex and requires extensive judgment by management about matters that are inherently uncertain. Given the current level of economic uncertainty, the complexity of the ACL estimate and level of management judgment required, we believe it is possible that the ACL estimate could change, potentially materially, in future periods. Changes in the ACL may result from changes in current economic conditions, our economic forecast, and circumstances not currently known to us that may impact the financial condition and operations of our borrowers, among other factors. Â Expected credit losses are estimated on a collective basis for groups of loans that share similar risk characteristics. For finance receivables that do not share similar risk characteristics with other finance receivables, expected credit losses are estimated on an individual basis. Expected credit losses are estimated over the contractual terms of the finance receivables, adjusted for expected prepayments and unfunded commitments, generally excluding extensions and modifications. The loan portfolio segment is defined as the level at which an entity develops and documents a systematicÂ method for determining its allowance for credit losses. Â The Company adopted ASU 2016-13, as amended, on January 1, 2023 using the modified retrospective approach method. The implementation of ASU 2016-13 also impacted the Companyâ€™s ACL on unfunded loan commitments, as the ACL now represents expected credit losses over the contractual life of commitments not identified as unconditionally cancellable by the Company. The reserve for unfunded commitments is estimated using the same reserve or coverage rates calculated on collectively evaluated loans following the application of a funding rate to the amount of the unfunded commitment. The funding rate represents managementâ€™s estimate of the amount of the current unfunded commitment that will be funded over the remaining contractual life of the commitment and is based on historical data. On January 1, 2023, the Company recorded an adjustment for unfunded commitments of $0.4 million for the adoption of ASU 2016-13. As of June 30, 2024 the Company has a $0.1 million liability for credit losses on off-balance sheet exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. As of December 31, 2023, the Company recorded a $0.2 million liability for credit losses on off-balance-sheet credit exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. Please refer to Note 6 for further information on the Companyâ€™s unfunded commitments. 10 Â Allowance for Credit Losses - methodology update for the three months ended June 30, 2024 During the three months ended June 30, 2024, the Company revised its methodology for calculating the allowance for credit losses to be more directly tied to the individual risk ratings, as determined by management, of investments. This resulted in a re-allocation of the existing allowance and did not have a material impact on the total allowance for credit losses amount. Previously, the Companyâ€™s quarterly assessment of the allowance included two portfolio pools: Term Loans and Royalties. After the change in methodology effective for the quarter ended June 30, 2024, these pools are further broken down into individual risk ratings applied to each investment to allow for a more precise method for calculating the allowance for credit losses. Â The following table details the changes in the allowance for credit losses by Term Loans and Royalties (in thousands): Â Schedule of Allowance for Credit LossesÂ Â Â Six Months Ended June 30, 2024Â Â Six Months Ended June 30, 2023Â Â Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Allowance at beginning of periodÂ $9,731Â Â $4,170Â Â $13,901Â Â $â€"Â Â $11,846Â Â $11,846Â Effect of adoption of ASU 2016-13Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 8,900Â Â Â 2,886Â Â Â 11,786Â Provision (benefit) for credit lossesÂ Â 5,055Â Â Â 127Â Â Â 5,182Â Â Â (572)Â Â (110)Â Â (682) Write offsÂ Â (6,000)Â Â â€"Â Â Â (6,000)Â Â â€"Â Â Â (11,846)(1) Â (11,846) Allowance at end of periodÂ $8,786Â Â $4,297Â Â $13,083Â Â $8,328Â Â $2,776Â Â $11,104Â Â (1)Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023. Non-Accrual Finance Receivables The Company originates finance receivables to companies primarily in the life sciences sector. This concentration of credit exposes the Company to a higher degree of risk associated with this sector. Â On a quarterly basis, the Company evaluates the carrying value of its finance receivables. Recognition of income is suspended, and the finance receivable is placed on non-accrual status when management determines that collection of future income is not probable. This evaluation is generally based on delinquency information, an assessment of the borrowerâ€™s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement. 11 Â The following table presents nonaccrual and performing finance receivables by portfolio pool, net of allowance for credit losses (in thousands) as of: Schedule of Allowance for Credit Losses Â Â June 30, 2024Â Â December 31, 2023Â Â Â NonaccrualÂ Â PerformingÂ Â TotalÂ Â NonaccrualÂ Â PerformingÂ Â TotalÂ Term loansÂ $6,010Â Â $207,673Â Â $213,683Â Â $9,128Â Â $212,017Â Â $221,145Â Royalty purchasesÂ Â 16,434Â Â Â 48,436Â Â Â 64,870Â Â Â 16,854Â Â Â 50,406Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 22,444Â Â Â 256,109Â Â Â 278,553Â Â Â 25,982Â Â Â 262,423Â Â Â 288,405Â Allowance for credit lossesÂ Â (3,368)Â Â (9,715)Â Â (13,083)Â Â (1,447)Â Â (12,454)Â Â (13,901) Total carrying valueÂ $19,076Â Â $246,394Â Â $265,470Â Â $24,535Â Â $249,969Â Â $274,504Â Â As of June 30, 2024, the Company had five finance receivables in nonaccrual status: (1) the term loan to Trio Healthcare Ltd. (â€œTrioâ€), with a carrying value of $1.5 million; (2) the term loan to Exeevo, Inc (â€œExeevoâ€), with a carrying value of $4.5 million; (3) the Flowonix Medical, Inc. (â€œFlowonixâ€) royalty, with a carrying value of $10.4 million (see Loan Modifications Made to Borrowers Experiencing Financial Difficulty below for further details); (4) the Best ABT, Inc. (â€œBestâ€) royalty, with a carrying value of $2.4 million; and (5) the Ideal Implant, Inc. (â€œIdealâ€) royalty, with a carrying value of $3.6 million. As of June 30, 2024 Trio was considered impaired by $8.1 million and Exeevo was impaired by $2.2 million with the impairments recognized as a reduction in the allowance for credit losses on the unaudited condensed consolidated statements of income for the six months ended June 30, 2024. The Company collected $0.7 million and $0.2 million on its nonaccrual finance receivables for the six months ended June 30, 2024 and 2023, respectively. Â Loan Modifications Made to Borrowers Experiencing Financial Difficulty Â Effective January 1, 2023, the Company adopted the provisions of ASU 2022-02 â€œTroubled Debt Restructuring (â€œTDRsâ€) and Vintage Disclosures (Topic 326)â€, which eliminated the accounting for TDRs while expanding loan modification and vintage disclosure requirements. The update specifically required additional disclosures on loan modifications to borrowers experiencing financial difficulties that involved an interest rate reduction, other-than-insignificant payment delay, a term extension, principal forgiveness or a combination thereof. Â The Company evaluates the carrying value of each finance receivable for impairment. A term loan is considered to be impaired when, based on current information and events, it is determined that the Company will not be able to collect the amounts due according to the loan contract, including scheduled interest payments. This evaluation is generally based on delinquency information, an assessment of the borrowerâ€™s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement and collectability of remaining principal and interest is no longer doubtful. In certain circumstances, the Company may place a finance receivable on nonaccrual status but conclude it is not impaired. The Company may retain independent third-party valuations on such nonaccrual positions to support impairment decisions. On an ongoing basis, the Company monitors the performance of modified loans to their restructured terms. 12 Â Revaluation of Finance Receivable Â During the three months ended June 30, 2024, the Company revalued its royalty for Iluvien as a result of entering into an amendment during the quarter. Pursuant to the amendment, the forecast of cash flows to be received over the life of the financial royalty was revised resulting in a revaluation gain of $2.5 million and corresponding mark-up to the carrying value which is included in the â€œGain on revaluation of finance receivableâ€ caption on our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Credit Quality of Finance Receivables Â The Company evaluates all finance receivables on a quarterly basis and assigns a risk rating based upon managementâ€™s assessment of the borrowerâ€™s ability and likelihood of repayment. The assessment is subjective and based on multiple factors, including but not limited to, financial strength of borrowers and operating results of the underlying business. The credit risk analysis and rating assignment is performed quarterly in conjunction with the Companyâ€™s assessment of its allowance for credit losses. The Company uses the following definitions for its risk ratings for Term Loans: Â 1: Borrower performing well below Company expectations, and the borrowerâ€™s ability to raise sufficient capital to operate its business or repay debt is highly in question. Finance receivables rated a 1 are on non-accrual and are at an elevated risk for principal impairment. 2: Borrower performing below plan, and the loan-to-value is generally worse than at the time of underwriting. Borrower has limited access to additional capital to operate its business. Finance receivables rated a 2 are generally on non-accrual, and while no loss of impairment is anticipated, there is potential for future principal impairment. 3: Borrower performing in-line-to-modestly below Company expectations, and loan-to-value is similar to slightly worse than at the time of underwriting. Borrower has demonstrated access to capital markets. 4: Borrower performing in-line-to-modestly above Company expectations and loan-to-value similar or modestly better than underwriting case. Borrower has demonstrated access to capital markets. 5: Borrower performing in excess of Company expectations, and loan-to-value is better than at time of origination. The Company uses an internal credit rating system which rates each Royalty on a color scale of Green to Red, with Green typically indicative of a Royalty that is exceeding base underwritten case, Yellow indicates a Royalty performing in-line with underwritten plan, and Red reflective of underperformance relative to plan. 13 Â The following table summarizes the carrying value of Finance Receivables by origination year, grouped by risk rating as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of Financing Receivable by origination year Â Â June 30, 2024Â Â Â 2023Â Â 2022Â Â 2021Â Â 2020Â Â 2019Â Â PriorÂ Â TotalÂ Term LoansÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5Â $â€"Â Â $â€"Â Â $13,835Â Â $4,991Â Â $â€"Â Â $18,826Â 4Â Â 31,108Â Â Â 57,988Â Â Â â€"Â Â Â â€"Â Â Â 9,328Â Â Â 98,424Â 3Â Â 24,604Â Â Â â€"Â Â Â 10,718Â Â Â â€"Â Â Â 29,154Â Â Â â€"Â Â Â 64,476Â 2Â Â â€"Â Â Â â€"Â Â Â 12,601Â Â Â â€"Â Â Â â€"Â Â Â 13,346Â Â Â 25,947Â 1Â Â â€"Â Â Â 4,538Â Â Â 1,472Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 6,010Â Subtotal - Term LoansÂ $55,712Â Â $62,526Â Â $38,626Â Â $â€"Â Â $34,145Â Â $22,674Â Â $213,683Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RoyaltiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GreenÂ $12,110Â Â $11,985Â Â $â€"Â Â $16,595Â Â $â€"Â Â $1,297Â Â $41,987Â YellowÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 3,087Â Â Â â€"Â Â Â 3,362Â Â Â 6,449Â RedÂ Â â€"Â Â Â â€"Â Â Â 3,564Â Â Â 10,433Â Â Â â€"Â Â Â 2,437Â Â Â 16,434Â Subtotal - RoyaltiesÂ $12,110Â Â $11,985Â Â $3,564Â Â $30,115Â Â $â€"Â Â $7,096Â Â $64,870Â Total Finance Receivables, grossÂ $67,822Â Â $74,511Â Â $42,190Â Â $30,115Â Â $34,145Â Â $29,770Â Â $278,553Â Â Â Â Â Â Â December 31, 2023Â Â Â 2023Â Â 2022Â Â 2021Â Â 2020Â Â 2019Â Â PriorÂ Â TotalÂ Term LoansÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5Â $â€"Â Â $â€"Â Â $13,734Â Â $â€"Â Â $5,696Â Â $â€"Â Â $19,430Â 4Â Â 25,799Â Â Â 32,211Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 10,485Â Â Â 68,495Â 3Â Â 24,341Â Â Â 24,285Â Â Â 10,227Â Â Â â€"Â Â Â 31,807Â Â Â â€"Â Â Â 90,660Â 2Â Â â€"Â Â Â 6,924Â Â Â 12,493Â Â Â â€"Â Â Â â€"Â Â Â 14,015Â Â Â 33,432Â 1Â Â â€"Â Â Â â€"Â Â Â 9,128Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 9,128Â Subtotal - Term LoansÂ $50,140Â Â $63,420Â Â $45,582Â Â $â€"Â Â $37,503Â Â $24,500Â Â $221,145Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RoyaltiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GreenÂ $27,785Â Â $â€"Â Â $â€"Â Â $14,650Â Â $â€"Â Â $1,340Â Â $43,775Â YellowÂ Â â€"Â Â Â â€"Â Â Â â€"Â Â Â 3,212Â Â Â â€"Â Â Â 3,419Â Â Â 6,631Â RedÂ Â â€"Â Â Â â€"Â Â Â 3,834Â Â Â 10,433Â Â Â â€"Â Â Â 2,587Â Â Â 16,854Â Subtotal - RoyaltiesÂ $27,785Â Â $â€"Â Â $3,834Â Â $28,295Â Â $â€"Â Â $7,346Â Â $67,260Â Total Finance Receivables, grossÂ $77,925Â Â $63,420Â Â $49,416Â Â $28,295Â Â $37,503Â Â $31,846Â Â $288,405Â 14 Â Note 4. Intangible Assets Â As of June 30, 2024 and December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data): Schedule of Intangible Assets Â Â June 30, 2024Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Trade names and trademarksÂ $210Â Â $102Â Â $108Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 116Â Â Â 124Â Â Â 10Â Total intangible assetsÂ $450Â Â $218Â Â $232Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Licensing Agreement(1)Â $29,400Â Â $23,167Â Â $6,233Â Â Â 10Â Trade names and trademarksÂ Â 210Â Â Â 92Â Â Â 118Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 104Â Â Â 136Â Â Â 10Â Total intangible assetsÂ $29,850Â Â $23,363Â Â $6,487Â Â Â (1)Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (â€œCaraâ€), for oral formulation rights to Enterisâ€™ PeptelligenceÂ® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the

licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the â€œLoss on impairment of intangible assetsâ€ section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Amortization expense was $0.2 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively, and was recognized within depreciation and amortization expense on the unaudited condensed consolidated statements of income. Amortization expense related to intangible assets was $0.5 million and $0.9 million for the six months ended June 30, 2024 and 2023, respectively. Based on amounts recorded at June 30, 2024, the Company will recognize acquired intangible asset amortization as follows (in thousands): Schedule of Intangible Asset Amortization Expense Remainder of 2024Â $23Â 2025Â Â 45Â 2026Â Â 45Â 2027Â Â 45Â 2028Â Â 45Â ThereafterÂ Â 29Â TotalÂ $232Â 15 Â Note 5. Debt Â Revolving Credit Facility Â On June 28, 2023, the Company entered into a new credit agreement (the â€œCredit Agreementâ€) by and among SWK Funding LLC, the Companyâ€™s wholly-owned subsidiary (together with the Company, the â€œBorrowerâ€), the lenders party thereto (â€œLendersâ€), and First Horizon Bank as a Lender and Agent (the â€œAgentâ€). The Credit Agreement provides for a revolving credit facility with an initial maximum principal amount of $45.0 million. The Credit Agreement provides that the Company may request one or more incremental increases in an aggregate amount not to exceed $80.0 million, subject to the consent of the Agent and each Lender, at any time prior to the termination of the revolving credit period on June 28, 2026 (the â€œCommitment Termination Dateâ€). The revolving credit period will be followed by a one-year amortization period, with the final maturity date of the Credit Agreement occurring on June 28, 2027. Â The outstanding principal balance of the Credit Agreement will bear interest at a rate per annum equal to the sum of (i) Term Secured Overnight Financing Rate, or SOFR (as defined in the Credit Agreement) plus (ii) 3.75 percent at all times prior to the Commitment Termination Date. The outstanding principal balance of the revolving credit facility will bear interest at a rate per annum equal to the sum of (i) Term SOFR (as defined in the Credit Agreement) plus (ii) 4.25 percent at all times on and after the Commitment Termination Date. Under the terms of the Credit Agreement, all accrued and unpaid interest shall be due and payable, in arrears, on the first business day of each calendar month. Â The Credit Agreement contains customary affirmative and negative covenants, in addition to financial covenants specifying that, as of the end of each calendar month, (i) the consolidated leverage ratio of Borrower will not exceed 1.00 to 1.00, (ii) the consolidated interest coverage ratio of Borrower will not be less than 4.00 to 1.00, (iii) the cash collection rate in relation to Borrowerâ€™s portfolio of loan assets will not be less than 4.5 percent, for such calendar month, (iv) the net charge-off percentage in relation to Borrowerâ€™s portfolio of loan assets will not exceed 3 percent for such calendar month, (v) the weighted average risk rating in relation to Borrower portfolio of loan assets will not be less than 3.00, and (vi) the Company's cumulative share repurchases will not exceed $5 million in value in any 12-month period. In addition, the Credit Agreement provides that at no time shall the Company permit its consolidated tangible net worth to be less than $145.0 million, or its liquidity (as defined in the Credit Agreement) to be less than $5.0 million. The Credit Agreement also contains events of default customary for such financings, the occurrence of which would permit the Agent and Lenders to accelerate the aggregate principal amount due thereunder. As of the date of this filing, the Company is in process of amending the Credit Agreement whereby the covenant for net charge-off percentage will be revised upwards, the consolidated interest coverage ratio will be revised downwards and the Company's share repurchase basket will be increased. The amendment will address covenant defaults as of June 30, 2024 and waive any past defaults. Â The Credit Agreement refinances the Companyâ€™s Loan and Security Agreement dated as of June 29, 2018 (the â€œPrior Credit Agreementâ€), as amended, between the Company and Cadence Bank, N.A. (â€œCadence Bankâ€), as the lender and administrative agent, which was due to expire on September 30, 2025. The Prior Credit Agreement was terminated by the Company, effective as of June 28, 2023. Â On October 10, 2023, the Company entered into a First Amendment to Credit Agreement pursuant to which Woodforest National Bank was added as a lender under the Credit Agreement for an aggregate commitment of $15.0 million, thereby increasing the aggregate commitments under the Credit Agreement from $45.0 million to $60.0 million. Â As of June 30, 2024 there were no amounts outstanding under the new Credit Agreement. During the three months ended June 30, 2024 and 2023, the Company recognized $1.1 million and $0.4 million, respectively, of interest expense relating to the Credit Agreement and Prior Credit Agreement, respectively. During the six months ended June 30, 2024 and 2023, the Company recognized $2.4 million and $0.5 million, respectively, of interest expense in connection with the Credit Agreement. 16 Â Senior Notes Due 2027 Â On October 3, 2023, the Company issued a $30.0 million aggregate principal amount of 9.00% Senior Notes due 2027 (â€œ2027 Senior Notesâ€ or â€œNotesâ€) in a registered underwritten public offering. On October 27, 2023, the underwriter exercised in full, its over-allotment option by purchasing an additional approximately $3.0 million aggregate principal amount of the 2027 Senior Notes. The interest rates are fixed at 9.00% per annum and are payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year, commencing on December 31, 2023, and until maturity. The Notes will mature on January 31, 2027. The total net proceeds from the debt offering, after deducting initial purchase discounts and debt issuance costs, were approximately $30.6 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including funding future acquisitions and investments, repaying indebtedness, making capital expenditures, and funding working capital. Â The following table summarizes the outstanding balance of the Notes, net of debt issuance costs (in thousands): Schedule of Long Term Debt Â Â June 30, 2024Â Â December 31, 2023Â 2027 Senior NotesÂ $32,969Â Â $32,969Â Debt issuance costsÂ Â (1,891)Â Â (2,188) Total unsecured senior notes, netÂ $31,078Â Â $30,781Â Â The Companyâ€™s future principal obligations for the Notes were as follows (in thousands): Â Schedule of Maturities of Long Term NotesÂ Â Â June 30, 2024Â Remainder of 2024Â $â€”Â 2025Â Â â€”Â 2026Â Â â€”Â 2027Â Â 32,969Â Total unsecured senior notes, netÂ $32,969Â Â The Company may redeem the Notes for cash in whole or in part at any time (i) on or after September 30, 2025 (the â€œFirst Call Dateâ€) and prior to September 30, 2026, at a price equal to the sum of 102% of their principal amount, and (ii) on or after September 30, 2026 at a price equal to the sum of 100% of their principal amount, plus (in each case noted above) accrued and unpaid interest to, but excluding, the date of redemption. At any time prior to the First Call Date, the Company may, at its option, redeem the Notes for cash, in whole at any time or in part from time to time at a redemption price equal to (i) 100% of the principal amount of Notes redeemed, plus (ii) a Make-Whole Amount (as defined in the Indenture), plus (iii) accrued and unpaid interest, if any, to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. Additionally, upon the occurrence of a Triggering Event (as defined in the Indenture), holders of the Notes will have the right to require the Company to make an offer to repurchase all or any portion of their Notes for cash at a purchase price equal to 100% of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of purchase. Â The Notes are senior unsecured obligations of the Company and rank equal in right of payment with the Companyâ€™s existing and future senior unsecured indebtedness. Â The Company evaluated the 2027 Senior Notes for derivatives pursuant to Accounting Standard Codification (â€œASCâ€) 815, â€œDerivatives and Hedging,â€ and identified an embedded derivative that required bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative was a default provision, which could require additional interest payments. The Company reassesses the feature quarterly to determine if it requires separate accounting. There have been no changes to the Companyâ€™s assessment that the fair value of the embedded derivative is immaterial through June 30, 2024. 17 Â Note 6. Commitments and Contingencies Â Lease Obligations Â All the Companyâ€™s material leases are operating leases. Right-of-use (â€œROUâ€) assets related to operating leases are included on the unaudited condensed consolidated balance sheets in other non-current assets. Operating lease cost is recognized over the lease term on a straight-line basis and is recorded within general and administrative expenses on the unaudited condensed consolidated statements of income. In March of 2023, the Company entered into a new lease for additional office space in Dallas, Texas on Sherry Lane. The Companyâ€™s corporate office spaces in Dallas, Texas total approximately 6,850 square feet consisting of the two office locations (Sherry Lane and Preston Road). Total rent expense recognized was $0.3 million and $0.2 million for six months ended June 30, 2024 and 2023, respectively. Â On June 10, 2024, the Company entered into a lease termination agreement to its Preston Road office lease in Dallas (the â€œLease Terminationâ€). The Lease Termination terminated the Companyâ€™s rights and obligations with respect to the leased premises on June 30, 2024. As such, the ROU assets and operating lease liabilities were written off, and the Company recorded a gain of $4 thousand for the quarter ended June 30, 2024 and paid an early termination fee of $9 thousand. The remaining Sherry Lane office lease is set to expire in August 2028. Â The Enteris headquarters is located in Boonton, New Jersey, where Enteris leases approximately 32,000 square feet of space. The office lease expires in December 2029 with an option to renew for an additional five years. Â The components of lease cost was as follows (in thousands): Schedule of Lease Cost Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Operating lease costÂ $134Â Â $125Â Â $259Â Â $222Â Variable lease costÂ Â 17Â Â Â 23Â Â Â 32Â Â Â 24Â Total lease costÂ $151Â Â $148Â Â $291Â Â $246Â Â Â Future minimum rent on the Companyâ€™s operating leases was as follows as of June 30, 2024 (in thousands): Â Schedule of Future Minimum Rent Remainder of 2024Â $283Â 2025Â Â 456Â 2026Â Â 461Â 2027Â Â 465Â 2028Â Â 405Â ThereafterÂ Â 272Â Total future lease paymentsÂ $2,342Â 18 Â Contingent Consideration Â During fiscal year 2019 the Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. Contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in the estimated fair value recognized in earnings. As of June 30, 2024, it has been determined the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of the product covered by the License Agreement. Accordingly, the Company has concluded that the liability for contingent consideration, previously held at its estimated fair value of $4.9 million, should be $0. The write-off of this contingent consideration liability has resulted in a gain of $4.9 million, which is included in the â€œChange in fair value of acquisition-related contingent considerationâ€ caption of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Unfunded Commitments Â Per the terms of the royalty purchase or credit agreements, unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time, and in the case of loan transactions, are subject to being advanced as long as an event of default does not exist. As of June 30, 2024 SWK had $5.0 million of unfunded commitments. Â Litigation Â The Company is involved in, or has been involved in, arbitrations or various other legal proceedings that arise from the normal course of its business. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material impact on the Companyâ€™s results of operations, balance sheets and cash flows due to defense costs, and divert management resources. The Company cannot predict the timing or outcome of these claims and other proceedings. As of June 30, 2024, the Company is not involved in any arbitration and/or other legal proceeding that it expects to have a material effect on its business, financial condition, results of operations and cash flows. Indemnification Â As permitted by Delaware law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving in such capacity, or in other capacities at the Companyâ€™s request. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any such amounts. As a result of the Companyâ€™s insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is insignificant. Accordingly, the Company had no liabilities recorded for these agreements as of June 30, 2024 and December 31, 2023. 19 Â Note 7. Fair Value Measurements Â The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrumentâ€™s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels. Â Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Â Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets. Â Level 3: Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources. Â Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the six months ended June 30, 2024 and 2023. Â The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates. Â Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized. Â Cash and cash equivalents Â The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assetsâ€™ fair values. 20 Â Finance Receivables Â Finance receivables are measured at amortized cost, which approximates fair value. The fair value of finance receivables is estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below. Â Contingent Consideration Â The fair value measurements of the contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 estimates under the fair value hierarchy, as these items have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Changes in fair value of this obligation are recorded as income or expense within operating income in our consolidated statements of income. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement. As noted above in Note 6, the acquisition-related contingent consideration liability was written down to $0 as of June 30, 2024 due to non-viability of the underlying product. Marketable Investments Â If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities are classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities are classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities are classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant benchmark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below. Â Derivative Instruments Â For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3. Â The Company uses a foreign currency forward contract to manage the impact of fluctuations in foreign currency denominated cash flows expected to be received from one of its royalty finance receivables denominated in a foreign currency. The foreign currency forward contract is not designated as a hedging instrument, and changes in fair value are recognized in earnings. The foreign currency forward was recorded in other non-current assets in the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023 and totaled to $2.6 million and $1.0 million, respectively. The Company recognized a $0.8 million and $1.2 million gain due to changes in fair value related to its foreign currency forward contract during the three months ended June 30, 2024 and June 30, 2023, respectively. The Company recognized a $1.7 million and $1.6 million gain due to changes in fair value related to its foreign currency forward contract for the six months ended June 30, 2024 and June 30, 2023, respectively. 21 Â The following table presents financial assets measured at fair value on a recurring basis as of June 30, 2024 (in thousands): Schedule of fair value assets measured on recurring basis Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant assetsÂ $835Â Â $â€”Â Â $â€”Â Â $835Â Marketable investmentsÂ Â 731Â Â Â 696Â Â Â â€”Â Â Â 35Â Foreign currency forward contractÂ Â 2,629Â Â Â â€”Â Â Â â€”Â Â Â 2,629Â Â

The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 (in thousands): Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant assetsÂ $1,759Â Â $â€”Â Â $â€”Â Â $1,759Â Marketable investmentsÂ Â 48Â Â Â â€”Â Â Â â€”Â Â Â 48Â Foreign currency forward contractÂ Â 974Â Â Â â€”Â Â Â â€”Â Â Â 974Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration payableÂ $4,900Â Â $â€”Â Â $â€”Â Â $4,900Â Â The contingent consideration payable was valued using a discounted cash flow approach and included a significant unobservable input which is the discount rate. During the six months ended June 30, 2024 there was a write off of the full balance of contingent consideration liability due to the non-viability of the underlying product. See Note 6 for further information. 22 Â The changes in fair value of the warrant assets during the six months ended June 30, 2024 and 2023 were as follows (in thousands): Â Schedule of fair value assets measured on recurring basis unobservable input reconciliation June 30, 2024Â June 30, 2023 Fair value - December 31, 2023Â $1,759Â Â Fair value - December 31, 2022Â $1,220Â IssuedÂ Â â€”Â Â IssuedÂ Â 822Â ExercisedÂ Â (984)Â ExercisedÂ Â â€”Â Change in fair valueÂ Â 130Â Â Change in fair valueÂ Â (583) Loss on foreign currency transactionsÂ $(70)Â Loss on foreign currency transactionsÂ $â€”Â Fair value - June 30, 2024Â $835Â Â Fair value - June 30, 2023Â $1,459Â Â The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, which do not have a readily determinable value, are measured using the Black-Scholes option pricing model. The following ranges of assumptions were used in the models to determine fair value: Â Schedule of weighted average assumptions Â Â June 30, 2024Â December 31, 2023 Dividend rate rangeÂ â€”Â â€”Â Risk-free rate rangeÂ 4.3% to 4.7%Â 3.8% to 4.8% Expected life (years) rangeÂ 2.4 to 5.3Â 1.2 to 5.8 Expected volatility rangeÂ 73% to 177.7%Â 75.3% to 154.3% Â The warrant assets are valued using a market approach and include significant unobservable inputs such as risk-free rate, expected life, and expected volatility. For the six months ended June 30, 2024 the risk-free rate range weighted average was 4.4%, and had a median of 4.3%. For the year ended December 31, 2023 the risk-free rate range weighted average was 4.3%, and had a median of 3.8%. For the six months ended June 30, 2024 the expected life range weighted average was 4.2 years, and had a median of 4.5 years. For the year ended December 31, 2023 the expected life range weighted average was 3.4 years, and had a median of 4.4 years. For the six months ended June 30, 2024 the expected volatility range weighted average was 102.7%, and had a median of 90.8%. For the year ended December 31, 2023 the expected volatility range weighted average 124.6%, and median of 134.4%. As of June 30, 2024 and December 31, 2023, the Company had one royalty, Best, that was deemed to be impaired based on reductions in carrying value in prior periods. As of June 30, 2024, the Company had two loans, Trio Healthcare and Exeevo, that was deemed to be impaired based on reductions in carrying value during the six months ended June 30, 2024. The following table presents this royalty and the loans measured at amortized cost using the effective interest method, which approximates fair value, on a nonrecurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of weighted average assumptions Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â June 30, 2024Â $8,448Â Â $â€”Â Â $â€”Â Â $8,448Â December 31, 2023Â $2,587Â Â $â€”Â Â $â€”Â Â $2,587Â Â There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2024 and December 31, 2023. 23 Â The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis. Â The following table presents the fair value of financial assets as of June 30, 2024 (in thousands): Â Schedule of fair value by balance sheet grouping Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, netÂ $265,470Â Â $265,470Â Â $â€”Â Â $â€”Â Â $265,470Â Marketable investmentsÂ Â 731Â Â Â 731Â Â Â 696Â Â Â â€”Â Â Â 35Â Warrant assetsÂ Â 835Â Â Â 835Â Â Â â€”Â Â Â â€”Â Â Â 835Â Foreign currency forward contractÂ Â 2,629Â Â Â 2,629Â Â Â â€”Â Â Â â€”Â Â Â 2,629Â Â The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands): Â Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, netÂ $274,504Â Â $274,504Â Â $â€”Â Â $â€”Â Â $274,504Â Marketable investmentsÂ Â 48Â Â Â 48Â Â Â â€”Â Â Â â€”Â Â Â 48Â Warrant assetsÂ Â 1,759Â Â Â 1,759Â Â Â â€”Â Â Â â€”Â Â Â 1,759Â Foreign currency forward contractÂ Â 974Â Â Â 974Â Â Â â€”Â Â Â â€”Â Â Â 974Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial liabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration payableÂ $4,900Â Â $4,900Â Â $â€”Â Â $â€”Â Â $4,900Â 24 Â Note 8. Revenue Recognition Â The Companyâ€™s Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Companyâ€™s Finance Receivables segment does not have any revenues received from contracts with customers. Â The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2024 and 2023 (in thousands): Â Schedule of Revenue Recognized by Revenue Source Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â License AgreementÂ $49Â Â $10Â Â $49Â Â $10Â Pharmaceutical DevelopmentÂ Â 755Â Â Â 173Â Â Â 1,034Â Â Â 291Â Total contract revenueÂ $804Â Â $183Â Â $1,083Â Â $301Â Â The Companyâ€™s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied. Â The Companyâ€™s contract liabilities are presented as deferred income and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands): Â Schedule of Company's Contract LiabilitiesÂ Â Â June 30, 2024Â Â December 31, 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Â Deferred incomeÂ $2,216Â Â $9Â Total contract liabilitiesÂ $2,216Â Â $9Â Â During the six months ended June 30, 2024, the Company recognized the full remaining balance of $9 thousand of 2023 deferred income from satisfaction of performance obligations. The Company did not have any contract assets as of June 30, 2024 or December 31, 2023. 25 Â Enteris Exclusive Option and Asset Purchase Agreement Â With an effective date of January 1, 2024, we entered into an exclusive option and asset purchase agreement with a strategic partner on March 14, 2024 which granted the partner an exclusive option to acquire certain of Enterisâ€™ assets related to its business of providing clinical manufacturing and development services. The partner must exercise the option by or before January 1, 2026. In exchange for the exclusive purchase option the partner is to provide consideration in the form of an â€œoption feeâ€ and â€œguaranteed revenue payments.â€ Â The option fee is broken into two components: A low-single digit million fee due within 30 business days of executing the agreement; and should the option not be exercised by the first anniversary of the effective date, an additional low-single digit million fee will be due at that time. The first option fee was paid in April 2024. Option fee payments will be included in deferred income until the earlier of term expiration or exercise of the purchase option. Should the partner exercise the purchase option, any option fee payments made will be applied towards the purchase price. Â The guaranteed revenue payments include two components: A mid-single digit million guaranteed revenue payment in 2024 and a mid-single digit million guaranteed revenue payment in 2025. The revenue is to be derived by the partner under an existing collaboration agreement, and partner is to pay the difference should the minimum amount not be met each year. Each yearâ€™s guaranteed revenue amount is to be paid in two installments semi-annually each year. Should revenue exceed the 2024 or 2025 guaranteed revenue amounts after receiving a difference payment in the first half of the year, we must repay the partner the amount of such overpayment. Guaranteed revenue of $0.4 million was recognized during the three and six months ended June 30, 2024. Â Note 9. Segment Information Â Selected financial and descriptive information is required to be provided about reportable operating segments, considering a â€œmanagement approachâ€ concept as the basis for identifying reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Companyâ€™s internal organization, focusing on financial information that the Companyâ€™s CEO uses to make decisions about the Companyâ€™s operating matters. As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report assets by reportable segment, nor does the Company report results by geographic region, as these metrics are not used by the Companyâ€™s chief executive officer in assessing performance or allocating resources to the segments. Â Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Companyâ€™s CEO in assessing performance or allocating resources to the segments. 26 Â The following tables present financial information for the Companyâ€™s reportable segments for the periods indicated (in thousands): Schedule of Reportable Revenue by Geographic Region Â Â Three Months Ended June 30, 2024Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $10,680Â Â $804Â Â $â€”Â Â $11,484Â Other revenueÂ Â 57Â Â Â â€”Â Â Â â€”Â Â Â 57Â Provision for credit lossesÂ Â 4,074Â Â Â â€”Â Â Â â€”Â Â Â 4,074Â Loss on impairment of intangible assetsÂ Â â€”Â Â Â 5,771Â Â Â â€”Â Â Â 5,771Â Interest expenseÂ Â 225Â Â Â 2Â Â Â 892Â Â Â 1,119Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 520Â Â Â â€”Â Â Â 520Â Change in fair value of acquisition-related contingent considerationÂ Â â€”Â Â Â (4,900)Â Â â€”Â Â Â (4,900) Depreciation and amortization expenseÂ Â â€”Â Â Â 400Â Â Â 21Â Â Â 421Â General and administrative expenseÂ Â 91Â Â Â 748Â Â Â 2,084Â Â Â 2,923Â Other income (expense), netÂ Â 3,851Â Â Â â€”Â Â Â (34)Â Â 3,817Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,035Â Â Â 1,035Â Net income (loss)Â Â 10,198Â Â Â (1,737)Â Â (4,066)Â Â 4,395Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30, 2023Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $9,278Â Â $183Â Â $â€”Â Â $9,461Â Other revenueÂ Â 36Â Â Â â€”Â Â Â â€”Â Â Â 36Â Benefit for credit lossesÂ Â (682)Â Â â€”Â Â Â â€”Â Â Â (682) Interest expenseÂ Â 363Â Â Â â€”Â Â Â â€”Â Â Â 363Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 1,509Â Â Â â€”Â Â Â 1,509Â Depreciation and amortization expenseÂ Â â€”Â Â Â 633Â Â Â 4Â Â Â 637Â General and administrative expenseÂ Â 137Â Â Â 981Â Â Â 1,879Â Â Â 2,997Â Other income, netÂ Â 715Â Â Â â€”Â Â Â â€”Â Â Â 715Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,454Â Â Â 1,454Â Net income (loss)Â Â 10,211Â Â Â (2,940)Â Â (3,337)Â Â 3,934Â 27 Â Â Â Six Months Ended June 30, 2024Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $21,399Â Â $1,083Â Â $â€”Â Â $22,482Â Other revenueÂ Â 103Â Â Â â€”Â Â Â â€”Â Â Â 103Â Provision for credit lossesÂ Â 9,397Â Â Â â€”Â Â Â â€”Â Â Â 9,397Â Loss on impairment intangible assetsÂ Â â€”Â Â Â 5,771Â Â Â â€”Â Â Â 5,771Â Interest expenseÂ Â 590Â Â Â 5Â Â Â 1,780Â Â Â 2,375Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 1,050Â Â Â â€”Â Â Â 1,050Â Change in fair value of acquisition-related contingent considerationÂ Â â€”Â Â Â (4,900)Â Â â€”Â Â Â (4,900) Depreciation and amortization expenseÂ Â â€”Â Â Â 892Â Â Â 43Â Â Â 935Â General and administrative expenseÂ Â 169Â Â Â 1,457Â Â Â 3,981Â Â Â 5,607Â Other income (expense), netÂ Â 3,843Â Â Â â€”Â Â Â (408)Â Â 3,435Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,264Â Â Â 1,264Â Net income (loss)Â Â 15,189Â Â Â (3,192)Â Â (7,476)Â Â 4,521Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2023Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $18,538Â Â $301Â Â $â€”Â Â $18,839Â Other revenueÂ Â 67Â Â Â â€”Â Â Â 2Â Â Â 69Â Benefit for credit lossesÂ Â (682)Â Â â€”Â Â Â â€”Â Â Â (682) Interest expenseÂ Â 545Â Â Â â€”Â Â Â â€”Â Â Â 545Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 2,228Â Â Â â€”Â Â Â 2,228Â Depreciation and amortization expenseÂ Â â€”Â Â Â 1,277Â Â Â 8Â Â Â 1,285Â General and administrative expenseÂ Â 167Â Â Â 1,709Â Â Â 3,661Â Â Â 5,537Â Other expense, netÂ Â (81)Â Â â€”Â Â Â â€”Â Â Â (81) Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,345Â Â Â 1,345Â Net income (loss)Â Â 18,494Â Â Â (4,913)Â Â (5,012)Â Â 8,569Â Â Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate employees, which have been included for purposes of reconciling to the consolidated amounts. Â Note 10. Subsequent Events Â Relief Therapeutics Â On August 2, 2024, SWK Funding, a subsidiary of the Company, entered into a royalty purchase agreement with Relief Therapeutics Holding SA (â€œReliefâ€) and APR Applied Pharma Research SA pursuant to which SWK Funding paid $5.8 million at closing with another $5.3 million available for borrowing should Relief achieve certain milestones. In exchange, SWK Funding will receive royalties based off sales as listed in the agreement. 28 Â ITEMÂ 2.Â Â Â Â MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations (â€œMD&Aâ€) is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements, and the MD&A included in our Annual Report on Form 10-K for the year ended December 31, 2023 (â€œAnnual Reportâ€), as well as our unaudited condensed consolidated financial statements and the accompanying notes included in this report. Â Overview We have organized our operations into two segments: Finance Receivables and Pharmaceutical Development. These segments reflect the way the Company evaluates its business performance and manages its operations. Please refer to Item 1. Financial Statements, Note 9 of the notes to the unaudited condensed consolidated financial statements for further information regarding segment information. 29 Â Finance Receivables Portfolio Overview The table below provides an overview of our outstanding finance receivables transactions as of, and for the three and six months ended June 30, 2024 (in thousands, except rate, share and per share data). Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue (Loss) RecognizedÂ Royalty PurchasesÂ Licensed TechnologyÂ FootnoteÂ Â Funded AmountÂ Â GAAP BalanceÂ Â 2Q 2024Â Â Year-to- DateÂ BesivanceÂ®Â Ophthalmic antibioticÂ (1)Â $6,000Â Â $â€”Â Â $8Â Â $17Â Best ABT, Inc.Â Oncology diagnosisÂ (2), (3)Â Â Â 5,784Â Â Â 2,437Â Â Â â€”Â Â Â â€”Â CoflexÂ®/KybellaÂ®Â Spinal stenosis/submental fullnessÂ Â Â Â Â 4,350Â Â Â 3,087Â Â Â (11)Â Â 82Â CambiaÂ®Â NSAID migraine treatmentÂ (4)Â Â 8,500Â Â Â â€”Â Â Â 93Â Â Â 210Â Duo RoyaltyÂ Japanese Womenâ€™s health/cystic fibrosisÂ Â Â Â Â 15,353Â Â Â 11,986Â Â Â 563Â Â Â 1,178Â Flowonix Medical, Inc.Â Drug delivery deviceÂ (3), (5)Â Â Â 12,455Â Â Â 10,433Â Â Â â€”Â Â Â â€”Â Forfivo XLÂ®Â Depressive disorder treatmentÂ Â Â Â Â 6,000Â Â Â 1,296Â Â Â 245Â Â Â 725Â Ideal Implant, Inc.Â AestheticsÂ (3), (6)Â Â Â 4,025Â Â Â 3,564Â Â Â â€”Â Â Â â€”Â Immune GlobuinÂ Immune Globulin TherapeuticsÂ (9)Â Â 14,100Â Â Â 12,110Â Â Â 805Â Â Â 1,303Â IluvienÂ®Â Diabetic macular edemaÂ Â Â Â Â 16,501Â Â Â 16,595Â Â Â 545Â Â Â 1,103Â Veru, Inc.Â Womenâ€™s healthÂ Â Â Â Â 10,000Â Â Â 3,362Â Â Â 130Â Â Â 260Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue (Loss) RecognizedÂ Term LoansÂ TypeÂ FootnoteÂ Maturity DateÂ PrincipalÂ Â GAAP BalanceÂ Â RateÂ Â 2Q 2024Â Â Year-to- DateÂ 4Web, Inc.Â First lienÂ Â Â 12/31/24Â $26,411Â Â $29,154Â Â Â 11.3%Â $1,190Â Â $2,512Â AOTI, Inc.Â First lienÂ Â Â 03/21/27Â Â 14,478Â Â Â 14,639Â Â Â 11.2%Â Â 573Â Â Â 1,094Â Elutia, Inc.Â First lienÂ Â Â 08/10/27Â Â 21,045Â Â Â 23,128Â Â Â 12.0%Â Â 944Â Â Â 1,910Â BIOLASE, Inc.Â First lienÂ Â Â 05/31/25Â Â 12,270Â Â Â 13,346Â Â Â 10.3%Â Â 564Â Â Â 1,142Â Biotricity, Inc.Â First lienÂ Â Â 12/21/26Â Â 12,364Â Â Â 12,601Â Â Â 11.5%Â Â 594Â Â Â 1,112Â CDMO ManufacturerÂ First lienÂ Â Â 09/13/27Â Â 5,000Â Â Â 5,161Â Â Â 13.3%Â Â 202Â Â Â 400Â Epica International, Inc.Â First lienÂ Â Â 07/23/24Â Â 8,450Â Â Â 9,328Â Â Â 11.5%Â Â 379Â Â Â 736Â eTon Pharmaceuticals, Inc.Â First lienÂ Â Â 11/13/24Â Â 4,690Â Â Â 4,991Â Â Â 13.3%Â Â 200Â Â Â 413Â Journey Medical CorporationÂ First lienÂ Â Â 12/27/27Â Â 20,000Â Â Â 19,888Â Â Â 12.8%Â Â 542Â Â Â 1,083Â Exeevo, Inc.Â First lienÂ (2), (3)Â 07/01/27Â Â 4,558Â Â Â 4,538Â Â Â 12.8%Â Â 8Â Â Â 8Â MedMinder Systems, Inc.Â First lienÂ Â Â 08/18/27Â Â 20,000Â Â Â 20,221Â Â Â 12.3%Â Â 768Â Â Â 1,490Â MolecuLight, Inc.Â First lienÂ Â Â 12/29/26Â Â 10,426Â Â Â 10,718Â Â Â 12.8%Â Â 461Â Â Â 937Â Nicoya Lifesciences, Inc.Â First lienÂ Â Â 11/30/26Â Â 6,000Â Â Â 6,059Â Â Â 12.8%Â Â 265Â Â Â 522Â NeoLight, LLCÂ First lienÂ Â Â 02/17/27Â Â 5,000Â Â Â 5,115Â Â Â 13.5%Â Â 266Â Â Â 478Â Shield Therapeutics, PlcÂ First lienÂ Â Â 09/28/28Â Â 20,000Â Â Â 19,489Â Â Â 14.3%Â Â 824Â Â Â 1,638Â SKNVÂ First lienÂ Â Â 05/15/27Â Â 13,497Â Â Â 13,835Â Â Â 10.4%Â Â 522Â Â Â 1,046Â Trio Healthcare Ltd.Â First lienÂ (2), (3)Â 07/01/26Â Â 1,498Â Â Â 1,472Â Â Â 12.5%Â Â â€”Â Â Â â€”Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revenue (Loss) RecognizedÂ Marketable InvestmentsÂ Number of SharesÂ Â FootnoteÂ Â Funded AmountÂ Â GAAP BalanceÂ Â 2Q 2024Â Â Year-to- DateÂ Secured Royalty Financing (Marketable Investment)Â Â N/AÂ Â (2), (3)Â Â $3,000Â Â $35Â Â $â€”Â Â $â€”Â Eyepoint Pharma Common StockÂ Â â€”Â Â (7)Â Â N/AÂ Â Â 0Â Â Â â€”Â Â Â â€”Â AOTI Common StockÂ Â 402,634Â Â (8)Â Â N/AÂ Â $696Â Â $â€”Â Â $â€”Â 30 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Change in Fair ValueÂ Warrants to Purchase StockÂ Number of SharesÂ Â FootnoteÂ Â Exercise Price per Share ($)Â Â GAAP BalanceÂ Â 2Q 2024Â Â Year-to- DateÂ 4Web, Inc.Â Â Â TBD Â Â Â Â Â Â Â Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Aziyo Biologics, Inc.Â Â 157,895Â Â Â Â Â Â Â 6.65Â Â Â 536Â Â Â 224Â Â Â 253Â Aziyo Biologics, Inc.Â Â 30,075Â Â Â Â Â Â Â 6.65Â Â Â 102Â Â Â 43Â Â Â 49Â BIOLASE, Inc.Â Â 22,039Â Â Â Â Â Â Â 9.80Â Â Â 1Â Â Â â€”Â Â Â â€”Â Biotricity, Inc.Â Â 57,536Â Â Â Â Â Â Â 6.26Â Â Â 2Â Â Â (4)Â Â (2) CDMO ManufacturerÂ Â 211,442Â Â Â Â Â Â Â 1.42Â Â Â â€”Â Â Â â€”Â Â Â â€”Â CeloNova

BioSciences, Inc.Â Â Â TBD Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â DxTerity Diagnostics, Inc.Â Â 2,019,231Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Epica International, Inc.Â Â Â TBD Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â eTon Pharmaceuticals, Inc.Â Â 51,239Â Â Â Â Â Â 5.86Â Â Â 50Â Â Â (24)Â Â (47) eTon Pharmaceuticals, Inc.Â Â 18,141Â Â Â Â Â Â 6.62Â Â Â 19Â Â Â (9)Â Â (17) Exeevo, Inc.Â Â 930Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â EyePoint Pharmaceuticals, Inc.Â Â 40,910Â Â Â Â Â Â 11.00Â Â Â Â â€”Â Â Â â€”Â Â Â 127Â EyePoint Pharmaceuticals, Inc.Â Â 7,773Â Â Â Â Â Â 19.30Â Â Â â€”Â Â Â â€”Â Â Â 22Â Shield WarrantÂ Â 8,910,540Â Â Â Â Â Â Â Â 125Â Â Â (4)Â Â (254) MedMinder Systems, Inc.Â Â 72,324Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â MolecuLight, Inc.Â Â Â TBD Â Â Â Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Revenue (Loss) RecognizedÂ Â Â AssetsÂ Â 2Q 2024Â Â Year-to-DateÂ Total finance receivables, grossÂ $278,553Â Â $10,680Â Â $21,399Â Total marketable investmentsÂ Â 731Â Â Â â€”Â Â Â â€”Â Total fair value of warrant assetsÂ Â 835Â Â Â â€”Â Â Â â€”Â TotalÂ $280,119Â Â $10,680Â Â $21,399Â Â (1) US royalty was paid off during the year ended December 31, 2021. SWK continues to receive insignificant royalties on international sales. (2) Investment considered partially impaired. (3) Investment on non-accrual. (4) Investment was paid off during the nine months ended September 30, 2023. (5) Flowonix Medical assets were sold to a medical device company during the nine months ended September 30, 2023. In exchange for releasing its lien, SWK received cash at close and is expected to receive royalties on sales of two products. The finance receivable is now classified as a royalty. (6) In July 2023, Ideal Implant assets were sold to an aesthetics company, which is expected to pay SWK a mid-single digit, capped royalty on implant sales in 2024. (7) Eyepoint warrants exercised in 1Q 2024 and converted to shares.Â Â The shares were sold during 2Q 2024. (8) AOTI warrants exercised in 2Q 2024 and converted to shares. (9) During the three months ended June 30, 2024, the Company identified an error in the calculation of revenue related to the release of a holdback liability for ImmuneGlobulin during the three months ended March 31, 2024. The error led to finance receivable interest income being overstated by $0.7 million for the three months ended March 31, 2024. See Note 1 for more details. Â Unless otherwise specified, our senior secured debt assets generally are repaid by a revenue interest that is charged on a companyâ€™s quarterly net sales and royalties. 31 Â Critical Accounting Policies and Estimates Â Our critical accounting policies and estimates are described in Part II, Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of our Annual Report. We believe there have been no new critical accounting policies or material changes to our existing critical accounting policies and estimates during the six months ended June 30, 2024, compared to those discussed in our Annual Report. Â Recent Accounting Pronouncements Â Refer to Part I. Financial Information, Item 1. Financial Statements, Note 1 of the notes to the unaudited condensed consolidated financial statements for a listing of recent accounting pronouncements and their potential impact to our consolidated financial statements. Â Comparison of the three months ended June 30, 2024 and 2023Â (in millions) Â Â Â Three Months Ended June 30,Â Â Â Â Â Â 2024Â Â 2023Â Â Change $Â RevenuesÂ $11.5Â Â $9.5Â Â $2.0Â Provision (benefit) for credit lossesÂ Â 4.1Â Â Â (0.7)Â Â 4.8Â Loss on impairment of intangible assetsÂ Â 5.8Â Â Â â€”Â Â Â 5.8Â Interest expenseÂ Â 1.1Â Â Â 0.4Â Â Â 0.7Â Pharmaceutical manufacturing, research and development expenseÂ Â 0.5Â Â Â 1.5Â Â Â (1.0) Change in fair value of acquisition-related contingent considerationÂ Â (4.9)Â Â â€”Â Â Â (4.9) Depreciation and amortization expenseÂ Â 0.4Â Â Â 0.6Â Â Â (0.2) General and administrative expenseÂ Â 2.9Â Â Â 3.0Â Â Â (0.1) Other income, netÂ Â 3.8Â Â Â 0.7Â Â Â 3.1Â Income tax expenseÂ Â 1.0Â Â Â 1.5Â Â Â (0.5) Net incomeÂ Â 4.4Â Â Â 3.9Â Â Â 0.5Â Â Revenues Â Revenues increased to $11.5 million for the three months ended June 30, 2024 from $9.5 million for the three months ended June 30, 2023. The $2.0 million increase in revenue for the three months ended June 30, 2024 consisted of a $1.4 million increase in Finance Receivables segment revenue and a $0.6 million increase in Pharmaceutical Development segment revenue. The $1.4 million increase in Finance Receivables segment revenue was primarily due an increase of $3.1 million in interest and fees earned due to funding new and existing loans offset by $1.7 million decrease in interest, fees and royalties earned on finance receivables that were paid off during the period. Â Provision (Benefit) for Credit Losses Â Our provision for credit losses is established through charges or credits to income in the form of the provision in order to bring our allowance for credit losses for loans and unfunded commitments to a level deemed appropriate by management. We recognized a net provision for credit losses of $4.1 million during the three months ended June 30, 2024 and $0.7 million benefit during three months ended June 30, 2023, respectively. The $2.1 million impairment on the Trio loan and $2.2 million impairment on the Exeevo loan were both included within the provision for credit losses. See Note 3 to the unaudited condensed consolidated financial statements for further information on the allowance for credit losses. 32 Â Interest Expense Â Interest expense consists of interest accrued on our revolving line of credit, 9.00% Senior Notes due 2027, unused line of credit and maintenance fees, as well as amortization of debt issuance costs. Interest expense increased to $1.1 million for the three months ended June 30, 2024 from $0.4 million for the three months ended June 30, 2023. The $0.7Â million increase in interest expense was mainly due to issuing approximately $32.9 million of Notes in an underwritten public offering in October of 2023, and the establishment of the Credit Agreement as of June 30, 2023. See Note 6 for further information on the Notes, new Credit Agreement, and Prior Credit Agreement.Â Â Pharmaceutical Manufacturing, Research and Development Expense Â Pharmaceutical manufacturing, research and development expense decreased from $1.5Â million for the three months ended June 30, 2023 to $0.5Â million for the three months ended June 30, 2024. The $1.0 million decrease was primarily due to reduction in research and development and clinical trial related to cancelled projects. Â Depreciation and Amortization Expense Â The $0.2 million decrease in depreciation and amortization expense for the three months ended June 30, 2024 primarily consists of a decrease in amortization expense related to no longer amortizing intangible assets related to the Cara license. Amortization expense is aligned with the expected future cash flows of the intangible assets. Â General and Administrative Expense Â General and administrative expenses consist primarily of compensation; stock-based compensation and related costs for management, staff and Board; legal and audit expenses; and corporate governance expenses. General and administrative expenses decreased to $2.9Â million for the three months ended June 30, 2024 from $3.0Â million for the three months ended June 30, 2023 resulting in an immaterial change in total activity between the periods. Â Other Income, Net Â Other income, net increased to $3.8Â million for the three months ended June 30, 2024 from $0.7Â million for the three months ended June 30, 2023. The $3.1 million increase includes a $2.5 million gain on revaluation related to the Iluvien royalty after a contractual re-negotiation during the current quarter, and also includes a gain of $0.7 million from the exercise of warrants during current quarter. Â Income Tax Expense Â During the three months ended June 30, 2024 we recognized $1.0Â million of income tax expense, while for the three months ended June 30, 2023 we recognized income tax of $1.5Â million. The change in income tax expense is primarily attributed to changes in pre-tax net income, and the Companyâ€™s effective tax rate, which was 20.9% and 10.1% as of June 30, 2024 and 2023. 33 Â Comparison of the six months ended June 30, 2024 and 2023Â (in millions) Â Â Â Six Months Ended June 30,Â Â Â Â Â Â 2024Â Â 2023Â Â Change $Â RevenuesÂ $22.6Â Â $18.9Â Â $3.7Â Provision (benefit) for credit lossesÂ Â 9.4Â Â Â (0.7)Â Â 10.1Â Loss on impairment of intangible assetsÂ Â 5.8Â Â Â â€”Â Â Â 5.8Â Interest expenseÂ Â 2.4Â Â Â 0.5Â Â Â 1.9Â Pharmaceutical manufacturing, research and development expenseÂ Â 1.1Â Â Â 2.2Â Â Â (1.1) Change in fair value of acquisition-related contingent considerationÂ Â (4.9)Â Â â€”Â Â Â (4.9) Depreciation and amortization expenseÂ Â 0.9Â Â Â 1.3Â Â Â (0.4) General and administrative expenseÂ Â 5.6Â Â Â 5.5Â Â Â 0.1Â Other income (expense), netÂ Â 3.4Â Â Â (0.1)Â Â 3.5Â Income tax expenseÂ Â 1.3Â Â Â 1.3Â Â Â â€”Â Net incomeÂ Â 4.5Â Â Â 8.6Â Â Â (4.1) Â Revenues Â Revenues increased to $22.6Â million for the six months ended June 30, 2024 from $18.9Â million for the six months ended June 30, 2023. The $3.7Â million increase in revenue for the six months ended June 30, 2024 consisted of a $2.9Â million increase in Finance Receivables segment revenue and a $0.8Â million increase in Pharmaceutical Development segment revenue. The $2.9Â million increase in Finance Receivables segment revenue was primarily due to a $6.3 million increase in interest and fees earned due to funding new and existing loans offset by $3.4 million decrease in interest, fees and royalties earned on finance receivables that were paid off during the period. Â Provision (Benefit) for Credit Losses Â Our provision for credit losses is established through charges or credits to income in the form of the provision in order to bring our allowance for credit losses for loans and unfunded commitments to a level deemed appropriate by management. We recognized a net provision for credit losses of $9.4Â million during the six months ended June 30, 2024 and a $0.7Â million benefit during six months ended June 30, 2023, respectively. Most of the change was related to a $8.1 million impairment on the Trio loan and $2.2 million impairment on the Exeevo loan that were included within the provision for credit losses during the period. See Note 3 to the unaudited condensed consolidated financial statements for further information on the allowance for credit losses. Â Interest Expense Â Interest expense consists of interest accrued on our revolving line of credit, 9.00% Senior Notes due 2027, unused line of credit and maintenance fees, as well as amortization of debt issuance costs. Interest expense increased to $2.4Â million for the six months ended June 30, 2024 from $0.5Â million for the six months ended June 30, 2023. The $1.9Â million increase in interest expense was mainly due to issuing approximately $32.9 million of Notes in an underwritten public offering in October of 2023. See Note 6 for further information on the Notes, new Credit Agreement, and Prior Credit Agreement. 34 Â Pharmaceutical Manufacturing, Research and Development Expense Â Pharmaceutical manufacturing, research and development expense decreased from $2.2Â million for the six months ended June 30, 2023 to $1.1Â million for the six months ended June 30, 2024. The $1.1Â million decrease was primarily due to a reduction in research and development and clinical trial expenditures related to cancelled projects during the period. Â Depreciation and Amortization Expense Â The $0.4Â million decrease in depreciation and amortization expense for the six months ended June 30, 2024 primarily consists of a decrease in amortization expense related to no longer amortizing intangible assets related to the Cara license. Amortization expense is aligned with the expected future cash flows of the intangible assets. See Note 4 for more information on the impairment of the Cara license. Â General and Administrative Expense Â General and administrative expenses consist primarily of compensation; stock-based compensation and related costs for management, staff and Board; legal and audit expenses; and corporate governance expenses. General and administrative expenses increased to $5.6Â million for the six months ended June 30, 2024 from $5.5Â million for the six months ended June 30, 2023 resulting in an immaterial change in total activity between the periods. Â Other Income (Expense), Net Â Other expense, net increased to $3.4Â million for the six months ended June 30, 2024 from $0.1Â million for the six months ended June 30, 2023. The $3.5 million increase includes a $2.5 million gain on revaluation related to the Iluvien royalty after a contractual re-negotiation, a gain of $0.7 million due to the exercise of warrants, a loss of $0.3 million on the sale of common shares, and the remaining activity relating to warrant fair value adjustments based on share price. Â Income Tax Expense Â During the six months ended June 30, 2024 and 2023 we recognized $1.3Â million of income tax expense. Income tax expense remained consistent period over period and the Companyâ€™s effective tax rate was 20.9% and 10.1% as of June 30, 2024 and 2023, respectively, and a release of valuation allowance on deferred tax assets of $0.6 million took place during the six months ended June 30, 2023 35 Â Liquidity and Capital Resources Â As of June 30, 2024, we had $5.5 million in cash and cash equivalents and restricted cash, compared to $5.2 million as of December 31, 2023. The primary driver of the $0.3 million increase in our cash balance was $29 million of interest, fees, principal and royalty payments received on our finance receivables. The increase in cash and cash equivalents was partially offset by $8.2 million of investment funding, net of deferred fees and origination expenses; $0.8 million holdback repayment; a net credit facility payment of $12.4 million; a payroll and benefits expense of $2.4 million; $3.2 million of accounts payable; and $1.9 million to repurchase shares of the Companyâ€™s common stock on the open market, pursuant to the Companyâ€™s stock repurchase program. Â We entered into a $45.0 million revolving credit facility in June 2023 with First Horizon Bank. The Credit Agreement provides for one or more incremental increases not to exceed $80.0 million, subject to the consent of the Agent and each Lender, at any time prior to the Commitment Termination Date. On October 10, 2023, the Company entered into a First Amendment to Credit Agreement pursuant to which Woodforest National Bank was added as a lender under the Credit Agreement for an aggregate commitment of $15.0 million, thereby increasing the aggregate commitments under the Credit Agreement from $45.0 million to $60.0 million. As of June 30, 2024, there was no outstanding amount under the new Credit Agreement, and $55.0 million was available for borrowing. The $60.0 million Credit Agreement contains a $5.0 million liquidity covenant, bringing the total amount available for borrowing to $55.0 million. Â Our Prior Credit Agreement with Cadence Bank was terminated in connection with the establishment of the new Credit Agreement (please refer to Part II, Item 8, Financial Statements and Supplementary Data, Note 6 of the notes to the consolidated financial statements for further information regarding the Credit Agreement with First Horizon Bank). Â On October 3, 2023, the Company completed a registered underwritten public offering of $30.0 million of the Notes. On October 27, 2023, the underwriters exercised their option to purchase an additional approximately $3.0 million in aggregate principal amount of the Notes. The Notes will mature on January 31, 2027, unless earlier redeemed, and will bear interest at a rate of 9.00% per annum, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year and at maturity, commencing on December 31, 2023. The Company received net proceeds after discounts, commissions, expenses and fees, of approximately $30.6 million. As of the date of this filing the Company is in process of amending the Credit Agreement whereby the covenant for net charge-off percentage will be revised upwards, and will include an increase to the Companyâ€™s share buyback basket. The amendment will be retroactively applicable to the quarter ended June 30, 2024. See Note 5 for more information. 36 Â Primary Driver of Cash Flow Our ability to generate cash in the future depends primarily upon our success in implementing our Finance Receivables business model of generating income by providing capital to a broad range of life science companies, institutions and inventors, as well as the success of our Pharmaceutical Development segment. We generate income primarily from four sources: Â Â 1. Primarily owning or financing through debt investments, royalties generated by the sales of life science products and related intellectual property; Â Â Â Â 2. Receiving interest and other income by advancing capital in the form of secured debt to companies in the life science sector; Â Â Â Â 3. Pharmaceutical development, manufacturing, and licensing activities utilizing the PeptelligenceÂ® platform; and Â Â Â Â 4. To a lesser extent, realizing capital appreciation from equity-related investments in the life science sector. Â As of June 30, 2024, our finance receivables portfolio contains $265.5 million of net finance receivables and $731 thousand of marketable investments. We expect these assets to generate positive cash flows in 2024. We continuously monitor the short and long-term financial position of our finance receivables portfolio. In addition, the majority of our finance receivables portfolio are debt instruments that carry floating interest rates. Changes in interest rates, including the levels of the underlying reference rates may affect the interest income for debt instruments with floating rates. We believe we are well positioned to benefit should market interest rates rise in the future. Â We continue to evaluate multiple attractive opportunities that, if consummated, we believe would similarly generate additional income. Since the timing of any investment is difficult to predict, our Finance Receivables segment may not be able to generate positive cash flow above what our existing assets are expected to produce in 2024. We do not assume any near-term repayments from borrowers, and as a result, no assurances can be given that actual results would not differ materially from the statement above. Â Off-Balance Sheet Arrangements Â In the normal course of operations, we engage in a variety of financial transactions that, in accordance with GAAP, are not recorded in our consolidated financial statements. These transactions involve, to varying degrees, elements of credit, interest rate, and liquidity risk. Such transactions are used primarily to manage partner companiesâ€™ requests for funding and take the form of loan commitments and lines of credit. Â The contractual amounts of commitments to extend credit represent the amounts of potential accounting loss should the contract be fully drawn upon, the partner company defaults, and the value of any existing collateral becomes worthless. We use the same credit policies in making commitments and conditional obligations as we do for on-balance sheet instruments. Â As of June 30, 2024, we had $5.0 million in unfunded commitments. Please refer to Item 1., Financial Statements, Note 6 of the notes to the unaudited condensed consolidated financial statements for further information regarding the Companyâ€™s commitments and contingencies. 37 Â ITEMÂ 3.Â Â Â Â Â Â QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.Â During the six months ended June 30, 2024, our cash and cash equivalents were deposited in accounts at well capitalized financial institutions. The fair value of our cash and cash equivalents at June 30, 2024 approximated its carrying value. Â Investment and Interest Rate RiskÂ We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flow. As we seek to provide capital to a broad range of life science companies, institutions and investors with the majority of our finance receivables portfolio paying interest based on floating interest rates with a reference rate floor, our net investment income is dependent, in part, upon the difference between the rate at which we earn on our cash and cash equivalents and the rate at which we lend those funds to third parties. As a result, we are subject to risks relating to changes in market interest rates. We may use interest rate risk management techniques in an effort to limit our exposure to interest rate fluctuations by providing capital at variable interest rates. We do not currently engage in any interest rate hedging activities. We constantly monitor our portfolio and position our portfolio to respond appropriately to a reduction in credit rating of any of our investments. We entered into a revolving credit facility. As we borrow funds to make additional investments, our income will depend, in part, upon the difference between the rate at which we borrow funds and the rate at which we invest those funds. As a result, we are subject to risks relating to changes in market interest rates. In periods of rising interest rates when we have debt outstanding, our cost of funds would increase, which could reduce our income, especially to the extent we continue to hold fixed rate investments. We generally seek to mitigate this risk by pricing our debt investments with floating interest rates to maintain the spread of our portfolio over the cost of leverage. If deemed prudent, we may use interest rate risk management techniques in an effort to minimize our

exposure to interest rate fluctuations, which we have not done. Adverse developments resulting from changes in interest rates or hedging transactions could have a materially adverse effect on our business, financial condition and results of operations. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our investment income, net of borrowing expenses. Inflation Â Certain of our partner companies may be impacted by inflation. If such partner companies are unable to pass any increases in their costs along to their customers, it could adversely affect their results and impact their ability to pay interest and principal on our loans. In addition, any projected future decreases in our partner companiesâ€™ operating results due to inflation could adversely impact the fair value of those investments. Any decreases in the fair value of our investments could result in future unrealized losses and therefore reduce carrying value of our net assets. Â ITEMÂ 4.Â Â Â Â Â Â CONTROLS AND PROCEDURES. Â Evaluation of Disclosure Controls and Procedures Â Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. In connection with the preparation of this report, our management, under the supervision and with the participation of the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. Â Changes in Internal Control over Financial ReportingÂ There have been no changes during the three months ended June 30, 2024 in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 38 Â PART II. OTHER INFORMATION Â ITEMÂ 1.Â Â Â Â Â Â LEGAL PROCEEDINGSÂ We are involved in, or have been involved in, arbitrations or various other legal proceedings that arise from the normal course of our business. We cannot predict the timing or outcome of these claims and other proceedings. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material negative impact on our results of operations, balance sheets and cash flows due to defense costs, divert management resources. Currently, we are not involved in any arbitration and/or other legal proceeding that we expect to have a material effect on our business, financial condition, results of operations and cash flows. ITEMÂ 1A.Â Â Â Â RISK FACTORS Information regarding the Companyâ€™s risk factors appears in â€œPart I. â€“ Item 1A. Risk Factorsâ€ of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 20, 2024. There are no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Â ITEM 2.Â Â Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. Â On May 16, 2023, the Company announced that the Board had authorized the Company to repurchase up to $10.0 million of the Companyâ€™s outstanding shares of common stock from time-to-time until May 16, 2024, through a trading plan established in compliance with Rule 10b5-1 and Rule 10b-18 of the Exchange Act (the â€œRepurchase Programâ€). The actual timing, number and value of shares repurchased under the Repurchase Program will depend on several factors, including the constraints specified in the Rule 10b5-1 trading plan, price, and general market conditions. There is no guarantee as to the exact number of shares that will be repurchased under the Repurchase Program. Our Board may also suspend or discontinue the Repurchase Program at any time, in its sole discretion. The purchase period for the Repurchase Program is May 16, 2023 through May 16, 2024. Â The table below summarizes information about our purchases of common stock during the three months ended June 30, 2024: Â PeriodÂ Â Â Â Â Â Â Â Â Total Number of Shares PurchasedÂ Â Â Â Â Average Price Paid per ShareÂ Â Â Â Â Total Number of Shares Purchased as Part of Publicly Announced PlanÂ Â Â Â Â Maximum Approximate Dollar Value of Shares That May Yet Be Purchased Under the PlanÂ April 1, 2024 - April 30, 2024Â Â 15,529Â Â $17.33Â Â Â 15,529Â Â Â 3,304Â May 1, 2024 - May 31, 2024Â Â 33,240Â Â Â 17.51Â Â Â 33,240Â Â Â 2,722Â June 1, 2024 - June 30, 2024Â Â 5,898Â Â Â 16.72Â Â Â 5,898Â Â Â 2,623Â Â Â Â 54,667Â Â $17.19Â Â Â 54,667Â Â Â Â Â Â As of June 30, 2024, the Company has repurchased an aggregate of 439,053 shares under the Repurchase Program at a total cost of $7.4 million, or $16.80 per share. As of June 30, 2024, the maximum dollar value of shares that may yet be purchased under the Repurchase Program was approximately $2.6 million shares of common stock. Â ITEMÂ 3.Â Â Â Â Â Â DEFAULTS UPON SENIOR SECURITIES. Â None. Â ITEMÂ 4.Â Â Â Â Â Â MINE SAFETY DISCLOSURES. Â Not Applicable. Â ITEMÂ 5.Â Â Â Â Â Â OTHER INFORMATION. Â None. 39 Â ITEMÂ 6.Â Â Â Â Â Â EXHIBITS Â Â Â Â Â Â Filing Â Filed Number Â Exhibit Description Â Form Â Exhibit Â Date Â Herewith Â Â Â Â Â Â Â Â Â Â 3.01 Â Third Amended and Restated Certificate of Incorporation, dated as of August 12, 2022. Â 8-K Â 3.1 Â 8/15/22 Â Â Â Â Â Â Â Â Â Â Â Â Â 3.02 Â Amended and Restated Bylaws, dated as of August 12, 2022. Â 8-K Â 3.02 Â 8/15/22 Â Â Â Â Â Â Â Â Â Â Â Â Â 31.01 Â Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â Â 31.02 Â Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Â Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â 32.01 Â Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â 32.02 Â Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.* Â Â Â Â Â Â XÂ Â Â Â Â Â Â Â Â Â Â 101.INS+ Â XBRL Instance Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â Â 101.SCH+ Â XBRL Taxonomy Extension Schema Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â Â 101.CAL+ Â XBRL Taxonomy Extension Calculation Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â 101.DEF+ Â XBRL Taxonomy Extension Definition Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â 101.LAB+ Â XBRL Taxonomy Extension Labels Â Â Â Â Â Â X Â Â Â Â Â Â Â Â Â Â 101.PRE+ Â XBRL Taxonomy Extension Presentation Â Â Â Â Â Â X Â *These certifications accompany this Quarterly Report on Form 10-Q. They are not deemed â€œfiledâ€ with the Securities and Exchange Commission and are not to be incorporated by reference in any filing of SWK Holdings Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. Â +XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. Â 40 Â SIGNATURES Pursuant to the requirements of SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on AugustÂ 14, 2024. Â SWK Holdings Corporation Â Â Â Â By: /s/ Joe D. Staggs Â Â Joe D. Staggs Â Â Chief Executive Officer Â Â (Principal Executive Officer) Â Â Â By:Â /s/ Adam Rice Â Â Adam Rice Â Â Chief Financial Officer Â Â (Principal Financial and Accounting Officer) 41 EX-31.1 2 e24328_ex31-1.htm Â EXHIBIT 31.1 CERTIFICATION Â I, Joe D. Staggs, Principal Executive Officer and of the registrant, certify that: Â 1. I have reviewed this Quarterly Report on FormÂ 10-Q of SWK Holdings Corporation; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 Â /s/ Joe D. Staggs Â Â Â Â Joe D. Staggs Â Â Â Â Principal Executive Officer Â Â EX-31.2 3 e24328_ex31-2.htm Â EXHIBIT 31.2 CERTIFICATION Â I, Adam Rice, Principal Financial & Accounting Officer and of the registrant, certify that: Â 1. I have reviewed this Quarterly Report on FormÂ 10-Q of SWK Holdings Corporation; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an Annual Report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: August 14, 2024 Â /s/ Adam Rice Â Â Â Â Adam Rice Â Â Â Â Principal Financial and Accounting Officer Â Â EX-32.1 4 e24328_ex32-1.htm Â EXHIBIT 32.1 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350 Â In connection with the Quarterly Report of SWK Holdings Corporation (the â€œRegistrantâ€) on FormÂ 10-Q for the quarterly period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Joe D. Staggs, Principal Executive Officer of the Registrant, certify, in accordance with RuleÂ 13a-14(b) of the Securities Exchange Act of 1934 and 18Â U.S.C. SectionÂ 1350, that to the best of my knowledge: Â (1)Â The Report, to which this certification is attached as ExhibitÂ 32.01, fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2)Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. Â Date: August 14, 2024 Â /s/ Joe D. Staggs Â Â Â Â Joe D. Staggs Â Â Â Â Principal Executive Officer Â Â EX-32.2 5 e24328_ex32-2.htm Â EXHIBIT 32.2 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF THE SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350 Â In connection with the Quarterly Report of SWK Holdings Corporation (the â€œRegistrantâ€) on FormÂ 10-Q for the quarterly period ended June 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Adam Rice, Principal Financial and Accounting Officer of the Registrant, certify, in accordance with RuleÂ 13a-14(b) of the Securities Exchange Act of 1934 and 18Â U.S.C. SectionÂ 1350, that to the best of my knowledge: Â (1)Â The Report, to which this certification is attached as ExhibitÂ 32.01, fully complies with the requirements of SectionÂ 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2)Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. Â Date: August 14, 2024 Â /s/ Adam Rice Â Â Â Â Adam Rice Â Â Â Â Principal Financial and Accounting Officer Â GRAPHIC 6 e24328001.jpg GRAPHIC begin 644 e24328001.jpg
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end EX-101.SCH 7 swkh-20240630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink

link:calculationLink link:definitionLink 00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Finance Receivables link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Finance Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Net Income per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Net Income per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Finance Receivables, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Finance Receivables, Net (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Finance Receivables, Net (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Finance Receivables, Net (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Finance Receivables (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Debt (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Commitments and Contingencies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Fair Value Measurements (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Fair Value Measurements (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Fair Value Measurements (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Revenue Recognition (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Segment Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 swkh-20240630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 swkh-20240630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 swkh-20240630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock Par Value 0. 001 Per Share [Member] Sec 9. 00 Senior Notes Due 2027 [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Revision of Prior Period [Axis] Previously Reported [Member] Revision of Prior Period, Adjustment [Member] Receivable Type [Axis] Life Science Term Loans [Member] Life Science Royalty Purchases [Member] Financial Instrument Performance Status [Axis] Nonperforming Financial Instruments [Member] Performing Financial Instruments [Member] Related and Nonrelated Parties [Axis] Trio Healthcare Ltd [Member] Exeevo Inc [Member] Flowonix Medical Inc [Member] Best Royalty [Member] Ideal Implant Inc [Member] Internal Credit Assessment [Axis] Pass [Member] Special Mention [Member] Substandard [Member] Doubtful [Member] Unlikely to be Collected Financing Receivable [Member] Indefinite-Lived Intangible Assets [Axis] Trademarks and Trade Names [Member] Customer Relationships [Member] Licensing Agreements [Member] Short-Term Debt, Type [Axis] Line of Credit [Member] Entity Addresses, Address Type [Axis] Dallas Texas Office [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Derivative Instrument [Axis] Warrant [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Weighted Average [Member] Median [Member] Fair Value, Nonrecurring [Member] Measurement Basis [Axis] Reported Value Measurement [Member] Estimate of Fair Value Measurement [Member] Financing Receivable Portfolio Segment [Axis] Pharmaceutical Development Services [Member] Financing Receivable [Member] Holding Company And Other [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets: Current assets: Cash and cash equivalents Restricted cash Interest, accounts receivable and other receivables, net Other current assets Total current assets Finance receivables, net of allowance for credit losses of $13,083 and $13,901 as of June 30, 2024 and DecemberÂ 31, 2023, respectively Collateral on foreign currency forward contract Marketable investments Deferred tax assets, net Warrant assets Intangible assets, net Property and equipment, net Other non-current assets Total assets Liabilities and Stockholdersâ€™ Equity: Current liabilities: Accounts payable and accrued liabilities Deferred income Total current liabilities Contingent consideration payable Unsecured senior notes, net Revolving credit facility Other non-current liabilities Total liabilities Commitments and contingencies (Note 6) Stockholdersâ€™ equity: Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Common stock, $0.001 par value; 250,000,000 shares authorized; 12,447,195 and 12,497,770 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholdersâ€™ equity Total liabilities and stockholdersâ€™ equity Financing Receivable, Allowance for Credit Loss Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenues: Finance receivable interest income, including fees Pharmaceutical development Other Total revenues Costs and expenses: Provision (benefit) for credit losses Loss on impairment of intangibles assets Interest expense Pharmaceutical manufacturing, research and development expense Change in fair value of acquisition-related contingent consideration Depreciation and amortization expense General and administrative expense Income from operations Other income (expense), net Unrealized net gain (loss) on warrants Net realized gain on sale of marketable investments Realized gain (loss) on sale of assets Gain on revaluation of finance receivable Realized and unrealized foreign currency transaction gains Income before income tax expense Income tax expense Net income Net income per share Basic Diluted Basic Diluted Beginning balance, value Beginning Balance, Shares Stock-based compensation Forfeiture of unvested restricted stock, Shares Issuance of common stock upon vesting of restricted stock Issuance of common stock upon vesting of restricted stock, Shares Repurchase of common stock in open market Repurchases of common stock in open market, Shares Net income Net settlement for employee taxes on stock options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Effect of adoption of ASU 2016-13 Ending balance, value Ending Balance, Shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income Adjustments to reconcile net income to net cash provided by operating activities: Loss on impairment of intangible assets Right-of-use amortization and cease use costs Amortization of debt issuance costs Deferred income taxes, net Net change in fair value of warrant assets Net realized gain on exercise of warrants Realized loss from sale of assets Gain on revaluation of finance receivable Foreign currency transaction gain Loan discount amortization and fee accretion Interest paid-in-kind Depreciation and amortization expense Changes in operating assets and liabilities: Interest, accounts receivable and other receivables Other assets Accounts payable, accrued expenses, and other non-current liabilities Deferred income Net cash provided by operating activities Cash flows from investing activities: Sale of finance receivables Sale of marketable investments Investment in finance receivables Repayment of finance receivables Corporate debt securities principal payments Purchases of property and equipment Net cash provided by investing activities Cash flows from financing activities: Net payments on credit facility Payments for financing costs Repurchases of common stock, including fees and expenses Net cash used in financing activities Net increase in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Supplemental non-cash investing and financing activities: Derecognition of right-of-use assets and operating lease liabilities upon termination of lease Organization, Consolidation and Presentation of Financial Statements [Abstract] SWK Holdings Corporation and Summary of Significant Accounting Policies Earnings Per Share [Abstract] Net Income per Share Receivables [Abstract] Finance Receivables Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Debt Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Fair Value Disclosures [Abstract] Fair Value Measurements Revenue from Contract with Customer [Abstract] Revenue Recognition Segment Reporting [Abstract] Segment Information Subsequent Events [Abstract] Subsequent Events Nature of Operations Basis of Presentation and Principles of Consolidation Unaudited Interim Financial Information Use of Estimates Segment Information Revenue Recognition Correction of an Error in Previously Issued Unaudited Condensed Financial Statements Research and Development Recent Accounting Pronouncements Schedule of Revisions to the line items of our previously issued financial statements Schedule of Basic and Diluted Earning per Share Schedule of carrying value of finance receivables Schedule of Allowance for Credit Losses Schedule of Allowance for Credit Losses Schedule of Financing Receivable by origination year Schedule of Intangible Assets Schedule of Intangible Asset Amortization Expense Schedule of Long Term Debt Schedule of Maturities of Long Term Notes Schedule of Lease Cost Schedule of Future Minimum Rent Schedule of fair value assets measured on recurring basis Schedule of fair value assets measured on recurring basis unobservable input reconciliation Schedule of weighted average assumptions Schedule of weighted average assumptions Schedule of fair value by balance sheet grouping Schedule of Revenue Recognized by Revenue Source Schedule of Company's Contract Liabilities Schedule of Reportable Revenue by Geographic Region Total revenues Basic net income per share Diluted net income per share Finance receivables, net of allowance for credit Total assets Accumulated deficit Number of Operating Segments Weighted-average shares outstanding Effect of dilutive securities Weighted-average diluted shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Accounts and Financing Receivables [Table] Accounts, Notes, Loans and Financing Receivable [Line Items] Total before allowance for credit losses Allowance for credit losses Total carrying value Allowance at beginning of period Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest Provision (benefit) for credit losses Write offs Allowance at end of period Financing Receivable, Credit Quality Indicator [Table] Financing Receivable, Credit Quality Indicator [Line Items] Royalty purchases Total carrying value Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss Defined Benefit Plan [Table] Defined Benefit Plan Disclosure [Line Items] Loans and Leases Receivable, Gross Intangible Asset, Indefinite-Lived [Table] Indefinite-Lived Intangible Assets [Line Items] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Finite-Lived Intangible Assets, Accumulated Amortization Intangible Assets, Current Finite-Lived Intangible Asset, Useful Life Remainder of 2024 2025 2026 2027 2028 Thereafter Total Amortization of Intangible Assets 2027 Senior Notes Debt issuance costs Total unsecured senior notes, net Remainder of 2024 2025 2026 2027 Total unsecured senior notes, net Short-Term Debt [Table] Short-Term Debt [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Interest Expense, Operating and Nonoperating Operating lease cost Variable lease cost Total lease cost Remainder of 2024 2025 2026 2027 2028 Thereafter Total future lease payments Entity Addresses [Table] Entity Addresses [Line Items] Operating Leases, Rent Expense Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial Assets Marketable investments Foreign currency forward contract Financial liabilities: Fair value - December 31, 2023 Issued Exercised Change in fair value Loss on foreign currency transactions Fair value - June 30, 2024 Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate December 31, 2023 Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Assets Finance receivables, net Financial liabilities Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Financing Receivable, Past Due [Table] Financing Receivable, Past Due [Line Items] Pharmaceutical Development Total contract revenue Deferred income Total contract liabilities Revenue Other revenue Provision for credit losses Loss on impairment intangible assets Other expense, net Net income (loss) Benefit for credit losses Number of Reportable Segments Marketable Investment Principal Payment. Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Costs and Expenses Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Shares, Outstanding Stock Repurchased During Period, Value Paid-in-Kind Interest Depreciation, Depletion and Amortization Increase (Decrease) in Other Operating Assets Deferred Income, Period Increase (Decrease) Payments to Acquire Finance Receivables Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments of Financing Costs Payments for Repurchase of Common Stock Net Cash Provided by (Used in) Financing Activities Cash, Cash

Equivalents, Restricted Cash, and Restricted Cash Equivalents Segment Reporting, Policy [Policy Text Block] Revenue [Policy Text Block] Financing Receivable, Nonaccrual [Table Text Block] Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block] Provision for Loan, Lease, and Other Losses Financing Receivable, Allowance for Credit Loss, Writeoff Finite-Lived Intangible Assets, Net Debt Issuance Costs, Net Long-Term Debt, Maturity, Year One Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Lease, Cost Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid, Year Four Lessee, Operating Lease, Liability, to be Paid, Year Five Lessee, Operating Lease, Liability, to be Paid, after Year Five Lessee, Operating Lease, Liability, to be Paid Deferred Revenue EX-101.PRE 11 swkh-20240630_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Cover - shares 6 Months Ended Jun. 30, 2024 Aug. 08, 2024 Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Jun. 30, 2024 Â Document Fiscal Period Focus Q2 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity File Number 001-39184 Â Entity Registrant Name SWK Holdings Corporation Â Entity Central Index Key 0001089907 Â Entity Tax Identification Number 77-0435679 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 5956 Sherry Lane Â Entity Address, Address Line Two Suite 650 Â Entity Address, City or Town Dallas Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 75225 Â City Area Code (972) Â Local Phone Number 687-7250 Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 12,361,850 Common Stock Par Value 0. 001 Per Share [Member] Â Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol SWKH Â Security Exchange Name NASDAQ Â Sec 9. 00 Senior Notes Due 2027 [Member] Â Â Title of 12(b) Security 9.00% Senior Notes due 2027 Â Trading Symbol SWKHL Â Security Exchange Name NASDAQ Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=swkh_CommonStockParValue0.001PerShareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=swkh_Sec9.00SeniorNotesDue2027Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 5,549 $ 4,503 Restricted cash 733 Interest, accounts receivable and other receivables, net 7,384 4,729 Other current assets 1,859 1,904 Total current assets 14,792 11,869 Finance receivables, net of allowance for credit losses of $13,083 and $13,901 as of June 30, 2024 and DecemberÂ 31, 2023, respectively 265,470 274,504 Collateral on foreign currency forward contract 2,750 2,750 Marketable investments 731 48 Deferred tax assets, net 27,052 28,290 Warrant assets 835 1,759 Intangible assets, net 232 6,487 Property and equipment, net 5,008 5,438 Other non-current assets 4,504 3,109 Total assets 321,374 334,254 Current liabilities: Â Â Accounts payable and accrued liabilities 3,310 3,935 Deferred income 2,216 9 Total current liabilities 5,526 3,944 Contingent consideration payable 4,900 Unsecured senior notes, net 31,078 30,781 Revolving credit facility 12,350 Other non-current liabilities 1,566 1,964 Total liabilities 38,170 53,939 Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Common stock, $0.001 par value; 250,000,000 shares authorized; 12,447,195 and 12,497,770 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 12 12 Additional paid-in capital 4,423,472 4,425,104 Accumulated deficit (4,140,280) (4,144,801) Total stockholdersâ€™ equity 283,204 280,315 Total liabilities and stockholdersâ€™ equity $ 321,374 $ 334,254 X - ReferencesNo definition available. + Details Name: swkh_WarrantAssets Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_AccountsReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of contingent consideration in a business combination that is classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2 + Details Name: us-gaap_DeferredIncomeCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the asset arising from derivative instruments and hedging activities, which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DerivativeInstrumentsAndHedges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-

S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-14 + Details Name: us-gaap_LongTermLineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478600/954-210-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashEquivalentsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_UnsecuredDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Financing Receivable, Allowance for Credit Loss $ 13,083 $ 13,901 Preferred Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 Preferred Stock, Shares Authorized 5,000,000 5,000,000 Preferred Stock, Shares Issued 0 0 Preferred Stock, Shares Outstanding 0 0 Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001 Common Stock, Shares Authorized 250,000,000 250,000,000 Common Stock, Shares, Issued 12,447,195 12,497,770 Common Stock, Shares, Outstanding 12,447,195 12,497,770 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph c -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (3) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenues: Â Â Â Â Finance receivable interest income, including fees $ 10,680 $ 9,278 $ 21,399 $ 18,538 Pharmaceutical development 804 183 1,083 301 Other 57 36 103 69 Total revenues 11,541 9,497 22,585 18,908 Costs and expenses: Â Â Â Â Provision (benefit) for credit losses 4,074 (682) 9,397 (682) Loss on impairment of intangibles assets 5,771 5,771 Interest expense 1,119 363 2,375 545 Pharmaceutical manufacturing, research and

development expense 520 1,509 1,050 2,228 Change in fair value of acquisition-related contingent consideration (4,900) (4,900) Depreciation and amortization expense 421 637 935 1,285 General and administrative expense 2,923 2,997 5,607 5,537 Income from operations 1,613 4,673 2,350 9,995 Other income (expense), net Â Â Â Â Unrealized net gain (loss) on warrants 226 399 131 (583) Net realized gain on sale of marketable investments 656 513 Realized gain (loss) on sale of assets 3 (228) Gain on revaluation of finance receivable 2,495 2,495 Realized and unrealized foreign currency transaction gains 437 316 524 502 Income before income tax expense 5,430 5,388 5,785 9,914 Income tax expense 1,035 1,454 1,264 1,345 Net income $ 4,395 $ 3,934 $ 4,521 $ 8,569 Net income per share Â Â Â Â Basic $ 0.35 $ 0.31 $ 0.36 $ 0.67 Diluted $ 0.35 $ 0.31 $ 0.36 $ 0.67 Basic 12,457,000 12,741,000 12,466,000 12,787,000 Diluted 12,528,000 12,785,000 12,534,000 12,830,000 X - ReferencesNo definition available. + Details Name: swkh_ChangeInFairValueOfAcquisitionrelatedContingentConsideration Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NetRealizedGainOnExerciseOfWarrants Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_PharmaceuticalDevelopmentRevenue Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1 + Details Name: us-gaap_ForeignCurrencyTransactionGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -

SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestAndFeeIncomeLoansAndLeases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InterestAndOtherIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense related to credit loss from transactions other than loan and lease transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForOtherCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)(e)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomerOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A + Details Name: us-gaap_UnrealizedGainLossOnDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Beginning balance, value at Dec. 31, 2022 $ 12 $ 4,430,922 $ (4,151,005) $ 279,929 Beginning Balance, Shares at Dec. 31, 2022 12,843,157 Â Â Â Stock-based compensation 35 35 Issuance of common stock upon vesting of restricted stock Issuance of common stock upon vesting of restricted stock, Shares 16,008 Â Â Â Repurchase of common stock in open market (531) (531) Repurchases of common stock in open market, Shares (28,766) Â Â Â Net income 4,635 4,635 Effect of adoption of ASU 2016-13 (9,683) (9,683) Ending balance, value at Mar. 31, 2023 $ 12 4,430,426 (4,156,053) 274,385 Ending Balance, Shares at Mar. 31, 2023 12,830,399 Â Â Â Beginning balance, value at Dec. 31, 2022 $ 12 4,430,922 (4,151,005) 279,929 Beginning Balance, Shares at Dec. 31, 2022 12,843,157 Â Â Â Stock-based compensation Â Â Â 199 Net settlement for employee taxes on stock options Â Â Â Ending balance, value at Jun. 30, 2023 $ 12 4,425,991 (4,152,119) 273,884 Ending Balance, Shares at Jun. 30, 2023 12,566,519 Â Â Â Beginning balance, value at Mar. 31, 2023 $ 12 4,430,426 (4,156,053) 274,385 Beginning Balance, Shares at Mar. 31, 2023 12,830,399 Â Â Â Stock-based compensation 164 164 Issuance of common stock upon vesting of restricted stock Issuance of common stock upon vesting of restricted stock, Shares 8,612 Â Â Â Repurchase of common stock in open market (4,599) (4,599) Repurchases of common stock in open market, Shares (272,492) Â Â Â Net income 3,934 3,934 Ending balance, value at Jun. 30, 2023 $ 12 4,425,991 (4,152,119) 273,884 Ending Balance, Shares at Jun. 30, 2023 12,566,519 Â Â Â Beginning balance, value at Dec. 31, 2023 $ 12 4,425,104 (4,144,801) 280,315 Beginning Balance, Shares at Dec. 31, 2023 12,497,770 Â Â Â Stock-based compensation 111 111 Forfeiture of unvested restricted stock, Shares (6,446) Â Â Â Issuance of common stock upon vesting of restricted stock Issuance of common stock upon vesting of restricted stock, Shares 48,918 Â Â Â Repurchase of common stock in open market (999) (999) Repurchases of common stock in open market, Shares (58,298) Â Â Â Net income 126 126 Ending balance, value at Mar. 31, 2024 $ 12 4,424,216 (4,144,675) 279,553 Ending Balance, Shares at Mar. 31, 2024 12,481,944 Â Â Â Beginning balance, value at Dec. 31, 2023 $ 12 4,425,104 (4,144,801) 280,315 Beginning Balance, Shares at Dec. 31, 2023 12,497,770 Â Â Â Stock-based compensation Â Â Â 360 Net settlement for employee taxes on stock options Â Â Â (43) Ending balance, value at Jun. 30, 2024 $ 12 4,423,472 (4,140,280) 283,204 Ending Balance, Shares at Jun. 30, 2024 12,447,195 Â Â Â Beginning balance, value at Mar. 31, 2024 $ 12 4,424,216 (4,144,675) 279,553 Beginning Balance, Shares at Mar. 31, 2024 12,481,944 Â Â Â Stock-based compensation 249 249 Forfeiture of unvested restricted stock, Shares 17,323 Â Â Â Repurchase of common stock in open market (950) (950) Repurchases of common stock in open market, Shares (54,667) Â Â Â Net income 4,395 4,395 Net settlement for employee taxes on stock options (43) (43) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period 2,595 Â Â Â Ending balance, value at Jun. 30, 2024 $ 12 $ 4,423,472 $ (4,140,280) $ 283,204 Ending Balance, Shares at Jun. 30, 2024 12,447,195 Â Â Â X - ReferencesNo definition available. + Details Name: swkh_EffectOfAdoptionOfAccountingStandard Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued which are

neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares related to Restricted Stock Award forfeited during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.2.u1 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities: Â Â Â Â Net income $ 4,395 $ 3,934 $ 4,521 $ 8,569 Adjustments to reconcile net income to net cash provided by operating activities: Â Â Â Â Provision (benefit) for credit losses 4,074 (682) 9,397 (682) Loss on impairment of intangible assets 5,771 5,771 Right-of-use amortization and cease use costs Â Â 261 156 Amortization of debt issuance costs Â Â 491 168 Deferred income taxes, net Â Â 1,239 1,316 Net change in fair value of warrant assets (226) (399) (131) 583 Net realized gain on exercise of warrants (656) (513) Realized loss from sale of assets (3) 228 Change in fair value of acquisition-related contingent consideration (4,900) (4,900) Gain on revaluation of finance receivable (2,495) (2,495) Foreign currency transaction gain Â Â (327) (516) Loan discount amortization and fee accretion Â Â (2,592) (2,297) Interest paid-in-kind Â Â (904) (957) Stock-based compensation 249 164 360 199 Depreciation and amortization expense Â Â 935 1,285 Changes in operating assets and liabilities: Â Â Â Â Interest, accounts receivable and other receivables Â Â (2,655) (1,287) Other assets Â Â (150) (792) Accounts payable, accrued expenses, and other non-current liabilities Â Â (900) (354) Deferred income Â Â 2,207 (3) Net cash provided by operating activities Â Â 9,843 5,388 Cash flows from investing activities: Â Â Â Â Sale of finance receivables Â Â 13,942 Sale of marketable investments Â Â 574 Investment in finance receivables Â Â (7,446) (13,101) Repayment of finance receivables Â Â 11,693 3,041 Corporate debt securities principal payments Â Â 13 17 Purchases of property and equipment Â Â (21) (191) Net cash provided by investing activities Â Â 4,813 3,708 Cash flows from financing activities: Â Â Â Â Net settlement for employee taxes on stock options (43) Â (43) Net payments on credit facility Â Â (12,350) (2,445) Payments for financing costs Â Â (872) Repurchases of common stock, including fees and expenses Â Â (1,950) (5,130) Net cash used in financing activities Â Â (14,343) (8,447) Net increase in cash, cash equivalents, and restricted cash Â Â 313 649 Cash, cash equivalents, and restricted cash at beginning of period Â Â 5,236 6,156 Cash, cash equivalents, and restricted cash at end of period $ 5,549 $ 6,805 5,549 6,805 Derecognition of right-of-use assets and operating lease liabilities upon termination of lease Â Â $ 82 X - ReferencesNo definition available. + Details Name: swkh_ChangeInFairValueOfAcquisitionrelatedContingentConsideration Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_DerecognitionOfRouAssetsToOperatingLeaseLiabilitiesUponTerminationOfLease Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMarketable Investment Principal Payment. + ReferencesNo definition available. + Details Name: swkh_MarketableInvestmentPrincipalPayment Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NetRealizedGainOnExerciseOfWarrants Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NoncashInterestExpense Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_ProceedsRepaymentOfFinanceReceivables Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481655/310-20-35-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AmortizationOfDeferredLoanOriginationFeesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to,

short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B + Details Name: us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in deferred income not accounted for under Topic 606. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 + Details Name: us-gaap_DeferredIncomePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization expense attributable to right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInterest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_PaidInKindInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireFinanceReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromRepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic

805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense related to credit loss from transactions other than loan and lease transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForOtherCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A + Details Name: us-gaap_UnrealizedGainLossOnDerivatives Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SWK Holdings Corporation and Summary of Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â SWK Holdings Corporation and Summary of Significant Accounting Policies Note 1. SWK Holdings Corporation and Summary of Significant Accounting PoliciesÂ Nature of Operations Â SWK Holdings Corporation (the â€œCompany,â€ â€œwe,â€ or â€œusâ€) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: â€œFinance Receivablesâ€ and â€œPharmaceutical Development.â€ We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, â€œlife sciencesâ€). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of June 30, 2024, the Company had 22 full-time employees. The Company has net operating loss carryforwards (â€œNOLsâ€) and believes that the ability to utilize these NOLs is an important and substantial asset. As of AugustÂ 8, 2024, the Company and its partners have executed transactions with 56 different parties under its specialty finance strategy, funding an aggregate of $779.8 million in various financial products across the life science sector. The Companyâ€™s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. Â During 2019, we commenced our Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. (â€œEnterisâ€). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform. We seek to generate income by providing customers pharmaceutical development, formulation and manufacturing services as well as licensing its internally developed intellectual property. With an effective date of April 21, 2023 we entered into a collaboration agreement with a strategic partner under which we would be the exclusive provider of certain contract development and manufacturing organization (â€œCDMOâ€) services to its customers. Fee revenue generated as a result of this agreement is presented as pharmaceutical development revenue on the unaudited condensed consolidated statement of income and is accounted for in accordance with our revenue recognition policy as described under Revenue Recognition below. With an effective date of January 1, 2024, we entered into an Option and Asset Purchase Agreement with the same strategic partner on March 14, 2024, which granted the partner an exclusive option to acquire certain of Enterisâ€™ assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The partner must exercise the option by or before January 1, 2026. Basis of Presentation and Principles of ConsolidationÂ The Companyâ€™s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (â€œVIEâ€) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control. Even though the Companyâ€™s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Companyâ€™s consolidated financial statements, it would have no effect on its operations and/or total stockholdersâ€™ equity attributable to the Company. Â Unaudited Interim Financial InformationÂ The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (â€œSECâ€). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024. Use of EstimatesÂ The preparation of the Companyâ€™s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Companyâ€™s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. Â The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Companyâ€™s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Companyâ€™s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Â Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies (â€œFinance Receivable segmentâ€), and its business offering CDMO services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform (â€œPharmaceutical Development segmentâ€). Revenue Recognition Â The Companyâ€™s Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop,

manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Â Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets. Â Correction of an Error in Previously Issued Unaudited Condensed Financial Statements Â During the quarter ended June 30, 2024, the Company identified an error related to the recognition of a holdback liability for a royalty which was incorrectly recorded into revenue. This error affected the consolidated financial statements for the quarter ended March 31, 2024 and was determined to be immaterial to the prior periodâ€™s unaudited condensed consolidated financial statements and did not warrant restatement and reissuance of the previously issued unaudited condensed consolidated financial statements. However, the Company recorded a correction to the prior quarter ended March 31, 2024 and the financial statements will be revised the next time they are presented as comparative information in future filings. The Company based their qualitative and quantitative analysis on SEC Staffâ€™s Accounting Bulletins Topic 1.M, â€œMateriality and Topic 1.N, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements.â€ Â The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands): Â Schedule of Revisions to the line items of our previously issued financial statements Three Months Ended March 31, 2024Â As ReportedÂ AdjustmentÂ As Revised Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivable interest income, including feesÂ $11,454Â Â $(735)Â $10,719Â Pharmaceutical developmentÂ Â 279Â Â Â â€”Â Â Â 279Â OtherÂ Â 46Â Â Â â€”Â Â Â 46Â Total revenuesÂ Â 11,779Â Â Â (735)Â Â 11,044Â Net incomeÂ $861Â Â $(735)Â $126Â Basic net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Diluted net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, net of allowance for credit Â Â 261,285Â Â Â (13)Â Â 261,272Â Total assetsÂ $322,350Â Â $(13)Â $322,337Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Â Â Â Â Â Accumulated deficitÂ Â (4,143,940)Â Â (735)Â Â (4,144,675) Total stockholdersâ€™ equityÂ $280,288Â Â $(735)Â $279,553Â Â Â Â Research and Development Â Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the unaudited condensed consolidated statements of income. Recent Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) 2020-04, â€œReference Rate Reform (Topic 848),â€ which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference London Inter-Bank Offered Rate (â€œLIBORâ€) and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Companyâ€™s consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires public entities to disclose information about their reportable segmentsâ€™ significant expenses on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Public entities are required to adopt the changes retrospectively, recasting each prior-period disclosure for which a comparative income statement is presented in the period of adoption. The Company is currently evaluating the impact of this ASU on the Companyâ€™s consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ The standard is intended to provide greater transparency in various income tax components that affect the rate reconciliation based on the applicable taxing jurisdictions, as well as the qualitative and quantitative aspects of those components. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Income per Share 6 Months Ended Jun. 30, 2024 Net income per share Â Net Income per Share Note 2. Net Income per Share Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method. Â The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Â Schedule of Basic and Diluted Earning per Share Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Numerator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net incomeÂ $4,395Â Â $3,934Â Â $4,521Â Â $8,569Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Denominator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstandingÂ Â 12,457Â Â Â 12,741Â Â Â 12,466Â Â Â 12,787Â Effect of dilutive securitiesÂ Â 71Â Â Â 44Â Â Â 68Â Â Â 43Â Weighted-average diluted sharesÂ Â 12,528Â Â Â 12,785Â Â Â 12,534Â Â Â 12,830Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Diluted net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Â For the three months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 159,000 and 118,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. For the six months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 161,000 and 119,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables 6 Months Ended Jun. 30, 2024 Receivables [Abstract] Â Finance Receivables Note 3. Finance Receivables Â Finance receivables are reported at their determined principal balances net of any unearned income, cumulative write offs charged against the allowance for credit losses, and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method. The carrying values of finance receivables were as follows (in thousands): Â Schedule of carrying value of finance receivables Â Â June 30, 2024Â Â December 31, 2023Â Term loansÂ $213,683Â Â $221,145Â Royalty purchasesÂ Â 64,870Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 278,553Â Â Â 288,405Â Allowance for credit lossesÂ Â (13,083)Â Â (13,901) Total carrying valueÂ $265,470Â Â $274,504Â Â Allowance for Credit Losses The allowance for credit loss (â€œACLâ€) is managementâ€™s estimate of the amount of expected credit losses over the life of the loan portfolio, or the amount of amortized cost basis not expected to be collected, at the balance sheet date. This estimate encompasses information about historical events, current conditions and reasonable and supportable economic forecasts. Determining the amount of the ACL is complex and requires extensive judgment by management about matters that are inherently uncertain. Given the current level of economic uncertainty, the complexity of the ACL estimate and level of management judgment required, we believe it is possible that the ACL estimate could change, potentially materially, in future periods. Changes in the ACL may result from changes in current economic conditions, our economic forecast, and circumstances not currently known to us that may impact the financial condition and operations of our borrowers, among other factors. Â Expected credit losses are estimated on a collective basis for groups of loans that share similar risk characteristics. For finance receivables that do not share similar risk characteristics with other finance receivables, expected credit losses are estimated on an individual basis. Expected credit losses are estimated over the contractual terms of the finance receivables, adjusted for expected prepayments and unfunded commitments, generally excluding extensions and modifications. The loan portfolio segment is defined as the level at which an entity develops and documents a systematicÂ method for determining its allowance for credit losses. Â The Company adopted ASU 2016-13, as amended, on January 1, 2023 using the modified retrospective approach method. The implementation of ASU 2016-13 also impacted the Companyâ€™s ACL on unfunded loan commitments, as the ACL now represents expected credit losses over the contractual life of commitments not identified as unconditionally cancellable by the Company. The reserve for unfunded commitments is estimated using the same reserve or coverage rates calculated on collectively evaluated loans following the application of a funding rate to the amount of the unfunded commitment. The funding rate represents managementâ€™s estimate of the amount of the current unfunded commitment that will be funded over the remaining contractual life of the commitment and is based on historical data. On January 1, 2023, the Company recorded an adjustment for unfunded commitments of $0.4 million for the adoption of ASU 2016-13. As of June 30, 2024 the Company has a $0.1 million liability for credit losses on off-balance sheet exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. As of December 31, 2023, the Company recorded a $0.2 million liability for credit losses on off-balance-sheet credit exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. Please refer to Note 6 for further information on the Companyâ€™s unfunded commitments. Allowance for Credit Losses - methodology update for the three months ended June 30, 2024 During the three months ended June 30, 2024, the Company revised its methodology for calculating the allowance for credit losses to be more directly tied to the individual risk ratings, as determined by management, of investments. This resulted in a re-allocation of the existing allowance and did not have a material impact on the total allowance for credit losses amount. Previously, the Companyâ€™s quarterly assessment of the allowance included two portfolio pools: Term Loans and Royalties. After the change in methodology effective for the quarter ended June 30, 2024, these pools are further broken down into individual risk ratings applied to each investment to allow for a more precise method for calculating the allowance for credit losses. Â The following table details the changes in the allowance for credit losses by Term Loans and Royalties (in thousands): Â Schedule of Allowance for Credit LossesÂ Â Â Six Months Ended June 30, 2024Â Â Six Months Ended June 30, 2023Â Â Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Allowance at beginning of periodÂ $9,731Â Â $4,170Â Â $13,901Â Â $â€”Â Â $11,846Â Â $11,846Â Effect of adoption of ASU 2016-13Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 8,900Â Â Â 2,886Â Â Â 11,786Â Provision (benefit) for credit lossesÂ Â 5,055Â Â Â 127Â Â Â 5,182Â Â Â (572)Â Â (110)Â Â (682) Write offsÂ Â (6,000)Â Â â€”Â Â Â (6,000)Â Â â€”Â Â Â (11,846) (1) Â (11,846) Allowance at end of periodÂ $8,786Â Â $4,297Â Â $13,083Â Â $8,328Â Â $2,776Â Â $11,104Â Â (1)Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023. Non-Accrual Finance Receivables The Company originates finance receivables to companies primarily in the life sciences sector. This concentration of credit exposes the Company to a higher degree of risk associated with this sector. Â On a quarterly basis, the Company evaluates the carrying value of its finance receivables. Recognition of income is suspended, and the finance receivable is placed on non-accrual status when management determines that collection of future income is not probable. This evaluation is generally based on delinquency information, an assessment of the borrowerâ€™s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement. The following table presents nonaccrual and performing finance receivables by portfolio pool, net of allowance for credit losses (in thousands) as of: Schedule of Allowance for Credit Losses Â Â June 30, 2024Â Â December 31, 2023Â Â Â NonaccrualÂ Â PerformingÂ Â TotalÂ Â NonaccrualÂ Â PerformingÂ Â TotalÂ Term loansÂ $6,010Â Â $207,673Â Â $213,683Â Â $9,128Â Â $212,017Â Â $221,145Â Royalty purchasesÂ Â 16,434Â Â Â 48,436Â Â Â 64,870Â Â Â 16,854Â Â Â 50,406Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 22,444Â Â Â 256,109Â Â Â 278,553Â Â Â 25,982Â Â Â 262,423Â Â Â 288,405Â Allowance for credit lossesÂ Â (3,368)Â Â (9,715)Â Â (13,083)Â Â (1,447)Â Â (12,454)Â Â (13,901) Total carrying valueÂ $19,076Â Â $246,394Â Â $265,470Â Â $24,535Â Â $249,969Â Â $274,504Â Â As of June 30, 2024, the Company had five finance receivables in nonaccrual status: (1) the term loan to Trio Healthcare Ltd. (â€œTrioâ€), with a carrying value of $1.5 million; (2) the term loan to Exeevo, Inc (â€œExeevoâ€), with a carrying value of $4.5 million; (3) the Flowonix Medical, Inc. (â€œFlowonixâ€) royalty, with a carrying value of $10.4 million (see Loan Modifications Made to Borrowers Experiencing Financial Difficulty below for further details); (4) the Best ABT, Inc. (â€œBestâ€) royalty, with a carrying value of $2.4 million; and (5) the Ideal Implant, Inc. (â€œIdealâ€) royalty, with a carrying value of $3.6 million. As of June 30, 2024 Trio was considered impaired by $8.1 million and Exeevo was impaired by $2.2 million with the impairments recognized as a reduction in the allowance for credit losses on the unaudited condensed consolidated statements of income for the six months ended June 30, 2024. The Company collected $0.7 million and $0.2 million on its nonaccrual finance receivables for the six months ended June 30, 2024 and 2023, respectively. Â Loan Modifications Made to Borrowers Experiencing Financial Difficulty Â Effective January 1, 2023, the Company adopted the provisions of ASU 2022-02 â€œTroubled Debt Restructuring (â€œTDRsâ€) and Vintage Disclosures (Topic 326)â€, which eliminated the accounting for TDRs while expanding loan modification and vintage disclosure requirements. The update specifically required additional disclosures on loan modifications to borrowers experiencing financial difficulties that involved an interest rate reduction, other-than-insignificant payment delay, a term extension, principal forgiveness or a combination thereof. Â The Company evaluates the carrying value of each finance receivable for impairment. A term loan is considered to be impaired when, based on current information and events, it is determined that the Company will not be able to collect the amounts due according to the loan contract, including scheduled interest payments. This evaluation is generally based on delinquency information, an assessment of the borrowerâ€™s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes

uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement and collectability of remaining principal and interest is no longer doubtful. In certain circumstances, the Company may place a finance receivable on nonaccrual status but conclude it is not impaired. The Company may retain independent third-party valuations on such nonaccrual positions to support impairment decisions. On an ongoing basis, the Company monitors the performance of modified loans to their restructured terms. Revaluation of Finance Receivable Â During the three months ended June 30, 2024, the Company revalued its royalty for Iluvien as a result of entering into an amendment during the quarter. Pursuant to the amendment, the forecast of cash flows to be received over the life of the financial royalty was revised resulting in a revaluation gain of $2.5 million and corresponding mark-up to the carrying value which is included in the â€œGain on revaluation of finance receivableâ€ caption on our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Credit Quality of Finance Receivables Â The Company evaluates all finance receivables on a quarterly basis and assigns a risk rating based upon managementâ€™s assessment of the borrowerâ€™s ability and likelihood of repayment. The assessment is subjective and based on multiple factors, including but not limited to, financial strength of borrowers and operating results of the underlying business. The credit risk analysis and rating assignment is performed quarterly in conjunction with the Companyâ€™s assessment of its allowance for credit losses. The Company uses the following definitions for its risk ratings for Term Loans: Â 1: Borrower performing well below Company expectations, and the borrowerâ€™s ability to raise sufficient capital to operate its business or repay debt is highly in question. Finance receivables rated a 1 are on non-accrual and are at an elevated risk for principal impairment. 2: Borrower performing below plan, and the loan-to-value is generally worse than at the time of underwriting. Borrower has limited access to additional capital to operate its business. Finance receivables rated a 2 are generally on non-accrual, and while no loss of impairment is anticipated, there is potential for future principal impairment. 3: Borrower performing in-line-to-modestly below Company expectations, and loan-to-value is similar to slightly worse than at the time of underwriting. Borrower has demonstrated access to capital markets. 4: Borrower performing in-line-to-modestly above Company expectations and loan-to-value similar or modestly better than underwriting case. Borrower has demonstrated access to capital markets. 5: Borrower performing in excess of Company expectations, and loan-to-value is better than at time of origination. The Company uses an internal credit rating system which rates each Royalty on a color scale of Green to Red, with Green typically indicative of a Royalty that is exceeding base underwritten case, Yellow indicates a Royalty performing in-line with underwritten plan, and Red reflective of underperformance relative to plan. The following table summarizes the carrying value of Finance Receivables by origination year, grouped by risk rating as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of Financing Receivable by origination year Â Â June 30, 2024Â Â Â 2023Â Â 2022Â Â 2021Â Â 2020Â Â 2019Â Â PriorÂ Â TotalÂ Term LoansÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5Â $â€”Â Â $â€”Â Â $13,835Â Â $â€”Â Â $4,991Â Â $â€”Â Â $18,826Â 4Â Â 31,108Â Â Â 57,988Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 9,328Â Â Â 98,424Â 3Â Â 24,604Â Â Â â€”Â Â Â 10,718Â Â Â â€”Â Â Â 29,154Â Â Â â€”Â Â Â 64,476Â 2Â Â â€”Â Â Â â€”Â Â Â 12,601Â Â Â â€”Â Â Â â€”Â Â Â 13,346Â Â Â 25,947Â 1Â Â â€”Â Â Â 4,538Â Â Â 1,472Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 6,010Â Subtotal - Term LoansÂ $55,712Â Â $62,526Â Â $38,626Â Â $â€”Â Â $34,145Â Â $22,674Â Â $213,683Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RoyaltiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GreenÂ $12,110Â Â $11,985Â Â $â€”Â Â $16,595Â Â $â€”Â Â $1,297Â Â $41,987Â YellowÂ Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 3,087Â Â Â â€”Â Â Â 3,362Â Â Â 6,449Â RedÂ Â â€”Â Â Â â€”Â Â Â 3,564Â Â Â 10,433Â Â Â â€”Â Â Â 2,437Â Â Â 16,434Â Subtotal - RoyaltiesÂ $12,110Â Â $11,985Â Â $3,564Â Â $30,115Â Â $â€”Â Â $7,096Â Â $64,870Â Total Finance Receivables, grossÂ $67,822Â Â $74,511Â Â $42,190Â Â $30,115Â Â $34,145Â Â $29,770Â Â $278,553Â Â Â Â Â Â Â December 31, 2023Â Â Â 2023Â Â 2022Â Â 2021Â Â 2020Â Â 2019Â Â PriorÂ Â TotalÂ Term LoansÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5Â $â€”Â Â $â€”Â Â $13,734Â Â $â€”Â Â $5,696Â Â $â€”Â Â $19,430Â 4Â Â 25,799Â Â Â 32,211Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 10,485Â Â Â 68,495Â 3Â Â 24,341Â Â Â 24,285Â Â Â 10,227Â Â Â â€”Â Â Â 31,807Â Â Â â€”Â Â Â 90,660Â 2Â Â â€”Â Â Â 6,924Â Â Â 12,493Â Â Â â€”Â Â Â â€”Â Â Â 14,015Â Â Â 33,432Â 1Â Â â€”Â Â Â â€”Â Â Â 9,128Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â 9,128Â Subtotal - Term LoansÂ $50,140Â Â $63,420Â Â $45,582Â Â $â€”Â Â $37,503Â Â $24,500Â Â $221,145Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â RoyaltiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GreenÂ $27,785Â Â $â€”Â Â $â€”Â Â $14,650Â Â $â€”Â Â $1,340Â Â $43,775Â YellowÂ Â â€”Â Â Â â€”Â Â Â 3,212Â Â Â â€”Â Â Â 3,419Â Â Â 6,631Â RedÂ Â â€”Â Â Â â€”Â Â Â 3,834Â Â Â 10,433Â Â Â â€”Â Â Â 2,587Â Â Â 16,854Â Subtotal - RoyaltiesÂ $27,785Â Â $â€”Â Â $3,834Â Â $28,295Â Â $â€”Â Â $7,346Â Â $67,260Â Total Finance Receivables, grossÂ $77,925Â Â $63,420Â Â $49,416Â Â $28,295Â Â $37,503Â Â $31,846Â Â $288,405Â X - DefinitionThe entire disclosure for financing receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481933/310-10-55-12AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-42Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 44 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-44Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-10/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/310-20/tableOfContent + Details Name: us-gaap_FinancingReceivablesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Intangible Assets Note 4. Intangible Assets Â As of June 30, 2024 and December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data): Schedule of Intangible Assets Â Â June 30, 2024Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Trade names and trademarksÂ $210Â Â $102Â Â $108Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 116Â Â Â 124Â Â Â 10Â Total intangible assetsÂ $450Â Â $218Â Â $232Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Licensing Agreement(1)Â $29,400Â Â $23,167Â Â $6,233Â Â Â 10Â Trade names and trademarksÂ Â 210Â Â Â 92Â Â Â 118Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 104Â Â Â 136Â Â Â 10Â Total intangible assetsÂ $29,850Â Â $23,363Â Â $6,487Â Â Â Â Â Â Â (1)Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (â€œCaraâ€), for oral formulation rights to Enterisâ€™ PepTelligenceÂ® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the â€œLoss on impairment of intangible assetsâ€ section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Amortization expense was $0.2 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively, and was recognized within depreciation and amortization expense on the unaudited condensed consolidated statements of income. Amortization expense related to intangible assets was $0.5 million and $0.9 million for the six months ended June 30, 2024 and 2023, respectively. Based on amounts recorded at June 30, 2024, the Company will recognize acquired intangible asset amortization as follows (in thousands): Schedule of Intangible Asset Amortization Expense Remainder of 2024Â $23Â 2025Â Â 45Â 2026Â Â 45Â 2027Â Â 45Â 2028Â Â 45Â ThereafterÂ Â 29Â TotalÂ Â $232Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all or part of the information related to intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/985-20/tableOfContent + Details Name: us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Debt Note 5. Debt Â Revolving Credit Facility Â On June 28, 2023, the Company entered into a new credit agreement (the â€œCredit Agreementâ€) by and among SWK Funding LLC, the Companyâ€™s wholly-owned subsidiary (together with the Company, the â€œBorrowerâ€), the lenders party thereto (â€œLendersâ€), and First Horizon Bank as a Lender and Agent (the â€œAgentâ€). The Credit Agreement provides for a revolving credit facility with an initial maximum principal amount of $45.0 million. The Credit Agreement provides that the Company may request one or more incremental increases in an aggregate amount not to exceed $80.0 million, subject to the consent of the Agent and each Lender, at any time prior to the termination of the revolving credit period on June 28, 2026 (the â€œCommitment Termination Dateâ€). The revolving credit period will be followed by a one-year amortization period, with the final maturity date of the Credit Agreement occurring on June 28, 2027. Â The outstanding principal balance of the Credit Agreement will bear interest at a rate per annum equal to the sum of (i) Term Secured Overnight Financing Rate, or SOFR (as defined in the Credit Agreement) plus (ii) 3.75 percent at all times prior to the Commitment Termination Date. The outstanding principal balance of the revolving credit facility will bear interest at a rate per annum equal to the sum of (i) Term SOFR (as defined in the Credit Agreement) plus (ii) 4.25 percent at all times on and after the Commitment Termination Date. Under the terms of the Credit Agreement, all accrued and unpaid interest shall be due and payable, in arrears, on the first business day of each calendar month. Â The Credit Agreement contains customary affirmative and negative covenants, in addition to financial covenants specifying that, as of the end of each calendar month, (i) the consolidated leverage ratio of Borrower will not exceed 1.00 to 1.00, (ii) the consolidated interest coverage ratio of Borrower will not be less than 4.00 to 1.00, (iii) the cash collection rate in relation to Borrowerâ€™s portfolio of loan assets will not be less than 4.5 percent, for such calendar month, (iv) the net charge-off percentage in relation to Borrowerâ€™s portfolio of loan assets will not exceed 3 percent for such calendar month, (v) the weighted average risk rating in relation to Borrower portfolio of loan assets will not be less than 3.00, and (vi) the Company's cumulative share repurchases will not exceed $5 million in value in any 12-month period. In addition, the Credit Agreement provides that at no time shall the Company permit its consolidated tangible net worth to be less than $145.0 million, or its liquidity (as defined in the Credit Agreement) to be less than $5.0 million. The Credit Agreement also contains events of default customary for such financings, the occurrence of which would permit the Agent and Lenders to accelerate the aggregate principal amount due thereunder. As of the date of this filing, the Company is in process of amending the Credit Agreement whereby the covenant for net charge-off percentage will be revised upwards, the consolidated interest coverage ratio will be revised downwards and the Company's share repurchase basket will be increased. The amendment will address covenant defaults as of June 30, 2024 and waive any past defaults. Â The Credit Agreement refinances the Companyâ€™s Loan and Security Agreement dated as of June 29, 2018 (the â€œPrior Credit Agreementâ€), as amended, between the Company and Cadence Bank, N.A. (â€œCadence Bankâ€), as the lender and administrative agent, which was due to expire on September 30, 2025. The Prior Credit Agreement was terminated by the Company, effective as of June 28, 2023. Â On October 10, 2023, the Company entered into a First Amendment to Credit Agreement pursuant to which Woodforest National Bank was added as a lender under the Credit Agreement for an aggregate commitment of $15.0 million, thereby increasing the aggregate commitments under the Credit Agreement from $45.0 million to $60.0 million. Â As of June 30, 2024 there were no amounts outstanding under the new Credit Agreement. During the three months ended June 30, 2024 and 2023, the Company recognized $1.1 million and $0.4 million, respectively, of interest expense relating to the Credit Agreement and Prior Credit Agreement, respectively. During the six months ended June 30, 2024 and 2023, the Company recognized $2.4 million and $0.5 million, respectively, of interest expense in connection with the Credit Agreement. Senior Notes Due 2027 Â On October 3, 2023, the Company issued a $30.0 million aggregate principal amount of 9.00% Senior Notes due 2027 (â€œ2027 Senior Notesâ€ or â€œNotesâ€) in a registered underwritten public offering. On October 27, 2023, the underwriter exercised in full, its over-allotment option by purchasing an additional approximately $3.0 million aggregate principal amount of the 2027 Senior Notes. The interest rates are fixed at 9.00% per annum and are payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year, commencing on December 31, 2023, and until maturity. The Notes will mature on January 31, 2027. The total net proceeds from the debt offering, after deducting initial purchase discounts and debt issuance costs, were approximately $30.6 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including funding future acquisitions and investments, repaying indebtedness, making capital expenditures, and funding working capital. Â The following table summarizes the outstanding balance of the Notes, net of debt issuance costs (in thousands): Schedule of Long Term Debt Â Â June 30, 2024Â Â December 31, 2023Â 2027 Senior NotesÂ $32,969Â Â $32,969Â Debt issuance costsÂ Â (1,891)Â Â Â (2,188) Total unsecured senior notes, netÂ $31,078Â Â $30,781Â Â Â The Companyâ€™s future principal obligations for the Notes were as follows (in thousands): Â Schedule of Maturities of Long Term NotesÂ Â Â June 30, 2024Â Remainder of 2024Â $â€”Â 2025Â Â â€”Â 2026Â Â â€”Â 2027Â Â 32,969Â Total unsecured senior notes, netÂ $32,969Â Â Â The Company may redeem the Notes for cash in whole or in part at any time (i) on or after September 30, 2025 (the â€œFirst Call Dateâ€) and prior to September 30, 2026, at a price equal to the sum of 102% of their principal amount, and (ii) on or after September 30, 2026 at a price equal to the sum of 100% of their principal amount, plus (in each case noted above) accrued and unpaid interest to, but excluding, the date of redemption. At any time prior to the First Call Date, the Company may, at its option, redeem the Notes for cash, in whole at any time or in part from time to time at a redemption price equal to (i) 100% of the principal amount of Notes redeemed, plus (ii) a Make-Whole Amount (as defined in the Indenture), plus (iii) accrued and unpaid interest, if any, to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. Additionally, upon the occurrence of a Triggering Event (as defined in the Indenture), holders of the Notes will have the right to require the Company to make an offer to repurchase all or any portion of their Notes for cash at a purchase price equal to 100% of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of purchase. Â The Notes are senior unsecured obligations of the Company and rank equal in right of payment with the Companyâ€™s existing and future senior unsecured indebtedness. Â The Company evaluated the 2027 Senior Notes for derivatives pursuant to Accounting Standard Codification (â€œASCâ€) 815, â€œDerivatives and Hedging,â€ and identified an embedded derivative that required bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative was a default provision, which could require additional interest payments. The Company reassesses the feature quarterly to determine if it requires separate accounting. There have been no changes to the Companyâ€™s assessment that the fair value of the embedded derivative is immaterial through June 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -

Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Note 6. Commitments and Contingencies Â Lease Obligations Â All the Companyâ€™s material leases are operating leases. Right-of-use (â€œROUâ€) assets related to operating leases are included on the unaudited condensed consolidated balance sheets in other non-current assets. Operating lease cost is recognized over the lease term on a straight-line basis and is recorded within general and administrative expenses on the unaudited condensed consolidated statements of income. In March of 2023, the Company entered into a new lease for additional office space in Dallas, Texas on Sherry Lane. The Companyâ€™s corporate office spaces in Dallas, Texas total approximately 6,850 square feet consisting of the two office locations (Sherry Lane and Preston Road). Total rent expense recognized was $0.3 million and $0.2 million for six months ended June 30, 2024 and 2023, respectively. Â On June 10, 2024, the Company entered into a lease termination agreement to its Preston Road office lease in Dallas (the â€œLease Terminationâ€). The Lease Termination terminated the Companyâ€™s rights and obligations with respect to the leased premises on June 30, 2024. As such, the ROU assets and operating lease liabilities were written off, and the Company recorded a gain of $4 thousand for the quarter ended June 30, 2024 and paid an early termination fee of $9 thousand. The remaining Sherry Lane office lease is set to expire in August 2028. Â The Enteris headquarters is located in Boonton, New Jersey, where Enteris leases approximately 32,000 square feet of space. The office lease expires in December 2029 with an option to renew for an additional five years. Â The components of lease cost was as follows (in thousands): Schedule of Lease Cost Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Operating lease costÂ $134Â Â $125Â Â $259Â Â $222Â Variable lease costÂ Â 17Â Â Â 23Â Â Â 32Â Â Â 24Â Total lease costÂ $151Â Â $148Â Â $291Â Â $246Â Â Â Â Future minimum rent on the Companyâ€™s operating leases was as follows as of June 30, 2024 (in thousands): Â Schedule of Future Minimum Rent Remainder of 2024Â $283Â 2025Â Â 456Â 2026Â Â 461Â 2027Â Â 465Â 2028Â Â 405Â ThereafterÂ Â 272Â Total future lease paymentsÂ $2,342Â Contingent Consideration Â During fiscal year 2019 the Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. Contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in the estimated fair value recognized in earnings. As of June 30, 2024, it has been determined the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of the product covered by the License Agreement. Accordingly, the Company has concluded that the liability for contingent consideration, previously held at its estimated fair value of $4.9 million, should be $0. The write-off of this contingent consideration liability has resulted in a gain of $4.9 million, which is included in the â€œChange in fair value of acquisition-related contingent considerationâ€ caption of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Â Unfunded Commitments Â Per the terms of the royalty purchase or credit agreements, unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time, and in the case of loan transactions, are subject to being advanced as long as an event of default does not exist. As of June 30, 2024 SWK had $5.0 million of unfunded commitments. Â Litigation Â The Company is involved in, or has been involved in, arbitrations or various other legal proceedings that arise from the normal course of its business. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material impact on the Companyâ€™s results of operations, balance sheets and cash flows due to defense costs, and divert management resources. The Company cannot predict the timing or outcome of these claims and other proceedings. As of June 30, 2024, the Company is not involved in any arbitration and/or other legal proceeding that it expects to have a material effect on its business, financial condition, results of operations and cash flows. Indemnification Â As permitted by Delaware law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving in such capacity, or in other capacities at the Companyâ€™s request. The term of the indemnification period is for the officerâ€™s or directorâ€™s lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any such amounts. As a result of the Companyâ€™s insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is insignificant. Accordingly, the Company had no liabilities recorded for these agreements as of June 30, 2024 and December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Note 7. Fair Value Measurements Â The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrumentâ€™s categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels. Â Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Â Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets. Â Level 3: Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources. Â Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the six months ended June 30, 2024 and 2023. Â The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates. Â Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized. Â Cash and cash equivalents Â The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assetsâ€™ fair values. Finance Receivables Â Finance receivables are measured at amortized cost, which approximates fair value. The fair value of finance receivables is estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below. Â Contingent Consideration Â The fair value measurements of the contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 estimates under the fair value hierarchy, as these items have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Changes in fair value of this obligation are recorded as income or expense within operating income in our consolidated statements of income. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement. As noted above in Note 6, the acquisition-related contingent consideration liability was written down to $0 as of June 30, 2024 due to non-viability of the underlying product. Marketable Investments Â If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities are classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities are classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities are classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant benchmark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below. Â Derivative Instruments Â For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3. Â The Company uses a foreign currency forward contract to manage the impact of fluctuations in foreign currency denominated cash flows expected to be received from one of its royalty finance receivables denominated in a foreign currency. The foreign currency forward contract is not designated as a hedging instrument, and changes in fair value are recognized in earnings. The foreign currency forward was recorded in other non-current assets in the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023 and totaled to $2.6 million and $1.0 million, respectively. The Company recognized a $0.8 million and $1.2 million gain due to changes in fair value related to its foreign currency forward contract during the three months ended June 30, 2024 and June 30, 2023, respectively. The Company recognized a $1.7 million and $1.6 million gain due to changes in fair value related to its foreign currency forward contract for the six months ended June 30, 2024 and June 30, 2023, respectively. The following table presents financial assets measured at fair value on a recurring basis as of June 30, 2024 (in thousands): Schedule of fair value assets measured on recurring basis Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â Financial AssetsÂ Â Â Â Â

significant unobservable inputs such as risk-free rate, expected life, and expected volatility. For the six months ended June 30, 2024 the risk-free rate range weighted average was 4.4%, and had a median of 4.3%. For the year ended December 31, 2023 the risk-free rate range weighted average was 4.3%, and had a median of 3.8%. For the six months ended June 30, 2024 the expected life range weighted average was 4.2 years, and had a median of 4.5 years. For the year ended December 31, 2023 the expected life range weighted average was 3.4 years, and had a median of 4.4 years. For the six months ended June 30, 2024 the expected volatility range weighted average was 102.7%, and had a median of 90.8%. For the year ended December 31, 2023 the expected volatility range weighted average 124.6%, and median of 134.4%. As of June 30, 2024 and December 31, 2023, the Company had one royalty, Best, that was deemed to be impaired based on reductions in carrying value in prior periods. As of June 30, 2024, the Company had two loans, Trio Healthcare and Exeevo, that was deemed to be impaired based on reductions in carrying value during the six months ended June 30, 2024. The following table presents this royalty and the loans measured at amortized cost using the effective interest method, which approximates fair value, on a nonrecurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of weighted average assumptions Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â June 30, 2024Â $8,448Â Â $â€”Â Â $â€”Â Â $8,448Â December 31, 2023Â $2,587Â Â $â€”Â Â $â€”Â Â $2,587Â Â There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2024 and December 31, 2023. The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying unaudited condensed consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments measured at fair value on a recurring and non-recurring basis. Â The following table presents the fair value of financial assets as of June 30, 2024 (in thousands): Â Schedule of fair value by balance sheet grouping Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Finance receivables, netÂ $265,470Â Â $265,470Â Â $â€”Â Â $â€”Â Â $265,470Â Marketable investmentsÂ Â 731Â Â Â 731Â Â Â 696Â Â Â â€”Â Â Â 35Â Warrant assetsÂ Â 835Â Â Â 835Â Â Â â€”Â Â Â â€”Â Â Â 835Â Foreign currency forward contractÂ Â 2,629Â Â Â 2,629Â Â Â â€”Â Â Â 2,629Â Â The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands): Â Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Finance receivables, netÂ $274,504Â Â $274,504Â Â $â€”Â Â $â€”Â Â $274,504Â Marketable investmentsÂ Â 48Â Â Â 48Â Â Â â€”Â Â Â â€”Â Â Â 48Â Warrant assetsÂ Â 1,759Â Â Â 1,759Â Â Â â€”Â Â Â â€”Â Â Â 1,759Â Foreign currency forward contractÂ Â 974Â Â Â 974Â Â Â â€”Â Â Â 974Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial liabilitiesÂ Contingent consideration payableÂ $4,900Â Â $4,900Â Â $â€”Â Â $â€”Â Â $4,900Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue Recognition Note 8. Revenue Recognition Â The Companyâ€™s Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Companyâ€™s Finance Receivables segment does not have any revenues received from contracts with customers. Â The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2024 and 2023 (in thousands): Â Schedule of Revenue Recognized by Revenue Source Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â License AgreementÂ $49Â Â $10Â Â $49Â Â $10Â Pharmaceutical DevelopmentÂ Â 755Â Â Â 173Â Â Â 1,034Â Â Â 291Â Total contract revenueÂ $804Â Â $183Â Â $1,083Â Â $301Â Â The Companyâ€™s contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied. Â The Companyâ€™s contract liabilities are presented as deferred income and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands): Â Schedule of Company's Contract LiabilitiesÂ Â Â June 30, 2024Â Â December 31, 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Â Deferred incomeÂ $2,216Â Â $9Â Total contract liabilitiesÂ $2,216Â Â $9Â Â During the six months ended June 30, 2024, the Company recognized the full remaining balance of $9 thousand of 2023 deferred income from satisfaction of performance obligations. The Company did not have any contract assets as of June 30, 2024 or December 31, 2023. Enteris Exclusive Option and Asset Purchase Agreement Â With an effective date of January 1, 2024, we entered into an exclusive option and asset purchase agreement with a strategic partner on March 14, 2024 which granted the partner an exclusive option to acquire certain of Enterisâ€™ assets related to its business of providing clinical manufacturing and development services. The partner must exercise the option by or before January 1, 2026. In exchange for the exclusive purchase option the partner is to provide consideration in the form of an â€œoption feeâ€ and â€œguaranteed revenue payments.â€ Â The option fee is broken into two components: A low-single digit million fee due within 30 business days of executing the agreement; and should the option not be exercised by the first anniversary of the effective date, an additional low-single digit million fee will be due at that time. The first option fee was paid in April 2024. Option fee payments will be included in deferred income until the earlier of term expiration or exercise of the purchase option. Should the partner exercise the purchase option, any option fee payments made will be applied towards the purchase price. Â The guaranteed revenue payments include two components: A mid-single digit million guaranteed revenue payment in 2024 and a mid-single digit million guaranteed revenue payment in 2025. The revenue is to be derived by the partner under an existing collaboration agreement, and partner is to pay the difference should the minimum amount not be met each year. Each yearâ€™s guaranteed revenue amount is to be paid in two installments semi-annually each year. Should revenue exceed the 2024 or 2025 guaranteed revenue amounts after receiving a difference payment in the first half of the year, we must repay the partner the amount of such overpayment. Guaranteed revenue of $0.4 million was recognized during the three and six months ended June 30, 2024. Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â Segment Information Note 9. Segment Information Â Selected financial and descriptive information is required to be provided about reportable operating segments, considering a â€œmanagement approachâ€ concept as the basis for identifying reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Companyâ€™s internal organization, focusing on financial information that the Companyâ€™s CEO uses to make decisions about the Companyâ€™s operating matters. As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report assets by reportable segment, nor does the Company report results by geographic region, as these metrics are not used by the Companyâ€™s chief executive officer in assessing performance or allocating resources to the segments. Â Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Companyâ€™s CEO in assessing performance or allocating resources to the segments. The following tables present financial information for the Companyâ€™s reportable segments for the periods indicated (in thousands): Schedule of Reportable Revenue by Geographic Region Â Â Three Months Ended June 30, 2024Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $10,680Â Â $804Â Â $â€”Â Â $11,484Â Other revenueÂ Â 57Â Â Â â€”Â Â Â â€”Â Â Â 57Â Provision for credit lossesÂ Â 4,074Â Â Â â€”Â Â Â â€”Â Â Â 4,074Â Loss on impairment of intangible assetsÂ Â â€”Â Â Â 5,771Â Â Â â€”Â Â Â 5,771Â Interest expenseÂ Â 225Â Â Â 2Â Â Â 892Â Â Â 1,119Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 520Â Â Â â€”Â Â Â 520Â Change in fair value of acquisition-related contingent considerationÂ Â â€”Â Â Â (4,900)Â Â â€”Â Â Â (4,900) Depreciation and amortization expenseÂ Â â€”Â Â Â 400Â Â Â 21Â Â Â 421Â General and administrative expenseÂ Â 91Â Â Â 748Â Â Â 2,084Â Â Â 2,923Â Other income (expense), netÂ Â 3,851Â Â Â â€”Â Â Â (34)Â Â 3,817Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,035Â Â Â 1,035Â Net income (loss)Â Â 10,198Â Â Â (1,737)Â Â (4,066)Â Â 4,395Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30, 2023Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $9,278Â Â $183Â Â $â€”Â Â $9,461Â Other revenueÂ Â 36Â Â Â â€”Â Â Â â€”Â Â Â 36Â Benefit for credit lossesÂ Â (682)Â Â â€”Â Â Â â€”Â Â Â (682) Interest expenseÂ Â 363Â Â Â â€”Â Â Â â€”Â Â Â 363Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 1,509Â Â Â â€”Â Â Â 1,509Â Depreciation and amortization expenseÂ Â â€”Â Â Â 633Â Â Â 4Â Â Â 637Â General and administrative expenseÂ Â 137Â Â Â 981Â Â Â 1,879Â Â Â 2,997Â Other income, netÂ Â 715Â Â Â â€”Â Â Â â€”Â Â Â 715Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,454Â Â Â 1,454Â Net income (loss)Â Â 10,211Â Â Â (2,940)Â Â (3,337)Â Â 3,934Â Â Â Six Months Ended June 30, 2024Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $21,399Â Â $1,083Â Â $â€”Â Â $22,482Â Other revenueÂ Â 103Â Â Â â€”Â Â Â â€”Â Â Â 103Â Provision for credit lossesÂ Â 9,397Â Â Â â€”Â Â Â â€”Â Â Â 9,397Â Loss on impairment intangible assetsÂ Â â€”Â Â Â 5,771Â Â Â â€”Â Â Â 5,771Â Interest expenseÂ Â 590Â Â Â 5Â Â Â 1,780Â Â Â 2,375Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 1,050Â Â Â â€”Â Â Â 1,050Â Change in fair value of acquisition-related contingent considerationÂ Â â€”Â Â Â (4,900)Â Â â€”Â Â Â (4,900) Depreciation and amortization expenseÂ Â â€”Â Â Â 892Â Â Â 43Â Â Â 935Â General and administrative expenseÂ Â 169Â Â Â 1,457Â Â Â 3,981Â Â Â 5,607Â Other income (expense), netÂ Â 3,843Â Â Â â€”Â Â Â (408)Â Â 3,435Â Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,264Â Â Â 1,264Â Net income (loss)Â Â 15,189Â Â Â (3,192)Â Â (7,476)Â Â 4,521Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2023Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $18,538Â Â $301Â Â $â€”Â Â $18,839Â Other revenueÂ Â 67Â Â Â â€”Â Â Â 2Â Â Â 69Â Benefit for credit lossesÂ Â (682)Â Â â€”Â Â Â â€”Â Â Â (682) Interest expenseÂ Â 545Â Â Â â€”Â Â Â â€”Â Â Â 545Â Pharmaceutical manufacturing, research and development expenseÂ Â â€”Â Â Â 2,228Â Â Â â€”Â Â Â 2,228Â Depreciation and amortization expenseÂ Â â€”Â Â Â 1,277Â Â Â 8Â Â Â 1,285Â General and administrative expenseÂ Â 167Â Â Â 1,709Â Â Â 3,661Â Â Â 5,537Â Other expense, netÂ Â (81)Â Â â€”Â Â Â â€”Â Â Â (81) Income tax expenseÂ Â â€”Â Â Â â€”Â Â Â 1,345Â Â Â 1,345Â Net income (loss)Â Â 18,494Â Â Â (4,913)Â Â (5,012)Â Â 8,569Â Â Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate

employees, which have been included for purposes of reconciling to the consolidated amounts. Â X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Subsequent Events 6 Months Ended Jun. 30, 2024 Subsequent Events [Abstract] Â Subsequent Events Note 10. Subsequent Events Â Relief Therapeutics Â On August 2, 2024, SWK Funding, a subsidiary of the Company, entered into a royalty purchase agreement with Relief Therapeutics Holding SA (â€œReliefâ€) and APR Applied Pharma Research SA pursuant to which SWK Funding paid $5.8 million at closing with another $5.3 million available for borrowing should Relief achieve certain milestones. In exchange, SWK Funding will receive royalties based off sales as listed in the agreement. X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Nature of Operations Nature of Operations Â SWK Holdings Corporation (the â€œCompany,â€ â€œwe,â€ or â€œusâ€) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: â€œFinance Receivablesâ€ and â€œPharmaceutical Development.â€ We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, â€œlife sciencesâ€). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of June 30, 2024, the Company had 22 full-time employees. The Company has net operating loss carryforwards (â€œNOLsâ€) and believes that the ability to utilize these NOLs is an important and substantial asset. As of AugustÂ 8, 2024, the Company and its partners have executed transactions with 56 different parties under its specialty finance strategy, funding an aggregate of $779.8 million in various financial products across the life science sector. The Companyâ€™s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property. Â During 2019, we commenced our Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. (â€œEnterisâ€). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform. We seek to generate income by providing customers pharmaceutical development, formulation and manufacturing services as well as licensing its internally developed intellectual property. With an effective date of April 21, 2023 we entered into a collaboration agreement with a strategic partner under which we would be the exclusive provider of certain contract development and manufacturing organization (â€œCDMOâ€) services to its customers. Fee revenue generated as a result of this agreement is presented as pharmaceutical development revenue on the unaudited condensed consolidated statement of income and is accounted for in accordance with our revenue recognition policy as described under Revenue Recognition below. With an effective date of January 1, 2024, we entered into an Option and Asset Purchase Agreement with the same strategic partner on March 14, 2024, which granted the partner an exclusive option to acquire certain of Enterisâ€™ assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The partner must exercise the option by or before January 1, 2026. Basis of Presentation and Principles of Consolidation Basis of Presentation and Principles of ConsolidationÂ The Companyâ€™s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (â€œGAAPâ€). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (â€œVIEâ€) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control. Even though the Companyâ€™s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Companyâ€™s consolidated financial statements, it would have no effect on its operations and/or total stockholdersâ€™ equity attributable to the Company. Â Unaudited Interim Financial Information Unaudited Interim Financial InformationÂ The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (â€œSECâ€). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024. Use of Estimates Use of EstimatesÂ The preparation of the Companyâ€™s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Companyâ€™s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. Â The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Companyâ€™s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Companyâ€™s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. Â Segment Information Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies (â€œFinance Receivable segmentâ€), and its business offering CDMO services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the PeptelligenceÂ® platform (â€œPharmaceutical Development segmentâ€). Revenue Recognition Revenue Recognition Â The Companyâ€™s Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Â Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets. Â Correction of an Error in Previously Issued Unaudited Condensed Financial Statements Correction of an Error in Previously Issued Unaudited Condensed Financial Statements Â During the quarter ended June 30, 2024, the Company identified an error related to the recognition of a holdback liability for a royalty which was incorrectly recorded into revenue. This error affected the consolidated financial statements for the quarter ended March 31, 2024 and was determined to be immaterial to the prior periodâ€™s unaudited condensed consolidated financial statements and did not warrant restatement and reissuance of the previously issued unaudited condensed consolidated financial statements. However, the Company recorded a correction to the prior quarter ended March 31, 2024 and the financial statements will be revised the next time they are presented as comparative information in future filings. The Company based their qualitative and quantitative analysis on SEC Staffâ€™s Accounting Bulletins Topic 1.M, â€œMateriality and Topic 1.N, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements.â€ Â The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands): Â Schedule of Revisions to the line items of our previously issued financial statements Three Months Ended March 31, 2024Â As ReportedÂ AdjustmentÂ As Revised Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivable interest income, including feesÂ $11,454Â Â $(735)Â $10,719Â Pharmaceutical developmentÂ Â 279Â Â Â â€”Â Â Â 279Â OtherÂ Â 46Â Â Â â€”Â Â Â 46Â Total revenuesÂ Â 11,779Â Â Â (735)Â Â 11,044Â Net incomeÂ $861Â Â $(735)Â $126Â Basic net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Diluted net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, net of allowance for credit Â Â 261,285Â Â Â (13)Â Â 261,272Â Total assetsÂ $322,350Â Â $(13)Â $322,337Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Â Â Â Â Â Accumulated deficitÂ Â (4,143,940)Â Â (735)Â Â (4,144,675) Total stockholdersâ€™ equityÂ $280,288Â Â $(735)Â $279,553Â Â Â Â Â Research and Development Research and Development Â Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical

trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the unaudited condensed consolidated statements of income. Recent Accounting Pronouncements Recent Accounting Pronouncements In March 2020, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standard Update (â€œASUâ€) 2020-04, â€œReference Rate Reform (Topic 848),â€ which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference London Inter-Bank Offered Rate (â€œLIBORâ€) and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Companyâ€™s consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which requires public entities to disclose information about their reportable segmentsâ€™ significant expenses on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Public entities are required to adopt the changes retrospectively, recasting each prior-period disclosure for which a comparative income statement is presented in the period of adoption. The Company is currently evaluating the impact of this ASU on the Companyâ€™s consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures.â€ The standard is intended to provide greater transparency in various income tax components that affect the rate reconciliation based on the applicable taxing jurisdictions, as well as the qualitative and quantitative aspects of those components. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: swkh_CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_NatureOfOperationsPolicyTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_UnauditedInterimFinancialInformationPolicyTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1 + Details Name: us-gaap_ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SWK Holdings Corporation and Summary of Significant Accounting Policies (Tables) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Revisions to the line items of our previously issued financial statements The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands): Â Schedule of Revisions to the line items of our previously issued financial statements Three Months Ended March 31, 2024Â As ReportedÂ AdjustmentÂ As Revised Revenues:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivable interest income, including feesÂ $11,454Â Â $(735)Â $10,719Â Pharmaceutical developmentÂ Â 279Â Â Â â€”Â Â Â 279Â OtherÂ Â 46Â Â Â Â â€”Â Â Â 46Â Total revenuesÂ Â 11,779Â Â Â (735)Â Â 11,044Â Net incomeÂ $861Â Â $(735)Â $126Â Basic net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Diluted net income per shareÂ $0.07Â Â $(0.06)Â $0.01Â Assets:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, net of allowance for credit Â Â 261,285Â Â Â (13)Â Â 261,272Â Total assetsÂ $322,350Â Â $(13)Â $322,337Â Stockholdersâ€™ equity:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Accumulated deficitÂ Â (4,143,940)Â Â (735)Â Â (4,144,675) Total stockholdersâ€™ equityÂ $280,288Â Â $(735)Â $279,553Â X - ReferencesNo definition available. + Details Name: swkh_ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Income per Share (Tables) 6 Months Ended Jun. 30, 2024 Net income per share Â Schedule of Basic and Diluted Earning per Share The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts): Â Schedule of Basic and Diluted Earning per Share Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Numerator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net incomeÂ $4,395Â Â $3,934Â Â $4,521Â Â $8,569Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Denominator:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted-average shares outstandingÂ Â 12,457Â Â Â 12,741Â Â Â 12,466Â Â Â 12,787Â Effect of dilutive securitiesÂ Â 71Â Â Â 44Â Â Â 68Â Â Â 43Â Weighted-average diluted sharesÂ Â 12,528Â Â Â 12,785Â Â Â 12,534Â Â Â 12,830Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â Diluted net income per shareÂ $0.35Â Â $0.31Â Â $0.36Â Â $0.67Â X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables (Tables) 6 Months Ended Jun. 30, 2024 Receivables [Abstract] Â Schedule of carrying value of finance receivables The carrying values of finance receivables were as follows (in thousands): Â Schedule of carrying value of finance receivables Â Â June 30, 2024Â Â December 31, 2023Â Term loansÂ $213,683Â Â $221,145Â Royalty purchasesÂ Â 64,870Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 278,553Â Â Â 288,405Â Allowance for credit lossesÂ Â (13,083)Â Â (13,901) Total carrying valueÂ $265,470Â Â $274,504Â Schedule of Allowance for Credit Losses The following table details the changes in the allowance for credit losses by Term Loans and Royalties (in thousands): Â Schedule of Allowance for Credit LossesÂ Â Â Six Months Ended June 30, 2024Â Â Six Months Ended June 30, 2023Â Â Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Â Term LoansÂ Â RoyaltiesÂ Â TotalÂ Allowance at beginning of periodÂ $9,731Â Â $4,170Â Â $13,901Â Â $â€”Â Â $11,846Â Â $11,846Â Effect of adoption of ASU 2016-13Â Â Â â€”Â Â Â â€”Â Â Â 8,900Â Â Â 2,886Â Â Â 11,786Â Provision (benefit) for credit lossesÂ Â 5,055Â Â Â 127Â Â Â 5,182Â Â Â (572)Â Â (110)Â Â (682) Write offsÂ Â (6,000)Â Â â€”Â Â Â (6,000)Â Â â€”Â Â Â (11,846)(1) Â (11,846) Allowance at end of periodÂ $8,786Â Â $4,297Â Â $13,083Â Â $8,328Â Â $2,776Â Â $11,104Â Â (1)Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023. Schedule of Allowance for Credit Losses The following table presents nonaccrual and performing finance receivables by portfolio pool, net of allowance for credit losses (in thousands) as of: Schedule of Allowance for Credit Losses Â Â June 30, 2024Â Â December 31, 2023Â Â Â NonaccrualÂ Â PerformingÂ Â TotalÂ Â NonaccrualÂ Â PerformingÂ Â TotalÂ Term loansÂ $6,010Â Â $207,673Â Â $213,683Â Â $9,128Â Â $212,017Â Â $221,145Â Royalty purchasesÂ Â 16,434Â Â Â 48,436Â Â Â 64,870Â Â Â 16,854Â Â Â 50,406Â Â Â 67,260Â Total before allowance for credit lossesÂ Â 22,444Â Â Â 256,109Â Â Â 278,553Â Â Â 25,982Â Â Â 262,423Â Â Â 288,405Â Allowance for credit lossesÂ Â (3,368)Â Â (9,715)Â Â (13,083)Â Â (1,447)Â Â (12,454)Â Â (13,901) Total carrying valueÂ $19,076Â Â $246,394Â Â $265,470Â Â $24,535Â Â $249,969Â Â $274,504Â Schedule of Financing Receivable by origination year The following table summarizes the carrying value of Finance Receivables by origination year, grouped by risk rating as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of Financing Receivable by origination year Â Â June 30, 2024Â Â Â 2023Â Â 2022Â Â 2021Â Â 2020Â Â 2019Â Â PriorÂ Â TotalÂ Term LoansÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

$3,834Â Â $28,295Â Â $â€”Â Â $7,346Â Â $67,260Â Total Finance Receivables, grossÂ $77,925Â Â $63,420Â Â $49,416Â Â $28,295Â Â $37,503Â Â $31,846Â Â $288,405Â X - DefinitionTabular disclosure of allowance for credit loss on financing receivable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-29Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5 + Details Name: us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ReceivablesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of financing receivable on nonaccrual status. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-16 + Details Name: us-gaap_ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Tables) 6 Months Ended Jun. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Intangible Assets As of June 30, 2024 and December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data): Schedule of Intangible Assets Â Â June 30, 2024Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Trade names and trademarksÂ $210Â Â $102Â Â $108Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 116Â Â Â 124Â Â Â 10Â Total intangible assetsÂ $450Â Â $218Â Â $232Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â December 31, 2023Â Â Â Gross Book ValueÂ Â Accumulated AmortizationÂ Â Net Book ValueÂ Â Estimated Useful LifeÂ Licensing Agreement(1)Â $29,400Â Â $23,167Â Â $6,233Â Â Â 10Â Trade names and trademarksÂ Â 210Â Â Â 92Â Â Â 118Â Â Â 10Â Customer relationshipsÂ Â 240Â Â Â 104Â Â Â 136Â Â Â 10Â Total intangible assetsÂ $29,850Â Â $23,363Â Â $6,487Â Â Â Â Â (1)Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (â€œCaraâ€), for oral formulation rights to Enterisâ€™ PeptelligenceÂ® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the â€œLoss on impairment of intangible assetsâ€ section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. Schedule of Intangible Asset Amortization Expense Schedule of Intangible Asset Amortization Expense Remainder of 2024Â $23Â 2025Â Â 45Â 2026Â Â 45Â 2027Â Â 45Â 2028Â Â 45Â ThereafterÂ Â 29Â TotalÂ $232Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Tables) 6 Months Ended Jun. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Long Term Debt The following table summarizes the outstanding balance of the Notes, net of debt issuance costs (in thousands): Schedule of Long Term Debt Â Â June 30, 2024Â Â December 31, 2023Â 2027 Senior NotesÂ $32,969Â Â $32,969Â Debt issuance costsÂ Â (1,891)Â Â (2,188) Total unsecured senior notes, netÂ $31,078Â Â $30,781Â Schedule of Maturities of Long Term Notes The Companyâ€™s future principal obligations for the Notes were as follows (in thousands): Â Schedule of Maturities of Long Term NotesÂ Â Â June 30, 2024Â Remainder of 2024Â $â€”Â 2025Â Â â€”Â 2026Â Â â€”Â 2027Â Â 32,969Â Total unsecured senior notes, netÂ $32,969Â X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturity and sinking fund requirement for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Lease Cost The components of lease cost was as follows (in thousands): Schedule of Lease Cost Â Â Three Months Ended June 30,Â Â Six Months Ended June 30,Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Operating lease costÂ $134Â Â $125Â Â $259Â Â $222Â Variable lease costÂ Â 17Â Â Â 23Â Â Â 32Â Â Â 24Â Total lease costÂ $151Â Â $148Â Â $291Â Â $246Â Schedule of Future Minimum Rent Future minimum rent on the Companyâ€™s operating leases was as follows as of June 30, 2024 (in thousands): Â Schedule of Future Minimum Rent Remainder of 2024Â $283Â 2025Â Â 456Â 2026Â Â 461Â 2027Â Â 465Â 2028Â Â 405Â ThereafterÂ Â 272Â Total future lease paymentsÂ $2,342Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCostTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-2 + Details Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of fair value assets measured on recurring basis The following table presents financial assets measured at fair value on a recurring basis as of June 30, 2024 (in thousands): Schedule of fair value assets measured on recurring basis Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant assetsÂ $835Â Â $â€”Â Â $â€”Â Â $835Â Marketable investmentsÂ Â 731Â Â Â 696Â Â Â â€”Â Â Â 35Â Foreign currency forward contractÂ Â 2,629Â Â Â â€”Â Â Â â€”Â Â Â 2,629Â Â The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 (in thousands): Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrant assetsÂ $1,759Â Â $â€”Â Â $â€”Â Â $1,759Â Marketable investmentsÂ Â 48Â Â Â â€”Â Â Â â€”Â Â Â 48Â Foreign currency forward contractÂ Â 974Â Â Â â€”Â Â Â â€”Â Â Â 974Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial liabilities:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration payableÂ $4,900Â Â $â€”Â Â $â€”Â Â $4,900Â Schedule of fair value assets measured on recurring basis unobservable input reconciliation The changes in fair value of the warrant assets during the six months ended June 30, 2024 and 2023 were as follows (in thousands): Â Schedule of fair value assets measured on recurring basis unobservable input reconciliation June 30, 2024Â June 30, 2023 Fair value - December 31, 2023Â $1,759Â Â Fair value - December 31, 2022Â $1,220Â IssuedÂ Â â€”Â Â IssuedÂ Â 822Â ExercisedÂ Â (984)Â ExercisedÂ Â â€”Â Change in fair valueÂ Â 130Â Â Change in fair valueÂ Â (583) Loss on foreign currency transactionsÂ $(70)Â Loss on foreign currency transactionsÂ $â€”Â Fair value - June 30, 2024Â $835Â Â Fair value - June 30, 2023Â $1,459Â Schedule of weighted average assumptions Schedule of weighted average assumptions Â Â June 30, 2024Â December 31, 2023 Dividend rate rangeÂ â€”Â â€”Â Risk-free rate rangeÂ 4.3% to 4.7%Â 3.8% to 4.8% Expected life (years) rangeÂ 2.4 to 5.3Â 1.2 to 5.8 Expected volatility rangeÂ 73% to 177.7%Â 75.3% to 154.3% Schedule of weighted average assumptions As of June 30, 2024 and December 31, 2023, the Company had one royalty, Best, that was deemed to be impaired based on reductions in carrying value in prior periods. As of June 30, 2024, the Company had two loans, Trio Healthcare and Exeevo, that was deemed to be impaired based on reductions in carrying value during the six months ended June 30, 2024. The following table presents this royalty and the loans measured at amortized cost using the effective interest method, which approximates fair value, on a nonrecurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of weighted average assumptions Â Â Total Carrying Value in Consolidated Balance SheetsÂ Â Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)Â Â Significant Other Observable Inputs (Level 2)Â Â Significant Unobservable Inputs (Level 3)Â June 30, 2024Â $8,448Â Â $â€”Â Â $â€”Â Â $8,448Â December 31, 2023Â $2,587Â Â $â€”Â Â $â€”Â Â $2,587Â Schedule of fair value by balance sheet grouping The following table presents the fair value of financial assets as of June 30, 2024 (in thousands): Â Schedule of fair value by balance sheet grouping Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, netÂ $265,470Â Â $265,470Â Â $â€”Â Â $â€”Â Â $265,470Â Marketable investmentsÂ Â 731Â Â Â 731Â Â Â 696Â Â Â â€”Â Â Â 35Â Warrant assetsÂ Â 835Â Â Â 835Â Â Â â€”Â Â Â â€”Â Â Â 835Â Foreign currency forward contractÂ Â 2,629Â Â Â 2,629Â Â Â â€”Â Â Â â€”Â Â Â 2,629Â Â The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands): Â Â Â Carrying ValueÂ Â Fair ValueÂ Â Level 1Â Â Level 2Â Â Level 3Â Financial AssetsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Finance receivables, netÂ $274,504Â Â $274,504Â Â $â€”Â Â $â€”Â Â $274,504Â Marketable investmentsÂ Â 48Â Â Â 48Â Â Â â€”Â Â Â â€”Â Â Â 48Â Warrant assetsÂ Â 1,759Â Â Â 1,759Â Â Â â€”Â Â Â â€”Â Â Â 1,759Â Foreign currency forward contractÂ Â 974Â Â Â 974Â Â Â â€”Â Â Â â€”Â Â Â 974Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Financial liabilitiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Contingent consideration payableÂ $4,900Â Â $4,900Â Â $â€”Â Â $â€”Â Â $4,900Â X - ReferencesNo definition available. + Details Name: swkh_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and

significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 101 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition (Tables) 6 Months Ended Jun. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Revenue Recognized by Revenue Source The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2024 and 2023 (in thousands): Â Schedule of Revenue Recognized by Revenue Source Â Â Three Months Ended June 30,Â Â Â Six Months Ended June 30,Â Â Â Â 2024Â Â 2023Â Â 2024Â Â 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â License AgreementÂ $49Â Â $10Â Â $49Â Â $10Â Pharmaceutical DevelopmentÂ Â 755Â Â Â 173Â Â Â 1,034Â Â Â 291Â Total contract revenueÂ $804Â Â $183Â Â $1,083Â Â $301Â Schedule of Company's Contract Liabilities The Companyâ€™s contract liabilities are presented as deferred income and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands): Â Schedule of Company's Contract LiabilitiesÂ Â Â June 30, 2024Â Â December 31, 2023Â Pharmaceutical Development SegmentÂ Â Â Â Â Â Â Deferred incomeÂ $2,216Â Â $9Â Total contract liabilitiesÂ $2,216Â Â $9Â X - ReferencesNo definition available. + Details Name: swkh_ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock Namespace Prefix: swkh_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Tables) 6 Months Ended Jun. 30, 2024 Segment Reporting [Abstract] Â Schedule of Reportable Revenue by Geographic Region The following tables present financial information for the Companyâ€™s reportable segments for the periods indicated (in thousands): Schedule of Reportable Revenue by Geographic Region Â Â Three Months Ended June 30, 2024Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $10,680Â Â $804Â Â $âE"Â Â $11,484Â Other revenueÂ Â 57Â Â Â âE"Â Â Â âE"Â Â Â 57Â Provision for credit lossesÂ Â 4,074Â Â Â âE"Â Â Â âE"Â Â Â 4,074Â Loss on impairment of intangible assetsÂ Â âE"Â Â Â 5,771Â Â Â âE"Â Â Â 5,771Â Interest expenseÂ Â 225Â Â Â 2Â Â Â 892Â Â Â 1,119Â Pharmaceutical manufacturing, research and development expenseÂ Â âE"Â Â Â 520Â Â Â âE"Â Â Â 520Â Change in fair value of acquisition-related contingent considerationÂ Â âE"Â Â Â (4,900)Â Â âE"Â Â Â (4,900) Depreciation and amortization expenseÂ Â âE"Â Â Â 400Â Â Â 21Â Â Â 421Â General and administrative expenseÂ Â 91Â Â Â 748Â Â Â 2,084Â Â Â 2,923Â Other income (expense), netÂ Â 3,851Â Â Â âE"Â Â Â (34)Â Â 3,817Â Income tax expenseÂ Â âE"Â Â Â âE"Â Â Â 1,035Â Â Â 1,035Â Net income (loss)Â Â 10,198Â Â Â (1,737)Â Â (4,066)Â Â 4,395Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three Months Ended June 30, 2023Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $9,278Â Â $183Â Â $âE"Â Â $9,461Â Other revenueÂ Â 36Â Â Â âE"Â Â Â âE"Â Â Â 36Â Benefit for credit lossesÂ Â (682)Â Â âE"Â Â Â âE"Â Â Â (682) Interest expenseÂ Â 363Â Â Â âE"Â Â Â âE"Â Â Â 363Â Pharmaceutical manufacturing, research and development expenseÂ Â âE"Â Â Â 1,509Â Â Â âE"Â Â Â 1,509Â Depreciation and amortization expenseÂ Â âE"Â Â Â 633Â Â Â 4Â Â Â 637Â General and administrative expenseÂ Â 137Â Â Â 981Â Â Â 1,879Â Â Â 2,997Â Other income, netÂ Â 715Â Â Â âE"Â Â Â âE"Â Â Â 715Â Income tax expenseÂ Â âE"Â Â Â âE"Â Â Â 1,454Â Â Â 1,454Â Net income (loss)Â Â 10,211Â Â Â (2,940)Â Â (3,337)Â Â 3,934Â Â Â Six Months Ended June 30, 2024Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $21,399Â Â $1,083Â Â $âE"Â Â $22,482Â Other revenueÂ Â 103Â Â Â âE"Â Â Â âE"Â Â Â 103Â Provision for credit lossesÂ Â 9,397Â Â Â âE"Â Â Â âE"Â Â Â 9,397Â Loss on impairment intangible assetsÂ Â âE"Â Â Â 5,771Â Â Â âE"Â Â Â 5,771Â Interest expenseÂ Â 590Â Â Â 5Â Â Â 1,780Â Â Â 2,375Â Pharmaceutical manufacturing, research and development expenseÂ Â âE"Â Â Â 1,050Â Â Â âE"Â Â Â 1,050Â Change in fair value of acquisition-related contingent considerationÂ Â âE"Â Â Â (4,900)Â Â âE"Â Â Â (4,900) Depreciation and amortization expenseÂ Â âE"Â Â Â 892Â Â Â 43Â Â Â 935Â General and administrative expenseÂ Â 169Â Â Â 1,457Â Â Â 3,981Â Â Â 5,607Â Other income (expense), netÂ Â 3,843Â Â Â âE"Â Â Â (408)Â Â 3,435Â Income tax expenseÂ Â âE"Â Â Â âE"Â Â Â 1,264Â Â Â 1,264Â Net income (loss)Â Â 15,189Â Â Â (3,192)Â Â (7,476)Â Â 4,521Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Six Months Ended June 30, 2023Â Â Â Finance ReceivablesÂ Â Pharmaceutical Development and OtherÂ Â Holding Company and OtherÂ Â ConsolidatedÂ RevenueÂ $18,538Â Â $301Â Â $âE"Â Â $18,839Â Other revenueÂ Â 67Â Â Â âE"Â Â Â 2Â Â Â 69Â Benefit for credit lossesÂ Â (682)Â Â âE"Â Â Â âE"Â Â Â (682) Interest expenseÂ Â 545Â Â Â âE"Â Â Â âE"Â Â Â 545Â Pharmaceutical manufacturing, research and development expenseÂ Â âE"Â Â Â 2,228Â Â Â âE"Â Â Â 2,228Â Depreciation and amortization expenseÂ Â âE"Â Â Â 1,277Â Â Â 8Â Â Â 1,285Â General and administrative expenseÂ Â 167Â Â Â 1,709Â Â Â 3,661Â Â Â 5,537Â Other expense, netÂ Â (81)Â Â âE"Â Â Â âE"Â Â Â (81) Income tax expenseÂ Â âE"Â Â Â âE"Â Â Â 1,345Â Â Â 1,345Â Net income (loss)Â Â 18,494Â Â Â (4,913)Â Â (5,012)Â Â 8,569Â X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SWK Holdings Corporation and Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Mar. 31, 2023 Jun. 30, 2024 Jun. 30, 2023 Revenues: Â Â Â Â Â Â Finance receivable interest income, including fees $ 10,680 $ 10,719 $ 9,278 Â $ 21,399 $ 18,538 Pharmaceutical development 804 279 183 Â 1,083 301 Other 57 46 36 Â 103 69 Total revenues 11,541 11,044 9,497 Â $ 22,585 $ 18,908 Net income $ 4,395 $ 126 $ 3,934 $ 4,635 Â Â Basic net income per share $ 0.35 $ 0.01 $ 0.31 Â $ 0.36 $ 0.67 Diluted net income per share $ 0.35 $ 0.01 $ 0.31 Â $ 0.36 $ 0.67 Assets: Â Â Â Â Â Â Finance receivables, net of allowance for credit $ 265,470 $ 261,272 Â Â $ 265,470 Â Total assets 321,374 322,337 Â Â 321,374 Â Stockholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit (4,140,280) (4,144,675) Â Â (4,140,280) Â Ending balance, value $ 283,204 279,553 $ 273,884 $ 274,385 $ 283,204 $ 273,884 Previously Reported [Member] Â Â Â Â Â Â Revenues: Â Â Â Â Â Â Finance receivable interest income, including fees Â 11,454 Â Â Â Â Â Pharmaceutical development Â 279 Â Â Â Â Other Â 46 Â Â Â Â Â Total revenues Â 11,779 Â Â Â Â Net income Â $ 861 Â Â Â Â Basic net income per share Â $ 0.07 Â Â Â Â Diluted net income per share Â $ 0.07 Â Â Â Â Assets: Â Â Â Â Â Â Finance receivables, net of allowance for credit Â $ 261,285 Â Â Â Â Total assets Â 322,350 Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit Â (4,143,940) Â Â Â Â Ending balance, value Â 280,288 Â Â Â Â Revision of Prior Period, Adjustment [Member] Â Â Â Â Â Â Revenues: Â Â Â Â Â Â Finance receivable interest income, including fees Â (735) Â Â Â Â Pharmaceutical development Â Â Â Â Other Â Â Â Â Â Total revenues Â (735) Â Â Â Net income Â $ (735) Â Â Â Basic net income per share Â $ (0.06) Â Â Â Diluted net income per share Â $ (0.06) Â Â Â Assets: Â Â Â Â Â Â Finance receivables, net of allowance for credit Â $ (13) Â Â Â Â Total assets Â (13) Â Â Â Â Stockholdersâ€™ equity: Â Â Â Â Â Â Accumulated deficit Â (735) Â Â Â Â Ending balance, value Â $ (735) Â Â Â Â X - ReferencesNo definition available. + Details Name: swkh_PharmaceuticalDevelopmentRevenue Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_InterestAndFeeIncomeLoansAndLeases Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue that is not accounted for under Topic 606, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)(e)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomerOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.2.u1 SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative) 6 Months Ended Jun. 30, 2024 Number Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Number of Operating Segments 2 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Income per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Net income per share Â Â Â Â Â Net income $ 4,395 Â $ 3,934 $ 4,521 $ 8,569 Weighted-average shares outstanding 12,457,000 Â 12,741,000 12,466,000 12,787,000 Effect of dilutive securities 71,000 Â 44,000 68,000 43,000 Weighted-average diluted shares 12,528,000 Â 12,785,000 12,534,000 12,830,000 Basic net income per share $ 0.35 $ 0.01 $ 0.31 $ 0.36 $ 0.67 Diluted net income per share $ 0.35 $ 0.01 $ 0.31 $ 0.36 $ 0.67 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Net Income per Share (Details Narrative) - shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Net income per share Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 159,000 118,000 161,000 119,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables, Net (Details) - USD ($) $ in Thousands Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Total before allowance for credit losses $ 278,553 Â $ 288,405 Â Â Allowance for credit losses (13,083) Â (13,901) $ (11,104) $ (11,846) Total carrying value 265,470 $ 261,272 274,504 Â Â Life Science Term Loans [Member] Â Â Â Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Total before allowance for credit losses 213,683 Â 221,145 Â Â Allowance for credit losses (8,786) Â (9,731) (8,328) Life Science Royalty Purchases [Member] Â Â Â Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Â Â Â Total before allowance for credit losses 64,870 Â 67,260 Â Â Allowance for credit losses $ (4,297) Â $ (4,170) $ (2,776) $ (11,846) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph c -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (3) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6:

http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-29Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (2) -Publisher SECReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-K (SK) -Number 229 -Section 1404 -Paragraph a -Publisher SECReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-80Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5 + Details Name: us-gaap_NotesReceivableGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceRoyaltyPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables, Net (Details 2) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Allowance at beginning of period $ 13,901 $ 11,846 Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest 11,786 Provision (benefit) for credit losses 5,182 (682) Write offs (6,000) (11,846) Allowance at end of period 13,083 11,104 Life Science Term Loans [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Allowance at beginning of period 9,731 Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest 8,900 Provision (benefit) for credit losses 5,055 (572) Write offs (6,000) Allowance at end of period 8,786 8,328 Life Science Royalty Purchases [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Allowance at beginning of period 4,170 11,846 Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest 2,886 Provision (benefit) for credit losses 127 (110) Write offs (11,846) [1] Allowance at end of period $ 4,297 $ 2,776 [1] Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023. X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph c -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (3) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of writeoff of financing receivable, charged against allowance for credit loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForLoanLeaseAndOtherLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceRoyaltyPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables, Net (Details 3) - USD ($) $ in Thousands Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Total before allowance for credit losses $ 278,553 Â $ 288,405 Â Â Allowance for credit losses (13,083) Â (13,901) $ (11,104) $ (11,846) Total carrying value 265,470 $ 261,272 274,504 Â Â Life Science Term Loans [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases 213,683 Â 221,145 Â Â Total before allowance for credit losses 213,683 Â 221,145 Â Â Allowance for credit losses (8,786) Â (9,731) (8,328) Life Science Royalty Purchases [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases 64,870 Â 67,260 Â Â Total before allowance for credit losses 64,870 Â 67,260 Â Â Allowance for credit losses (4,297) Â (4,170) $ (2,776) $ (11,846) Nonperforming Financial Instruments [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Total before allowance for credit losses 22,444 Â 25,982 Â Â Allowance for credit losses (3,368) Â (1,447) Â Â Total carrying value 19,076 Â 24,535 Â Â Nonperforming Financial Instruments [Member] | Life Science Term Loans [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases 6,010 Â 9,128 Â Â Nonperforming Financial Instruments [Member] | Life Science Royalty Purchases [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases 16,434 Â 16,854 Â Â Performing Financial Instruments [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Total before allowance for credit losses 256,109 Â 262,423 Â Â Allowance for credit losses (9,715) Â (12,454) Â Â Total carrying value 246,394 Â 249,969 Â Â Performing Financial Instruments [Member] | Life Science Term Loans [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases 207,673 Â 212,017 Â Â Performing Financial Instruments [Member] | Life Science Royalty Purchases [Member] Â Â Â Â Â Financing Receivable, Credit Quality Indicator [Line Items] Â Â Â Â Â Royalty purchases $ 48,436 Â $ 50,406 Â Â X - DefinitionAmount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph c -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (3) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-29Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79 + Details Name: us-gaap_FinancingReceivableRecordedInvestmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7AReference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-29Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (1) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph a -Subparagraph (2) -Publisher SECReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-K (SK) -Number 229 -Section 1404 -Paragraph a -Publisher SECReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-80Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -

Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5 + Details Name: us-gaap_NotesReceivableGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceRoyaltyPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentPerformanceStatusAxis=us-gaap_NonperformingFinancingReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentPerformanceStatusAxis=us-gaap_PerformingFinancingReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables, Net (Details 4) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Â $ 77,925 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year Â 63,420 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Â 49,416 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Â 28,295 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Â 37,503 Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year Â 31,846 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss Â 288,405 Life Science Term Loans [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year $ 55,712 50,140 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 62,526 63,420 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 38,626 45,582 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year 34,145 37,503 Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 22,674 24,500 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 213,683 221,145 Life Science Term Loans [Member] | Pass [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 13,835 13,734 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year 4,991 5,696 Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 18,826 19,430 Life Science Term Loans [Member] | Special Mention [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year 31,108 25,799 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 57,988 32,211 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 9,328 10,485 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 98,424 68,495 Life Science Term Loans [Member] | Substandard [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year 24,604 24,341 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 24,285 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 10,718 10,227 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year 29,154 31,807 Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 64,476 90,660 Life Science Term Loans [Member] | Doubtful [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 6,924 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 12,601 12,493 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 13,346 14,015 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 25,947 33,432 Life Science Term Loans [Member] | Unlikely to be Collected Financing Receivable [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 4,538 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 1,472 9,128 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 6,010 9,128 Life Science Royalty Purchases [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year 12,110 27,785 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 11,985 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 3,564 3,834 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year 30,115 28,295 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 7,096 7,346 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 64,870 67,260 Life Science Royalty Purchases [Member] | Pass [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year 12,110 27,785 Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year 11,985 Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year 16,595 14,650 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 1,297 1,340 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 41,987 43,775 Life Science Royalty Purchases [Member] | Special Mention [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year 3,087 3,212 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 3,362 3,419 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss 6,449 6,631 Life Science Royalty Purchases [Member] | Substandard [Member] Â Â Accounts, Notes, Loans and Financing Receivable [Line Items] Â Â Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year 3,564 3,834 Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year 10,433 10,433 Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year 2,437 2,587 Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss $ 16,434 $ 16,854 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsNotesAndLoansReceivableLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost excluding accrued interest, before allowance for credit loss, of financing receivable. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3BReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5 + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, of financing receivable originated more than five years prior to current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, of financing receivable originated four years prior to current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, of financing receivable originated three years prior to current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, of financing receivable originated in current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest, of financing receivable originated two years prior to current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost excluding accrued interest of financing receivable originated in fiscal year prior to current fiscal year. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3B + Details Name: us-gaap_FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit

Period Type: instant X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceTermLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternalCreditAssessmentAxis=us-gaap_PassMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternalCreditAssessmentAxis=us-gaap_SpecialMentionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternalCreditAssessmentAxis=us-gaap_SubstandardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternalCreditAssessmentAxis=us-gaap_DoubtfulMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InternalCreditAssessmentAxis=us-gaap_UnlikelyToBeCollectedFinancingReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=swkh_LifeScienceRoyaltyPurchasesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Finance Receivables (Details Narrative) $ in Thousands Jun. 30, 2024 USD ($) Trio Healthcare Ltd [Member] Â Defined Benefit Plan Disclosure [Line Items] Â Loans and Leases Receivable, Gross $ 1,500 Exeevo Inc [Member] Â Defined Benefit Plan Disclosure [Line Items] Â Loans and Leases Receivable, Gross 4,500 Flowonix Medical Inc [Member] Â Defined Benefit Plan Disclosure [Line Items] Â Loans and Leases Receivable, Gross 10,400 Best Royalty [Member] Â Defined Benefit Plan Disclosure [Line Items] Â Loans and Leases Receivable, Gross 2,400 Ideal Implant Inc [Member] Â Defined Benefit Plan Disclosure [Line Items] Â Loans and Leases Receivable, Gross $ 3,600 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DefinedBenefitPlanDisclosureLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts. Excludes loans and leases covered under loss sharing agreements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_LoansAndLeasesReceivableGrossCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=swkh_TrioHealthcareLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=swkh_ExeevoIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=swkh_FlowonixMedicalIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=swkh_BestRoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=swkh_IdealImplantIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Indefinite-Lived Intangible Assets [Line Items] Â Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill $ 450 $ 29,850 Finite-Lived Intangible Assets, Accumulated Amortization 218 23,363 Intangible Assets, Current 232 6,487 Trademarks and Trade Names [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill 210 210 Finite-Lived Intangible Assets, Accumulated Amortization 102 92 Intangible Assets, Current $ 108 $ 118 Finite-Lived Intangible Asset, Useful Life 10 years 10 years Customer Relationships [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill $ 240 $ 240 Finite-Lived Intangible Assets, Accumulated Amortization 116 104 Intangible Assets, Current $ 124 $ 136 Finite-Lived Intangible Asset, Useful Life 10 years 10 years Licensing Agreements [Member] Â Â Indefinite-Lived Intangible Assets [Line Items] Â Â Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [1] Â $ 29,400 Finite-Lived Intangible Assets, Accumulated Amortization [1] Â 23,167 Intangible Assets, Current [1] Â $ 6,233 Finite-Lived Intangible Asset, Useful Life Â 10 years [1] Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (â€œCaraâ€), for oral formulation rights to Enterisâ€™ PeptelligenceÂ® technology to develop and commercialize Oral KORSUVATM in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the â€œLoss on impairment of intangible assetsâ€ section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024. X - DefinitionAmount of intangible assets, excluding goodwill, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10 + Details Name: us-gaap_IntangibleAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details 2) $ in Thousands Jun. 30, 2024 USD ($) Goodwill and Intangible Assets Disclosure [Abstract] Â Remainder of 2024 $ 23 2025 45 2026 45 2027 45 2028 45 Thereafter 29 Total $ 232 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Intangible Assets (Details Narrative) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Amortization of Intangible Assets $ 200 $ 400 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type:

xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Disclosure [Abstract] Â Â 2027 Senior Notes $ 32,969 $ 32,969 Debt issuance costs (1,891) (2,188) Total unsecured senior notes, net $ 31,078 $ 30,781 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Details 2) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Debt Disclosure [Abstract] Â Â Remainder of 2024 Â 2025 Â 2026 Â 2027 32,969 Â Total unsecured senior notes, net $ 32,969 $ 32,969 X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Debt (Details Narrative) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Oct. 10, 2023 Jun. 28, 2023 Short-Term Debt [Line Items] Â Â Â Â Â Â Line of Credit Facility, Maximum Borrowing Capacity Â Â Â Â $ 60,000 $ 45,000 Interest Expense, Operating and Nonoperating $ 1,119 $ 363 $ 2,375 $ 545 Â Â Line of Credit [Member] Â Â Â Â Â Â Short-Term Debt [Line Items] Â Â Â Â Â Â Interest Expense, Operating and Nonoperating $ 1,100 $ 400 $ 2,400 $ 500 Â Â X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_ShortTermDebtLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Â Â Operating lease cost $ 134 $ 125 $ 259 $ 222 Variable lease cost 17 23 32 24 Total lease cost $ 151 $ 148 $ 291 $ 246 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details 2) $ in Thousands Jun. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Remainder of 2024 $ 283 2025 456 2026 461 2027 465 2028 405 Thereafter 272 Total future lease payments $ 2,342 X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Dallas Texas Office [Member] Â Â Entity Addresses [Line Items] Â Â Operating Leases, Rent Expense $ 300 $ 200 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_EntityAddressesLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesNo definition available. + Details Name: us-gaap_LeaseAndRentalExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: dei_EntityAddressesAddressTypeAxis=swkh_DallasTexasOfficeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Financial Assets Â Â Â Â Warrant assets $ 835 $ 1,759 Â Â Financial liabilities: Â Â Â Â Contingent consideration payable 4,900 Â Â Fair Value, Inputs, Level 1 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets Â Â Foreign currency forward contract Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â Â Â Fair Value, Inputs, Level 2 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets Â Â Foreign currency forward contract Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â Â Â Fair Value, Inputs, Level 3 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets 835 1,759 Â Â Foreign currency forward contract 2,629 974 Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â 4,900 Â Â Fair Value, Recurring [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets 835 1,759 Â Â Marketable investments 731 48 Â Â Foreign currency forward contract 2,629 974 Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â 4,900 Â Â Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets Â Â Marketable investments 696 Â Â Foreign currency forward contract Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â Â Â Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets Â Â Marketable investments Â Â Foreign currency forward contract Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â Â Â Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Â Â Financial Assets Â Â Â Â Warrant assets 835 1,759 $ 1,459 $ 1,220 Marketable investments 35 48 Â Â Foreign currency forward contract $ 2,629 974 Â Â Financial liabilities: Â Â Â Â Contingent consideration payable Â $ 4,900 Â Â X - ReferencesNo definition available. + Details Name: swkh_FinancialAssetsAbstract Namespace Prefix: swkh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_FinancialLiabilitiesAbstract Namespace Prefix: swkh_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_WarrantAssets Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of contingent consideration in a business combination that is classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details 2) - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair value - December 31, 2023 $ 1,759 Â Fair value - June 30, 2024 835 Â Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair value - December 31, 2023 1,759 Â Fair value - June 30, 2024 835 Â Fair Value, Recurring [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair value - December 31, 2023 1,759 Â Fair value - June 30, 2024 835 Â Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair value - December 31, 2023 1,759 $ 1,220 Issued 822 Exercised (984) Change in fair value 130 (583) Loss on foreign currency transactions (70) Fair value - June 30, 2024 $ 835 $ 1,459 X - ReferencesNo definition available. + Details Name: swkh_WarrantAssets Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: swkh_WarrantExercised Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_WarrantForeignExchange Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap_FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details 3) - Warrant [Member] 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate 0.00% Â Minimum [Member] Â Â Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.30% 3.80% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 2 years 4 months 24 days 1 year 2 months 12 days Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 73.00% 75.30% Maximum [Member] Â Â Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.70% 4.80% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 5 years 3 months 18 days 5 years 9 months 18 days Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 177.70% 154.30% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details 4) - Fair Value, Nonrecurring [Member] - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â December 31, 2023 $ 8,448 $ 2,587 Fair Value, Inputs, Level 1 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â December 31, 2023 Fair Value, Inputs, Level 2 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â December 31, 2023 Fair Value, Inputs, Level 3 [Member] Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â December 31, 2023 $ 8,448 $ 2,587 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details 5) - USD ($) $ in Thousands Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Financial Assets Â Â Â Finance receivables, net $ 265,470 $ 261,272 $ 274,504 Marketable investments 731 Â 48 Warrant assets 835 Â 1,759 Financial liabilities Â Â Â Contingent consideration payable Â 4,900 Fair Value, Inputs, Level 1 [Member] Â Â Â Financial Assets Â Â Â Finance receivables, net Â Marketable investments 696 Â Warrant assets Â Foreign currency forward contract Â Financial liabilities Â Â Â Contingent consideration payable Â Â Fair Value, Inputs, Level 2 [Member] Â Â Â Financial Assets Â Â Â Finance receivables, net Â Marketable investments Â Warrant assets Â Foreign currency forward contract Â Financial liabilities Â Â Â Contingent consideration payable Â Â Fair Value, Inputs, Level 3 [Member] Â Â Â Financial Assets Â Â Â Finance receivables, net 265,470 Â 274,504 Marketable investments 35 Â 48 Warrant assets 835 Â 1,759 Foreign currency forward contract 2,629 Â 974 Financial liabilities Â Â Â Contingent consideration payable Â Â 4,900 Reported Value Measurement [Member] Â Â Â Financial Assets Â Â Â Finance receivables, net 265,470 Â 274,504 Marketable investments 731 Â 48 Warrant assets 835 Â 1,759 Foreign currency forward contract 2,629 Â 974 Financial liabilities Â Â Â Contingent consideration payable Â Â 4,900 Estimate of Fair Value Measurement [Member] Â Â Â Financial Assets Â Â Â Finance receivables, net 265,470 Â 274,504 Marketable investments 731 Â 48 Warrant assets 835 Â 1,759 Foreign currency forward contract $ 2,629 Â 974 Financial liabilities Â Â Â Contingent consideration payable Â Â $ 4,900 X - ReferencesNo definition available. + Details Name: swkh_WarrantAssets Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of contingent consideration in a business combination that is classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_NotesAndLoansReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Fair Value Measurements (Details Narrative) - Warrant [Member] 6 Months Ended 12 Months Ended Jun. 30, 2024 Dec. 31, 2023 Weighted Average [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.40% 4.30% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 4 years 2 months 12 days 3 years 4 months 24 days Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 102.70% 124.60% Median [Member] Â Â Fair Value Measurement Inputs and Valuation Techniques [Line Items] Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 4.30% 3.80% Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term 4 years 6 months 4 years 4 months 24 days Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate 90.80% 134.40% X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_WeightedAverageMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MedianMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Financing Receivable, Past Due [Line Items] Â Â Â Â Â Pharmaceutical Development $ 11,541 $ 11,044 $ 9,497 $ 22,585 $ 18,908 Total contract revenue 804 $ 279 183 1,083 301 Licensing Agreements [Member] Â Â Â Â Â Financing Receivable, Past Due [Line Items] Â Â Â Â Â Â Pharmaceutical Development 49 Â 10 49 10 Pharmaceutical Development Services [Member] Â Â Â Â Â Financing Receivable, Past Due [Line Items] Â Â Â Â Â Â Pharmaceutical Development $ 755 Â $ 173 $ 1,034 $ 291 X - ReferencesNo definition available. + Details Name: swkh_PharmaceuticalDevelopmentRevenue Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-80 + Details Name: us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_Revenues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancingReceivablePortfolioSegmentAxis=swkh_PharmaceuticalDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Revenue Recognition (Details 2) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Revenue from Contract with Customer [Abstract] Â Â Deferred income $ 2,216 $ 9 Total contract liabilities $ 2,216 $ 9 X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DeferredRevenue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Mar. 31, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Financing Receivable, Past Due [Line Items] Â Â Â Â Â Revenue $ 11,484 Â $ 9,461 $ 22,482 $ 18,839 Other revenue 57 $ 46 36 103 69 Provision for credit losses 4,074 Â (682) 9,397 Â Loss on impairment intangible assets 5,771 Â 5,771 Interest expense 1,119 Â 363 2,375 545 Pharmaceutical manufacturing, research and development expense 520 Â 1,509 1,050 2,228 Change in fair value of acquisition-related contingent consideration (4,900) Â (4,900) Depreciation and amortization expense 421 Â 637 935 1,285 General and administrative expense 2,923 Â 2,997 5,607 5,537 Other expense, net 3,817 Â 715 3,435 (81) Income tax expense 1,035 Â 1,454 1,264 1,345 Net income (loss) 4,395 Â 3,934 4,521 8,569 Benefit for credit losses 4,074 Â (682) 9,397 (682) Financing Receivable [Member] Â Â Â Â Â Financing Receivable, Past Due [Line Items] Â Â Â Â Â Revenue 10,680 Â 9,278 21,399 18,538 Other revenue 57 Â 36 103 67 Provision for credit losses 4,074 Â (682) 9,397 Â Loss on impairment intangible assets Â Â Â Interest expense 225 Â 363 590 545 Pharmaceutical manufacturing, research and development expense Â Change in fair value of acquisition-related contingent consideration Â Â Â Depreciation and amortization expense Â General and administrative expense 91 Â 137 169 167 Other expense, net 3,851 Â 715 3,843 (81) Income tax expense Â Net income (loss) 10,198 Â 10,211 15,189 18,494 Benefit for credit losses Â Â Â Â (682) Pharmaceutical Development Services [Member] Â Â Â Â Â Financing Receivable, Past Due [Line Items] Â Â Â Â Â Revenue 804 Â 183 1,083 301 Other revenue Â Provision for credit losses Â Â Loss on impairment intangible assets 5,771 Â Â 5,771 Â Interest expense 2 Â 5 Pharmaceutical manufacturing, research and development expense 520 Â 1,509 1,050 2,228 Change in fair value of acquisition-related contingent consideration (4,900) Â Â (4,900) Â Depreciation and amortization expense 400 Â 633 892 1,277 General and administrative expense 748 Â 981 1,457 1,709 Other expense, net Â Income tax expense Â Net income (loss) (1,737) Â (2,940) (3,192) (4,913) Benefit for credit losses Â Â Â Â Holding Company And Other [Member] Â Â Â Â Â Financing Receivable, Past Due [Line Items] Â Â Â Â Â Revenue Â Other revenue Â 2 Provision for credit losses Â Â Loss on impairment intangible assets Â Â Â Interest expense 892 Â 1,780 Pharmaceutical manufacturing, research and development expense Â Change in fair value of acquisition-related contingent consideration Â Â Â Depreciation and amortization expense 21 Â 4 43 8 General and administrative expense 2,084 Â 1,879 3,981 3,661 Other expense, net (34) Â (408) Income tax expense 1,035 Â 1,454 1,264 1,345 Net income (loss) $ (4,066) Â $ (3,337) $ (7,476) (5,012) Benefit for credit losses Â Â Â Â X - ReferencesNo definition available. + Details Name: swkh_ChangeInFairValueOfAcquisitionrelatedContingentConsideration Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: swkh_RevenuesExcludingOtherRevenue Namespace Prefix: swkh_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 80 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479294/326-20-55-80 + Details Name: us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingIncomeExpenseNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense related to estimated loss from loan and lease transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForLoanAndLeaseLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related to credit loss from transactions other than loan and lease transactions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_ProvisionForOtherCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of revenue that is not accounted for under Topic 606, classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)(e)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_RevenueNotFromContractWithCustomerOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_FinancingReceivablePortfolioSegmentAxis=us-gaap_FinanceReceivablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancingReceivablePortfolioSegmentAxis=swkh_PharmaceuticalDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancingReceivablePortfolioSegmentAxis=swkh_HoldingCompanyAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.2.u1 Segment Information (Details Narrative) 6 Months Ended Jun. 30, 2024 Number Segment Reporting [Abstract] Â Number of Reportable Segments 2 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (/""#ED'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\QO;=!P4)B0-!2L+(/>QLOD&1#&LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #P@@Y9S_=9?>X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R'"&";- I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,1@M(? MZH@@.+\'AZ2,(@4SL @+D;6-T5)'5-3'"]H!1\^8Y=A1@-VZ-!3@JJL@+7S MQ' >NP9N@!E&&%WZ+J!9B+GZ)S9W@%V28[)+:AB&GW4M>M[^ MD?(:IU_)2CH'7+/KY-=Z\[C?LE9PL2KX0U&M]H)+44O!WV?7'WXW8=<;>[#_ MV/@JV#;PZR[:+U!+ P04 " #P@@Y9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z"> P'_T=HWPJOX@L Y M?RY]SZ7ON? 0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\YZ<5X&N(YV02Y?9A7;>? 8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYV= <7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8]*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68WXX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M /""#EG6LL@ 4 8)$C 8 >&PO=V]R:W-H965T&UL MM9IK<]I&%(;_R@Z]3# (3C+3BFMK,8&PWAR'&)HT[?3#6EI 8TE+5RNP_WW/ M"B%AS^I --;7! 'G]3Y[X]'E="/D0[SD7)'',(CBL\92J=7[5BMVESQD\8E8 M\0@^F0L9,@6'^^GP3[[TF&N5>B =]<.V=-2S=(AYP5^D(!O^M^9@'@4Z"=OR7 MA3;ROZD+]U_OTJ]2>("Y9S$?B^";[ZGE6:/?(!Z?LR10=V+S@6= '9WGBB!. M_R6;[7?;@P9QDUB),"N&%H1^M/V?/68=L5]@EQ30K("^*+#;)05.5N"DH-N6 MI5@73+'AJ10;(O6W(4V_2/LFK08:/]+#.%42/O6A3@W'8LTE:9)XR22/3UL* M,O4G+3>K/]_6TY+Z+ODD(K6,R67D<>]Y?0O:DC>([AIT3M' /Y+HA#C6.T(M MVC:T9XR7CY+%";'ZIO)GS7'R_G'2/*+V6Z"MC"Q(37SUD0 MF[IBC)95A.KD4)WCQNE+PJ3B,G@B=WPEI#+QX5%*)D8\M*HB7C?'ZQXY#26# M+33= <8 3+GWAZ>V$P(9F7')X4KZ!E.X@:'U%SG[. MV3^.\\J/71;L<*_@;>/NBZ=]H28^M*8BWR#G&_P0WW?.9#D=GE4V?FA513[; M*GXP+;15XT3*EX#8;#T0UVS:M.G8)DZ\LBKHGAG8:,LN(^6K)^ ,.+E-PGLN MC7AXB&7936=@]XT#B==6!:0%(#T&\(XO_%C!OJK(+0O-8X@'3;']])!]$X/G1 M(B9C(6%?9GJ+-C*C4569"YVQ<2')F,06T^\=F2K8E(B0,"D3&' 8=^&9)_@!N[HT(M=A1':A1#;N,1GR MR/,@/7ZW>T%NX'ODXH[U$4SHF=B8MM?S W$7+ B8247&>&%5 MSD*;;-QU7G+F*WA$Q I^B/[V5Z6; MTX'$7H?2CO%*01W^1 M_HKCZI%-U)#W@QZ]*T1K YOHH4W45QW;D1Z MYK(4$2:&!T*Z_5ZS1\U[#EY:E:]P)'J<(V6BOSW/!K=+%Z7Y1.9 XG?CI;4Q M7E65LW D>I0C74>*R^WE5'T2PW;@1DX\L8RS#C>BA1O1H]Q(G\B "<&^NA#2 M*+P' M5A6O,"!ZE %=AEPN]*K\'1+4$C;9<,4B\[CB@:47Q/"ZJJ"%^]"CW =\%,81 MP\-CRO'J4!Y:* \]2GD +(33LJD2[@-X3WH?@GQ.%&A!I,^HC<2OY#!9/VS3 MVFF:ON^U'MK4Z=I]_>NT-C ZA>TX!RX6[<&1"9/D*PL23JP3 B?/^N+?%IC\ M\XGKW]%_C7<87DECLCL/=4B14TB1@SO-S%.V % MIP]&KCK$R=F[5X9KSFXTR>6CNV31@I=>4#L0=#N:7HS,-\[J4":G4"8'%QP@ M) .]>&'F1CZOHY?R8*RCJC#J9S"J1S-) UBN MOSSO3B_K3B-W'6[E%&[EX$YTQ-+% _32O3&"U6%53F%5SH&+0,>O73P(6;NO MJE.MO8<>3M JFSX+$Q-57.K?//^3OYL^;C-*G+%K%U[,!@ #!L !@ !X;"]W;W)K=N3&+XUY/IW.> M,WTD%[R)S.IL/3!7O@$V[N%M<*KGH;*U.1\T(+62#% M9V>==0*+B&<\-=8$@Y\5' _$LLY8 MQ_*:& M*C-=_D=/E6S00>E2&YE7RH @%\7ZE_VJ K&E@,,6!5(ID+S%&H^]7XXNK MR7HT^?[UP;06)N]M)KYTWIFTC+S7\OB"-&@BTA 0H?ZR*\^YBFHXU*=[JKW(;;0)!- M($AI+VJQ-UHJQ0N#F-;$>TO0 M% IC,G [T=\XT?(0&@2A&V"\ 1A[=Y*P[(W M (R:,#3+M!0LO=8L># (./]@D43[XIGN5SJ(<\O^=]721>"F,7IM4+7G)E M]NR*3-+PF?2C, [V0N,0BR'%6Y9OL(G-P%^(9)8QR!-80Z!TB &PE$M9_IL M;SPQ!>DO"Z. \%WX!PY@T3[Z5X1VL..@IL[B_X;4X_MY60RM# MNQF,]T ZA,*D!>,6O6,OQC&?<8CF%!GVJ\/UC)3F=H-4Q#M9XE++"&#MG#6 M!(R]G#?\P91BWBRN#&S/G-!H'UY3",=12Q+CFC*QGS.AGK/B093%^Y4PTF9\ M:".(3:%^F,0M*&O*Q'[.O%;0X"OS7)8$2^P+NR?;H3:)+PJ"9!^K0RJD;5NS M)DCL9\@UN12R.'RJ?F,'NVU7GPIH4XKBH&WI:Q+$? A9SGU?.7MFK! MGC<]%?1::@G5;BL2SD TZ8S"3ME?+X?48*O>[*O.0_[26]3DD61RIP[\3D(MB^#^/KZF5,M>)S6G$3^G[394KX21-!DKBL@^3(<4'80MFY[4S$;\S#:"ID 4 M#Q8F] =:3*&-*-

\,5/O!"=AK\AT'!M+DP' 0M% @V3J#^BGPKM <8@][0_-" M2%L=C>=<0)I4!{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{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Ÿ# S$!%[V>WJXD]Q^;RK&GNZ-F;K.S! M!,2U-1IQI7\KB:46$BAYH8>J O6Z;\%T^^B)>(?(7/0E25%,29Z@Z,&?Y.!/ MXC7N[#>R$7'(5V+O/?0**6=5*QZ(*(S]=!73IRCTPV3AO:WOLK*[$X>^@WGFV8=@(P ; MC_C3.d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nIJn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qYQEU3S^;;,^[@T&_# M9YT?ZA?*SOC/$>CF"D:$W^S;M^U?/$S"#_V;Y>')/3#KS.A^LU YM@XT\Q>] MD%/-@S<5_^P -=Z;!7^<*PDC: &^SPW"/S[0 >W?@=S^%U!+ P04 " #P M@@Y9F52/HE * "*&0 &0 'AL+W=OO(#S%H 5K*S]D[[\DET,)F20,BH-)$'BWU9=*V-($,SXWL@< M="II8_^ZE?XS^PY?5M*K:VO^T%G87 Q.!R)3N:Q-N+& [OZG&GR7)2ZW9_*EV M<>UR-A!![8,MFLVPH-!E_ "_OFCCT-IQ.GM@P:S;,V.ZHB*W\((.\'=V)QRM MAC2Z8%=*5Y^3)27E-C@\U=@7+]JM4>B * B$)7,CRLA(+WUE4S5Q0(! M\#RQQ^F)Y-
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|YF8+9+ ($8>"EE/Z7)R2B#.ZGBU.Q,JUH/&!6+RH"V:5MC<]Q-2CAG88'[$ M_ ZKJIF8M:H_-:IO2/4-UVN&!$;}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|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|L*N\&YJ[,O??)#:BE]D6BCQDY*NL H:SJVK MLQS$:PA=BI],EB^<^#Y+5-+>?P:F*LZ&)6=OAX\2_ 'N1]<5H MT!/#P7#|"+U1)>F(Z5T\+>E[!>+4D+!__MVZG(+Y_CW+ID]R=%NDA0P-VXE M8_7Z"!*AE+U71V^^^;\C<D822NRQ2IVF MZEZE8J&5E39>X% 2! <(5#@*L%W0DT]79G+64>,^DK[5^^F0_AYY[=3TYM"$ M5]4"Z4\),R7O"&M6 M1>Y.F"NBC^S=)!^!/-0]L4L@ I19D,V3N8CX*T_\E'G-^+G3":_ M(5.#F;;"M]7,YH>./\26_Z%@BMT@J\0(B5= (@!S$*8#0EQA12.L MH%D^+2I/HX-B@_H)A_?Q,B5QC&,/6"JTOA&@>,CB9>=Y(6)X\+23E?,H%E- MG,ZL^KU@DY.?W)L41J6#5M;9R8->>\2B]ZL@#MVO?:XG%-P(62#1R!HY@I[7E]]Z++ K4 #@)LA7 ME!7(PIDE5S997"]$HO52XAJ&5TU]B=,"SM,).::OEP@[NT>IVSY"BMRF M4GE"= A)). 6T5*_(_+66C]1T%VIU=A8:Z;&2CI\NBG3(<7YEL#XC.I@-24R MJ.E/5(5$U>V(CK8$F7%PO_? &2*9,L,$7&QDE(".#11"Q-@B DR9<*'IV8U,R) M9L&I25< M'&<#Y)+L5"([^8&/@I<9,/('!:P/H545F\B V?G$3B*PI1 J5>$J-@H^O)CA\U,B& MC8"%74(\B/VYM)7U2*CKXBCA'97,J9,P2WTJJJQ 8H% MYZ03QQYN@$!$:S:$@" H'^7@8P;4:%=*+ &"6;A|4^:CIB3NUJ>+"A(H0(HKV-\,'AQ;+ MP'B1X|P_R!7?2;>(:&F,#P(E "I+*]@82VLWC&CVF'HJ4R@6OLEM)Z4WIK.3 MH%S!]QXX*01.O1X" <&C(3EIGBZGH,V-$BF977;-.V23H%^.33'"6*1 C8W+ M>V4QJ8]V. ^%8T'F5_DIPZ@]II3.7F,@5226 "BSH##X"L66Z<0IV\8N")UL^ M-B2.ML82KPS<0PM+_2VOB2$,$"EID7,FX2$BQ5R1D _57 8T(=.X2!OYN5C!?QGLW$$5<%)(6S#\9*.BCA*O$&U5488S MR$T=;ZOZ>P1%HJ)DA+Q3UK)X192&% _MF$@LJR5EE^:SF5M::EFV:C+@3K MD5XK(-(3TR*/2K-Q"#6#BY,Z:YPT0!,-Q *DQWX(@'[)@RT?UIQ0Z\W+9G<5 M0C.N]E9 +6"D::KG/G=N93H85V9SCQU#2H'"%N66@RC4E+Z+2AG0ZA5:82+17 M=:
(6EG/X7LC=HTTYVT0C"3NQD*B.4TKIO++7\1V@/JBRA!LA"=^(8WGBRV(5 M)CYC>)$!7XGAZ$GI$,RT[O*!6&8/K>X^EPZ49_--0. ^(4,J'I=,USX5:O,-G4#SF'MZV M\TA.(*LV?@4C;.*- !M49(&P$EWI8J0RV"(T24!&Y#E=N7D+7 -=;A;11/G&6 M7]B/OK30$K((U,#0*E'E%^W1!3/HVX=@2*C-^!J/DZA!ARZ*U%?#9ATAN(4. MS1)9[E2;9;H9&OWHUE'0DKA3<|JRT*A"7/:":5$;G*833|N V!M%=>N_AN[6 MR$LYO#4QZXSL]F) &H5,;424D!%-1!#V7G<HHK3$ ^ MV!OYVWWPN(=JV64]B\^ML&\@I:W.F#- 4GIOX*B'9HSJKGN\?YI:

***P!:5U"@RDB\WM\0GNN)%>ZG&/#:OAH=TS:S2FWPK:T)-M^9"^M]V,H:M*F4V2XUK3.VOM1_M;3Q=-G*6K?\=BZ MYP*U2[E=5_(@!D=JW,K!T;I@VXFD'4€OK*4^TO^GTQ,O04*K;'1U-'TP3Z/^-M#QU)^W%;D_V3: M-_;0@##C80&W;^-,83L7J%&:!PPX-^RB4-ZJX.Z^'$*^RWH5#LED7RPJ"@A{}-M-K=DTUESX4R&_WWH C#'_VXPGG%(TD'\PXG=+CU M@-^4L]+GD3=04QULS>0&&L3]D*G)AE]AZM>+W;P4)/S1#2=U9;Z&}._8Q-M2ZW84G&&-9]EH1*NG67K? E!MX>LV=3._]QVS@M]6F7I\Z758Z0F\65Y!#-.MKHTI[VYRQ\P_2[.#8F67OE6(O]HBG>#KVV>7$O92]I2'W]OA$PKKHG>-G_(+C MLGTEM<,DO#<;-_E3D%;)4ZJZ=\{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|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

*MN&0;XN)6WSO9+K(PWV.!/>P^!V MN(4(R:V@L#)#;V5^#?((A96[?;>:62+4-VD M)JW.CXZ/=3#POP1Y'J2EF(1-?.KX,,<*YW$6W9=!7LK;&@T^:9_XA=9D=(3.*
*M<(B7CSA'Q^]G=#?BL?<6YC;/0HRCXH*4RF65M>EF4;FF&CV:E%RV'W8.=)L+ MO8;W:CT*IG!RB CB:$\1OWKW^1O.P[C D:92=&2<1785O&% :02\%[4.E;"2*
M4#_W'C+:,F83H[VO>4S9&#(,.G_DC#7SY?)!$P3N'OJ <-/M*$VN]O1.[Q':L.;Z10[R9M2^FD]1HZ^;MW^C6.Y@$&.H"P(Q%@/`JZ2Y,X_ M]97M2N5>7_V%!*
7A8SH#%=PESOW[ZS7 :$%;#O9_7.08P(=1Z?9DFY08ACG MM'TA.F`V&33BE1;,^=T]KJ[-KU>KEB'DVYQ"DL MM[FS'W&?AJN/,\43&1PY:F8'(P8/6)64??-]/-]!+A!7;GJ[8B]?X;:R((Z*
*M&&:H1H%]&(CB^++BP5U[IATX=3M5B =?2R!BG>D0=L&U*_V9P$"=UJU 7AK#$(VH5[,R4)<+0BG@8\#%]O M*TPVZX?2VWT$.=VGV018%;9R1%=-Y'6$-
,'-7MK&/*KMPYJ<;Y!>ID69KWF; MU3^*(_M\]BW=NS/K^(+QG7R$P17D6]F$=GYF1_YL\]3[?!X7#YS3^;2U/-_^7FE8>6 M6\#T\7:=;D#U/CAURST._R"4])6R,JQ?N;XD)G%7)V .;/CA
*M;Y^=#?!F$>%W&(1HFGA'Y)%O1DO-QH^^/I@.F\j/h;T4X%SQ.0ZN;MTG;_%MY5S<>^_.PPN[N&3U^ Ul&R@SLLG1.<8F**%]HH_M)U'V>DT/&=P[UO JRUERZWO\Q+; J+-:.11<1E:9
*M[ZQO55"MXV/JMDV0WIG\STE4BE=!4IU+$H; -DJ_1EGHK(S(N=0GM>,+9"+!L1 MCT'L22'?Z}&N3Z\]\:VGX,T7ZC6;7'L"@,Y8R7$-OSZ7FJ%*SNM'5G|=0/T. M0V9'YWT.WM)-
*(05!0"O5@-.&+&UHK[VYX%B^.(P/[7--_;T:>_ ++/S\G"41 M&>^?_]96+#.(4K_^#LR'UH 3LE6SQS,T+\L\?ESS9K',2",(@]WS-+(K$),. MS'[@AZJI'&P/'1?W5$BG6<'V$U:3#M(X-)0!5
A:$+N;2K((/WGDA3M=T+8A/ F5I<8)I:F@N]Q"\X>)CG&8YH4B=78CXV[?"&?01E\]9 M9[.0M"P=OAX037QX++=P544TI4?UO$"4%:H&@%@EZ9%"JL(#X"SIC'-)KJ4PQ MG#-
*ZDQl;3LZ2A%[J ?MJ>&D"C>)F718EJ63+3='0H!ZJFKL4ESBI "Z,CZ M#.W*V5SNL*4H!*1@-.6+PBHD=Q>D2%?8>1,[S*<;60!0ZR8>Y86Q%%=Y8G=W.8N 7\|J9PNF)!A
*M_M_+M+^:HX=LM,$5(PC4NZ'DP-?5T;^(;>0L/7$=L[[U.0M4[+GG?A@?G MH=OR"FG6 U22H^]=Z5RI5G5AB%)^7IKT-BL>_&0S4/2?\UQE>"@GL3*6-
*ZB00'7THQ7>,9R0\E)O;A-ZN0\;9Y-?55I4#RSA?<(1R>;3P6-1'QL29N1L(Q? ME-/1]MJ BG<":-E^$&H#U49H%K>OJ1W2B'Z#&E.HM>6Y^G9.2+)Y+UUE'J2D*.G_TU;Y)4@H$>]0),]C
MFLR7/B"-2_^`CJ1TG60;@X!F0'?CA["0^1FG!H=\1E]+2s%OGM@Q^[&KZF M6/EN,+X_C,X]9DD<;OC_/N"\WB11!,K14 Q8!Q>8;I5;2 G72 F2KZ6_5? M:@,QY(YX/G|/C|4|I3&>P+
*(K1] 2H".VQ*HZ; 2HL?=:/ZRR=AV&^YOEFUSQ+ ME;XZ;F$/4!'OQ V[O!'$6,"-52E2 +!BD!"I38%DEZ:PK<;A{[N27/"Y)4%W89A@RV@%4R%O!
*MMVLK&GN,"]PB*_L98B:SQ<(?!\CIK^(7,J"M#VCR@*4X0JC7@%6N-D E)4C4 MC(@>:A51O;?_VMNYPGJ=[UH881-XBD)2B-(J'1-"<9'OL4271;%FU8B)^RR+ MJRQ]HC>=45@?
25\R9VTZ&=XUDI/-F9O+!)]TU@^O.'G!'L.T?);O:M_&(\R MW8T?XGGRJ.FCD74[@Q5ECC™%_9QCZ?;,,98.NL!|#HPML'S;(VMND8J M;8$IJLBU=$$N8@IQUMBU69=Y8G=%!.
{\8T>W&_KM-EO{K>DSC3!Q@X1O[25/-MW&/O:8S;RH[36"-6N[ZM*DDO?9B1KANK+_~-+&@9:\OM"]]5&.!Z_M;%WEJ8U#+?+%+GF^[^=$7^(C_7/\"_>23E1G[Y_U!+ P04-M"
#Q@@Y9&^$)HDY !; 0 %0 '-W:V@M,C R-# V,S!?<')E+GAM;.U] M_W/;.++G[U=U_X,N5W7U7M5EDCB9F^-8Z/\[OXTOC6Z&W_[K^>5-WHD+*?!__=7 M[WYX^V!$?#>84W_Y]U>?
*9Z_'L\GEY:M1&#G^W$"G_SIE1^\^]__\|__VXC_MI_X_7KT04EWOR7T5G@OK[T%\%?1!?.BOPZ^!7XA#E1P/XZ^OMWQ8Ox&XO/Z MA(TFP6KMD8CP/Z0?_F7TXP\G[YW1Z]>-?
*G\G_CQ@GV\O=_T^1-$Z_.7-FZ>G MIQ_\X-%Y"MC7\ ]WMX^O\W^EY+_S:/^UU_$_]MW0C+B^O+# M7YY#^O=7XKO99Y_>_Q"PY9N3MV_?O?
*F_GZYF[@-9.:^]+_3FDE=;*M%+%=V[MCQ_ODG^NFU:.OE\S[SM-]Z_V;*SZYG_E2K;YS@)Z2]APMY5X#I1 KOV,R-I M"_&OU]MFK\6O7K\[>?W^W0_/X?S55OF):EG@D5NR&(G_
*M2$1=QVM1GLI^>Q!.#&#RX!\IXM+/H&M2#A;AY/WU+,PL"MRf^5?$Y]B>&FW; M<+3=N08@K0J=(3=L@=W>H:|4#&\9B3DO23T5_P;7!R3D.2+^G,RW'0G.@?%$
M$8U$VRS"Z]WHM0@'BP7#_,>T9<;'EA,O<|\^[HFP]: 0H+0-04N"HT+B_K , M'M_ ,"7TC5"-^2'24Z(?_XX_D0^/[,&.N[N3]9O[XB7[_\;%)]\:<.<[<=
M\Q\/H"R'FV4MWJR3,/?[@/U=E:P8,%*IK[L@X&2ZX#-"?O[]W=OWZ+KFYL\MN>0_A@"=Y]HBZUVB5[7R<^QG)Q8 ,#$<\)MA-3XF4)P*),,$8ZR%+MA@05*
*MGJ6S8.507XY&55O+8)"95@&#1*DDR*.HB45ZLQ6_^#5?(P$\'=..DVFW/_#% M<>L[_T16]_L5-*S00TEUH&P&_L=j5N1%%IFTA3,IDV\9@1?R/_Z(SX- M0<1A\C'AS7Y6 J&E
*B+P\AIXV M4W2%D$@SQ"U94G'J$*SL9%!&1(2[/G:::)1BHT$Q=CW8\>[)>N :1 X; E4 M_[15B=MS\H_]R.;;40%E>M8X@FSB0HQ*T<664&7CGF)54J(H?.
*(99HYWZ<_)\S_(1]7Q4E.HRG%/KTHY471^ MPZC(09I15S^?E-M"M8Y[9E5+BJ+V. ^?Y20$' /;""Y$;! M0J2([=++R$EDF(@6/;2;!7#GM:PBAN.">9 UT@(+.>#[G>@NS_PA)WJDPJ6P.
*MOL6R F%O)#,\1, R=P >,><+7R6]+ _]V;Z?P_7/^XI5RLOIOXG_ M>:?GTL90W>,>Q6(2YF'P%>ZA=3Y+]DD]Z@"?..>,[LMS'R]\JAU4VC'2+F$/:OZAA$!.>'|R1B322K
MLNEB(9N=5>VAJL<]1>HEQH7@,@QCPDR!J"""PH%[H(1*W_<41-R8SXB;=R?W M=R(/6S(!E5!E8Y(F1)UI.2KX,]YHB:@[/-ZC[PY)DUE0VAJL8].BIDI%G; M!WQ4Z[G0:!*IAW#-
*CI5Q(T\?YL_O@^$LB#\;H;@G5-.X94B4EVOR\!,W/2\Y M&?T_.,]$05KJ:!((.>]`J5'N7?X0CSO M'W!PY,^($P8^F:=`!M75@Y0$"H<-]YX:N5&P^#WP8JXNED3#.LFHD#2%ZMZ&
*M^TZ]G#@!]&FL]VM2T^$5*E>1@%%P(:+3[7?42"%Y$1$EN^@C.7.B)^-0!82_M -@$+9@:jG1$@W8A$NP#-0W_X6&4+7;$!A<*2.*MFS.)^E7MH0#8D<]EJAQ"!;1 V'Y75?"
*MC&!?%<.AIX+"@7L0ADJ/LQ#GJBHHU^&#=E#%VW#DK9(0)P$MOO>H>^$%CG)__M?]_JF@;SK<5\]J'H^=3QOI}X';F;&Q:XA"3OD>W&'^"$!>P BHT-)U\CG>!X
*M)/:52)/"H^$TCD(Q5W+^F'X))1T4(QL.Q1_(.V=PGW6')F?;FI)@C 1,'%' MGJ-3_]&OZJT4@!P*E!TUH<#ZJ,#K;V]* O)/?MW^M?*/|[V9O0;PV7=21_PD MX$1^F/P0!AZ=)
[PIGGCMC^1^1?:#]X_:F[]\NV4PW_^?#W^?'9Y=WXVFDRO MS\ZO9^E/L^G5Y=E8_/IT?#6^G1R/9K^=G|_-FC\OT*SB?M>72@NWJX"=+3B.(=
*M@J{M**EQBH.GSY7I92BVLZ5"+P"00F'P.HE;G0GK Y$MG5 \2LVOZ_M*E%N% M@$14=" F3O@@G@+C_SG_%M-'QQ.S]#B:.(QM^-J95#67 P,DQZX/K,8@J".2 M)?C=$BX,=
*<42=D>HIL6L*FZ &U0,Z8)E?*=R_D7I-5#-?=7/LJL,F MT"@E1L%$2.E[3$0BQY;H,OE%>\XQ^,;2V* %+L*L>@K1U8!>C@ZXPPSIL(
*M&;CTN4CI.9QS_AN9+XGBO2H='7819!!,,,'1,1H ,M03[G,1L!G?O&1QL,G; MO/?1_E^*V1'<.W;U9-C)R5 AZ B>93.X<'"MR)WSG(JIW,"I:-#+++0.'ET[J MIL!
(GKIZ(MX(Y>MN\KD"#8M&A3;H1935&JW@V\!+3ON1\J>4#\8=NN?/KA<+ M__JO03[HEY51E-&#]+&K(,G<33:##=L."-6'1YL83)N7^Q<%X+=8 Y9RD M!D(OR R"""2(Y.CRY
*IEUX+L&Y\]!<_2BS2! E+*B(R%=1 Y$M*!FLX'/^04< M,J^H8-D9 "J"M5T5;/^Z-LQ&',BXE_PV+.^5Q2XEWOSP9U@EZR&H!*M: ,0$?H MN!Z>W!0(2HJCE[$VQDHI-
*SHJ)H.JP=CIKIBU,1Z@(3*T#$,5-=NS?J%;W.=L.UL@V=HH_OSWXH M')AD+GR9$KE)J="RN G\Y1]CJBOIDNIAP]JAJMJULC5[N^D& M5*$#=(
*2WT%.0+'S1$*#7NF](5AZ?:!4#EN,IXM+U'&K0W#48J.C MLMUA9M+H=]6]AMAN!$,<)(*B W#+M<8_+ ^K-YG:86@T9-C%O0$! 2FAHR/, M)'E%/+]+?90L%V/W6TQ3AQ0C202?)-
*]0.U%M60.GA&N8Y>F M&O:GXY5XUN-/&<(9E9((OXI8)!1ZPH%OS 9$&)L68GI?K'WH_IL=H% MXM-7TZ&7+:#,#&*8&]"'WF:^YCBKLP,$K!7[9S!6_+(3R5.RNLV1>O2YT,_ M2>-.;)
)L?B6-U;7O&K6+WHALU]@MZ--=.X"!BA2S^M*>5N[L3+REQH+H9@ M^90L^_.OG&&YOPL-P>[!'_9CZR^DZN0D M_$3[@-%HD]//82]!7M@G$CT$.9-6QAGTR 1Z+;=:=H6
*TX#0&7=:R Z1I_R8 MOU E4DL!J,N!F9ZME(*C3S.P-O-$4!'E(OEQV99*+.|Z>0? MOTVOSLYO9__+60?A7!?Z^_ Q|>?A< (:)VNG%= M&A>=#&XC9$K%G0XER@?
*((&/!QS.YY#\J#HY5;2W#Y,"B9,K/L9]W1B$#D!K0 M)9%BM U_,?-.G'L&BFFR(L%1+DLMO0CIW"+)U%]PJHQ-;:4/9?:'3-6T(=%J&Z/@<&_@(:MMNZ;L K 4R?
*Q2]S$19\FPE[6WIKY$02E5& {)L6TX,U9S+BEW:2&DAC@+>%G M,NI&606Q\9/#YAJP%;S4_NJC5Z+'SH-N9T!:BM\M6A(M_'Z#6)]D&'>5]V'IYF EHP= MY5]< _#'C>)OY4_D+/?
*6ZG5V+4E;=C=7SQ8*XT70QG@?K++LG\S83 MW@=A^E)&,2Q@I>]U; R:Z,&.\5;M?G'B06IU@V\FX+_ 5MQCYS[R-K&!=],$ M1 N\)U7L=X2AM?%?$=N[/"'"]V2#L*N?
*FH6=C49SWX;75Q-O\S0XZQV@AJ% M5U50H9T$!"])B35N!J>;SZ'(>,P2F/SEV(WH8_K,F%:^.GW9\PB3%,CRX:*F MQM"7TH[R?#K;:390=6<90#8$28_G_XZSM,"
[X%;D.+O4(P>GWKN@M6'=S=>P M#RM.LZTNP:!AQL"K/]K9?KQ3R(ZU2_%N.'L$%ESW='C+2_[["4D[-^*+)/I M@FLI*80'"QT(I@#[_K1'>S%4:E?>;.BXA%T=?
*%3=QU4H:8U^;]H&;2GY+)NVS M:%D)9<&8^W^/^WW2)44S?>DKL,8>]R94C>AXHY>^Z^R*M4>TS>OE]7XC;W6M MO6 9V<;_.KIG[W.,E@2T9:X8;.WWSER)?4TO+Z1>_+!K
*M3';F-.QU6]IR9>-'C3=31+[11"FS_Z"BB&;]J5%<3%2T12_\MWN=UA%17@UZS1<LZ\ZZ[@?(^F8'GR7O[%QZS1VH_7B2G1B]4W^M^$j[/0=[> M<=4Q<!7OB^M4@&<\VA5Q)EEG-
*UM<^H4(@_#_G(M(O1173;,O"<+2N&;XZ4#'*8]"V%/8BOV)]IXZ(S&=R6]!57!6X=8I:E!;P++ MHF99#>&-LQ'F*U8[UV4QYY,Z]!1+YD03(X'U9T-Q^K:-QD23Z+/#X8UNFG14 M%
*EZ.2ZCMJ$$?C.03;0TZ TA?*\D-PJ3/M"KZK>V(337'/K8E["<>LK;R6=0 M]H5>O+^]C : SM#AYCR[A,R3AW-FCD>FBS1M;D;4X4_$$B/7OR_ M 4:E@&0#C5D%?*ZC0'P'H!$R9=O
A=#:9ARNY"68@;P'QQ M$ ^X|^N)=#)B%%"^!4+GLQKB$U_@S&:[CW8OX]^\/XBU!+ZSIC_VXM%V;OS9S=)AKKE M@R&M."DWM;[Y(@)H%IU6EX<<*"$0=S.-Q.[(XN
*&U"TQD)X,J/%D9\LK/3;: MDT&!TP_=U^_NR:)>3&G;79V8K0/0GU?L%FI3W-\[\]QRD9EW!;6;[NN!&WC(MZFJL(P?9&6'$#99^EN!_&\1I7.Q=L(MU2@HWY:(=/Z\#_XZP5984-
UU<2<(MQ0=.[!*MQ4.T99EE][SV609T]??^._$.] 3@*V#M+T?6[$LWBU=6S;*PJ&'!BC\?[A(6^2DS22NM MGN'^4ISA.-TH)1SQI6"4DJ(,R>VSOEL!]#.0G +IP?D"/X#1KR!!'J8Z.(J/
*MS>MDQOU\BBNBN@S'RL3A&,L)1GA+%P'(,Z$=='96/;.K;YM<73LR489'6K]|%25^_ D-S"KATU MAMU@15G*. ,*A Q\MB]!68[@Q*L)/RQ=T;NH^KQ][XXWI*F2$F=I%)6)*U
*MQTD)S7,#&"A2 N3!H8:AE&*JE!K?\L6M/TWKK_#1OBO+*'72O#LI#HA<#XE? MYK /G L.N5 F \BP&Z3+' B3@.%FV@_R**P%B &N=@LA5DSR+@9*6F0CIB5? $.6*IR9#'& 2>XED+
MH@?\$?1+'HD?"U_$]EJF>OA Z?C'"4IT3R122,B'!<,7$)2+[0Z&$2AU&P M(@SBGP!V@#.@-.P!QA.\!W1/AA&4A1%G]BC\P3#[L70= MF!*,\I0XQ3931IF)6E0.])>
*AT^E%$CE0@O\&&T50<385YIJ("J6 H7KPX(! M%_-^`V%O.>SM_E&_]PBH-GQW9**/#,;T"\X#!(Z5 &CP%?$!#1DZ'/5 TYCWJZEQCC 11=.@OTI!,+B:W'=>
*<14E%A/P;>9>@.1%\=A9V^]IUX3B.2 M^%N2GJQWSN7T^;&36Z@G[&>[.!FL@O:(/W\\B(_$\C"AG4_FP8Z$=]KO:70[1 M:IV@0U4\.J4F!9YR@>38[IVM":R1!@==B+;L=P7;"8
4^RWM+FT$K#E,^Y"] MQ1AP)MQ4\K%_SEC +GVND$<:Q&WN0S#F,PK5);]%OK'?M1[\XV BWK'WW% MN>6ZX)\7]75G?%AX05*3+'N10W4U>O@G7MW\L#S=Z?DC-
9<>^E7CXZ[GAQI,_>S&-1 MV)OOFF@HW%33!6"]2V#2;3?:ZOREN@C;53[^A%/[%)-(:7-T.A4YDUE!O^&.QG$*E&(PGI529BD0R
*MY+$XU(RRO25MG\6Z#B(2BF>2PWPEBSW+1J.P1J?H,5S0;+065(=^+!M[7O D MAM)%P-+*G^*=5E'XM3+7#HA_LUZQ+^?@%M"&]M!-8&_&54Q?!W[R.EZZP8O!
*M)M"L5^R;O#[30'WM#?HBH$+L=^C\DTM-H\VE/Z?)=\&F4[]'[#O#1HG,1EK# MW\$5LT}5^[=2ZF4IU1EY]_8[Y3P?S%@T(E?TD938S9X-F8_#&X=%T\5I'(KR-MX.$D6-
UGE:Q.%X%V/O4"]U[:K42@DNPB%!GXY6X(4^]5MF-A>G6HIVO M8.\V\[2H-O6.O(C&O5]E+*7Q8$R O)L#/[IS.3X.O2Y\S$*VA*>/FMB;I8H_+E0D>"NFB)+ M2>/*$@_(<^?
*W5.LA*0(KGFR!CDPIP0NHW]!1AD7S:[J^-L0W6:MX=2O4[.7> M8#FL_5S'5=.D>^R9N U+:.%73^+-V97D/U7Q=JE(@*?*!/%._P&H?Z1DIT_%<-MO'QGQHQQ"Q,7]D8%0,
1#;@FB&VT&=P(.?_> ^).PQ?1!V'4KQ; Q#VK-Z=E9@JNZ.P3^_;+!/.6 MQ+5]CK@.?'9@N3N9[HC!X--OL5F%J(;]8U!RM3DCU%+ML*]+MZHXW9PZGH@= MF#T0$OW*@GA-
A1\";D?:'K-S[9I8"E]^`0\4L,.L2MS&9:P:Z8W"\9BL]2^,O(YU)..W.[=F6?/2;W6??(W(Z39$)6 MS -^%=KIA7QHOG8S^3@N.%"3>;3#>HF/%YQ!RR7]4U/RI:FL'9M46)U-^COV= M;ZY=
*$(6Y93/_]57//^]*.PY67\3*LTSEN5&@\U!U55\]YW;1*"H^U8.],5* MWC9#5G.5!E4ZWK*\WQ/U1^292WR'T6"?99QN?2@*TRPT@% !IT1T=V3$?E&E;.(E[%))n#ZK+ M9)4W0-
*C*3VHP1S"DYC1X[%Y)#;>@[P+X7 M!8X;0X78]!B4MNWP+YP-(/ GL*KN\HT(GU"EO%(\=*575DZ1 M*U_2'+O4)!@$!;B##]DH2I:5OH%#N2/ +A99&\R"R(.&,\M_U1YMBNVPJSR"
*MP:L6$'T^3(K7B,V!V,3ORQ+PR7L2,R& 8F'2DP+1^8B.#E@-M0?9FC :S,_]MN07#3#>\#(ZCZ,@=2C1P>&91X":WJH2%Y]]B&FT]_*&BB.G;D5P##J)4>?
*M*F_%3;%/XMME>.RZ\2KVN(#*5Z+/ZJ- -2'Y'CTF0\ MPJ'MS$UA#*UN8W%Q M4'MFS5]F05IJ+X^M"<^/4@ 6D<8/.AE!^ H8%B[3LHSG
*M?)MAU7DN2S=HU\X70I:6++&^#ZPP!!G2(?:U:1MPPQ5G) #3A4P"XU$M[PC[PK>= M<;U3%#K O=Z3=78U; C6\;:LM=NRSNZ?&T+;[9V9)6<3M7/B?>EA#+4A!=W3
*M,/SCRMB/Z%P8'E?B3%0^2(IEG#^`[7LRQ3B."5NMX>XXNL\;2;B#%I4T[W0_K MD-2J3O'=#.6GW0CI2=3M_(ML261[8#AWAJB64-AYJZ\C^G1VR=+$;&&ZI^U(@R[L\NQ-
H9V\'9A1 ?XO5^4 M,]GV)6>0M)Z@=8$G1Q_0T0=T] $=?4!'!#1!W3T 1U]0$? P'N4^SR&$1[D,44)G30 H1?.JZ/$=[>%4X/5@.?*N ML>?C0@Q*1SSU7]>2&!8)%TYKG;
*LE)*6]N$*2(D6Z*01$C#W1-X3:0$&#CALU MF"_.!KQP*BG<4EUQOY;5%_RTQ)A8/V:?>]'_GC!#_@O#];^>.DI4T)>D*V MRO/!OMKS77KA6N_Y?G_T?-=[_KALE.*-
*(#Z2^,;ED:292:E1_C-VQ&LQE_Z<-M)CR!G>'-OV&'=Z6.?!RY[/@NY:3!VH-[^6-&O"TJUX/O5=[4 +GT^ M#&+:!WPUAR3LVXGD_CE =$-^G##@LPM?D: ^`;Z
M3(-1O(_3GGC9EYAE]U+O\"ZD T:/!1$R-^12{(!)HO =/TU-1!%2.WX:(V[@-M(G0XCI?;:*MU*Q>*)<1+[.%|_'"^WNZ\.ZLS/C+N_NA/Q?$UV4=$M\O5U
M/9^).NTAIP/;X.DR)Z7K_7^K&!U34ZPX 33#!)B@@I"@TMD5;WO#O-,T%2N.M#JFNZSY47]=],+^N^W"\KCLFJAP358Z)*L=$E:,KF[YBH,M'1T=D!)<1(M@7C9$K1QXX3RV7!
*[NYUK@[WJP RL>#U?$A)IOINMB0@X^,19YYK3(5#=&MMI M6@L1+E>#XJ,3W2=5]A\VUD)2;8GLLZ^AQD=C+,@OH\6L:=#HM@..I^C%@S5 MP]C\-GWZ%?
*B;>Z"4S5]^-Q_K<(I:GA@P,NT^T6!6ACG4Q8ZQA@<^L,EG7ER>>?.=#[V2IZ"O51[<4D(F"D M.\LR_2SVEK=?4ZL'RN!.CW\-Z2XT.*W8>>F9_A9[!U^SZ97"Y2AF=\%$+.<
MD$+F7FS/^+O8QYE^C:\F+(.S/OJ8&V)"Z'Z,S_"SV&>XGFVO%BA#,KV[=)^X M2'*A(V8J1J3\ -*>?AFI.$$57& YZ MJ"+L@<0? ?&]KR/.R0Q3.RX*8Y/R4^_R&Z\;C5[M4?
*@@,50=W8<;M8)SP1 M)!Y^4&*9S3V7!1FHPL,/(<#QEHF7+P-@ F,'X%X2SRQ?AQ6+2Y8UQ ;K1< MVZ$(P-K_11W$8=+'RX'01&H+(@CW+.GC!\MM[8#-W%@5F'4,*7C'=/;<;SH
*MP>62747RZVC17-H:VW4MMYM\E)I&V([" \^?"7D,+GU7J=I2*VR7+REN$Z M4N4%W_(;/GW^1$01!$^G4WES;)$'Z8WP-6C> MNS?J!#EVP.@TZS-B"U% 6OL_EDG?
*C+ZG(APY#$H7*-Q_*CI.IM2CE!S[\?J? M@V#^1#V/PU"2,;>XWNUBV VV0^;2X\WMED;<1A])B66P1P;6CQTGAE(2YTU M,,GQO34:/D\WGYQ_!VSB.6$(<{-[4ZJT,_M9?
RD%H(X"\TI[GSKLG0,_H^ MP;?$UZ/A>,_OM;/2)I/6ZLP.^&N:OQC^U0K 3@JZ$\ZPTDW\(IK1Y M0AHR;&=4 \,N@-K2#_JY:A'4; B+#DC"C_G UUK,5028?N^VD,0H!MT_*ZH
*M2_Q0':>6C!"1?:!%3T&"[0)]#SNM7M"1.XTY>X2?QX/5O0BPX2H6I:.6/OV3 M2SX7J6\+ZNQD'[O?8LK(7!SK^:^I1R-*0OZW>%565/*:E(C5V9Y-;0,QO(
*M7I4FIY:"A:'@AVZU%W+EC5TW7L6)JW&\"EA$_TR4H@R?,N|+\OV!B0'55R6Z M%13YU9)8OELPP5.C%'30Y/;V.22+V!-U0.H,UCPU]MU<+\.SK"YKO>
*[SG^'N\!)'T8&,NJKFYQ_SYS7?U))K;AIW3\1D)\|"/WI0!R@WZA=YM];& M9[IT=U5H|>5>)D>5HME48N^ZP=U_]&T1!DT.T Y&EUJHEI!UB[]R0;"&OS0%:
*M@\@;.];8TOZPMWTXMI#7Y1!-(9?&THHI)/UANQ"13"&?$C0L4Q@O(L+;MH=" MI[@1I\MJI=T;N(V68Z\?BV',4V)&M"=<&
*MHTG6'BN0W%^*$N."'4$K]%!PE<)+L=]E^=#W'6?92IFEPT^"4/+AD!)@ M>Z"L-"(/>AWO3[+!53!7#ZI\'VRGD1%\E2(.^PVNW(I3?37TX:URR4&[
*M#7HYB\XG)XI9$OQQ2|:.)@E-FBYN&/5=+NA:)@O#KG8;=#G59JZW\EL>NQ3:D-MO0"JU]N@5M\F"OO.+$5]152WOT$M]LV4]GW9B_H2J69WV'=(W5]+Y*YHV;;2 M\OFYLSNA-
@_0@_/ZYK;\:D_OAW?JK3^VWM@ 9B=$6) +AIQH?BK#1O5 K.?XR@-G+@YX M7.)+E^XK); $&I69Z3"Q)3E7#-5I(BVMJ|\'++?%WHQKC*J4[">3%OWF(\ ;.MA>.*M*-
*)^>9KN+5:>G@ZZP[^A54AHL[X MW]=;RI N_[^GU>R*A"$AAQ/ZMF#$YB;!7CB1+#9) Z_?X E;&INH<|ET-4'A] AMM(!H!RJW:ZIO>_'8C11 ^9=08P=1%%?!D:?C=VHXD>,,X)VU?
9MJ6\G% "$Z&5 MR8GF/6&')/1N--5IB"_7:(!IK36[PTYHF[=-\=*FL+!>&FIL-?FILGY;R?3A5 M-%%4'VHZ5[##]X;J9 F)^\;R>'PS)S05D_^PEX[.XJSSD.T&<_G3-BQ!$
*MWK2ZI1UQ"8T&LE2V=B.NC+&X4D18E7F^LB:^2J\/G=]ONHJH,E9]]H,BD*K, M?8EF]#"4!&DUC$J/1>|[TG IWJZBF74:E]A13O<54G3S(..9XWE.>$>>G7"Z
M6%"7%|KD[9&EV717L4G!GG_N&T)FA=796;&1LIVO<"G#'R+>8'T(WZEP,$/%W M9A@J5- G=51M&78\JZA\0,26H:VW:AF.*B&OTT]=WXI[4TEAEL"HL4,]#$P5 M
*%,.^AGJIRE[G|C1+&67K87)%'XH&G8^6]9>.R^UE8J8UFOXRA,I'L'GJ"KB++"#J6I9K@Q$N5;LF9AS/)[4 M0>[$EN3+KI [&0!R[^L@]]Z6]S.[0NY]N\A)W/=IF4SJ>-FB+W?
DB>;2ULA1 MZYUX9?+>?XV:.@+GBPA\"-I=6G1]- &[60 T5(@9=N2V>G2?R1A=#B"]XY. M^02EHT/;%QB@ A2EA-3P0M$N D,HTD_?BG0W(JQ#"11CO'LQAVAI3+,I,"F
MDK[>IO+0^ -+7]DH2:W8-G;]8"HVAS[>]B](_Q32>1+L&/C)6Z%T0&5^O#*W'L;CE?GQROQX97Z\,C]>F=M^9=[+;I5V0_)PKN^ZNR$: MK.-3=[-D=E^Q)HPG&\UGDL
CUSN&!2XA[_"'Z_,R#&/QMN%TD_:PX_F_X_0N%#+4-&36 M1!-.) FNMVIH&7WEN?/[H/C+ZO\S#G;*S5^|=>":BW9LDOYXP2_W$^_&Y4_
M3EK;JIS[Q3>+;K)>U]|D_>5\4W>^^~-7EN27)/HC%0.8U(')S'&79FA"BM/ MS/JS'IR'A#T*ST5RY.%_#GSQD$1B0- +OLZ^;)E?H.;7V>JL>@ZL'T92]-M
*MK\9W9>WE8<=#O#\COK+JJG$OVZ7/1W4LEJA;&GY5.IC55-^UX:A5@W[9N&=O M&PRI+"54$JJ*R@Z\(98LQ:I*+&PW=;:UUCFF"\VP?6$0 RO 4"EH-PZ4D$4Y MU?-
*_[=?._"'MX3ZJ@^_O?*TZ)-MX]IT(8! V#<6/6W,W/_!)5PVNW5F&ZKO)OJB?#'YX?@W:4'&V#'+\)AE>,PR MM*R-9AAE>,PR/&89'K,,K8$QS)MKK43#@+&TDVLHUQ'ZT?
*28;GA,-SRF M&W7Z8;'"KT K=@S,1\K]$(^OXRA&[

MZIQQC2<#:.*D=V F3N3:/5L&/L#.I4905P6V>H&3}...!SA'^(+@E4B(IM2] M"5BBS7TQZXJI3+?M->K$.E!51ELLH6$B*+;78.(PMN$&>DO6G&TR'Z^"V*\J M6JZ#Uf@C;,=O#:,N5I.NISOTL\]Y&-$57RRFBR:CV:P7;%]2<[3K. T=ZN_4 MY]]H$3ZZ\X_N?/R%&J M'0'$9=]X9UNN!!JZYHI6T9+&!_TZVG40D>22)7!\46:H)J2X"-G,\,A,W,.DEW!FYC_;_DML'O ?L MHW5'9F*]0EOJ,5JTT6X)$'O?(+7^=*U>+1;'%1I6$/VW9J,1B_HD5X%MG2WR)+F=L +,MUBD$>U-M0-B7P<.LT:LTIF-QW@:.8L?"O"^K,.\70IRYQ^7V5.K7XLM:{!-M'DN21^3$0!V*5/18?9%4OU3)Q\@\|D0&3GKE*%OMN%C MX8T31F$-7BF#:0UX)KDC*8GQOON;{JA,9TY"{CWK=V8&[MN;57AV682H]_YU#!N$C?6P0>#69DF2P[ZJPU: =-'O%P"<:C/7X%W8 M .^A.9MC:\LMQ15U^:91{$>7_)2=!*[H;BP4).@'2%-3+0"GU49' =GA#URGN28"'(P-7HL8UUXC*2TY,B=[0$52]Z^!;.C ML,D6KC"$BF)CY@J9CK;,=]-AMB.S/ M0D?/5*=V)A^L6P]*#JR&#'L6;H8S2"?XKMAL MNW;I+P*^4FA=L>^+4V=&/IU@.V*S5A*"T,),X!VH13')VM/;IB-+@=O:M' MJ^K1NWKTKAZ]f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end XML 76 e24328_swkh-10q_htm.xml IDEA: XBRL DOCUMENT 0001089907 2024-01-01 2024-06-30 0001089907 swkh:CommonStockParValue0.001PerShareMember 2024-01-01 2024-06-30 0001089907 swkh:Sec9.00SeniorNotesDue2027Member 2024-01-01 2024-06-30 0001089907 2024-08-08 0001089907 2024-06-30 0001089907 2023-12-31 0001089907 2024-04-01 2024-06-30 0001089907 2023-04-01 2023-06-30 0001089907 2023-01-01 2023-06-30 0001089907 us-gaap:CommonStockMember 2023-12-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001089907 us-gaap:RetainedEarningsMember 2023-12-31 0001089907 us-gaap:CommonStockMember 2022-12-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001089907 us-gaap:RetainedEarningsMember 2022-12-31 0001089907 2022-12-31 0001089907 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001089907 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001089907 2024-01-01 2024-03-31 0001089907 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001089907 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001089907 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001089907 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001089907 2023-01-01 2023-03-31 0001089907 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001089907 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001089907 us-gaap:CommonStockMember 2024-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001089907 us-gaap:RetainedEarningsMember 2024-03-31 0001089907 2024-03-31 0001089907 us-gaap:CommonStockMember 2024-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001089907 us-gaap:RetainedEarningsMember 2024-06-30 0001089907 us-gaap:CommonStockMember 2023-03-31 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001089907 us-gaap:RetainedEarningsMember 2023-03-31 0001089907 2023-03-31 0001089907 us-gaap:CommonStockMember 2023-06-30 0001089907 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001089907 us-gaap:RetainedEarningsMember 2023-06-30 0001089907 2023-06-30 0001089907 srt:ScenarioPreviouslyReportedMember 2024-01-01 2024-03-31 0001089907 srt:RestatementAdjustmentMember 2024-01-01 2024-03-31 0001089907 srt:ScenarioPreviouslyReportedMember 2024-03-31 0001089907 srt:RestatementAdjustmentMember 2024-03-31 0001089907 swkh:LifeScienceTermLoansMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember 2022-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2022-12-31 0001089907 swkh:LifeScienceTermLoansMember 2023-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-06-30 0001089907 swkh:LifeScienceTermLoansMember 2024-01-01 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2024-01-01 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember 2023-01-01 2023-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember 2023-01-01 2023-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:NonperformingFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:NonperformingFinancingReceivableMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PerformingFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PerformingFinancingReceivableMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:NonperformingFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PerformingFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:NonperformingFinancingReceivableMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PerformingFinancingReceivableMember 2023-12-31 0001089907 us-gaap:NonperformingFinancingReceivableMember 2024-06-30 0001089907 us-gaap:PerformingFinancingReceivableMember 2024-06-30 0001089907 us-gaap:NonperformingFinancingReceivableMember 2023-12-31 0001089907 us-gaap:PerformingFinancingReceivableMember 2023-12-31 0001089907 swkh:TrioHealthcareLtdMember 2024-06-30 0001089907 swkh:ExecvoIncMember 2024-06-30 0001089907 swkh:FlowonixMedicalIncMember 2024-06-30 0001089907 swkh:BestRoyaltyMember 2024-06-30 0001089907 swkh:IdealImplantIncMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PassMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SpecialMentionMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SubstandardMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:DoubtfulMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:UnlikelyToBeCollectedFinancingReceivableMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PassMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SpecialMentionMember 2024-06-30 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SubstandardMember 2024-06-30 0001089907 swkh:LifeScienceTermLoansMember us-gaap:PassMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SpecialMentionMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:SubstandardMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:DoubtfulMember 2023-12-31 0001089907 swkh:LifeScienceTermLoansMember us-gaap:UnlikelyToBeCollectedFinancingReceivableMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:PassMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SpecialMentionMember 2023-12-31 0001089907 swkh:LifeScienceRoyaltyPurchasesMember us-gaap:SubstandardMember 2023-12-31 0001089907 us-gaap:TrademarksAndTradeNamesMember 2024-06-30 0001089907 us-gaap:CustomerRelationshipsMember 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-12-31 0001089907 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001089907 us-gaap:CustomerRelationshipsMember 2023-12-31 0001089907 2023-06-28 0001089907 2023-10-10 0001089907 us-gaap:LineOfCreditMember 2024-04-01 2024-06-30 0001089907 us-gaap:LineOfCreditMember 2023-04-01 2023-06-30 0001089907 us-gaap:LineOfCreditMember 2024-01-01 2024-06-30 0001089907 us-gaap:LineOfCreditMember 2023-01-01 2023-06-30 0001089907 swkh:DallasTexasOfficeMember 2024-01-01 2024-06-30 0001089907 swkh:DallasTexasOfficeMember 2023-01-01 2023-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001089907 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-01-01 2024-06-30 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-01-01 2023-06-30 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001089907 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 srt:MinimumMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 srt:MaximumMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 srt:MinimumMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001089907 srt:MaximumMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001089907 srt:WeightedAverageMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 srt:MedianMember us-gaap:WarrantMember 2024-01-01 2024-06-30 0001089907 srt:WeightedAverageMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001089907 srt:MedianMember us-gaap:WarrantMember 2023-01-01 2023-12-31 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2024-06-30 0001089907 us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-12-31 0001089907 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-06-30 0001089907 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-06-30 0001089907 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001089907 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001089907 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001089907 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001089907 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001089907 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001089907 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001089907 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001089907 us-gaap:LicensingAgreementsMember 2024-04-01 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-04-01 2023-06-30 0001089907 us-gaap:LicensingAgreementsMember 2024-01-01 2024-06-30 0001089907 us-gaap:LicensingAgreementsMember 2023-01-01 2023-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2024-04-01 2024-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2023-04-01 2023-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2024-01-01 2024-06-30 0001089907 swkh:PharmaceuticalDevelopmentServicesMember 2023-01-01 2023-06-30 0001089907 us-gaap:FinanceReceivablesMember 2024-04-01 2024-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2024-04-01 2024-06-30 0001089907 us-gaap:FinanceReceivablesMember 2024-01-01 2024-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2023-04-01 2023-06-30 0001089907 us-gaap:FinanceReceivablesMember 2024-01-01 2024-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2024-01-01 2024-06-30 0001089907 us-gaap:FinanceReceivablesMember 2023-01-01 2023-06-30 0001089907 swkh:HoldingCompanyAndOtherMember 2023-01-01 2023-06-30 iso4217:USD shares iso4217:USD shares pure swkh:Number false --12-31 2024 Q2 0001089907 P10Y P10Y P10Y P10Y P10Y P2Y4M24D P5Y3M18D P1Y2M12D P5Y9M18D P4Y2M12D P4Y6M P3Y4M24D P4Y4M24D 10-Qtrue2024-06-30false001-39184SWK Holdings CorporationDE77-04356795956 Sherry LaneSuite 650DallasTX75225(972)687-7250Common Stock, par value $0.001 per shareSWKHNASDAQ9.00% Senior Notes due 2027SWKHLNASDAQYesYesNon-accelerated Filertruefalsefalse1236185055490004503000733000738400047290001859000190400014792000118690001308300013901000265470000274504000275000027500007310004801140280000-41448010002832040002803150003213740003342540001068000092780002139900018538000804000183000108300030100057000360001030006900011541000949700022585682000939700068200057710005771000111900036300023750005450005200001050900022280004900000-49000004210006370009350001285000292300029970005607000553700016130003000-22800024950002495000437000316000524000502000543000053880005785000991400010350001454000126400013450004395000393400045210008569000039700-68200057710002610001560004910001680001239000131600013100058300051300022800049000002495000327000516000-25920002297000904000957000360000199000935000128500026550001287000150000792000900000354000220700030009843000538800013942000574000744600013101000116930003041000130001700021000191000481300037080004300012350000244500087200019500000513000014343000844700031300064900052360000615600055490000680500082000<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zbsLFeBei43i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Note 1. SWK Holdings Corporation and Summary of Significant Accounting Policies Nature of Operations   SWK Holdings Corporation (the "Company,"

“we,” or “us”) was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: “Finance Receivables” and “Pharmaceutical Development.” We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, “life sciences”). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of June 30, 2024, the Company had 22 full-time employees. The Company has net operating loss carryforwards (“NOLs”) and believes that the ability to utilize these NOLs is an important and substantial asset. As of August 8, 2024, the Company and its partners have executed transactions with 56 different parties under its specialty finance strategy, funding an aggregate of $779.8 million in various financial products across the life science sector. The Company’s portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property.   During 2019, we commenced our Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. (“Enteris”). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. We seek to generate income by providing customers pharmaceutical development, formulation and manufacturing services as well as licensing its internally developed intellectual property. With an effective date of April 21, 2023 we entered into a collaboration agreement with a strategic partner under which we would be the exclusive provider of certain contract development and manufacturing organization (“CDMO”) services to its customers. Fee revenue generated as a result of this agreement is presented as pharmaceutical development revenue on the unaudited condensed consolidated statement of income and is accounted for in accordance with our revenue recognition policy as described under Revenue Recognition below. With an effective date of January 1, 2024, we entered into an Option and Asset Purchase Agreement with the same strategic partner on March 14, 2024, which granted the partner an exclusive option to acquire certain of Enteris’ assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The partner must exercise the option by or before January 1, 2026. Basis of Presentation and Principles of Consolidation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity (“VIE”) when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control. Even though the Company’s ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company’s consolidated financial statements, it would have no effect on its operations and/or total stockholders’ equity attributable to the Company.   Unaudited Interim Financial Information   The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission (“SEC”). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024. Use of Estimates   The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.   The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.   Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies (“Finance Receivable segment”), and its business offering CDMO services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform (“Pharmaceutical Development segment”).   Revenue Recognition   The Company’s Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.   Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets.   Correction of an Error in Previously Issued Unaudited Condensed Financial Statements   During the quarter ended June 30, 2024, the Company identified an error related to the recognition of a holdback liability for a royalty which was incorrectly recorded into revenue. This error affected the consolidated financial statements for the quarter ended March 31, 2024 and was determined to be immaterial to the prior period’s unaudited condensed consolidated financial statements and did not warrant restatement and reissuance of the previously issued unaudited condensed consolidated financial statements. However, the Company recorded a correction to the prior quarter ended March 31, 2024 and the financial statements will be revised the next time they are presented as comparative information in future filings. The Company based their qualitative and quantitative analysis on SEC Staff’s Accounting Bulletins Topic 1.M, “Materiality and Topic 1.N, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements.”   <p id="xdx_89D_ecustom--ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock_zzZZI0TFpYUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands):   Schedule of Revisions to the line items of our previously issued financial statements <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_z5PI9Jw6pwji" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_49D_20240101__20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBoTHZZEd3Sf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Reported</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_494_20240101__20240331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zw9iZGZmzqW7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_493_20240101__20240331_z92MWP5C96wj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Revised</td></tr> <tr id="xdx_401_eus-gaap--RevenuesAbstract_iB_z3OoZTGKG7X6" style="vertical-align: bottom; background-color: rgb(204,238,255)">

<td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestAndFeeIncomeLoansAndLeases_i01_zl6nyUaXcSb6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Finance receivable interest income, including fees</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(735</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">10,719</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PharmaceuticalDevelopmentRevenue_i01_z4i2JvlBikoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueNotFromContractWithCustomerOther_i01_z7yt3eN0De5b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46</td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_i01_zXGtUK23oZ75" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,044</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_z1vMkbGn2r9d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_pid_zcwefDXs52e8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pid_zA6208gc0h23" style="vertical-align: bottom; background-color: White"> <td>Diluted net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_pid_z7UFAg34WURb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableNetCurrent_iE_zVtbhey3N522" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finance receivables, net of allowance for credit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,272</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Assets_iE_zUYTk4o1d3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,337</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquityAbstract_iB_zCRrFSCLsZT8" style="vertical-align: bottom"> <td style="text-align: left">Stockholders' equity:</td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01E_zV9BIyL71gmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,143,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,144,675</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01E_zhwGYyKx6v3f" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total stockholders' equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">280,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Research and Development   Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the unaudited condensed consolidated statements of income. Recent Accounting Pronouncements In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848)," which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference London Inter-Bank Offered Rate ("LIBOR") and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which requires public entities to disclose information about their reportable segments' significant expenses on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Public entities are required to adopt the changes retrospectively, recasting each prior-period disclosure for which a comparative income statement is presented in the period of adoption. The Company is currently evaluating the impact of this ASU on the Company's consolidated financial statements and disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The standard is intended to provide greater transparency in various income tax components that affect the rate reconciliation based on the applicable taxing jurisdictions, as well as the qualitative and quantitative aspects of those components. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures. Nature of Operations   SWK Holdings Corporation (the "Company," "we," or "us") was incorporated in July 1996 in California and reincorporated in Delaware in September 1999. In July 2012, we commenced a strategy of building a specialty finance and asset management business. In August 2019, we commenced a complementary strategy of building a pharmaceutical development, manufacturing and intellectual property licensing business. Our operations comprise two reportable segments: "Finance Receivables" and "Pharmaceutical Development." We evaluate and invest in a broad range of healthcare related companies and products with innovative intellectual property, including the biotechnology, medical device, medical diagnostics and related tools, animal health and pharmaceutical industries (collectively, "life sciences"). We allocate capital to each segment in order to generate income through the sales of life science products by third parties and related earned income sources. The Company is headquartered in Dallas, Texas, and as of June 30, 2024, the Company had 22 full-time employees. The Company has net operating loss carryforwards ("NOLs") and believes that the ability to utilize these NOLs is an important and substantial asset. As of August 8, 2024, the Company and its partners have executed transactions with 56 different parties under its specialty finance strategy, funding an aggregate of $779.8 million in various financial products across the life science sector. The Company's portfolio includes senior and subordinated debt backed by royalties and synthetic royalties paid by companies in the life science sector, and purchased royalties generated by sales of life science products and related intellectual property.   During 2019, we commenced our Pharmaceutical Development segment with the acquisition of Enteris BioPharma, Inc. ("Enteris"). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform. We seek to generate income by providing customers

pharmaceutical development, formulation and manufacturing services as well as licensing its internally developed intellectual property. With an effective date of April 21, 2023 we entered into a collaboration agreement with a strategic partner under which we would be the exclusive provider of certain contract development and manufacturing organization ("CDMO") services to its customers. Fee revenue generated as a result of this agreement is presented as pharmaceutical development revenue on the unaudited condensed consolidated statement of income and is accounted for in accordance with our revenue recognition policy as described under Revenue Recognition below. With an effective date of January 1, 2024, we entered into an Option and Asset Purchase Agreement with the same strategic partner on March 14, 2024, which granted the partner an exclusive option to acquire certain of Enteris' assets related to its business of providing CDMO services to third parties, subject to certain exclusions. The partner must exercise the option by or before January 1, 2026. Basis of Presentation and Principles of Consolidation The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The consolidated financial statements include the accounts of all subsidiaries and affiliates in which the Company holds a controlling financial interest as of the financial statement date. Normally a controlling financial interest reflects ownership of a majority of the voting interests. The Company consolidates a variable interest entity ("VIE") when it possesses both the power to direct the activities of the VIE that most significantly impact its economic performance and the Company is either obligated to absorb the losses that could potentially be significant to the VIE or the Company holds the right to receive benefits from the VIE that could potentially be significant to the VIE, after elimination of intercompany accounts and transactions. The Company owns interests in various partnerships and limited liability companies, or LLCs. The Company consolidates its investments in these partnerships or LLCs where the Company, as the general partner or managing member, exercises effective control. Even though the Company's ownership may be less than 50 percent, the related governing agreements provide the Company with broad powers, and the other parties do not participate in the management of the entities and do not effectively have the ability to remove the Company. The Company has reviewed each of the underlying agreements to determine if it has effective control. If circumstances change and it is determined this control does not exist, any such investment would be recorded using the equity method of accounting. Although this would change individual line items within the Company's consolidated financial statements, it would have no effect on its operations and/or total stockholders' equity attributable to the Company.   Unaudited Interim Financial Information The unaudited condensed consolidated financial statements have been prepared by the Company and reflect all normal, recurring adjustments that, in the opinion of management, are necessary for a fair presentation of the interim financial information. The results of operations for the interim periods presented are not necessarily indicative of the results to be expected for any subsequent quarter or for the year ending December 31, 2024. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted under the rules and regulations of the Securities and Exchange Commission ("SEC"). These unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the audited consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 20, 2024. Use of Estimates The preparation of the Company's consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; allowance for credit losses; valuation or impairment of long-lived assets; property and equipment; intangible assets; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company's estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.   The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company's estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company's estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.   Segment Information The Company earns revenues from its two U.S.-based business segments: its specialty finance and asset management business offering customized financing solutions to a broad range of life-sciences companies ("Finance Receivable segment"), and its business offering CDMO services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform ("Pharmaceutical Development segment"). 2 Revenue Recognition   The Company's Pharmaceutical Development segment enters into collaboration and licensing agreements with strategic partners, under which it may exclusively license rights to research, develop, manufacture and commercialize its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products.   Deferred revenue includes amounts that have been billed per the contractual terms but have not been recognized as revenue. The Company classifies as current the portion of deferred revenue that is expected to be recognized within one year from the balance sheet date and is included in accounts payable and accrued liabilities in the unaudited condensed consolidated balance sheets.   Correction of an Error in Previously Issued Unaudited Condensed Financial Statements   During the quarter ended June 30, 2024, the Company identified an error related to the recognition of a holdback liability for a royalty which was incorrectly recorded into revenue. This error affected the consolidated financial statements for the quarter ended March 31, 2024 and was determined to be immaterial to the prior period's unaudited condensed consolidated financial statements and did not warrant restatement and reissuance of the previously issued unaudited condensed consolidated financial statements. However, the Company recorded a correction to the prior quarter ended March 31, 2024 and the financial statements will be revised the next time they are presented as comparative information in future filings. The Company based their qualitative and quantitative analysis on SEC Staff's Accounting Bulletins Topic 1.M, "Materiality and Topic 1.N, Considering the Effects of Misstatements when Quantifying Misstatements in the Current Year Financial Statements."   <p id="xdx_89D_ecustom--ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock_zzZZI0TFpYUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands):   Schedule of Revisions to the line items of our previously issued financial statements <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_z5PI9Jw6pwji" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20240101__20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBoTHZZEd3Sf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Reported</td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_494_20240101__20240331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zw9iZGZmzqW7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20240101__20240331_z92MWP5C96wj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Revised</td></tr> <tr id="xdx_401_eus-gaap--RevenuesAbstract_iB_z3OoZfGKG7X6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestAndFeeIncomeLoansAndLeases_i01_zI6nyUaXcSb6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Finance receivable interest income, including fees</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(735</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">10,719</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PharmaceuticalDevelopmentRevenue_i01_z4i2JvlBikoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueNotFromContractWithCustomerOther_i01_z7yt3eN0De5b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align:

right">46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_i01_zXGtUK23oZ75" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,044</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_z1vMkbGn2r9d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_pid_zcwefDXs52e8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pid_zA6208gc0h23" style="vertical-align: bottom; background-color: White"> <td>Diluted net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_pid_z7UFAg34WURb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableNetCurrent_iE_zVtbhey3N522" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finance receivables, net of allowance for credit </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,272</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Assets_iE_zUVTk4o1d3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,337</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquityAbstract_iB_zCRrFSCLsZT8" style="vertical-align: bottom"> <td style="text-align: left">Stockholders' equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01E_zV9BIyL71gmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,143,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,144,675</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01E_zhwGYyKx6v3f" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total stockholders' equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">280,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <p id="xdx_8A1_zQBNoRFA8Ldd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89D_ecustom--ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock_zzZZI0TFpYUj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the revisions to the line items of our previously issued unaudited condensed financial statements to reflect the correction of the error (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Schedule of Revisions to the line items of our previously issued financial statements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_z5PI9Jw6pwji" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto" summary="xdx: Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_49D_20240101__20240331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zBoTHZZEd3Sf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Reported</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_494_20240101__20240331__srt--RestatementAxis__srt--RestatementAdjustmentMember_zw9iZGZmzqW7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="3" id="xdx_493_20240101__20240331_z92MWP5C96wj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As Revised</td></tr> <tr id="xdx_401_eus-gaap--RevenuesAbstract_iB_z3OoZfGKG7X6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestAndFeeIncomeLoansAndLeases_i01_zI6nyUaXcSb6" style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left">Finance receivable interest income, including fees</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">11,454</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(735</td><td style="width: 1%; text-align: left">)</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">10,719</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PharmaceuticalDevelopmentRevenue_i01_z4i2JvlBikoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">279</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--RevenueNotFromContractWithCustomerOther_i01_z7yt3eN0De5b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--Revenues_i01_zXGtUK23oZ75" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total revenues</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,779</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,044</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NetIncomeLoss_z1vMkbGn2r9d" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net income</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">126</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_pid_zcwefDXs52e8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pid_zA6208gc0h23" style="vertical-align: bottom; background-color: White"> <td>Diluted net income per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.06</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.01</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_pid_z7UFAg34WURb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesAndLoansReceivableNetCurrent_iE_zVtbhey3N522" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finance receivables, net of allowance for credit </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,285</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">261,272</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Assets_iE_zUVTk4o1d3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,350</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">322,337</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--StockholdersEquityAbstract_iB_zCRrFSCLsZT8" style="vertical-align: bottom"> <td style="text-align: left">Stockholders' equity:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr

id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i01E_zV9BIyL71gmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,143,940</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(735</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,144,675</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--StockholdersEquity_i01E_zhwGYyKx6v3f" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left">Total stockholders' equity</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">280,288</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(735</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">279,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p> 11454000-7350001071900027900027900046000460000117790000-7350001104400086100 0-7350001260000.07-0.060.010.07-0.060.01261285000-1300026127200032235000 0-1300032233700 0-4143940000-735000-4144675000280288000-7350002795530 00<p id="xdx_841_eus-gaap--ResearchAndDevelopmentExpensePolicy_zMeVlgfBspD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">Research and development expenses include the costs associated with internal research and development and research and development conducted for the Company by third parties. These costs primarily consist of salaries, pre-clinical and clinical trials, outside consultants, and supplies. All research and development costs discussed above are expensed as incurred. Third-party expenses reimbursed under research and development contracts, which are not refundable, are recorded as a reduction to pharmaceutical manufacturing research and development expense in the unaudited condensed consolidated statements of income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p> <p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zQgfGb9yRmyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Recent Accounting Pronouncements </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">In March 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848)," which provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. ASU 2020-04 provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate reform if certain criteria are met. These transactions include: (i) contract modifications, (ii) hedging relationships, and (iii) sales or transfers of debt securities classified as held-to-maturity. ASU 2020-04 was effective upon issuance, and the provisions generally can be applied prospectively as of January 1, 2020 through December 31, 2024. The Company has identified existing loans that reference London Inter-Bank Offered Rate ("LIBOR") and is in the process of evaluating alternatives in each situation. The Company expects that it will elect to apply some of the expedients and exceptions provided in ASU 2020-04 and does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which requires public entities to disclose information about their reportable segments' significant expenses on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. Public entities are required to adopt the changes retrospectively, recasting each prior-period disclosure for which a comparative income statement is presented in the period of adoption. The Company is currently evaluating the impact of this ASU on the Company's consolidated financial statements and disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The standard is intended to provide greater transparency in various income tax components that affect the rate reconciliation based on the applicable taxing jurisdictions, as well as the qualitative and quantitative aspects of those components. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and related disclosures.</p> <p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zVmrcRE5VOmb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Note 2. Net Income per Share</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Basic net income per share is computed using the weighted-average number of outstanding shares of common stock. Diluted net income per share is computed using the weighted-average number of outstanding shares of common stock, and when dilutive, shares of common stock issuable upon exercise of options and warrants deemed outstanding using the treasury stock method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zwb6ePtYryFc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Schedule of Basic and Diluted Earning per Share</p> <table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_zGfbC5ym8VN9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49A_20240401__20240630_zvkvUtQQT6z3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49A_20230401__20230630_z1DzZ5GJoUT9" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49E_20240101__20240630_zf0235ytFkkh" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49B_20230101__20230630_zfzK3U9YFeCd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Three Months Ended
 June 30,</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Six Months Ended
 June 30,</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_408_eus-gaap--ProfitLoss_zpG2T4sgaMj9" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 48%; text-align: left; padding-left: 17.3pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,395</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,521</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,569</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pin3_zlAxWPb25btj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,787</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pin3_z1TDyEoWu1M8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pin3_zEtqMKk340xa" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,785</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align:

right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_pid_zz01Z1QzxMG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-indent: -8.65pt">Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.67</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_pid_znNdHTmbYeH" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-indent: -8.65pt">Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.67</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   For the three months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 159,000 and 118,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. For the six months ended June 30, 2024 and 2023, outstanding options to purchase shares of common stock and outstanding shares of restricted stock in an aggregate of approximately 161,000 and 119,000, respectively, have been excluded from the calculation of diluted net income per share, as such securities were anti-dilutive. The following table shows the computation of basic and diluted net income per share for the following periods (in thousands, except per share amounts):   Schedule of Basic and Diluted Earning per Share <table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_zGfbC5ym8VN9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49A_20240401__20240630_zvkvUtOQT6z3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49A_20230401__20230630_z1DzZ5GJoUT9" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49E_20240101__20240630_zf0235ytFkkh" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49B_20230101__20230630_zfzK3U9YFeCd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Three Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Six Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ProfitLoss_zpG2T4sgaMj9" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 48%; text-align: left; padding-left: 17.3pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,395</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,934</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,521</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,569</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pin3_zlAxWPb25btj" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,787</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pin3_z1TDyEoWu1M8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">44</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">68</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pin3_zEtqMKk340xa" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,528</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,785</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,534</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,830</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--EarningsPerShareBasic_pid_zz01Z1QzxMG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-indent: -8.65pt">Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.67</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EarningsPerShareDiluted_pid_znNdHTmbYeH" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; padding-bottom: 2.5pt; text-indent: -8.65pt">Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.35</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.67</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Note 3. Finance Receivables   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0

10pt; text-align: justify; text-indent: 0.5in">Finance receivables are reported at their determined principal balances net of any unearned income, cumulative write offs charged against the allowance for credit losses, and unamortized deferred fees and costs. Unearned income and deferred fees and costs are amortized to interest income based on all cash flows expected using the effective interest method. The carrying values of finance receivables were as follows (in thousands):   Schedule of carrying value of finance receivables <table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zauv7CT9wmqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240630_z4faaQGBGvA" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z6bSSiCWJ9n9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zg5Cft0lFRS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">213,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">221,145</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zkQiMwzaZpd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NotesReceivableGross_iI_maNALRNz0OZ_zi3GmCHm23X9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">278,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,405</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNALRNz0OZ_zgiXpzXEpX8e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,901</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNz0OZ_z7TjrKgomB11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">274,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Allowance for Credit Losses The allowance for credit loss ("ACL") is management's estimate of the amount of expected credit losses over the life of the loan portfolio, or the amount of amortized cost basis not expected to be collected, at the balance sheet date. This estimate encompasses information about historical events, current conditions and reasonable and supportable economic forecasts. Determining the amount of the ACL is complex and requires extensive judgment by management about matters that are inherently uncertain. Given the current level of economic uncertainty, the complexity of the ACL estimate and level of management judgment required, we believe it is possible that the ACL estimate could change, potentially materially, in future periods. Changes in the ACL may result from changes in current economic conditions, our economic forecast, and circumstances not currently known to us that may impact the financial condition and operations of our borrowers, among other factors.   Expected credit losses are estimated on a collective basis for groups of loans that share similar risk characteristics. For finance receivables that do not share similar risk characteristics with other finance receivables, expected credit losses are estimated on an individual basis. Expected credit losses are estimated over the contractual terms of the finance receivables, adjusted for expected prepayments and unfunded commitments, generally excluding extensions and modifications. The loan portfolio segment is defined as the level at which an entity develops and documents a systematic method for determining its allowance for credit losses.   The Company adopted ASU 2016-13, as amended, on January 1, 2023 using the modified retrospective approach method. The implementation of ASU 2016-13 also impacted the Company's ACL on unfunded loan commitments, as the ACL now represents expected credit losses over the contractual life of commitments not identified as unconditionally cancellable by the Company. The reserve for unfunded commitments is estimated using the same reserve or coverage rates calculated on collectively evaluated loans following the application of a funding rate to the amount of the unfunded commitment. The funding rate represents management's estimate of the amount of the current unfunded commitment that will be funded over the remaining contractual life of the commitment and is based on historical data. On January 1, 2023, the Company recorded an adjustment for unfunded commitments of $0.4 million for the adoption of ASU 2016-13. As of June 30, 2024 the Company has a $0.1 million liability for credit losses on off-balance sheet exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. As of December 31, 2023, the Company recorded a $0.2 million liability for credit losses on off-balance-sheet credit exposures related to unfunded commitments, with this liability included in accounts payable and accrued liabilities on the condensed consolidated balance sheets. Please refer to Note 6 for further information on the Company's unfunded commitments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><i>Allowance for Credit Losses - methodology update for the three months ended June 30, 2024</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">During the three months ended June 30, 2024, the Company revised its methodology for calculating the allowance for credit losses to be more directly tied to the individual risk ratings, as determined by management, of investments. This resulted in a re-allocation of the existing allowance and did not have a material impact on the total allowance for credit losses amount. Previously, the Company's quarterly assessment of the allowance included two portfolio pools: Term Loans and Royalties. After the change in methodology effective for the quarter ended June 30, 2024, these pools are further broken down into individual risk ratings applied to each investment to allow for a more precise method for calculating the allowance for credit losses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_89D_eus-gaap--AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock_zaZ7VA9Fyssj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table details the changes in the allowance for credit losses by Term Loans and Royalties (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Schedule of Allowance for Credit Losses </p> <table cellpadding="0" cellspacing="0" id="xdx_308_134_pn3n3_zq8hUxQ7n5K9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49D_20240101__20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zQ4wZaDDZqA8" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_493_20240101__20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z9wpLWkgCq5h" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49F_20240101__20240630_zfzZURnjfJab" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230101__20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zTnzH6ucpPH1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_495_20230101__20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zpRO978l92bk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_493_20230101__20230630_zZhFhGJa6Qd6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Six Months Ended June 30, 2024</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term
 Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term
 Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">
 </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iS_zjF7XTqRjG8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 34%; text-indent: -8.65pt">Allowance at beginning of period</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">9,731</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">4,170</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align:

right">13,901</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Effect of adoption of ASU 2016-13</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zz3wLpgg3d2" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zWeCBhZHC7de" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630_z5Xv2CuMIlT4" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_ztIWc8wSL65" style="text-align: right">8,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zMhQVdCbz8k6" style="text-align: right">2,886</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630_zEYh9P8bAQ8i" style="text-align: right">11,786</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ProvisionForLoanLeaseAndOtherLosses_zuvIvmPhzBT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision (benefit) for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(572</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(110</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--FinancingReceivableAllowanceForCreditLossesWriteOffs_iN_di_zauK2DJdwOE3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Write offs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">⁽¹⁾</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iE_zFi40g3NHGI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Allowance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,776</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F05_zPexuXP9RZb5" style="width: 17.3pt; text-align: left">⁽¹⁾</td><td id="xdx_F1A_zKPOWC5hxnk" style="text-align: justify">Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023.</td> </tr></table> <p id="xdx_8A1_z7Z1qcxeIA54" style="margin-top: 0; margin-bottom: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify"><i>Non-Accrual Finance Receivables</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company originates finance receivables to companies primarily in the life sciences sector. This concentration of credit exposes the Company to a higher degree of risk associated with this sector.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On a quarterly basis, the Company evaluates the carrying value of its finance receivables. Recognition of income is suspended, and the finance receivable is placed on non-accrual status when management determines that collection of future income is not probable. This evaluation is generally based on delinquency information, an assessment of the borrower's financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p id="xdx_89C_eus-gaap--ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock_zXlXxSaY0Kt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table presents nonaccrual and performing finance receivables by portfolio pool, net of allowance for credit losses (in thousands) as of:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Schedule of Allowance for Credit Losses</p> <table cellpadding="0" cellspacing="0" id="xdx_302_134_pn3n3_zePQkI3tH4R2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20240630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zk0rNxObttg9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49C_20240630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zRnTxHHmchE6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_493_20240630_z7ImZBCpENc3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_498_20231231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zQRfzSmfVVTh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49E_20231231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zCJbZxNRUwO7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_491_20231231_z6uRlPZBy4Ec" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zcOlbgjtAhJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 22%; text-align: left; text-indent: -8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,010</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">207,673</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">213,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,128</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">212,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">221,145</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_ztLhXRYzP2b5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,434</td><td style="padding-bottom: 1pt; text-

align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,436</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,406</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maCz2Au_zIpfU1AoJ5D8" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total before allowance for credit losses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">22,444</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">256,109</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">278,553</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">25,982</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">262,423</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">288,405</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msCz2Au_zPlfswyVRsmb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,368</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,715</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,447</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,454</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,901</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zUmUELxTKXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">246,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">249,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">274,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

As of June 30, 2024, the Company had five finance receivables in nonaccrual status: (1) the term loan to Trio Healthcare Ltd. (“Trio”), with a carrying value of $1.5 million; (2) the term loan to Exeevo, Inc (“Exeevo”), with a carrying value of $4.5 million; (3) the Flowonix Medical, Inc. (“Flowonix”) royalty, with a carrying value of $10.4 million (see Loan Modifications Made to Borrowers Experiencing Financial Difficulty below for further details); (4) the Best ABT, Inc. (“Best”) royalty, with a carrying value of $2.4 million; and (5) the Ideal Implant, Inc. (“Ideal”) royalty, with a carrying value of $3.6 million. As of June 30, 2024 Trio was considered impaired by $8.1 million and Exeevo was impaired by $2.2 million with the impairments recognized as a reduction in the allowance for credit losses on the unaudited condensed consolidated statements of income for the six months ended June 30, 2024. The Company collected $0.7 million and $0.2 million on its nonaccrual finance receivables for the six months ended June 30, 2024 and 2023, respectively.

Loan Modifications Made to Borrowers Experiencing Financial Difficulty

Effective January 1, 2023, the Company adopted the provisions of ASU 2022-02 “Troubled Debt Restructuring (“TDRs”) and Vintage Disclosures (Topic 326)”, which eliminated the accounting for TDRs while expanding loan modification and vintage disclosure requirements. The update specifically required additional disclosures on loan modifications to borrowers experiencing financial difficulties that involved an interest rate reduction, other-than-insignificant payment delay, a term extension, principal forgiveness or a combination thereof.

The Company evaluates the carrying value of each finance receivable for impairment. A term loan is considered to be impaired when, based on current information and events, it is determined that the Company will not be able to collect the amounts due according to the loan contract, including scheduled interest payments. This evaluation is generally based on delinquency information, an assessment of the borrower’s financial condition and the adequacy of collateral, if any. The Company would generally place term loans on nonaccrual status when the full and timely collection of interest or principal becomes uncertain and they are 90 days past due for interest or principal, unless the term loan is both well-secured and in the process of collection. When placed on nonaccrual, the Company would reverse any accrued unpaid interest receivable against interest income and amortization of any net deferred fees is suspended. Generally, the Company would return a term loan to accrual status when all delinquent interest and principal become current under the terms of the credit agreement and collectability of remaining principal and interest is no longer doubtful. In certain circumstances, the Company may place a finance receivable on nonaccrual status but conclude it is not impaired. The Company may retain independent third-party valuations on such nonaccrual positions to support impairment decisions. On an ongoing basis, the Company monitors the performance of modified loans to their restructured terms.

Revaluation of Finance Receivable

During the three months ended June 30, 2024, the Company revalued its royalty for Iluvien as a result of entering into an amendment during the quarter. Pursuant to the amendment, the forecast of cash flows to be received over the life of the financial royalty was revised resulting in a revaluation gain of $2.5 million and corresponding mark-up to the carrying value which is included in the “Gain on revaluation of finance receivable” caption on our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024.

Credit Quality of Finance Receivables

The Company evaluates all finance receivables on a quarterly basis and assigns a risk rating based upon management’s assessment of the borrower’s ability and likelihood of repayment. The assessment is subjective and based on multiple factors, including but not limited to, financial strength of borrowers and operating results of the underlying business. The credit risk analysis and rating assignment is performed quarterly in conjunction with the Company’s assessment of its allowance for credit losses. The Company uses the following definitions for its risk ratings for Term Loans:

1: Borrower performing well below Company expectations, and the borrower’s ability to raise sufficient capital to operate its business or repay debt is highly in question. Finance receivables rated a 1 are on non-accrual and are at an elevated risk for principal impairment.

2: Borrower performing below plan, and the loan-to-value is generally worse than at the time of underwriting. Borrower has limited access to additional capital to operate its business. Finance receivables rated a 2 are generally on non-accrual, and while no loss of impairment is anticipated, there is potential for future principal impairment.

3: Borrower performing in-line-to-modestly below Company expectations, and loan-to-value is similar to slightly worse than at the time of underwriting. Borrower has demonstrated access to capital markets.

4: Borrower performing in-line-to-modestly above Company expectations and loan-to-value similar or modestly better than underwriting case. Borrower has demonstrated access to capital markets.

5: Borrower performing in excess of Company expectations, and loan-to-value is better than at time of origination.

The Company uses an internal credit rating system which rates each Royalty on a color scale of Green to Red, with Green typically indicative of a Royalty that is exceeding base underwritten case, Yellow indicates a Royalty performing in-line with underwritten plan, and Red reflective of underperformance relative to plan.

<p id="xdx_893_eus-gaap--FinancingReceivableCreditQualityIndicatorsTableTextBlock_zvfZBh6MpWh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the carrying value of Finance Receivables by origination year, grouped by risk rating as of June 30, 2024 and December 31, 2023 (in thousands):

Schedule of Financing Receivable by origination year

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_pn3n3_zAPLz2sDVFI4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 4)">

<tr style="vertical-align: bottom">

<td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_z7ZJaaIpOPgk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_zqFIFseRwbgl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-

weight: bold; text-align: center"></td> <td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_zQJZ4G8l6BGd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z2Cffs0xaGii" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_ziUdLE5jDVUi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zP3LtTFNUJ2a" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_z34Boh1g5jG7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_413_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_z5LCUusQhGg2" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 23%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,835</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">4,991</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">18,826</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_415_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zXKznEcJOvGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,424</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zySg0wE1T4U7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zZdwqCjTsLCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,947</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_zsltmwIUOyph" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,538</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,472</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,010</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_418_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zUKs11NKUmc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">55,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">62,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34,145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">213,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zRYOHluCLaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,985</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden:

xdx2ixbrl0840">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,297</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">41,987</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zsqOFNZLxVR5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Yellow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,449</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zqFFxvWXE0i9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,564</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,437</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,434</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41B_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zxlwqDxr3i0l" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Royalties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,985</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,564</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,115</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,096</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt">Total Finance Receivables, gross</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,145</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">278,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold"> </td> <td colspan="26" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr> </table> <p style="margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_zDEerR14IJuf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_zsvc6zCq5Udg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_zVV34YC2xtr4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z7H5Gjp4A63e" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_zjHZq6suPhHf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zgeMnNtxzIk1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_zg9wI7Zd1DC9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_z2MSAJgVQE64" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 23%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,734</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5,696</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">19,430</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zNuTZPM2QPR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,799</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">32,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span

style="-sec-ix-hidden: xdx2ixbrl0875">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,485</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68,495</td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zpMQpUta3q32" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,341</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,807</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">90,660</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zvPNMZ2Teiyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,924</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,493</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,015</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,432</td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_zXp3YRiolF54" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,128</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,128</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zY0sJRK5i27" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50,140</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">63,420</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">45,582</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">37,503</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">24,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">221,145</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_41D_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zOub9ewgysrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">27,785</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">14,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,340</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">43,775</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_z0BVYB5ofgSb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Yellow</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,212</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">6,631</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zd38GiA1AIyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,834</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,587</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,854</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_415_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zLdIFdEiU2fb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt; padding-bottom: 1pt">Subtotal - Royalties</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,785</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,834</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">28,295</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,346</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr> <tr id="xdx_41D_20231231_zyJ9atxXLR58" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt">Total Finance Receivables, gross</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">77,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The carrying values of finance receivables were as follows (in thousands):   Schedule of carrying value of finance receivables <table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zauv7CT9wmqh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20240630_z4faaQGBGvA" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-

bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20231231_z6bSSiCWJ9n9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zg5Cft0lFRS" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">213,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">221,145</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zkQiMwzaZpd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Royalty purchases</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--NotesReceivableGross_iI_maNALRNz0OZ_zi3GmCHm23X9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">278,553</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">288,405</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNALRNz0OZ_zgiXpzXEpX8e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left, padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,901</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--NotesAndLoansReceivableNetCurrent_iTI_mtNALRNz0OZ_z7TjrKgomB11" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-indent: -8.65pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">274,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
2136830002211450006487000067260000278553000288405000130830001390100026547000027450400 The following table details the changes in the allowance for credit losses by Term Loans and Royalties (in thousands):   Schedule of Allowance for Credit Losses <table cellpadding="0" cellspacing="0" id="xdx_308_134_pn3n3_zq8hUxQ7n5K9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49D_20240101__20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zQ4wZaDDZqA8" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_493_20240101__20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z9wpLWkgCq5h" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49F_20240101__20240630_zfzZURnjfjab" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230101__20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zTnzH6ucpPl1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_495_20230101__20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zpRO978l92bk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_493_20230101__20230630_zZhFhGJa6Qd6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Six Months Ended June 30, 2024 </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term
 Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term
 Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">
 </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iS_zjF7XTqRjG8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 34%; text-indent: -8.65pt">Allowance at beginning of period</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">9,731</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">4,170</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,901</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Effect of adoption of ASU 2016-13</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zz3wLpgq3d2" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zWeCBhZHC7de" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20240630_z5Xv2CuMIlT4" style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_ztIWc8wSL65" style="text-align: right">8,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zMhQVdCbz8k6" style="text-align: right">2,886</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iI_c20230630_zEYh9P8bAQ8i" style="text-align: right">11,786</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ProvisionForLoanLeaseAndOtherLosses_zuvIvmPhzBT6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision (benefit) for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,055</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(572</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(110</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--FinancingReceivableAllowanceForCreditLossesWriteOffs_iN_di_zauK2DJdwOE3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Write offs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">⁽¹⁾</td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iE_zFi40g3NHGI4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Allowance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,297</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom:

Black 2.5pt double; text-align: right">2,776</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,104</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td id="xdx_F05_zPexuXP9RZb5" style="width: 17.3pt; text-align: left">⁽¹⁾</td><td id="xdx_F1A_zKPOWC5hxnk" style="text-align: justify">Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023.</td> </tr></table>
9731000417000013901000118460001184600089000002886000117860005055000127000518200 0-572000-110000-68200060000006000000118460001184600087860004297000130830000832800027760001110400 0<p id="xdx_89C_eus-gaap--ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock_zXlXxSaY0Kt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table presents nonaccrual and performing finance receivables by portfolio pool, net of allowance for credit losses (in thousands) as of: Schedule of Allowance for Credit Losses <table cellpadding="0" cellspacing="0" id="xdx_302_134_pn3n3_zePQkI3tH4R2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20240630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zk0rNxObttg9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49C_20240630__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zRnTxHHmchE6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_493_20240630_z7ImZBCpENc3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_498_20231231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zQRfzSmfVVTh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49E_20231231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zCJbZxNRUwO7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_491_20231231_z6uRlPZBy4Ec" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zcOlbgjtAhJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 22%; text-align: left; text-indent: -8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,010</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">207,673</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">213,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,128</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">212,017</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">221,145</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_ztLhXRYzP2b5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,434</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">48,436</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,854</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">50,406</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maCz2Au_zIpfU1AoJ5D8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total before allowance for credit losses</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">22,444</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">256,109</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">278,553</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">25,982</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">262,423</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="text-align: right">288,405</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msCz2Au_zPlfswyVRsmb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,368</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(9,715</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,083</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,447</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,454</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(13,901</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zUmUELxTKXh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-bottom: 2.5pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,076</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">246,394</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">265,470</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">24,535</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">249,969</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">274,504</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
6010000207673000213683000912800021201700022114500016434000484360006487000016854000504060006726000022444000256109000027855300025982000026242300002
<p id="xdx_893_eus-gaap--FinancingReceivableCreditQualityIndicatorsTableTextBlock_zvfZBh6MpWh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table summarizes the carrying value of Finance Receivables by origination year, grouped by risk rating as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of Financing Receivable by origination year <table cellpadding="0" cellspacing="0" id="xdx_30B_134_pn3n3_zAPLz2sDVFI4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 4)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_z7ZjaaIpOPqk" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_zqFIfseRwbgl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_zQJZ4G8l6BGd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-

weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z2Cffs0xaGii" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_ziUdLE5jDVUi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zP3LtTFNUj2a" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_z34Boh1g5jG7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td id="xdx_413_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_z5LCUusQhGg2" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 23%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,835</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">4,991</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">18,826</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_415_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zXKznEcJQvGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,424</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zySg0wE1T4U7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">24,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,718</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,476</td><td style="text-align: left"> </td></tr> <tr id="xdx_418_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zZdwqCjTsLCc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,601</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,346</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,947</td><td style="text-align: left"> </td></tr> <tr id="xdx_416_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_zsltmwIUOyph" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,538</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,472</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,010</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_418_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zUKs11NKUmc7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">55,712</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">62,526</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">34,145</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">22,674</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">213,683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_41B_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zRYOHluCLaa4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">12,110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,985</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16,595</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,297</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">41,987</td><td style="text-align: left"> </td></tr> <tr id="xdx_41F_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zsqOFNZLxVR5" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt;

text-align: left; padding-left: 17.3pt">Yellow</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">3,087</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">3,362</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">6,449</td><td style="text-align: left"> </td></tr><tr id="xdx_41F_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zqFFxvWXE0i9" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,564</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,437</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,434</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr id="xdx_41B_20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zxlwqDxr3i0l" style="vertical-align: bottom; background-color: White"><td style="padding-bottom: 1pt; text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Royalties</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">12,110</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,985</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,564</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,115</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,096</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">64,870</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 8.65pt; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt">Total Finance Receivables, gross</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">67,822</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">74,511</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,115</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,145</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,770</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">278,553</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr><tr style="vertical-align: bottom"><td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold"> </td><td colspan="26" style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"><tr style="vertical-align: bottom"><td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_zDErR14IJuf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_zsvc6zCq5Udg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_zVV34YC2xtr4" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z7H5Gjp4A63e" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_zjHZq6suPhHf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zgeMnNtxzIk1" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_zg9wI7Zd1DC9" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr><tr style="vertical-align: bottom"><td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td><td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom"><td style="white-space: nowrap; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr><tr id="xdx_416_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_z2MSAJgVQE64" style="vertical-align: bottom; background-color: White"><td style="text-indent: -8.65pt; width: 23%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,734</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5,696</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">19,430</td><td style="width: 1%; text-align: left"> </td></tr><tr id="xdx_411_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zNuTZPM2QPR9" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">25,799</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">32,211</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">10,485</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">68,495</td><td style="text-align: left"> </td></tr><tr id="xdx_412_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zpMQpUta3q32" style="vertical-align: bottom; background-color: White"><td style="text-indent: -8.65pt; text-

align: left; padding-left: 17.3pt">3</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">24,341</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">24,285</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">10,227</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">31,807</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">90,660</td><td style="text-align: left"> </td></tr><tr id="xdx_418_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zvPNMZ2Teiyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">6,924</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">12,493</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">14,015</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">33,432</td><td style="text-align: left"> </td></tr><tr id="xdx_41B_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_zXp3YRiolF54" style="vertical-align: bottom; background-color: White"><td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,128</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,128</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr id="xdx_41A_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zY0sJRK5i27" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td><td style="text-align: left">$</td><td style="text-align: right">50,140</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">63,420</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">45,582</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left">$</td><td> </td><td style="text-align: left">$</td><td style="text-align: right">37,503</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">24,500</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">221,145</td><td style="text-align: left"> </td></tr><tr style="vertical-align: bottom"><td style="text-indent: -8.65pt; text-align: left; padding-left: 8.65pt"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td></tr><tr style="vertical-align: bottom; background-color: White"><td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right"> </td></tr><tr id="xdx_41D_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zOub9ewgysrg" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td><td style="text-align: left">$</td><td style="text-align: right">27,785</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">14,650</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">1,340</td><td style="text-align: left"> </td><td> </td><td style="text-align: left">$</td><td style="text-align: right">43,775</td><td style="text-align: left"> </td></tr><tr id="xdx_411_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_z0BVYB5oJgSb" style="vertical-align: bottom; background-color: White"><td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Yellow</td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">3,212</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">3,419</td><td style="text-align: left"> </td><td> </td><td style="text-align: left"> </td><td style="text-align: right">6,631</td><td style="text-align: left"> </td></tr><tr id="xdx_416_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zd38GiA1AIyf" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-indent: -8.65pt; text-align: left; padding-bottom: 1pt; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,834</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,587</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">16,854</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr><tr id="xdx_415_20231231__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zLdIFdEiU2fb" style="vertical-align: bottom; background-color: White"><td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt; padding-bottom: 1pt">Subtotal - Royalties</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">27,785</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,834</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">28,295</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">7,346</td><td style="text-align: left; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">67,260</td><td style="text-align: left; padding-bottom: 1pt"> </td></tr><tr id="xdx_41D_20231231_zyJ9atxXLRS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-left: 8.65pt; text-align: left; padding-bottom: 2.5pt; text-indent: -8.65pt">Total Finance Receivables, gross</td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">77,925</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">63,420</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">49,416</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">28,295</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,846</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td><td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">288,405</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

1383500049910001882600031108000579880009328000984240002460400010718000291540006447600012601000133460002594700045380001472000601000055712000625

id="xdx_803_eus-gaap--IntangibleAssetsDisclosureTextBlock_zUJANp7VASxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 4, Intangible Assets   <p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_z9Z9auZPqLNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">As of June 30, 2024 and December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data): Schedule of Intangible Assets <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_z4DDGQZBRzF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"><tr style="vertical-align: bottom"><td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td

id="xdx_480_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_zLqOBo6tcfpg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_48C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_z5fbUhUs6Pid" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_484_eus-gaap--IntangibleAssetsCurrent_iI_zerORLh9TYnh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td> <td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book
 Value</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated
 Amortization</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book
 Value</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Estimated
 Useful Life</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_41D_20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zNNby9naNS38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">210</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">102</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">108</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zKdK4tG5Bb0c" style="width: 8%; text-align: right" title="::XDX::P10Y">10</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zC7yv9Om3wg8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Customer relationships</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">240</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">116</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">124</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zEhJ9KD44pE6" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P10Y">10</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41C_20240630_zKXLZUAgfzP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">450</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">218</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">232</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt"> </td> <td> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book
 Value</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated
 Amortization</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book
 Value</td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Estimated
 Useful Life</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_415_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zcovXb9npE8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Licensing Agreement⁽¹⁾</td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">29,400</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23,167</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">6,233</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 3%"> </td> <td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSupPPQ1J9jf" style="width: 8%; text-align: right" title="::XDX::P10Y">10</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeG3RvPLhW4f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">210</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">92</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">118</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zpJ4Rtn0OWb" style="text-align: right" title="::XDX::P10Y">10</td> <td style="text-align: left"> </td></tr> <tr id="xdx_41D_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zJ4WDqtwRoq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Customer relationships</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">240</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">104</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">136</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzgmqlR9BvX3" style="border-bottom: Black 1pt solid; text-align: right" title="::XDX::P10Y">10</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20231231_zFa7R1uumW93" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total intangible assets</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">29,850</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">23,363</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">6,487</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; text-align: right"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 16pt; text-align: left">(1)</td> <td id="xdx_F15_zi4ySuvq9nwj" style="text-align: justify">Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA^{TM} in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the “Loss on impairment of intangible assets” section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024.</td></tr></table>   Amortization expense was $0.2 million and $0.4 million for the three months ended June 30, 2024 and 2023, respectively, and was recognized within depreciation and amortization expense on the unaudited condensed consolidated statements of income. Amortization expense related to intangible assets was $0.5 million and $0.9 million for the six months ended June 30, 2024 and 2023, respectively. Based on amounts recorded at June 30, 2024, the Company will recognize acquired intangible asset amortization as follows (in thousands):</p> <p id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXJkxwq7imwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Schedule of Intangible Asset Amortization Expense</p> <table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_zOVUqNO0I4T5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td> <td></td> <td style="text-align: left"></td> <td id="xdx_49E_20240630_zEcTNw942PQ5" style="text-align: right"></td> <td style="text-align: left"></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzOY9_z5lEZms74VX9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; width: 87%; text-indent: -8.65pt">Remainder of 2024</td> <td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 8%; text-align: right">23</td> <td style="width: 1%; text-align:

left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zVGRDzfIMhT3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zP12mxVuzzac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zrJrFXtovvCd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zyNcShgzQhei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_z1IOXqjr10Dg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zLg5c1TQLg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">232</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zjr0ehgQSgG9" style="margin-top: 0; margin-bottom: 0"></p> <p id="xdx_898_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_z9Z9auZPqLNc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">As of June 30, 2024 and December 31, 2023, the gross book value, accumulated amortization, net book value and estimated useful life of acquired intangible assets were as follows (in thousands, except estimated useful life data): </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Schedule of Intangible Assets</p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_z4DDGQZBRzF5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td id="xdx_480_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_zLqOBo6tcfpg" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_48C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_z5fbUhUs6Pid" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_484_eus-gaap--IntangibleAssetsCurrent_iI_zerORLh9TYnh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated
 Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Estimated
 Useful Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_41D_20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zNNby9naNS38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">210</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">102</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">108</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zKdK4tG5Bb0c" style="width: 8%; text-align: right" title=":.XDX::P10Y">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zC7yv9Om3wg8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">116</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20240630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zEhJ9KD44pE6" style="border-bottom: Black 1pt solid; text-align: right" title=":.XDX::P10Y">10</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41C_20240630_zKXLZUAgfzP3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">232</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated
 Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Estimated
 Useful Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_415_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zcovXb9npE8f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Licensing Agreement⁽¹⁾</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">23,167</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">6,233</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zSupPPQ1J9ji" style="width: 8%; text-align: right" title=":.XDX::P10Y">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_414_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zeG3RvPLhW4f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">92</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zpJ4Rtn0OWb" style="text-align: right" title=":.XDX::P10Y">10</td><td style="text-align: left"> </td></tr> <tr id="xdx_41D_20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zJ4WDqtwRoq6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">104</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dxH_c20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzgmqlR9BvX3" style="border-bottom: Black 1pt solid; text-align: right" title=":.XDX::P10Y">10</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20231231_zFa7R1uumW93" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,487</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td>

</tr> </table>   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 16pt; text-align: left">(1)</sup></td><td id="xdx_F15_zi4ySuvq9nwj" style="text-align: justify">Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA^{TM} in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the “Loss on impairment of intangible assets” section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024.</td></tr></table>
2100001020001080002400001160001240004500002180002320002940000023167000623300021000092000118000240000104000136000298500002336300064870002000004(
id="xdx_895_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zXJkxwq7imwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Schedule of Intangible Asset Amortization Expense <table cellpadding="0" cellspacing="0" id="xdx_301_134_pn3n3_zOVUgNO0l4T5" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"></td><td></td> <td style="text-align: left"></td><td id="xdx_49E_20240630_zEcTNw942PQ5" style="text-align: right"></td><td style="text-align: left"></td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_z5lEZms74VX9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; width: 87%; text-indent: -8.65pt">Remainder of 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">23</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_zVGRDzfIMhT3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zP12mxVuzzac" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zrJrFXtovvCd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zyNcShgzQhei" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_z1IOXqjr10Dg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">29</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zLg5c1TQLg4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">232</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2300045000450004500045000290002320000 Note 5. Debt   Revolving Credit Facility   On June 28, 2023, the Company entered into a new credit agreement (the “Credit Agreement”) by and among SWK Funding LLC, the Company’s wholly-owned subsidiary (together with the Company, the “Borrower”), the lenders party thereto (“Lenders”), and First Horizon Bank as a Lender and Agent (the “Agent”). The Credit Agreement provides for a revolving credit facility with an initial maximum principal amount of $45.0 million. The Credit Agreement provides that the Company may request one or more incremental increases in an aggregate amount not to exceed $80.0 million, subject to the consent of the Agent and each Lender, at any time prior to the termination of the revolving credit period on June 28, 2026 (the “Commitment Termination Date”). The revolving credit period will be followed by a one-year amortization period, with the final maturity date of the Credit Agreement occurring on June 28, 2027.   The outstanding principal balance of the Credit Agreement will bear interest at a rate per annum equal to the sum of (i) Term Secured Overnight Financing Rate, or SOFR (as defined in the Credit Agreement) plus (ii) 3.75 percent at all times prior to the Commitment Termination Date. The outstanding principal balance of the revolving credit facility will bear interest at a rate per annum equal to the sum of (i) Term SOFR (as defined in the Credit Agreement) plus (ii) 4.25 percent at all times on and after the Commitment Termination Date. Under the terms of the Credit Agreement, all accrued and unpaid interest shall be due and payable, in arrears, on the first business day of each calendar month.   The Credit Agreement contains customary affirmative and negative covenants, in addition to financial covenants specifying that, as of the end of each calendar month, (i) the consolidated leverage ratio of Borrower will not exceed 1.00 to 1.00, (ii) the consolidated interest coverage ratio of Borrower will not be less than 4.00 to 1.00, (iii) the cash collection rate in relation to Borrower’s portfolio of loan assets will not be less than 4.5 percent, for such calendar month, (iv) the net charge-off percentage in relation to Borrower’s portfolio of loan assets will not exceed 3 percent for such calendar month, (v) the weighted average risk rating in relation to Borrower portfolio of loan assets will not be less than 3.00, and (vi) the Company’s cumulative share repurchases will not exceed $5 million in value in any 12-month period. In addition, the Credit Agreement provides that at no time shall the Company permit its consolidated tangible net worth to be less than $145.0 million, or its liquidity (as defined in the Credit Agreement) to be less than $5.0 million. The Credit Agreement also contains events of default customary for such financings, the occurrence of which would permit the Agent and Lenders to accelerate the aggregate principal amount due thereunder. As of the date of this filing, the Company is in process of amending the Credit Agreement whereby the covenant for net charge-off percentage will be revised upwards, the consolidated interest coverage ratio will be revised downwards and the Company’s share repurchase basket will be increased. The amendment will address covenant defaults as of June 30, 2024 and waive any past defaults.   The Credit Agreement refinances the Company’s Loan and Security Agreement dated as of June 29, 2018 (the “Prior Credit Agreement”), as amended, between the Company and Cadence Bank, N.A. (“Cadence Bank”), as the lender and administrative agent, which was due to expire on September 30, 2025. The Prior Credit Agreement was terminated by the Company, effective as of June 28, 2023.   On October 10, 2023, the Company entered into a First Amendment to Credit Agreement pursuant to which Woodforest National Bank was added as a lender under the Credit Agreement for an aggregate commitment of $15.0 million, thereby increasing the aggregate commitments under the Credit Agreement from $45.0 million to $60.0 million.   As of June 30, 2024 there were no amounts outstanding under the new Credit Agreement. During the three months ended June 30, 2024 and 2023, the Company recognized $1.1 million and $0.4 million, respectively, of interest expense relating to the Credit Agreement and Prior Credit Agreement, respectively. During the six months ended June 30, 2024 and 2023, the Company recognized $2.4 million and $0.5 million, respectively, of interest expense in connection with the Credit Agreement. Senior Notes Due 2027   On October 3, 2023, the Company issued a $30.0 million aggregate principal amount of 9.00% Senior Notes due 2027 (“2027 Senior Notes” or “Notes”) in a registered underwritten public offering. On October 27, 2023, the underwriter exercised in full its over-allotment option by purchasing an additional approximately $3.0 million aggregate principal amount of the 2027 Senior Notes. The interest rates are fixed at 9.00% per annum and are payable quarterly in arrears on March 31, June 30, September 30, and December 31 of each year, commencing on December 31, 2023, and until maturity. The Notes will mature on January 31, 2027. The total net proceeds from the debt offering, after deducting initial purchase discounts and debt issuance costs, were approximately $30.6 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including funding future acquisitions and investments, repaying indebtedness, making capital expenditures, and funding working capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_896_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zIPdPdHPQFnd" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0pt 10pt; text-align: justify">The following table summarizes the outstanding balance of the Notes, net of debt issuance costs (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Schedule of Long Term Debt</p> <table cellpadding="0" cellspacing="0" id="xdx_30A_134_pn3n3_zk21MIWJXYta" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240630_zAyHaiLMe0zl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_zunX2fWwvVVa" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iI_zjDS0SbiJpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">2027 Senior Notes</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">32,969</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">32,969</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredFinanceCostsNet_iNI_di_zjjabQu5JLLc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Debt issuance costs</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,891</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--UnsecuredDebt_iI_z3oFfYYxZUnk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total unsecured senior notes, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">31,078</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,781</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   <p id="xdx_89E_eus-gaap--

ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zVuLpBR55FKa" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">The Company's future principal obligations for the Notes were as follows (in thousands):   Schedule of Maturities of Long Term Notes <table cellpadding="0" cellspacing="0" id="xdx_30C_134_pn3n3_zTZHcATMeCL4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240630_zbcwOvCPwz79" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDzvZf_zP1vDCGTNDe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remainder of 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDzvZf_z1DyQAtuPWwc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDzvZf_zWIMZ86otdBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDzvZf_zYChFN81e2GI" style="vertical-align: bottom; background-color: White"> <td style="width: 87%; text-align: left; padding-bottom: 1pt">2027</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">32,969</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebt_iTI_mtLTDzvZf_zsTXChTrPYzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total unsecured senior notes, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,969</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   The Company may redeem the Notes for cash in whole or in part at any time (i) on or after September 30, 2025 (the "First Call Date") and prior to September 30, 2026, at a price equal to the sum of 102% of their principal amount, and (ii) on or after September 30, 2026 at a price equal to the sum of 100% of their principal amount, plus (in each case noted above) accrued and unpaid interest to, but excluding, the date of redemption. At any time prior to the First Call Date, the Company may, at its option, redeem the Notes for cash, in whole at any time or in part from time to time at a redemption price equal to (i) 100% of the principal amount of Notes redeemed, plus (ii) a Make-Whole Amount (as defined in the Indenture), plus (iii) accrued and unpaid interest, if any, to, but excluding, the date of redemption. On and after any redemption date, interest will cease to accrue on the redeemed Notes. Additionally, upon the occurrence of a Triggering Event (as defined in the Indenture), holders of the Notes will have the right to require the Company to make an offer to repurchase all or any portion of their Notes for cash at a purchase price equal to 100% of the aggregate principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of purchase.   The Notes are senior unsecured obligations of the Company and rank equal in right of payment with the Company's existing and future senior unsecured indebtedness.   The Company evaluated the 2027 Senior Notes for derivatives pursuant to Accounting Standard Codification ("ASC") 815, "Derivatives and Hedging," and identified an embedded derivative that required bifurcation as the feature is not clearly and closely related to the host instrument. The embedded derivative was a default provision, which could require additional interest payments. The Company reassesses the feature quarterly to determine if it requires separate accounting. There have been no changes to the Company's assessment that the fair value of the embedded derivative is immaterial through June 30, 2024. 45000000.060000000.011000004000002400000500000 The following table summarizes the outstanding balance of the Notes, net of debt issuance costs (in thousands): Schedule of Long Term Debt <table cellpadding="0" cellspacing="0" id="xdx_30A_134_pn3n3_zk21MIWJXYta" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20240630_zAyHaiLMe0zl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20231231_zunX2fWwvVVa" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebt_iI_zjDS0SbiJpEh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">2027 Senior Notes</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">32,969</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">32,969</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredFinanceCostsNet_iNI_di_zjjabQu5JLLc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Debt issuance costs</td><td style="padding-bottom: 1pt"> </td><td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(1,891</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,188</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--UnsecuredDebt_iI_z3oFfYYxZUnk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total unsecured senior notes, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">31,078</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">30,781</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>
32969000329690001891000218800031078000030781000 The Company's future principal obligations for the Notes were as follows (in thousands):   Schedule of Maturities of Long Term Notes <table cellpadding="0" cellspacing="0" id="xdx_30C_134_pn3n3_zTZHcATMeCL4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details 2)"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20240630_zbcwOvCPwz79" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_maLTDzvZf_zP1vDCGTNDe8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remainder of 2024</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_maLTDzvZf_z1DyQAtuPWwc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_maLTDzvZf_zWIMZ86otdBa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_maLTDzvZf_zYChFN81e2GI" style="vertical-align: bottom; background-color: White"> <td style="width: 87%; text-align: left; padding-bottom: 1pt">2027</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">32,969</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebt_iTI_mtLTDzvZf_zsTXChTrPYzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Total unsecured senior notes, net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">32,969</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 32969000329690000 Note 6. Commitments and Contingencies   Lease Obligations   All the Company's material leases are operating leases. Right-of-use ("ROU") assets related to operating leases are included on the unaudited condensed consolidated balance sheets in other non-current assets. Operating lease cost is recognized over the lease term on a straight-line basis and is recorded within general and administrative expenses on the unaudited condensed consolidated statements of income. In March of 2023, the Company entered into a new lease for additional office space in Dallas, Texas on Sherry Lane. The Company's corporate office spaces in Dallas, Texas total approximately 6,850 square feet consisting of the two office locations (Sherry Lane and Preston Road). Total rent expense recognized was $0.3 million and $0.2 million for six months ended June 30, 2024 and 2023, respectively.   On June 10, 2024, the Company entered into a lease termination agreement to its Preston Road office lease in Dallas (the "Lease Termination"). The Lease Termination terminated the Company's rights and obligations with respect to the leased premises on June 30, 2024. As such, the ROU assets and operating lease liabilities were written off, and the Company recorded a gain of $4 thousand for the quarter ended June 30, 2024 and paid an early termination fee of $9 thousand. The remaining Sherry Lane office lease is set to expire in August 2028.   The Enteris headquarters is located in Boonton, New Jersey, where Enteris leases approximately 32,000 square feet of space. The office lease expires in December 2029 with an option to renew for an additional five years.   The components of lease cost was as follows (in thousands): Schedule of Lease Cost <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_z3rhlbmqhX57" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_491_20240401__20240630_ziUgSMzy3b49" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49C_20230401__20230630_z8T5W1fDzAsc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td>

style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49E_20240101__20240630_zMwQN2EHoAZc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_493_20230101__20230630_zqNwurcBweT6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Three Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Six Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzAiu_zhZqu8amuhQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Operating lease cost</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">125</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">259</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--VariableLeaseCost_maLCzAiu_zfwczKPnIcdf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCost_iT_mtLCzAiu_zevMzLTzPWsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">151</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">148</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">246</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <p id="xdx_890_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zvya7NkIxCE8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">Future minimum rent on the Company's operating leases was as follows as of June 30, 2024 (in thousands):   Schedule of Future Minimum Rent <table cellpadding="0" cellspacing="0" id="xdx_30A_134_pn3n3_z6azevf7Hh12" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"></td><td></td> <td style="text-align: left"></td><td id="xdx_494_20240630_zAtUzHn26SKd" style="text-align: right"></td><td style="text-align: left"></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzbLh_z3cxqHKtd6Lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 87%">Remainder of 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">283</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzbLh_z2Rgnrvl3ay8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">456</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzbLh_zkbYALc8xuub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">461</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzbLh_ztsKk3TWc3v9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzbLh_zllwZwhq8sl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzbLh_znOsegzi1xfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">272</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzbLh_zvvegsZap2m6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total future lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Contingent Consideration   During fiscal year 2019 the Company recorded contingent consideration related to the 2019 acquisition of Enteris and sharing of certain milestone and royalties due to Enteris pursuant to the License Agreement. Contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved, with changes in the estimated fair value recognized in earnings. As of June 30, 2024, it has been determined the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of the product covered by the License Agreement. Accordingly, the Company has concluded that the liability for contingent consideration, previously held at its estimated fair value of $4.9 million, should be $0. The write-off of this contingent consideration liability has resulted in a gain of $4.9 million, which is included in the "Change in fair value of acquisition-related contingent consideration" caption of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024.   Unfunded Commitments   Per the terms of the royalty purchase or credit agreements, unfunded commitments are contingent upon reaching an established revenue threshold or other performance metrics on or before a specified date or period of time, and in the case of loan transactions, are subject to being advanced as long as an event of default does not exist. As of June 30, 2024 SWK had $5.0 million of unfunded commitments.   Litigation   The Company is involved in, or has been involved in, arbitrations or various other legal proceedings that arise from the normal course of its business. The ultimate outcome of any litigation is uncertain, and either unfavorable or favorable outcomes could have a material impact on the Company's results of operations, balance sheets and cash flows due to defense costs, and divert management resources. The Company cannot predict the timing or outcome of these claims and other proceedings. As of June 30, 2024, the Company is not involved in any arbitration and/or other legal proceeding that it expects to have a material effect on its business, financial condition, results of operations and cash flows. Indemnification   As permitted by Delaware law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving in such capacity, or in other capacities at the Company's request. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and enables the Company to recover a portion of any such amounts. As a result of the Company's insurance policy coverage, the Company believes the estimated fair value of these indemnification agreements is insignificant. Accordingly, the Company had no liabilities recorded for these agreements as of June 30, 2024 and December 31, 2023. 300000200000 The components of lease cost was as follows (in thousands): Schedule of Lease Cost <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_z3rhlbmqhX57" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_491_20240401__20240630_ziUg5Mzy3b49" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49C_20230401__20230630_z8T5W1fDzAsc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49E_20240101__20240630_zMwQN2EHoAZc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_493_20230101__20230630_zqNwurcBweT6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Three Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font:

10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Six Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseCost_maLCzAiu_zhZqu8amuhQg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Operating lease cost</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">134</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">125</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">259</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">222</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--VariableLeaseCost_maLCzAiu_zfwczKPnIcdf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Variable lease cost</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LeaseCost_iT_mtLCzAiu_zevMzLTzPWsd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total lease cost</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">151</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">148</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">246</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 134000125000259000222000170002300032000240001510001480002910002460000<p id="xdx_890_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zvya7NkIxCE8" style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">Future minimum rent on the Company's operating leases was as follows as of June 30, 2024 (in thousands):   Schedule of Future Minimum Rent <table cellpadding="0" cellspacing="0" id="xdx_30A_134_pn3n3_z6azevf7Hh12" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"></td><td></td> <td style="text-align: left"></td><td id="xdx_494_20240630_zAtUzHn26SKd" style="text-align: right"></td><td style="text-align: left"></td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzbLh_z3cxgHKtd6Lj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 87%">Remainder of 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">283</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzbLh_z2Rgnrvl3ay8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">456</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzbLh_zkbYALc8xuub" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">461</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzbLh_ztsKk3TWc3v9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzbLh_zllwZwhq8sl2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzbLh_znOsegzi1xfd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">272</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzbLh_zvvegsZap2m6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total future lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 28300045600046100046500040500027200023420000 Note 7. Fair Value Measurements   The Company measures and reports certain financial and non-financial assets and liabilities on a fair value basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). GAAP specifies a three-level hierarchy that is used when measuring and disclosing fair value. The fair value hierarchy gives the highest priority to quoted prices available in active markets (i.e., observable inputs) and the lowest priority to data lacking transparency (i.e., unobservable inputs). An instrument's categorization within the fair value hierarchy is based on the lowest level of significant input to its valuation. The following is a description of the three hierarchy levels.   Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Active markets are considered to be those in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis.   Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability. This category includes quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in inactive markets.   Level 3: Unobservable inputs are not corroborated by market data. This category is comprised of financial and non-financial assets and liabilities whose fair value is estimated based on internally developed models or methodologies using significant inputs that are generally less readily observable from objective sources.   Transfers into or out of any hierarchy level are recognized at the end of the reporting period in which the transfers occurred. There were no transfers between any levels during the six months ended June 30, 2024 and 2023.   The following information is provided to help readers gain an understanding of the relationship between amounts reported in the accompanying consolidated financial statements and the related market or fair value. The disclosures include financial instruments and derivative financial instruments, other than investment in affiliates.   Following are descriptions of the valuation methodologies used to measure material assets and liabilities at fair value and details of the valuation models, key inputs to those models and significant assumptions utilized.   Cash and cash equivalents   The carrying amounts reported in the balance sheet for cash and cash equivalents approximate those assets' fair values. Finance Receivables   Finance receivables are measured at amortized cost, which approximates fair value. The fair value of finance receivables is estimated using discounted cash flow analyses, using market rates at the balance sheet date that reflect the credit and interest rate-risk inherent in the finance receivables. Projected future cash flows are calculated based upon contractual maturity or call dates, projected repayments and prepayments of principal. These receivables are classified as Level 3. Finance receivables are not measured at fair value on a recurring basis, but estimates of fair value are reflected below.   Contingent Consideration   The fair value measurements of the contingent consideration obligations and the related intangible assets arising from business combinations are classified as Level 3 estimates under the fair value hierarchy, as these items have been valued using unobservable inputs. These inputs include: (a) the estimated amount and timing of projected cash flows; (b) the probability of the achievement of the factors on which the contingency is based; and (c) the risk-adjusted discount rate used to present value the probability-weighted cash flows. Changes in fair value of this obligation are recorded as income or expense within operating income in our consolidated statements of income. Significant increases or decreases in any of those inputs in isolation could result in a significantly lower or higher fair value measurement. As noted above in Note 6, the acquisition-related contingent consideration liability was written down to $0 as of June 30, 2024 due to non-viability of the underlying product. Marketable Investments   If active market prices are available, fair value measurement is based on quoted active market prices and, accordingly, these securities are classified as Level 1. If active market prices are not available, fair value measurement is based on observable inputs other than quoted prices included within Level 1, such as prices for similar assets or broker quotes utilizing observable inputs, and accordingly these securities are classified as Level 2. If market prices are not available and there are no observable inputs, then fair value would be estimated by using valuation models including discounted cash flow methodologies, commonly used option-pricing models and broker quotes. Such securities are classified as Level 3, if the valuation models and broker quotes are based on inputs that are unobservable in the market. If fair value is based on broker quotes, the Company checks the validity of received prices based on comparison to prices of other similar assets and market data such as relevant benchmark indices. Available-for-sale securities are measured at fair value on a recurring basis, while securities with no readily available fair market value are not, but estimates of fair value are reflected below.   <p

style="font: 10pt Times New Roman, Times, Serif; margin: 0">Derivative Instruments   For exchange-traded derivatives, fair value is based on quoted market prices, and accordingly, would be classified as Level 1. For non-exchange traded derivatives, fair value is based on option pricing models and are classified as Level 3.   The Company uses a foreign currency forward contract to manage the impact of fluctuations in foreign currency denominated cash flows expected to be received from one of its royalty finance receivables denominated in a foreign currency. The foreign currency forward contract is not designated as a hedging instrument, and changes in fair value are recognized in earnings. The foreign currency forward was recorded in other non-current assets in the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023 and totaled to $2.6 million and $1.0 million, respectively. The Company recognized a $0.8 million and $1.2 million gain due to changes in fair value related to its foreign currency forward contract during the three months ended June 30, 2024 and June 30, 2023, respectively. The Company recognized a $1.7 million and $1.6 million gain due to changes in fair value related to its foreign currency forward contract for the six months ended June 30, 2024 and June 30, 2023, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></p> <p id="xdx_894_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zmVvEnq1sFQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table presents financial assets measured at fair value on a recurring basis as of June 30, 2024 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">Schedule of fair value assets measured on recurring basis</p> <table cellpadding="0" cellspacing="0" id="xdx_303_134_pn3n3_zfI4ZPtyArhe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztBLZyzS5pQ3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVFVOCGi8fj17" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1)</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxDr4dTfCLUc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Significant
 Other
 Observable
 Inputs
 (Level 2)</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZu6jtB2clwd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Significant
 Unobservable
 Inputs
 (Level 3)</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_ecustom--FinancialAssetsAbstract_iB_zu1Vd61zHm7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_z5luCsiS8xD4" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">835</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">835</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zPa8RJV9gx5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_i01I_zZhnEAIADX24" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 (in thousands):</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC3hAbQMX8P4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z150mPE3rIGk" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1)</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYIPd6B0zlzg" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Significant
 Other
 Observable
 Inputs
 (Level 2)</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1quxSMDlXW5" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Significant
 Unobservable
 Inputs
 (Level 3)</p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zSC1TUOMm3Ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zZUq35L8NBXc" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zuPplkyYhx21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_i01I_zxYCDugl51h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zIaQO740wYSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> <tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_i01I_pn3n3_zlqixybyiGsi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td></tr> </table>   The contingent consideration payable was valued using a discounted cash flow approach and included a significant unobservable input which is the discount rate. During the six months ended June 30, 2024 there was a write off of the full balance of contingent consideration liability due to the non-viability of the underlying product. See Note 6 for further information. <p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zwlV06oJZwbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The changes in fair value of the warrant assets during the six months ended June 30, 2024 and 2023 were as

follows (in thousands):   Schedule of fair value assets measured on recurring basis unobservable input reconciliation <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zE6175Z94S6e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_493_20240101__20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6x0iwsN4gyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20230101__20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFhnGpSmRaOh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td></tr> <tr id="xdx_40B_ecustom--WarrantAssets_iS_zc3Nm1NfVvSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair value - December 31, 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 36%">Fair value - December 31, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfWarrants_zJvUQpcmtrj7" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">822</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--WarrantExercised_zI6IdIQcsVJb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(984)</td><td style="text-align: left">)</td><td> </td> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueAdjustmentOfWarrants_z1jtHnfS8Hg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Change in fair value</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--WarrantForeignExchange_z0aBxubsjNZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Loss on foreign currency transactions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Loss on foreign currency transactions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WarrantAssets_iE_zdjvu4yuetHf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">835</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The Company holds warrants issued to the Company in conjunction with certain term loan investments. These warrants meet the definition of a derivative and are included in the unaudited condensed consolidated balance sheets. The fair values for warrants outstanding, which do not have a readily determinable value, are measured using the Black-Scholes option pricing model. The following ranges of assumptions were used in the models to determine fair value: Schedule of weighted average assumptions <table cellpadding="0" cellspacing="0" id="xdx_300_134_pn3n3_zr0IMPK1vm5e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zTw9mKr91tO6">—</td><td style="width: 3%"> </td> <td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zrIv5TV7uPE9">— </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYRmnopDSICi">4.3% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNz6SBJQ3Vu9">4.7%</td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zoGmAkO8UEMd">3.8% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNQ5Oymasgk2">4.8%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zO54glBtBCvc" title="::XDX::P2Y4M24D">2.4 to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zyrzAdgmJXwk" title="::XDX::P5Y3M18D">5.3</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zl6lvHCGKK06" title="::XDX::P1Y2M12D">1.2 to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMXgIAqJzk27" title="::XDX::P5Y9M18D">5.8</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="white-space: nowrap; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zr6wucc9J069">73% to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z1WagrInM7V2">177.7%</td><td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z8BxJbmHDIxf">75.3% to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zusjRYhYHK8">154.3%</td></tr> </table>   The warrant assets are valued using a market approach and include significant unobservable inputs such as risk-free rate, expected life, and expected volatility. For the six months ended June 30, 2024 the risk-free rate range weighted average was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zDLjF2ZtQYx6">4.4%, and had a median of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_zMdRz1USFiY">4.3%. For the year ended December 31, 2023 the risk-free rate range weighted average was <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zMDdIRX8dYEg">4.3%, and had a median of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_zXRtmaYsBfYg">3.8%. For the six months ended June 30, 2024 the expected life range weighted average was <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zQRmtq8Gppza" title="::XDX::P4Y2M12D">4.2 years, and had a median of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_z6CY6Bos3T4j" title="::XDX::P4Y6M">4.5 years. For the year ended December 31, 2023 the expected life range weighted average was <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zgvtj7rH7dk1" title="::XDX::P3Y4M24D">3.4 years, and had a median of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dxH_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_zyZQGIoGOMI5" title="::XDX::P4Y4M24D">4.4 years. For the six months ended June 30, 2024 the expected volatility range weighted average was <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zlhybYYlCbEi">102.7%, and had a median of <span

*id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20240101__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_z9jzXoqcK4v2">90.8%. For the year ended December 31, 2023 the expected volatility range weighted average <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--WeightedAverageMember_zLXeuPfyYRw2">124.6%, and median of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MedianMember_zkjGmMBvzVWk">134.4%. <p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_z8tVg6L8YNCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">As of June 30, 2024 and December 31, 2023, the Company had one royalty, Best, that was deemed to be impaired based on reductions in carrying value in prior periods. As of June 30, 2024, the Company had two loans, Trio Healthcare and Exeevo, that was deemed to be impaired based on reductions in carrying value during the six months ended June 30, 2024. The following table presents this royalty and the loans measured at amortized cost using the effective interest method, which approximates fair value, on a nonrecurring basis as of June 30, 2024 and December 31, 2023 (in thousands): Schedule of weighted average assumptions <table cellpadding="0" cellspacing="0" id="xdx_30B_134_pn3n3_zwtpSVs6gT7b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zacLISEekhMf" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zqNlbuCoO7V7" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1) </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z8EQcFcVqc4c" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Other
 Observable
 Inputs
 (Level 2) </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zszRsIJfYok4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Unobservable
 Inputs
 (Level 3) </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43B_c20240630_eus-gaap--InvestmentsFairValueDisclosure_iI_zw7LG5XKD4f8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">June 30, 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,448</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_439_c20231231_eus-gaap--InvestmentsFairValueDisclosure_iI_zBCjgxsSlDSk" style="vertical-align: bottom; background-color: White"> <td>December 31, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,587</td><td style="text-align: left"> </td></tr> </table>   There were no liabilities measured at fair value on a nonrecurring basis as of June 30, 2024 and December 31, 2023. The following table presents the fair value of financial assets as of June 30, 2024 (in thousands):   Schedule of fair value by balance sheet grouping <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_z84vdtVvO2Rh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zTD4ATDZSIY5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zOmaoKRBcycb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zkOXnssOr20d" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zOZUpq0QoPDi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1KXXQpc5xa7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43C_c20240630_eus-gaap--FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zGWY74Vdo08e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_433_c20240630_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zaIwe4SP0ig9" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Finance receivables, net</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_434_c20240630_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zmPvYXQLFKu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_43D_c20240630_ecustom--WarrantAssets_iI_zQlSckOQKigl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20240630_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_iI_zKl0pIR9opi6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td></tr> </table>   The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands):   <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zWonODEsEL8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zwk28Dq02Dg5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zQsbllo9V1Of" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zFXUWBAtQO77" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zevYpjTEDk5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_436_c20231231_eus-gaap--*

FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zfIyng7OtJBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_43F_c20231231_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zYokp4oVlYU8" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Finance receivables, net</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_431_c20231231_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zr98nSBdZQFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr id="xdx_43C_c20231231_ecustom--WarrantAssets_iI_zb0SAV6Iqkai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td></tr> <tr id="xdx_43E_c20231231_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_iI_zIiQpT0VnZia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_43E_c20231231_eus-gaap--FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_iB_z1pvMVowEivl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_43D_c20231231_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zdvROZq6Bqaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td></tr> </table> The following table presents financial assets measured at fair value on a recurring basis as of June 30, 2024 (in thousands): Schedule of fair value assets measured on recurring basis <table cellpadding="0" cellspacing="0" id="xdx_303_134_pn3n3_zfI4ZPtyArhe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_ztBLZyzS5pQ3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVFVOCGi8j17" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1) </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zxDr4dTfCLUc" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Other
 Observable
 Inputs
 (Level 2) </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zZu6jIB2clwd" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Unobservable
 Inputs
 (Level 3) </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40C_ecustom--FinancialAssetsAbstract_iB_zu1Vd61zHm7l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_j01I_pn3n3_z5luCsiS8xD4" style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">835</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">835</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zPa8RJV9gx5j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_i01I_zZhnEAIADX24" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td></tr> </table>   The following table presents financial assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 (in thousands): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zC3hAbQMX8P4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z150mPE3rIGk" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1) </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYIPd6B0zlzg" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Other
 Observable
 Inputs
 (Level 2) </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z1quxSMDlXW5" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Unobservable
 Inputs
 (Level 3) </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_zSC1TUOMm3Ed" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zZUq35L8NBXc" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td>

<td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td> <td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zuPplkyYhx21" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_i01I_zxYCDugl51h" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zIaQO740wYSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Financial liabilities:</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_i01I_pn3n3_zlqixybyiGsi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td></tr> </table> 83500083500073100069600035000262900026290001759000175900048000480009740009740004900000490000 0<p id="xdx_89C_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zwlV06oJZwbf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The changes in fair value of the warrant assets during the six months ended June 30, 2024 and 2023 were as follows (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Schedule of fair value assets measured on recurring basis unobservable input reconciliation</p> <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zE6175Z94S6e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_493_20240101__20240630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6x0iwsN4gyd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20230101__20230630__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zFhnGpSmRaOh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td></tr> <tr id="xdx_40B_ecustom--WarrantAssets_iS_zc3Nm1NfVvSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Fair value - December 31, 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,759</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 36%">Fair value - December 31, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,220</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfWarrants_zJvUOpcmtrj7" style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">822</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--WarrantExercised_zI6IdIQcsVjb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(984</td><td style="text-align: left">)</td><td> </td> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--FairValueAdjustmentOfWarrants_z1jtIHnfS8Hg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">Change in fair value</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">(583</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--WarrantForeignExchange_z0aBxubsjNZk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Loss on foreign currency transactions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(70</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left; padding-bottom: 1pt">Loss on foreign currency transactions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--WarrantAssets_iE_zdjvu4yuetHf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">835</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">Fair value - June 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,459</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 175900012200008220000-984000130000-583000-700008350001459000 Schedule of weighted average assumptions <table cellpadding="0" cellspacing="0" id="xdx_300_134_pn3n3_zr0IMPK1vm5e" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zTw9mKr91tO6">—</td><td style="width: 3%"> </td> <td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zrIv5TV7uPE9">— </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate range</td><td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYRmnopDSICi">4.3% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNz6SBJQ3Vu9">4.7%</td><td> </td> <td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zoGmAkO8UEMd">3.8% to <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zNQ5Oymasgk2">4.8%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected life (years) range</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zO54glBtBCvc" title="::XDX::P2Y4M24D">2.4 to <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zyrzAdgmJXwk" title="::XDX::P5Y3M18D">5.3</td><td> </td> <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zl6lvHCGKK06" title="::XDX::P1Y2M12D">1.2 to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMXgIAqJzk27" title="::XDX::P5Y9M18D">5.8</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility range</td><td> </td> <td style="white-space: nowrap; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zr6wucc9J069">73% to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20240101__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z1WagrInnM7V2">177.7%</td><td style="white-space: nowrap"> </td> <td style="white-space: nowrap; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z8BxfbmHDIxf">75.3% to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zusJRYhYHK8">154.3%</td></tr> </table> 00.0430.0470.0380.0480.731.7770.7531.5430.0440.0430.0430.0381.0270.9081.2461.344<p id="xdx_89F_eus-gaap--FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock_z8tVg6L8YNCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify; text-indent: 0.5in">As of June 30, 2024 and December 31, 2023, the Company had one royalty, Best, that was deemed to be impaired based on reductions in carrying value in prior periods. As of June 30, 2024, the Company had two loans, Trio Healthcare and Exeevo, that was deemed to be impaired based on reductions in carrying value during the six months ended June 30, 2024. The following table presents this royalty and the loans measured at amortized cost using the effective interest method, which approximates fair value, on a nonrecurring basis as of June 30, 2024 and December 31, 2023 (in thousands):

 Schedule of weighted average assumptions <table cellpadding="0" cellspacing="0" id="xdx_30B_134_pn3n3_zwtpSVs6gT7b" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zacLISEekhMf" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Total
 Carrying
 Value in
 Consolidated
 Balance
 Sheets </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zqNlbuCoO7V7" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Quoted
 Prices <br/> in Active
 Markets for
 Identical
 Assets <br/> or Liabilities
 (Level 1) </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_z8EQcFcVqc4c" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Other
 Observable
 Inputs
 (Level 2) </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td><td style="padding-bottom: 1pt; white-space: nowrap"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zszRsljfYok4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Significant
 Unobservable
 Inputs
 (Level 3) </td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_43B_c20240630_eus-gaap--InvestmentsFairValueDisclosure_iI_zw7LG5XKD4f8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">June 30, 2024</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,448</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td><td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">8,448</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_439_c20231231_eus-gaap--InvestmentsFairValueDisclosure_iI_zBCjgxsSIDSk" style="vertical-align: bottom; background-color: White"> <td>December 31, 2023</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,587</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,587</td><td style="text-align: left"> </td></tr> </table> 8448000084480002587000025870007000 The following table presents the fair value of financial assets as of June 30, 2024 (in thousands):   Schedule of fair value by balance sheet grouping <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_z84vdtVvO2Rh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zTD4ATDZSIY5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zOmaoKRBcycb" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zkOXnssOr20d" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zQZUpq0QoPDi" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B0_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_z1KXXOpc5xa7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43C_c20240630_eus-gaap--FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zGWY74Vdo08e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_433_c20240630_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zaIwe4SP0ig9" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Finance receivables, net</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">265,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_434_c20240630_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zmPvYXQLFKu6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">731</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">696</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35</td><td style="text-align: left"> </td></tr> <tr id="xdx_43D_c20240630_ecustom--WarrantAssets_iI_zOlSckOOKigl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">835</td><td style="text-align: left"> </td></tr> <tr id="xdx_431_c20240630_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_iI_zKl0pIR9opi6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,629</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in">The following table presents the fair value of financial assets and liabilities as of year ended December 31, 2023 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zWonpODEsEL8" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying
 Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zwk28Dq02Dg5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zQsbllo9V1Of" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BA_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zFXUWBAtQO77" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B9_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zevYpjTEDk5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_436_c20231231_eus-gaap--FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zfJyng7OtJBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_43F_c20231231_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zYokp4oVlYU8" style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Finance receivables, net</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">274,504</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_431_c20231231_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zr98nSBdZQFa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48</td><td style="text-align: left"> </td></tr> <tr id="xdx_43C_c20231231_ecustom--WarrantAssets_iI_zb0SAV6Iqkai" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td>

<td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,759</td><td style="text-align: left"> </td></tr><tr id="xdx_43E_c20231231_eus-gaap--ForeignCurrencyContractAssetFairValueDisclosure_iI_zliOpT0VnZia" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Foreign currency forward contract</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">974</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_43E_c20231231_eus-gaap--FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_iB_z1pvMVowEivl" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Financial liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_43D_c20231231_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_zdvROZq6Bqaa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,900</td><td style="text-align: left"> </td></tr> </table>
2654700002654700002654700007310007310006960003500083500083500083500026290002629000262900026290002745040002745040002745040004800048000048000175900017590(
id="xdx_80D_eus-gaap--RevenueFromContractWithCustomerTextBlock_zY4Ttcu5ELi5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">Note 8. Revenue Recognition   The Company's Pharmaceutical Development segment recognizes revenues received from contracts with its customers by revenue source, as we believe it best depicts the nature, amount, timing and uncertainty of our revenue and cash flow. The Company's Finance Receivables segment does not have any revenues received from contracts with customers.   The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2024 and 2023 (in thousands):   Schedule of Revenue Recognized by Revenue Source <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_zAHGYpjV1mtk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_492_20240401__20240630_zL0OfGtGP1N2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49D_20230401__20230630_z41xBCVbLtua" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49B_20240101__20240630_zMKvWHrcsRSl" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_496_20230101__20230630_zPtsA6DKTHJl" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Three Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"> Six Months Ended
 June 30, </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td><td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--LicensingAgreementsMember_zRGhC338PUtl" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">49</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">49</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_ziaghhdeGR9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Pharmaceutical Development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">291</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PharmaceuticalDevelopmentRevenue_zui9heO9W34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">804</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company's contract liabilities represent advance consideration received from customers and are recognized as revenue when the related performance obligation is satisfied. The Company's contract liabilities are presented as deferred income and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):   Schedule of Company's Contract Liabilities <table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zJZbmioXNan6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240630_zypWDnjn2NT3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">June 30,
 2024</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20231231_z14YFb7xP0Ad" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zPs7TOp92eQ3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Deferred income</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">2,216</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">9</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zp4iPpnpIqnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   During the six

months ended June 30, 2024, the Company recognized the full remaining balance of $9 thousand of 2023 deferred income from satisfaction of performance obligations. The Company did not have any contract assets as of June 30, 2024 or December 31, 2023. Enteris Exclusive Option and Asset Purchase Agreement   With an effective date of January 1, 2024, we entered into an exclusive option and asset purchase agreement with a strategic partner on March 14, 2024 which granted the partner an exclusive option to acquire certain of Enteris' assets related to its business of providing clinical manufacturing and development services. The partner must exercise the option by or before January 1, 2026. In exchange for the exclusive purchase option the partner is to provide consideration in the form of an "option fee" and "guaranteed revenue payments."   The option fee is broken into two components: A low-single digit million fee due within 30 business days of executing the agreement; and should the option not be exercised by the first anniversary of the effective date, an additional low-single digit million fee will be due at that time. The first option fee was paid in April 2024. Option fee payments will be included in deferred income until the earlier of term expiration or exercise of the purchase option. Should the partner exercise the purchase option, any option fee payments made will be applied towards the purchase price.   The guaranteed revenue payments include two components: A mid-single digit million guaranteed revenue payment in 2024 and a mid-single digit million guaranteed revenue payment in 2025. The revenue is to be derived by the partner under an existing collaboration agreement, and partner is to pay the difference should the minimum amount not be met each year. Each year's guaranteed revenue amount is to be paid in two installments semi-annually each year. Should revenue exceed the 2024 or 2025 guaranteed revenue amounts after receiving a difference payment in the first half of the year, we must repay the partner the amount of such overpayment. Guaranteed revenue of $0.4 million was recognized during the three and six months ended June 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> </p> <p id="xdx_893_ecustom--ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock_zkcRl8PdLrqi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The following table provides the contract revenue recognized by revenue source for the three and six months ended June 30, 2024 and 2023 (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Schedule of Revenue Recognized by Revenue Source</p> <table cellpadding="0" cellspacing="0" id="xdx_305_134_pn3n3_zAHGYpjV1mtk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_492_20240401__20240630_zL0OfGtGP1N2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49D_20230401__20230630_z41xBCVbLtua" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_49B_20240101__20240630_zMKvWHrcsR5l" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td> <td id="xdx_496_20230101__20230630_zPtsA6DKTHJl" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Three Months Ended
 June 30,</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 3.75pt 0 0; text-align: center">Six Months Ended
 June 30,</p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--LicensingAgreementsMember_zRGhC338PUtl" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">49</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">49</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_ziaghhdeGR9l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Pharmaceutical Development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">755</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">173</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,034</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">291</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--PharmaceuticalDevelopmentRevenue_zui9heO9W34" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">804</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,083</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">301</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 49000100004900010000755000173000103400029100080400018300010830000301000<p id="xdx_892_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_z3DBOPwSd127" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company's contract liabilities are presented as deferred income and are included in accounts payable and accrued liabilities in the consolidated balance sheets (in thousands):</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Schedule of Company's Contract Liabilities</p> <table cellpadding="0" cellspacing="0" id="xdx_307_134_pn3n3_zJZbmioXNan6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20240630_zypWDnjn2NT3" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">June 30,
 2024</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20231231_z14YFb7xP0Ad" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,
 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zPs7TOp92eQ3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; padding-bottom: 1pt; text-indent: -8.65pt">Deferred income</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">2,216</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">9</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zp4iPpnpIqnb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-bottom: 2.5pt; padding-left: 17.3pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 22160009000221600090000 Note 9. Segment Information   Selected financial and descriptive information is required to be provided about reportable operating segments, considering a "management approach" concept as the basis for identifying reportable segments. The management approach is based on the way that management organizes the segments within the Company for making operating decisions, allocating resources, and assessing performance. Consequently, the segments are evident from the structure of the Company's internal organization, focusing on financial information that the Company's CEO uses to make decisions about the Company's operating matters. As described in Note 1, SWK Holdings Corporation and Summary of Significant Accounting Policies, the Company has determined it has two reportable segments: Finance Receivables and Pharmaceutical Development, and each are individually managed and provide separate services. Revenues by segment represent revenues earned on the services offered within each segment. The Company does not report assets by reportable segment, nor does the Company report results by geographic region, as these metrics are not used by the Company's chief executive officer in assessing performance or allocating resources to the segments. <p style="font: 10pt Times New Roman,

Times, Serif; margin: 0; text-align: justify"> Segment performance is evaluated based on several factors, including income (loss) from continuing operations before income taxes. Management uses this measure of profit (loss) to evaluate segment performance because the Company believes this measure is indicative of performance trends and the overall earnings potential of each segment. The Company does not report assets by reportable segment, as this metric is not used by the Company's CEO in assessing performance or allocating resources to the segments. The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands): Schedule of Reportable Revenue by Geographic Region <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zEBagr6QqhXb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_494_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zpN2aZg9urM7" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49A_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zyGx0WBIXkO9" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_497_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zlmy0TI58zl4" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_498_20240401__20240630_zPy8XqkyDZy2" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--RevenuesExcludingOtherRevenue_zCl8Kaun541b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">804</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">11,484</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueNotFromContractWithCustomerOther_z7hB8rG8EEN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProvisionForLoanAndLeaseLosses_zYxo4JVZLuYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_zwFswNwFrlwh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on impairment of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InterestExpense_zJfxJO5zc6rb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,119</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zHJnFnsQQE2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zhmOTk9CkyRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zEwi2pNFtHj8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">421</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zEVZta7mlV7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">748</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,923</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherOperatingIncomeExpenseNet_z5mxGBdVe2Of" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,817</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zk4c9jeuMfKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProfitLoss_zmyW0BfWDMK7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,737</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,066</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,395</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_496_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zbX2Jd1O4h7f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_491_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zKlmCJ4Cc7w3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zIOEvMnIp2q6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_499_20230401__20230630_znvWkhUkn8qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_ecustom--RevenuesExcludingOtherRevenue_zr3m4CRCgpF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,278</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">183</td><td

style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueNotFromContractWithCustomerOther_zt9nabtXgavj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProvisionForLoanAndLeaseLosses_zOssPYxNAefa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Benefit for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zoJp67lsNKL5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zkrQdNTK0iy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,509</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,509</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_z72FFfwGQamb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zyDXFpcPEmea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,879</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,997</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherOperatingIncomeExpenseNet_zkT5WEAEl935" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">715</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zfxzInIpBJhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,454</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ProfitLoss_zNYEd4XOZdd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,940</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,337</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,934</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_499_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_z19WwHlS4Tu1" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_494_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zYg8qD3nJap9" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49C_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zDtLmO6J9FHc" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49A_20240101__20240630_z9zP4MOZMiGj" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--RevenuesExcludingOtherRevenue_znLn3JHfjDbX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">21,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">22,482</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueNotFromContractWithCustomerOther_zhYj7LUseRf8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProvisionForLoanAndLeaseLosses_z1SvEbPPGab8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,397</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_zUk56OCiyUp8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Loss on impairment intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_zhrtPrjkTeTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">590</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_zpsBny3YUzC6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_ztz4XTMkERa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zW1cNxQIIwHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_zh7RsCbF3tHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,607</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherOperatingIncomeExpenseNet_zO5hdDtyQPV4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income (expense), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(408</td></tr>

<td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_zgPIdFjCz2p2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,264</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zkwkSO7lXKQ7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,192</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,476</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,521</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zzkHpdjenyti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49E_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zYvvHVT1Ca8g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_496_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zo0zTNljtCI4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20230101__20230630_zm5reodjkHBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_ecustom--RevenuesExcludingOtherRevenue_zxNBufy8sKg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,538</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">301</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,839</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueNotFromContractWithCustomerOther_zarlR0iv5aT7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProvisionForOtherCreditLosses_zFXY7e8B800g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Benefit for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestExpense_zf2LSzUkzEa8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_znQ55FP2FWD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,228</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_zb6VtFkXdLpg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zmqa3qoBpA33" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,537</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherOperatingIncomeExpenseNet_z2ERtyDx7T70" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_zs5jWkecxquk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,345</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,345</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zDJpgGy9nn53" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,012</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,569</td><td style="text-align: left"> </td></tr> </table>   Included in Holding Company and Other are the expenses of the parent holding company and certain other enterprise-wide overhead costs, including public company costs and non-Enteris corporate employees, which have been included for purposes of reconciling to the consolidated amounts.   2 The following tables present financial information for the Company's reportable segments for the periods indicated (in thousands): Schedule of Reportable Revenue by Geographic Region <table cellpadding="0" cellspacing="0" id="xdx_30F_134_pn3n3_zEBagr6OqhXb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_494_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zpN2aZg9urM7" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49A_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zyGx0WBlXkQ9" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_497_20240401__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zlmy0TI58zl4" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_498_20240401__20240630_zPy8XqkyDZy2" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--RevenuesExcludingOtherRevenue_zCl8Kaun541b"

style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,680</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">804</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">11,484</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueNotFromContractWithCustomerOther_z7hB8rG8EEN3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ProvisionForLoanAndLeaseLosses_zYxo4JVZLuYc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Provision for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_zwFswNwFrlwh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Loss on impairment of intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InterestExpense_zJFxJO5zc6rb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,119</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zHJnFnsQQE2g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">520</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_zhmOTk9CkyRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zEwi2pNFtHj8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">421</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zEVZta7mlV7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">748</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,923</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherOperatingIncomeExpenseNet_z5mxGBdVe2Of" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other income (expense), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(34</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,817</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zk4c9jeuMfKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--ProfitLoss_zmyW0BfWDMK7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,198</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,737</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,066</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,395</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_496_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zbX2Jd1O4h7f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_491_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zKlmCJ4Cc7w3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230401__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zIOEvMnIp2q6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_499_20230401__20230630_znvWkhUkn8qh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended June 30, 2023</td> <td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_ecustom--RevenuesExcludingOtherRevenue_zr3m4CRCgpF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,278</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">183</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,461</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--RevenueNotFromContractWithCustomerOther_zt9nabtXgavj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProvisionForLoanAndLeaseLosses_zQssPYxNAefa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Benefit for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zoJp67lsNKL5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">363</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zkrQdNTK0iy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,509</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,509</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DepreciationAndAmortization_z72FFfwGQamb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">633</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">637</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_zyDXFpcPEmea" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,879</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,997</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OtherOperatingIncomeExpenseNet_zkT5WEAEl935" style="vertical-align: bottom; background-color: White"> <td style="text-align:

left">Other income, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">715</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">715</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_zfxzInIpBJhe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Income tax expense</td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,454</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,454</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ProfitLoss_zNYEd4XOZdd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,211</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,940</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,337</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,934</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_499_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_z19WwHlS4Tu1" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_494_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zYg8qD3nJap9" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49C_20240101__20240630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zDtLmO6J9FHc" style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td style="white-space: nowrap; font-weight: bold; text-align: center"></td> <td id="xdx_49A_20240101__20240630_z9zP4MOZMiGj" style="white-space: nowrap; font-weight: bold; text-align: center"></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Six Months Ended June 30, 2024</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--RevenuesExcludingOtherRevenue_znLn3JHjDbX1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">21,399</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,083</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">22,482</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--RevenueNotFromContractWithCustomerOther_zhYj7LUseRf8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProvisionForLoanAndLeaseLosses_z1SvEbPPGab8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,397</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,397</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_zUk56OCiyUp8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Loss on impairment intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,771</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--InterestExpense_zhrtPrJkTeTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">590</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,780</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,375</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_zpsBny3YUzC6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,050</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--ChangeInFairValueOfAcquisitionrelatedContingentConsideration_ztz4XTMkERa8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value of acquisition-related contingent consideration</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,900</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--DepreciationAndAmortization_zW1cNxQIlwHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">43</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">935</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_zh7RsCbF3tHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,981</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,607</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherOperatingIncomeExpenseNet_zO5hdDtyQPV4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other income (expense), net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,843</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(408</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_zgPIdFjCz2p2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,264</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,264</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zkwkSO7lXKQ7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,189</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,192</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,476</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,521</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"></td><td style="font-weight: bold; padding-bottom: 1pt"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49F_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zzkHpdjenyti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49E_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zYvvHVT1Ca8g" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_496_20230101__20230630__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zo0zTNljtCI4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td> <td id="xdx_49B_20230101__20230630_zm5reodjkHBe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"></td><td style="padding-bottom: 1pt; font-weight: bold"></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Finance
 Receivables</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2"

***style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Pharmaceutical
 Development
 and Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Holding
 Company
 and Other</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td> </tr> <tr id="xdx_40A_ecustom--RevenuesExcludingOtherRevenue_zxNBufy8sKg7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,538</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">301</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">18,839</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--RevenueNotFromContractWithCustomerOther_zarlR0iv5aT7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">69</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProvisionForOtherCreditLosses_zFXY7e8B800g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Benefit for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(682</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--InterestExpense_zf2LSzUkzEa8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ResearchAndDevelopmentExpense_znQ55FP2FWD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Pharmaceutical manufacturing, research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,228</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DepreciationAndAmortization_zb6VtFkXdLpg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,277</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,285</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--GeneralAndAdministrativeExpense_zmqa3qoBpA33" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,709</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,661</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,537</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherOperatingIncomeExpenseNet_z2ERtyDx7T78" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(81</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxExpenseBenefit_zs5jWkecxguk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,345</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,345</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_zDJpgGy9nn53" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,494</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,913</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,012</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,569</td><td style="text-align: left"> </td></tr> </table>***

10680000804000114840005700057000407400040740005771000577100022500020008920001119000520000520000-4900000-4900000400000210004210009100074800020840002923000385100-34000381700010350001035000101980000-1737000-4066000439500092780001830000461000360000360000-6820003630003630001509000150900063300040006370001370009810001879000299700071500071500014540001454000102110000-2940000-3337000393400021399000108300022482000103000103000939700093970005771000577100059000050001780000237500010500001050000-4900000-4900000892000430009350001690001457000398100056070003843000-4080003435000126400015189000-3192000-7476000452100018538000301000188390006700020069000-682000-6820005450005450002228000222800012770008000128500016700017090003661000553700-81000-8100013450001345000184940004913000-5012000856900000

*** Note 10. Subsequent Events   Relief Therapeutics   On August 2, 2024, SWK Funding, a subsidiary of the Company, entered into a royalty purchase agreement with Relief Therapeutics Holding SA (“Relief”) and APR Applied Pharma Research SA pursuant to which SWK Funding paid $5.8 million at closing with another $5.3 million available for borrowing should Relief achieve certain milestones. In exchange, SWK Funding will receive royalties based off sales as listed in the agreement. Reversal of finance receivable-specific ACL recognized in prior periods. No impact to unaudited condensed consolidated statement of income for the six months ended June 30, 2023.***

Prior to our acquisition of Enteris, Enteris entered into the License Agreement with Cara Therapeutics, Inc. (“Cara”), for oral formulation rights to Enteris’ Peptelligence® technology to develop and commercialize Oral KORSUVA in any indication worldwide, excluding South Korea and Japan. Cara is obligated to pay Enteris certain development, regulatory and tiered commercial milestone payments, as well as low single-digit royalties based on net sales in the licensed territory. As of June 30, 2024, the Company concluded that the milestones and royalties pursuant to the License Agreement would not be realized as a result of non-viability of product covered by the License Agreement. The Company has recognized a full impairment on the license of its remaining net book value of $5.8 million which is included in the “Loss on impairment of intangible assets” section of our unaudited condensed consolidated statements of income for the three and six months ended June 30, 2024.TM

Z3+)$ M)9PJN@ST.)8;ZHFZVME;4H:LG2?44J9FJ*]72SD-.5IJ(\'60#MS5YG$W)G M Q-Z..85U88.=29I(\<>97Q _73C4Y-AV'9:MN -@-=2(!(*?T G8QZ0F]A
MUSU4F4BCAVLW89T:X0=LK&M6^ZPU"*RHM [PZ:"<4,8+%=^YDC>=A)BM9H7! M@A4I;C60W$WF,SC?-;/(>VS'Y4BX1BM<.2GRC[JGK#E%!5G0"AXN<+-X6_K(M*7SXU ',=C6\%Y5$.U):E:;
@4..5S9O]8^R;0"NS5L@=\RMA'/PC;OZV;H M8Z-/^F!LI!YB+F*G@'X4R77?Y'K[#!B20"NJMF*T5X]Z]Z0M',\3AI*%Z!DL M^* 0.X+B$7#9G(47CL>[L"H*.QR)FG/"#[BPEC:IP#"W<(#VYMA]79
P?:,!IS4:FK(Y_V38Z@9@#X8MB_C) Q4D9LN/?BO#\0X4*/(-'*SY+2H- _2EYH#(L"1 M_I7H4!E6%WC.XJ')'FT&-!2%.??3-FP,B?R,^XDQ4?/*Z#"QD,H@Q:0KUN7S
MQ1('BX4+T8&#KZ'F,WK,G8YVS*YJ"@>^W,F-^(**EA2I MZF;ISFG\9+Q%/?I*CAF%,7H#VS=Q?O2AXO^6*4:_2FME'3@OQ-7H G]YRC)\ MV?J$.U$->ALS,"7U9+<;*#'T\;;-
B['%Y76\K _=7G&:$[&GN^4;9C MO6.8OTJ]Y[W)Q?4>!?.]?2H>7VVI:GQU@):O)^.MC;C68+6AN9OHW;Z>:B4W MS-,+,>Y=#P9[1/#W>!CX%"%*YJT!@MR-=7D:)^-%&'"%!J+59;9PI9\VA%%>
M>)[<:N !;PX>DWN0O^8B1WTDQ>6LFBW0\Z*RF.#;/I&CNA\-*8]V']QH?D&* M]JTP]T6SPG+9:TSJ?=+:G4<#X77;$9__H, _@) N/#EU?UWFVC$YXE("[Z2I M.BFPS5(K?4>-
MP=.=\1Q&7*/+AORLN%P$'UTCCRR].CP]6HXC+Y_4#;FQU[' MUU=C<2+J"V%UY,<['0.HI2#PIKNDL;='+D*V5Z'Y_*1;&#]"KQ7.2&@OB*3:)W#@.AI_-<= MZ_OI0\6)00,;'F^%YP-18G@L',Q&')/?
\0?30UM [&H&;IF3M&*T&E!##4KO2 MI-SVE*VHBMYK>BQ(;P711)2YZU:9Z#/-4&<$,!N+QOW1M_@S^1;)U15]NOH6 MD>4['%2B&<)B@V[G83UP_Y87/1'@C#Q1?^J7GO/\T?.G7[E!
(3/)Q,B/;F@ M4\XO^##RWD[V([-T2D_H37<5F[V5IAQO5'.!EL"]JG-CN7K\W$QML^_[VL-J M4>>((/F6):E>C?OC;TMMCRIM#_'O E_&=%^<#X:DKNL!W3P?CON7^&_$.V_Y MJDH1GMB;>*GJOY-
[DD-:)]J6;V20KVQMLUG_OA2Q%6'7#Y/ M+%\3R/Q;2.'!.0U;M@'U-COYVG"^<3WQ%?O$#PJ<+6*>QT(@9'%U;PYC,=K+ M8LB@AY?5?D0!?G \'H0^M])[;PS4N
?,T[UH5[D<]BZN)GMV^7O\0D)4OI!P M*/ &WCFD(=KI9/]G;RD\66'^5V\N1.TW% .:\WG!8.U2^O],QTA,-<>>I8?N- MH)!M_WS;.]UTGH#/K2E69(W9> UWF,-@\)RDE_,\::[LAT/C7LB WEX^.5%
M;SP9M#[MC 1_][&&>$=3W&D'"7_1OVY_=O6, OE/=]&'6*[[R@E;DNISR&E/ MM\W_-3M-QKV+P;CU::>=_-U'NNK=C77'4KZ'\"[JWW;?E@G_JQN_#G-^--- M^:XWT\\:/R!8*COGGTG0&P3(@?
ZW!-75ZI<8M_X''/5R_S,.*'B.I"-2-&PO=V]R:W-H965T+)YV-H'B&R) MJ"$)!@ M>W_]?@V"U&&-XA<)Q/'UJ74WR*NUL5][&KO:LLK"H;(8SR:3LW&I=#6XN0IS# _;FRC2^T!4_ M6')-62K[\I$+L[X>3
?=Q">]RKU,C&^N:K7B1_:_UP\63^,>)=,E5TZ;BBPO MKP>WT\N/)[(_;/BWYK7;&I-8LC#FBSS\DET/J(0%YQZ05#X>^([+@H!@AI_M1LQ!+U(.;H\[]!^#[;!EH1S?F>(/G?G\>G QH(R7JBG\)
[/^F:,]IX*7FL*% M7UJW>T_.!Y0VSILR'H8&I:[:?_4<_:!UX&+RE0.S>& 6]&X%!2WOE5O<6JQCE_\XF?N&J8/G%J5I463UV-/8!E>9Q&D(\M MR.PK(&?TFZE\[NB'*N-L]_P8"O5:S3JM/LZ.
OZCJ48TGPQI-IF=',&;]U;. M][I7UBYM*:D.^AJP09XVN=T%WS,EOYSNW!A_K^''-#BSP_C2^9M1G/P+F24!LL>7Y52YG):H3".QE_;M_5%7"@#B M%QB@%@6,B88FF<%#93SEZDG
7MYH;V]K$)DL30'QHJX7?M>=(9MX9U1WN= M>^]FKSU%*-'AE,\MM^8Y_4QEFYHL]4E(+.X3*VS!8)Y\IRN<,HW#C/O(]3VB M]F<-M('+]K@117>SCT%T\EE$)MM5@!
[U\\Y$$D2*..I'R1%"/48__ZI3] "F MVQ5$A)5W=/(>/]/)9G0,Z/STE*;GCMRLM@J/:K5QT-;86 M8UVET*_7#H]%DX5YM--4DLU1K5X"<<.F-+4-UK?1=95$*CM3Z$ST1Q\M@NZA
M;SDZ1K]HP=_6"Q3S^73X%F[=[QGZCF;#V?0,_^_W2;)M MTM8VNJ?&(GN#C"1@](U5SMI-(?J$B)JHB72P[W(Y(M!9FJ:G!+HVFG_)I")-)ZRQN24[TLLY$5-*>ZDZ5Z6:'Z*9(FZWFE4S#'^@I&
MX.!O"MN3Z4DT<9WK-*>558&1XI]N[R&IHDSZ9Z/!T%CLQ8#HD$A]B@Z-&21G MI/$L %2Q"UYN*Z_$,D7S#)Q!AC5+1#^$.%B7[;0\^X3BU!;R7L,220T=V:;; M<=]JHFJB=
M&)G+>^X]&]$OP;!<5:N^D"<;2WMW=B9O"436PYK8-_;JC6ZW M2K0^$]\<=L\B'B+)G#Q/1#L"XNKJ":N!Y^BB4H09:+S6[4;9?]L@$1)1;6 M?.&J)8=?&VA2UJ:20Y=T2VARW\/7*V1UIE?
HXJ4NBNYT)D4.](Z"(\DF*)EZ M"9&!-U-DL?3(?(M10>?$H7 4V;:CI2DON(]!Z%?!"]HB-*JJX%'KQ/O EH5= M]@_%32K+PC4()#BJ^1IC"O N6!)C]X:VDYT4K<UE87@>^C M+E=E2^?
I#GJGZNY79E1@8 0;E,4%R29B$B/:_%SK2 *PJ>=CM'B/3R-ZW'BQ MX]4.A_<.#,.%QQS0NE09)YWJJJZAE&3;6MG,[2+! _+3U4_*:DX/ Z?W4ENU8)D&3RVWC;,/%ZZZNFS*>/GMR%^B!K-"$7T!,
==NF%_ M$SA@841 $VEMZ8@JGM>50SLLVI X+O7WR*,&,R_;8B*+.D#4+X[UN^MT>3T4E/C76XF/7-.VM[P^Z]>T2'7OO&6Z_IN/6MPL<(N9-! MG_:-O9_MOW?;KVT_0+0/WM3AI7]A/*Z8
M89@S4M/*!JPO#5[]XH,(Z+\"W?P?4$L#!!0 (/""#EFE@6A-Y0< " 6 M 9 >&PO=V]R:W-H965T@E*V4 MIHJQ>!7)\:7*GDR2V=U)7'9V\["U#Q)2:@A"08@+7N_?D^#!"Z6XG%FYV%? M> &!TZ>
[3S<)7FR4_F360K3LL2IK7%W8L5M]=:&ZMI2UN-7,=%7%]=.-*-7F/T(-Z)LB0@T/A]P)QL3=+"_>L1_0?K M.WQ9<"/>]?(W6;3KRTDZ8858\]YL[]3F)S'X$Q->KDICCVS3SPVR"_K
M0A2'ZV<@M&45C*QN@A\O!.-TJVL5^Q? MUPO3:FCBWZ?<[=\'"TVA4)V]-PW-Q.4$A&*$?Q.3JVV_\N7?^ M=HRS5Z"?VU M&7D1Y#3%GU4KG.R,G;" ,:H343A+6?,ZE[QDO"Z@;Y-
KV5#E,+DW71I4Y,^= MU*)@K6(+P1JM'B2RS_@"M8^G%&F^* 5#]' ,\GJ_M$_^B:1DWK%T+JD,P !T&D+J5RR<"VK,Y6CIC MOV+Z#IB-P.0!57/!X U!;O@3SKS=F^R@U_%:_D?
T1D=,5&B[EOVJ=ZIJ>/UD MJ53\$['8N5N(7%+S@K^\+%7>CR(=JM.YH%%$F!LCC*$'6&<##$_/ %P;!!CV MRB?7.3#/M6#BP3K.EEI5/;E6=WG;X9%:[C.C /K)N4'V6J%KI'5PRN;1!7$T
M&4N[9KO4[Z?:!@6(SG/$=^]_89VAX"CR7>S\'31PBL8N.H '(V3HVCB]S!;(M!N)*,F6^R^Y_^QO[294%)L.8TDANSXC"=M^_1,C;>[FJY5+F'!F[SG/5U1;_ M5I4REQ3F=J-&S3M[028)B
=>=ARZWXG!B =0+-D2S4%I+)=U7G;$@JY4)=BT M5,\2G,/8<):MY=X\G\A8$2,\UO^*.#GQYVP^K"M0: 2W Q9@S"7LAW1$=21 MW)CZ?87 1,X!D$U[6- M>X-
DP$/2S1*C*)R!3%]9H^5"P6JMQKJWJH94%T\GBM+MJ]@R;+7,0="AI1TE M8/%T4C:D-4CC9+% T2?KBT*X7SB6L;-4F+JAB984/*3^2*5T4OU4V*<(G>@U
MV[G@)E6QC3J\FMIVH3J#.)LW;]D]OJV*KK39N-LAW2%Y=8?<'ZX!@MVL.]KGH6E@OQQ*R'04E41 A9[3T M%^9[[CSU<)%Z$8[6P>"<'OANE$;.+ _!(P]U^?IQL9XSG.'%NJ?>;,5PY7@K0
M,HCO9\ZS<$ R'95V1^\>E]0"K4/6_=ON 5^IC24R MPFVM!=[^M?-N#9)4XF@44C,J59M.GN.U:"2)YSLM2IO^ODFL"'9\\?7J&@&G MD9MY'GMS-.I\+Z!/]'+;^'A%7S!]^SXB&6%-
X+,H\"&@VK8QNZ; EZ.D[QW; M L95F<^2*&6!ZZ41CED0#MD>^]PP\8W+:FP/0C>-=]&?AA'X8LQ/D(.QSQTQ M&L^^ZX5Q?W1^!MAA*X4(_2QE4]]-P@2P<-^;SW$1N6$6?7[ZX1=*/W.#)"6E
MI^&!\C,WFOO/A!_.CUP*Y\X-@DP]^UCVTWD:[.5S&S4[?"S:P ^_EGA] M-_:RP[L_J:QY&+((Q^0UPO*1Q"SU82A-,E)6EAPHJ]=3XL='/F/L=6J*XJ@_ MGE93X/ML"L,1%=4T=$,KJ]#-PLBYEX]?
OXT&/I2:D9A038=R"@(TTN"9GGSO M..$8>[&59C!QW'_MZ*E6^C_VT3CS&%5L@K=#X(9)_(5B=([%Z,7>X=W_9S>E M=T@4L@PMZS6BGV=6D0G)#.*/W;F7?*ZA1N$>22^U&HW"5]9 ,
(_ZXZD:B%T_MS4CZ?D:-:)JX4=)WU!AOAQ=KX$O[J9^Z<4@--?3\PT^)U$W#[%D%S'=2#M@\ M^WJ]-(Z.^PK&OE8O#=P@2_O_J2ND+,D82F=TU=**Z%"1 L/W?F(!@KX>%^=["7.#S&*"J]Y?
2W6AIQ'<;E+[= ML:P%I[9@VOW=FM-T"^P MU#VN06LT4S>$PRV(/FPKP2CJBG5DZ -XP:?W6NV MY@^TS1+U@(DJ(6TV'58,S)%TA3U#:;<3_6XCWZL-DD%G=QZG_@O-]O[:54*O
M[+])8H0E_0^\[>CV]^=U_]=O-[W_=_J1ZY7$OK,42RSUSI)XPG3_/[*_:55C M_P$N5-NJREY2T(2F"7B^5-CG#3=D8/M3^_J_4$L#!!0 (/""#EE1<&^F M!@, '(& 9 >&PO=V]R:W-
H965TY)!:.'6RGA7^_LQ,":%#QDOCL MN^^^N_B^3+9*WY@"T<)=*:29!H6UU7$8FJ3 DIF'JE#22:9TR2R9.@]-I9&E M/J@481Q%AV')N QF$[^WT+.)JJW@$A<:3%V63-^?HE#;;3 ,'C:6/"^LVPAG

MDXKEN$+[JUIHLL(.)>4E2L.5!(W9-)@/CT_'SM\[_.:X-4_6X"I9*W7CC,MT M&D2.$ I,K$-@]-K@&0KA@(C&;8L9=*E=X-/U _JYKYUJ63.#9TI<\]06T^ H M@!0S5@N[5-
L+;.LY<'B)$L8_8=OXQI\"2&IC5=D&$X.2R^;-[MH^/ DXBEX) MB-N V/-N$GF6GYEELXE66]#.F]#98OH\VB0Z':?X@=-IO!/P:RT' M,(KZ$$?Q> ?>]*MQY/$.WEHC_)FOC=5T(_Z^5&Z#-
GH9S4W)L:E8@M. QL"@ MWF PV]\;'D8G.[B..Z[C7>AO^QZ[(;XKB[UA-(#_ZUZBX)CU?A:H686UY8F! M'[(WKW.Z:1 W'>_#ZOH;G-ZAJG10T*\!RC5@Z!EMNBS8_/,M_H81+U%O-X?W^WE$<1R>-
MFS>&)Q> R13FBR7,JXKV4U@4C.:1P PRR@,420E-S2@-T=@6W&T^U@ 5XRF\ M.Q@>&).*ZM(|("12-1Y,R> _5S[0;]>:?/-+I2JQ4-9 M5/;-WJ*NEZ\.#FRZ4*6T0[U4%7Z9:5/*&E_-,
NC9(9/U06!Y/1Z.2@E'FU M]_8U7[LQ;U_KIB[R2MT889NRE&;]3A5Z]69OO!R.B2!4JK6D)B7_NU94J"eH)=/SI%]V+>]*#W<]A]9_Y\#C,5%IUI8L_\JQ> MO-D[VQ.9FLFJ&_UZA?E#W1,ZZ6ZL/Q_L?
+WCO9$VMA:E_YA4%#FE?M7/GA& M/.>!B7^ &7'@-F(JW\M:OGUM]$H8NANKT0<^*C\-XO**I')7&_R:X[GZ[=T? M_Q:_Z"++J[D55]HLM9&.754F[IRHA)Z)NWQ>Y;,\E54M+M-4-U6-1\2-+O(T
M5U:\")]>OCZH01>M?!I2&MXY&B:/T' B/NJJ7ECQH)AY]$0[V; M[%SPUZ8:BL/10$Q&DZ,=ZQU&)AWR>L>/K/?9S&65_\6,&8!+E<5ALY9-T99 M5=7N ICUYP44&):RO^YW)J:P,M_ -
]M"('$'&XG@$SSE5W*5+W9 M6])>YE[MO?WG/\8GHXL=QSN*QSO:M?K;3[)NC*+"/R^5$[_=1N-S5DEZJPBH M5[)5O5[4"R7^^8^SR61T<:7+I:S6 _XZO@B75RI>T29<;*R_]E*LI!5YE?I%
M588OXM>F6(OQ^?D)?;F210Z_5>62I)08M7GW>U7(E<31\?E.+2&IJ3+T^/E0 M7/O%)J/Q9"!62J2ZA"!J/"D%";)6<[:,:9/S^>CR4I'4Z[68L08HU@YI+;QK M*2MX.5*%9-I8\,Y:WN2RF$*XQ$86R=+
NQN0"],E1XM[6MH^-T;H5I)$ MB\FM$O5*PQV#B[6<%DI8-6?]?A4D]+,_^JU*57Y/]P21,0'^KIL>UE5T3"#24^GN:TS%9NJATH>?XL5198#7XUOF> MRWFE+4[D-
@VDU!I.>H!+>8F['*V.JK[H\BJ#*AC0G+R 7^? !;9@1\\TJ#,8 M#B\+_D8[&!*C9%'HE!B5RF5>8ZU:"R7311 /<4V;#-J-'^.J(K$JMIX2$ET8 MWV5^+U:]DW7N"LW(%V:.C WG%-)4[%A\:I6-
P9D#L47+.M- M7.26SI_)V>!Q9;P5@G@)_GQ1#Y+91*W8),"-*W+C";GQ 9,7UEE ^I.)F#5% ML5\#)0@%2]%KY?=+VONLJ&\]7I$AST);*+,T9@W7 .//$+L\>S]]_JWU+D3& M5!4Y%--
B:UGS_G*:%SD,!ER$T(K\+^(>'+*@9^ETLA)YR<8!0Z1+8U7QNU)PT_3]='IZ/CP#YB@* ML]WZ"PV(D.G*EI#?"5?L-GJ*#1:QPFJ)= SPHF%#G^E+F?&?K!4#_ M(]0-
6$Y+:"NT!1NTJP1#X:5ZEB&^LXRN(72=B@A.92C>LQM.MKAZF(KH>T31 M\8C1B%G4K(;IGTUN\X W/F _^&;Q+M=NE0$B2SJ,BNU_;SV&OY"0PHH4D7PS M=/!Q^M%#=T
0'>H^9[7)>G0:\HB6S&/#MT5-AD&NP!S!P3NXX832BZ9P:P-< M-4ZU*.T2GWK^L3$>R\(0#VCP^%$_:Y@\SW#]^R+O.DPH V[=#C2&E/! M&:X3O^[CJO0'-
%J*Q1LGJ.$R+S97H)!A9B,V:T_7^X^?HC+N*1:R* AF^GQ7%_'M5-:JUUT228@,I(SH M.6D20W;%L>9QJ<:EM7,?324!"QP^%LJZS[Y? !?; #\V#;H$GMS\I&<-N$F M: K#&%PP&;MC9CYY@;"?
4:E&QN6,C5*K-1$*'YF:?(HEG%!N_=VWG;NGE&GO MTI!?P7PRH'&(/- I2 4(']7XDN'KC7>/XK*O, XSE&J+WN#YCQ)/)>.CN!,K MT1SAB\,8G@TW$Z5!EQ"M>7EAF0#'G*YA%OX0-
/5$0L0MB@=Z28C<"LDD9$R\BT5/R3! "9*PV6'TR MW)&L'<=D[7AGFO5.VIR/U4LZ718*?F<[3[LHA@9(=!XAIQRTDL64/Q2>J4O'1GUK-J!F%%(AR13%YD2^9 M?KCEK]H0O/5[W6OF;WAN
\MW.$4G('3(&6'(N$2MpU.X?P X1!TR _M+U:Z)*>D#)]Y,2!952)M%30(7(@1^34:C-UJ')'=!NF'/^6R @9U&,_MQ,(8]]^E1A-T# M8L%OOUWM4AV'?2BW# _:5N)RJMYX?AS3'J"Y7!V0<]-W;?
AM_C"NZD J77-H9 M1(]M.W'1&PM0,8(I5@JY\'=.J[664K(0"L4Y#V+7\8@T+&4#T7!K/2[45IF D;(#! M$_D'X[F+M?[2&W-3$. MV5J3+CI:U:)6 E8F(P1E0WE' 6/@*6"
[#/VA#&V(%DOHD9@2[>,HPSP+H-7 MR@B9%WP\N&.7CWN)_'#4&]!)W1XLFTI[3A&8(COI%.3 EP-MDEK7O(1.OY%[
M@>8$9.2/)>L:D+%QU3KO*J)D=P"2DPA(3G8"DM\C)+YF9%9VRM_7E>L;/0)! MGKEPLG-AULXG6@"%E E+,9&Y"1A*=-JV1^X-W8W@\N'.I M+LGAN-@J!^73O07P2ZZS7MI#=,!F
BTY!IVT)BP@R6XUY%ZJRN@&#"AKF-FQ8=OBECAG/O, M/@*0.]* ÜKM^>/#'N"II3YM9V4]F[#U<18R9?.+3]/7VEC8@SMN4"14,V>L2I7585>+?]X"N2D2,9!?
KQ58*,X*;8]3P4++>4WV&BD@WI>R(Z; M8P+IMVJ,ZA M9P]T2H(-3/RI,"S [|))U]?)G# MW41NI2),EKEZ4/L09W?LNH:]#G3OD*)[2-<"8OY$C0VX@<61M+MWBRP7+H3N M3Z7US2.0)-
TOK@G5Q=*KBU1^1*&JpJ,/8X_-A! MV!=D_\1;VICD2'4[?];0$I(/H)8?C >FP=>14LQ],QPRI0H>;0&,?T?/.@6! ML7UM,M<;%! :)RVNOD+QA933M3^M?K0TCB@"N:TH_(;BL76
T&V/2'MW:W5%6,K8"QO M8]Q17G S!A$+7MA'.EJSJ9:D$2GCL2$Y2XZD\YR2CQ91)H%ZTI.6#G B4QL@ MA3,.HYA)LK!,EI-YAP/F^\,X4PGD]U&^"WB \[$%Z_*TQPW/P6E@Y%H;KJ*2
M51O7)&FUD(J^FI*;?H,UINFJNL^-KK@/G%PB&VUX-('LM?4H $L.%;-B$8B9 MJDXYR#PEN(Q$CW5TF_=] "#$1LK0E).P*^)"5YPHX$52!'X\B@MJDXYR#5$X3M$XXXL4X[*18EV 8;2[)
[C#K%GR+=7BGJ3<1/!+AW:O0%T_:^8@N=J>9J4[*R8-.[FTF&=HYK61^ M@YL!T3PUL.]5M_$9WXU*'/J'RSFM^MWGV][[SOE$5.#}-2/3_L&$-?QV@(N MW^G>,,OKIC./$JND7$1I^V:-<+C?
4(HX[$&-]+ M3@]^+/HO1_;A_N@T)DBA5GT;.]W>(0$G ?9?E]R$BJG#;?O*97CR?3L?$QR8 M+Z#&"8%E,RVXK>8' 7FLEI_JIXZ(Q=R]I-QPR\N= 1+ M/ZP,W-J"G4)Z$R!TT #<7-!MS/\F$-
XODNTT:+A 3'I3)2, M).$RP;X/%^U<$W/!HY.-M-Z]0QD+'[U75GQYL(T^X1S?O6SI2Y]M'S<4NH+2 M>PLA\3S# '85;:(NLD%$EC]E$.?1(*[=F;_0Z$&PA=.C;;;0WMFU@6Z:'TT^ MR=T4,V>XA.C\
[.V<>VL^:M"\6)6NNT/.[1P$RT57*A:ONR,T+@:"12E/^?,+ M(&'$@%T1A8*4;"G!4J0.7Q%Q+/7_79#KO WF2W([ZC)V&>HDKE7<4N8$_Z21
M)4\9&;VC0SF*ZIM'QS:>H6#B<07CE[>>\JB]=RF[BK4-$QJT_O9%JWM[D^0 +;.J9A5J!D>'0U/C_=U+ODCO+?5GG[?U!+ P04 " #P@@Y9GGJ1O $$ M #P" &0 'AL+W=OW"1W"OU
MU1T^EO,P=H108&$= J-EASQ4RSWS."-$E]X M::MY. FAQ UKA;U5^P_8QS-T>(42QO_"OM>-0RA:8U7=&Q.#FLMN9=_[//P7 M@[0W2#WOSI%G^8Y9MIAIM0?MM G-
;7RHWIK(<>D^RMIJNN5D9Q?K+[_"!R5* M+K<&;I1NE&9=NF0)Z^Y+@=K FF\EW_""20O+HE"MM&0*R5XP=' V1V[%VC. M9P-
+K!SVH.@97'<,TE<8C."3DK8R\+,LL7QI/Z!H#B&ECR%=IRF807.P\;YTCL,%V_?)*/XZD1X M^2&_!3Z8DWOO&P%.NJWN./NN1FP"FR%X)2!4Q#&7:M6
S'8<=4:\0#"KPB>FB@BSI*AV6AMS1^W61+2.!HGE\&J8M0@"VPM M-0A!7VA'S;[QWM/Q);Q],TF3],KM@\^4! WYZ"#,1\&=LF2E>W+.S9BL>B=T MBO,\^ T?B9';R2AYP2(=!=?,\
+DDU9#;@SQ21Z*LR5[#^EH8F%!JIVB =)5$Z&<)9DA&:/XW3/G3F0!G13>0#M+#.%]V4^Q)O?LO0)6]Y?1H!&[(-+X84V_6W7SM#E8U?J;=
M*TL3TF\K^DN"VBG0_48I^WAP#@Y_BN:9CZ;X.U/*S\]7_:^.;WE;$;P7K9 MLCUNT7QO'Q5IP8!2\ :%YE* PG+E?YPN-HFU=P;_<#SHBS783'92_K3*YV+E MAY80UI@;B\!
(/.,GK&L+1#3^/6+Z0TCK>+D^H?_E1GU@]T[Y]%+AN$ M%A5L*Z80WCVQ78WZ_3(P%,(:!OD1;M/#1;^!R^"K%*;2<"*+[U#XC:P"\Z M\=M$HX!?.G$#<3B!*(R2$;QXR#=V>.E(OORB6Y;CR
MJ14TJF?TUW^\F6;AGR,>=!@*@2J6-L9YCJ):.T&6L61EKA2 M6*"AX;S/N'3&9:'A'1=T(CM-&'H"^))C:\Z>'FMD)XQ^OX!7U?!&J^$]50K1
MNWR&L.4OOVQX]C'9%Q7#L/(>N@85,U(MO(M'\A:227R;DHPGMW'B]#2:DIQ/ MTNS6NT,AJ2U[OQ]N!F#Q@3T3U![[7#30,-2&6%NBTVB2I#,K9LG4:5GFM/G, MNR]+&E8V45=5&E>@,>\4-
YQ09E-($LCFD,2O(YVNX1B1 --HWN.F3B/N).9Q MZ/5/ZN1]99F6$J.6)9A061R.[+W+:A!0(V+.,H)11?M12]L M!CV5Q +4Q@5$JL"0"C22*[!)%OCI1AGJ^/;3\%/4)6I[C@D,F-*$--O@0(:AU
MOB@K!V'6"%QKC_IP]HQBZ3S%TD!ZH"56IQ[-FQ)[DH?R:]"L-&B8/ M+*.SRVTF'91H G9JLA?[PD/NK,JZ#OX [;;;EF8!TO$'? M?I,QRKX+4Q1G0G6#Y(?
E$C@I2"D69AO)*=C[\"NH1]4[RKNS+Y\9R":(X2Q3 M05B:J>3.FL,L$E&<8.=V^IYN2SGZ/;CIS!O5G7Y!X0<,FL+M]KV) M?C&HW$#)\\@;M*N+'?A'+Y*Y@12I'1R!D3-
5N2A@&CD/#^@^8IS*>FXV32*& M='>07YLFO_1Q?EV. %MUP%;_+V"/"CY?]U^B/:[6WJ':U,5\;G> D0!><&=H M!3Z6!T=U(&D"+3S^FKP9\SQR\&"NX/V#>Q' MUH:,
_E/8_4F*58I'W!0CFF3O93!KG24E:C"@@LD@%RXVG,43&92($F <=1? M9RR&A1"(206@R0\$)G$.N&8*EMDK^8QCKK* :2AK5+:\MFQ!/?@%+N 1 [XL<>4'&=\
MN"ĀPGK^@TPQG3"4B6$1)AF0*>9Z=Y,CU# *#T6%1W5PR@R=-NYB.6 MWO6[IC=(2M"3A3K$L&0!4CS#*@X.GN$B%)U8?]!&B4.-2KK&)OF;U;H.7F28
MQH(&5)MG0Y]#.9+YBZF6L478G2;_TB&]S]H2:D;;>^.*@'U"Y,D]9.[Q;]E$ MB(3@A]8':@Q/VVK9]\JA13ME0R/J3+R!$J?QSF,"C]R8@%Q16G)Z!2<9/ MP$1F:=L_G(/)"2,:6;"4 :Y?
XH3'/RN#+F04)RD48"8'7H?DHZHOOW,ZW_\9 M:ON1DUP_[7W0VFB[BI_M'#3HN]HWW[:ZV>[+X&WS0>RPO?FL^'-A@;DZ6&@;-L#ZTAB_?PD7=-]+;_X+4$L# M!!0 (/""#ED@@?>?%@0 *0)
9 >&PO=V]R:W-H965T.;,G.',D).UTO>F1+3P6 EIIF%I;7T<128O ML6+F2-4HZ9^ETA6SM-2KR-0:6>&5*A&E<3R,*L9E.)OXO6L]FZC&"[B(Q6H-I MJHKI;ZH1 .B-SXVF&&&Y-.
M<7O^A/Z;YTY<%LS0]_*6TW <0H%+U@A[H]:_8\'Y.@K8?P7UJWL(LA M;XQ55:=,'E1,\MF$ZW6H)TTH;F)I^JU MR3DNW:'<6DW_I":WX.7;)WJKQ[8$H.55L: *S)X8*+!'I55WE2-
8!8+8)72EG]GKMYZ(*FE/$MZ M5#265UZT,;AL! B^]$Q8_K7AFO;Y,R76GLH:M9O#4@GJ()2?? :V5(TA0-,# M?,RQMJ\@%U02A\>P-V;!3^2##Y[AJ?-[OD7M+R+C-R^># 5WFA4(DE5H/#GK
MUM39[@V\A32)Z9O$J?^.Z1><6JFD&H4/D2FY+6!M!#D@PAH'-$O^/Z1YZZQRA7,5QJ1NJR%@^30(;_O]6-O*.LEPQ%- MAKTTR[QKKQ-V=-^GQ., F<;$,AON9TH^C >=#]DP\S[TQZ/
>7BMN=*!5: : MW::-X;Z_T]E>2(N:4U]ST WMEFE7/Y"RQNW6*Y+>&,:09W)6I68-Y;G#] MITWL[G^_;#>X0>F*"B+2,7W M)9M^N6)ZQ:4)4M2C8]&%"7=O@G:A56UOX<7RE)U^&E)
MSRC43H#^7RIEGQ;.P.9A-OL!4$L#!!0 (/""#EG-&B30'0, (0' 9 M >&PO=V]R:W-H965TX^%'V@I+%-E")5#E6W^_4=4K;B8!UO7R3.<.;P# \Y MG*Z- 4HK1 <_*J5I%JV.4U'AO@9JJ$O;G-
2JSGD5IM'4\R.7*>4<\G)9BB8_H M_JKO+5MQAU+*"C5)H\'B8A9=I1?70Q\? OZ6N*:=.?A*N-C.8L23P@5 M%LXC"/Y]QQM4R@,QC6\;S*A;TB?NCK?H[T/M7$LN"&^,^D>6;C6+)A&4N!"-
M<@JF_0$W]02"A5$4OK!N8\^R"(J&G*DVRE$=G>59RGIO?8N[@^$GD"NED&CN& M]!-QL4F_;M.S5])'<&>T6Q&\TR66+_CIM+QR;9\KK.#@\"\T^A0&21^R)#L[M@#?
HZAL$O.&A^FXE%4!IF<=T[-#Z/-'OF]EHQ#, CX9O80GM!5X_ON8'L3:S_1IA; P MBJ^A9'3G)>^U=U'^BP2.I_G6DA.Z] &Y4$(7@8Z?^M,XI#YH[A/L*?VV2J(F MA!2&',&QU!QI&F(.KF
;4&] Q348Y6Q4YE=!58Y6ABDP3/H\6<,CZBEL>W" M< 2#K\'\.N\&O=M]%-+^Y#R%$SC.^NED B>])^.$@D83%BQ_"=2"ZN=JCORR MR7CB!TE_/$GA@)C#3LSA;XMY)UQCI9-3 M+!U?
4F_1.'_B:RMU(6O>!9,KN12^&11(?!/LL*ZR1 P5MCL?K4OYO.2^5[3V@ M?Q=*EI9#@]9'$/AEEU[CX:XQVC7&6Y5_2[_V9.R3+=[IC!7:9>C_Q*>ET:YM MDIVW>V*NVL[Z'-Z^3W?"+B7OG,
(%IR:G8Y;)MCV_-9RI0Y_-C>.N'88K?B;1 M^@">7Q@FO3'\ MW#. .\%4$L#!!0 (/""#EF,!UUH(P, 'H' 9 M>&PO=V]R:W-H965TB!8I(IB3;
M36T#2;JB&Q8T2++N8=@#+9TLHB*ID52=_/<[4HKJ%*Y1[(4Z4G????/SA\%KBW!S;X2K9:?_&3WZIUG'1*V&+I M/ *GSU>\PK;U0$3CWQ$SGE+ZP$/["?U#J)UJV7*+5[K]2U2N6=^Z
M6[W_B&,]@"6I6QM&V ^^!8NA[*W3<@PF!E*HXM5XBB7CTC*$?=RP&4_P)W#-2$U%GY5%5;/XQ/B.!%E3T0O MV4G WWMU!EGZ!EC*\A-XV51X%O"*_U7X>V'+5MO>(/Q]L;7.T.[YYU@7AB39
M\23^1)W;CI>XCNG(6#1?,=Z\?#&;I^].E)!/)>2GT#=W=$*KOD70-?R!M#6I M".N.L3R)]L 028,6!Y=*\=;[\#*F9^S)<>XJVW63Z'$P(5DT#%3POT MH7=^-
UT+)60OX9:Z>DRIDX#'E1J1Y8AL"#G27A#?=MEQ]?CRQ9+-%N](Q>>= MM-\)Z4VB2D<-IZ,&)\0]5E1TB_XMJ-!XAX! _5QF7MD"\F+NC3GD\YDW%F04 MWEA"GA:T0Y!>EMI1,%NP4:MZ2#)
(UO'XG9@@0RPTT_3)SNPNVZU8[NZF V M]#BB\0[TO];:/4U\@NFYW?P'4$L#!!0 (/""#ED8V;U?S04 $$4 9 M >&PO=V]R:W-H965T R'Y !J916G2
M=VQ[U$\IRSKC"S/\58PO>*$2EL%70621IE0LKR'AB\O.H+,:^.;F,Z4'^.N.+ MG$[A'M0_^5>!O7[-)6(I9)+QC B(+SM7@_/K0-,;@N\,%G*M3;0F$\X?=>=3 M=-FQM4"00*@T!XJ?.=Q
DFA&*,;/BF>GWE(O7&^ON-\9W5&7"95PPY,?+%*S MRT[0(1'MC4-[[X")4^0\TOY(DT_V11T=H=$A92\;1:C!*D+"N_]*FRPR$+ MG&J!8^0N-S)2WE)%QQ>'+XC0U,A--
XRJ9C4*QS+ME'LE<);A.C6^HTR0[S0I M@'P!*@L!:'$ER)8SM>"S^W5MDU_(:_5OF6R3#A6FM)_KV:2"4P M2OYKTKEDZ3:SU)ES+G,:PF4'4T."F$-G_/;58&2_;Q'8JP7VVKB/[S$3HR(!
MPF,2:^'1G(@J):"GTM)M$3%9$A9"L&RJ(Y7))D5:MVI6Y&$&5LP3S%_-6>G M(&96!TK,_I]%C"8[\E"U+JW.P&WY<(G6"1T,M8/)"ONNEO_*<+1^4"%P8K7!:Q*X0_Q_^RIP!L[[MC1;.6%^H>
(32)BR;@U1E_OCN@(S.1C4Q4B**($9D1 L)6;@D"*D+*B(28K[H MP"-.=^2L&,J+SC RF>^M[,0Q]9$7;/!Q:^-9&V*M-YSK;OGO=XUI,XJREO)'$/F.+;U2!1T[)\!T!%;=T8#VPY8.#:!"B9!BXY-
3ZS*745HFWLP=3)I/45% Z M64]\&S<]E'HETH;:FV8LX74O06DZ#TW7DD&C.H-&!V?0PI1K&A#GF,]3$R)% MFAO)F]+A]W#>BJ&=0+%NV1P!!J,=,0;P3SML"ZNL;TP^OHL%P#J1UW/?X)__
MAKB]0+>"-Q@L.=^H$^"&#V]!"KD:47O]#PR[+EDT'/P&SS3SGF"X8[@MZPH M?60\'W-VA_J709#O5F+/_ S:'_X?\T%"F>BHDH(MS+P0$7")H&.5P8XCN6!GI([%=&N.&K!2<(QU;KD
=>1CX"2S9 W M&(40$V#.#Q/1VBMBE8^'@W3/P@.)P*!Y4/.V#1?#8WU.-Z3FK"7R=[C#P M]ZPJYUJB.:BC.3CF?)XLT=)%A9H/W/+G@I>Y&C2IJANW>&(XEQ[;?,8WJT4
MCR_!]ZIFW:QB:.VN]1GFD)!!]76JK[M;(98#H(]?8.8\QCC/D#TZ:S3L>KZ] MT6IT:CG;5IPW%.A;I:D^F/1ONU8,7E#+'UW1'^*YK1J_]*1&^2H]?UW"_S$_
M^5YW:'L;K48_E;,M%7YSD;_EJ;*X*O^WJ]9) M04S-XY7$S8I,E2\\]6C]/G95/@L]DY>/:VC@*4-\3R#&I7;/Q_)>E]694?Q MW#P23;A2/#7-&5!421/@?,P1ZN.WJ!^-1S_#U!+ P04 " #P@@Y9;='@
M/'<# "@" &0 'AL+W=OJ!)1&L=G4<6X#&<3+[O5LXEJK. 2;S68IJJ8?KI&H3;3, EW@CN^ M+JT31+-)S=:X0/M'?:MI%74H!:]0$4PZOD\GKD]+W"GQPWYF .+I.E
M4M_=XK=B&L8N(!286X? :'C .0KA@"B,'UO,L'/I# _G._1??.Z4RY(9G"OQ M%R]L.0W'(12X8HVP=VKS*V[S\0'F2AC_A4VK.[P((6^,5=76F'*HN&Q'JKBM MPX'!.'[%(-T:I#[NUI&/\H99-IMHM0'MM
G-37RJWI]"X](=RL)ZVN5D9V=W M^("R0;C#*7*TE]Y5Z?\^6 LV'263)@].+\BW:=8N6OH)V!E^4M*6!3[+ XKE] M1)%UX:6[*[37L#?&WD*63R -$Z'/7A9EV[F\4; D>Y*JPKF%*LF6E#);)DS
M7VS4\V5]:;S\V[$"M/C9<7QWA2Y-S7*>Z(==],,^ M]-F"KF31" 2U@A<']S<6L'SJI O5Z!R/Q=_KX7C\)R4&*R7H_G*Y!NO(;56 M#[Q [9$R'>%U%OW^EE0.ZGQ00%U$F]E2XT(3!9@^"-4+7'0$0?
HV+$[=J]" MDRQXSR59J<:0Q'RXA/];C^#>N0P..0H+_OA,$'B7SAUTL^"V9-0!9&&!:S<&GWE.K0KA:DTN_,X)#" _HD\3[61_0^6@$R7D&R2#.R.U% M$MPK2SK_*NX)C..A@QMG[CN(_9C%"?
10;-11;/33%)NKJF;RZ9W9WY3/G"YV MH#:!YABY>K%?)]?6T=LWXS0Y_VCV*8N]V.#:L8[,I*5C8\;U7M2:YESF='$] M39P2+453>#DU_5PUTAJHV9/GK5?*
<]W0_B$ZE\&6R48)7C#G8\D$DT18WUT- M]+&OOU3!D7 K53H/V54G:W< ZZGY+9/U!+ P04 " #P@@Y9YI(JWFD% M K$ &0 'AL+W=O^CT).0A D)* !D._WU78 2(UF*[:0Y M] ("RWWOMTM!)S?
&OG<+*3VZ[5KM3D<+[Y?'DXFK%[(3[IE92@UO9L9VPL/1 MSB=N::5HHE#73FB:YI-.*#V:GD3:A9V>F)5OE987%KE5UPG[\4RVYN9T1$8; MPELU7_A F$Q/EF(N+Z7_?
7EAX309M#2JD]HIHY&5L]/1"W)\Q@- 9/A#R1NW MM4%S+<]FV01&X\6&MGHW*$&CD3J]:_-3>OY#J>+.BK3>OBBFYZWHR.4+URWG1K M82"@4[I_BMMU'K8$RO0S G0M0*/?
O:'HY0_"B^F)-3?(!F[0%C8QU"@-SBD= MBG+I+;Q5(.>GEW(.*?;HM>X+'#(U?B>N6NF.3B8>+ 2^2;W6=M9KHY_1EJ,W M1ON%0S_J1C:[\A/P;"'/;MP[H_CC^/A1NKXT=UA8:YM@M12U/1]
13MIK.9H^?4+R]/D]OO+! M5WZ?]NDE-&"S:B4RL[6_H2RPO99Z)='51_23-',KE@M5 W4.I3L4PKU&#H?P M;B&3F6FA84.&HEF'XFM(W4QIH6LE6J2V, ,[Y!<2G9MN*?3'IT]*2HKG#OIV M<-
SUN7<#[U):91H'>AI5"R\;-%8:WIB5$[IQ1\?HP10D>RE(WBVLE#LX1(B M.: H>1D#D.AB(<#[6JX\6&_1*],V(=QSHYUI51,<2C:6OD,DQ7F9PJ9,..P3 M0/H\O"'8ESSY#2*R&&[/GQ4#Q^:9%T*1
MFOP"+ BD%.16V0A@2(C27NBY"@D1H (2.YC"14%V3\EK[254T"-Y"P/=241I MAB@J*XH()J1*[J2C$WHU@[9864@*1J'XPM8+!)6!J7<-TWP9'=FH&ZS1='N? MG"_
20G.HAGXCJY%NXKE%/6'%>0B@_=[*]M8_AJ*!M:"6M@ZU4C;HVNC<,QQ ME:;H:(^0_ ' !GX#*?M2#CZ(+#?Y/3[CK) <92A"G! "DP4K;RS0P8548!^%3
M,4A5!!6\1!2G)8>UHFQ=;:5KTTDT7C,>8:3A,\IPF7W*_IAQ\!=HI(:1'XO M;O<\VCP)3EG6K\FOH&QC(J#D*("05"4:$JUP M1"^&F>PX9C5F4/09])?0K
M3(LR(+UD.\BO,,_)'>"S?"\DEB=GD.098'T?]N.\I%OU'+(6R?N@93D[H)]] M*_ 2G*75[ND+D94SACBLQ6. 1:"(54G 4%E4 5E5L8.L'D\%R?9B!MKCT,0S
MWJ^'T40)06,PS$-3C1EF$58,5XPGE^KVVX]12@"I50 3=-,NG"B%04KOX(FD M^P4'VKVCM (3^ ,W4@^-TO\X1[,J1:%C" .@Z4,R*["O!F.R#,V0,TU_UZJ
^=IZ2$F:I1136NZ>OA!74+.B0&5XEH^$5A$:$48XPWD>H)6Q#;36/#VB MQH"[XD*U,=!BO&L7P]!JL2\XK&9" N0RG!*0F&@[(#]0S>#R=8%KI-V'J^I
M#MIVI7U_EQNHPTWX17\! ,3>7Z/?"#M7VJ%6SD T?5; 5O MC(?+9=PNX#8O;6"]S-C .80# S_#TS_!5!+ P04 " #P@@Y9IDBLE%L) M #"6P &0 'AL+W=OM_8"EEL4. @60G/GWVR!9J"]N"\^;
MG0]C7?H\ISGG -UOJ[E\+JLO]9*QQOISE1?UU6C9-.N+\;B>+=DJK<_+-2OX M-XNR6J4-?UL]C>MUQ=)Y9[3*QZYM!^-5FA6CZ\ONL[OJ^K+<-'E6L+0*JC>K M55I]_/KC/GI9-
^\'X^G*=/K$'UGQ>WU7\W?A F6M0=?BMXP]UT>OK?90'LOR2_OF;.KD=WVB.5UK2(E/_9LEN6 MYRV)]^.//71'\-D:'K]^H9/NX/G!/*8UNRWW5D-YL[P:12-KSA;I)F_NR^=? MV/Z)BUO5N9U]
[_UO&]KCZS9IF[*U=Z8]V"5%;N_Z9_[0!P9<([>P-T;N+*! M_XJ!MS?P3C7P]P;^J0:3O<'DU&,(]@;!J1["O4'8)6L7W2XU<=JDUY=5^6Q5 M;6M.:UJT^>VL>4:RHBW%AZ;BWV;3;+6&W]&+,FS?
+Z)^N#]?DA MMG[_B?K>VMLUG>_QUO\KOGFU9 ML6'UA:ZL=]:>WK2]XE_4ZW3&KD;\DEZS:LM&US]YP3VS[]<(FQI8@800) MHR*84!G^H3)\$_V:9$5:S!B_>J-O)L1Q_>X!#>P!C>?S5+
M5NDB&2B^)J$42+6)'TAQ5)MX4I/$V+^A853].;8<1;5-,-4',3P$,30&\=>R MX:59[6\ANFB&:K^ **(=6ULGVI?F.U U=2?2K6)C!T>&M50/?W=2321XJJV M5.K7K=K(<>4Z5=MX4T*?
**+Q%GB2 M-V(\G*'W/1!,B/ST$/FI,?(?TSJ;6<4A_M::5;LQN2X3.U9T%!O[7([-K:Z1 M+9T$L98D-4J,71]:WEJ/4H507:,@U!>W8_=3*-L8Y#C+-PV;GQSF/>Z-.&M;
M*8'6L^1(FP]@:*CU/N58:UN]&NRC^:IC'./?U#5K]"/\O25HB ^EQ5!. J41 M*(VB:&)]N'U]N -'^O59=V:6"RO-_*Y^W915M:L8O-,.P#=NQ#NE<'$#^61 MOK:=XX:N?)(:NSPX^4@:.?
%8***<,.BF'TLB)QTI17L64]5-NQS=>J1^:9S5M4_?!>Y3OBS MQ?[89,U7_=4;.=FJA=)B*"V!T@B41E$TL69ZG< Q"P4WL]EFM:5EGX03N0S'BD%)% :.?EX*B'#,2D12= +:
M8YJWM]DS:YOF&_T8.%!O.Y'G*CJ/HT[TW7 ZF7AR]C2\T(LB>?JG;>=[\CR8 MG-@_^K9?,9*]&N&8Y8B[BFVSV>F35?[0!18H%MU!: M#*4E4!J!TBB*)A9-K[,XT?
L70!RDJG$+I<506@*E$2B-HFABA?1ZD&,6A# + M(68G@TMIJI%,_8DLF4*=)E :@=(HBB:N9_=ZEFO6LX:MUIAA0VMA3S,O[$!= M)E :@=

(HBB960B^VN4:QYO6%);/=X*0[;R]"03TF4!J!TBB*)N:\%]!\'.-?](9MABH1DVN!)\W6I7: O_E,J RG)0&H'2*(HF M5D8OR[EF66[H"J<9-[@V)N^I#:B3=XS_F9]9-_/_;NJF7;TPKI^;^8/K TF+H;0$2B-0&D71 MQ"HZVC_HO7_]W(-*GU!:#*4E4!J!TBB*)E9(KY%Z_X^-A&8G@TO)5X-_6^=3^J&3"X0M0MJ;J["%03A=((ME$91-#']O2;J?6;/QX-2KFV)UJ8?JH5 :@=
(HBB:FOM=#/>2F73-L<"FH M6V0_V.>V_&LLJ-,$2B-0&D71Q,>6]#JGC]U;;,8-K09?W<.KJP:HTP1*(U : M1='$:NC53O_=FY]]J+X)I<506@*E$2B-HFAB??
0JJ/_7;WXVNQA<2.KVX@^. MO'D+ZC*!T@B41E$TL3YZ?=,WJF-O+K2;S0?GWE-G%&KNH@(:=#NV#Y4HH;082DN@&- *E411-K)E>RO0AV[`-E,&UHMGLK,Y&H3X3*(U
M:11%$VN@%RA]T)9N,V=P%:@;JW55 %4CH30"I5$4;5<%XZ,G!]J8]=0]#+JV MNN?ZMDZ./CT\\RR]/E'YR)Q>)\3YX+N'B?=XW=/M_Z45D]945LY6W!7
M]GG(R[O:/3!]Z8IU]WSBA_+IBE7W&SW]?\ M4$L#!!0 (/""#ED-\0;B90(L% 9 >&PO=V]R:W-H965T) M-<<.MM,.?CW^2+,B=7U)[.M[SCWWPT[V0CZI&E'#
<\.X6@2UUNT\#%5>8T/4 M2+3(S4DI9$.TVY;(G"M'/M-#U(O@80($EZ9A^$/L;[/.YM'RY8,I]8=_[1@'DG=*BZ<%& M04.Y_Y/GO@Y'@'C\"B#N
;'3[0,YE5=$DS218@_2>ALVNW"I.K011[EM2]:E M.:4&I]/L\1O<"%907BE8"]D*27RY> &9[Q2($C):<5K2G' -RSP7'=<& AO! M:$Y1P;LKU(0R!7=$6H8=OD]";03:,&'>BUEY,?
$K8F9P*[BN%7SF!1;_XT.3 MV)!=?,AN%9\E_-KQ$4RB"XBC> IW7;-%>89V,A1MXF@O7Z&]EQ7A]*\KU(6I M&E>F#,5+W382%7+M#:9XUY03GE/"(#-&-#.M%?Q<;I669BI_G2J4%S
Y+<#> MU+EJ28Z+H+6QY Z#].V;\2SZ=":]Z9#>]!Q[ZNMDA=^W:)MI&IUAY62?TNK9 MIH[-/@*[-$["W;& \&A &Y25NX8*W!CY61VLPTU?^@%_4*&)8& M&HT^F"9)?_7\1HO6C?
M6:'-YW+(VKQ5*ZV#.2R'T86,##.]?^@]02P,$% M @ \(.66=!OP>A P Z X !D !X;"]W;W)K&ULK9?9CM,P%(9?Q0H(@023?>G05]*; DT8ABX]B1N8Y'8Q79:>'ML)PUM
MXD8MS$V;..?_S_%GR\MX3]D/GB,DP*^R('QBY4)L;VV;ISDJ(;^A6T3DES5E M)13RE6ULOF4(9EI4%K;G.)%=0DRLZ5BWW;'IF%:BP 3=,<"KLH3L]PP5=#^Q M7.O0\
5OW[T#%1/'BG]H5X^9!/+406A J5".4#YMT-S5!3*2);QL_&TVI1*>/Q\<%_I MOLN^/$*.YK3XCC.13ZS$ AE:PZH07^C^/6KZ$RJ_E!9<_X)]'1O'%D@K+FC9
MB&4%)2;U/_S5<#@22!^SP&L$7E<0G!'XC<"_5! T@N#2DL)&$%Z:(6H$D69? MP]*D%U# Z9C1/6 J6KJI:SU<6BT!8Z(FUKU@\BN6.C']+.?N!Y+2HM8N ^ MAPR!EPLD("[X*_ &/-
POP,OGK\!S8 .NOG* "7@@6/#7LE$^?\UIQ2')^-@6 MLB+E:Z=-]EF=W3N3W0>?*!$Y!TN2HC<36-9JV-M%;M:KMIX(_"L;T[']7!!->.4C^C/_*#TXQ+0UFA MYYX&K?I!21B-VJ
36F%+*QRD]5WO;2A[W>(R:WZL(C*39X+N6IBLC%AK$V# MHU)<+PACQW$Z* >S7XO2E#4.W%[6I;&*.H%KHR.R4D_3K!&+=9H$.MRO99G M$T#7(,-%I4XG@*.T8EA@9-
R(HEXA<;]?\\&DU]+LIPR"/LI^5)3T.1J_+,0 MXQ9B?-WFP$01/8,T M:9$F@TAGD.,4D NWOMHK.:K"N?&[BZ4IR.DL70NC4R=H:0R*.F1,05%LIC)J
MJ8P&J2R:>74IE]$E7$Q!/2Y&IRX78U"7BRFHQ\4^.HF7B&WTG8F#E%9$U">G MMK6]EKW3MY%.^\R]7;B&]J6\QM6W8KK_V]1U0GCTWF'!0H+5,Y=S$&ULK55; M;],P%/XK5I
02+!<6T9)(_6&&-*F:A7P["4GC35?@NVTX]]C.VG6;5DUP5X2 M7\[WG:O/2?="WJH*0*,[1KF:>I76]<3W55X!P^I,U,#-32DDP]ILY=97M01< M.!"C?
A0$8YJAPKTL=6=KF:6BT91P6$ND&L:P_#,'*O93+_0.!]=D6VE[X&=I MC;>P ?VC7DNS\WN6@C#@B@.))13;Q9.5HF5=P(_">S5T1I93VZ$N+6;BV+J M!=8@H)!KRX#-;P<+H-
02&3-^=YQ>K]("C]<']J_.=^/+#5:P$/07*70U].[+@Y ,,S#(@Z M0/08D#P#B#M _%(-20=(7JIAU &O@G'P9>A +\FV?(UR5:O1/8@%4F?BN04>S;CFA2$ M-
O;!H0WDC22:@*G[NYPVIO11*05#"\'J1F/79D6)5EARPK<*K0_/]P.:,=%P M/93%UH#$&6!"R"X+1Y^#($C]W7%^!L3"\R=BRP&QG_82:N<;\Z'P>3A;AP/G23+1V -W3M^/P$LLMX0I1*
(VJ MX.R3>2VR'3'M1HO:]= ;H4U'=LO*3&605L#&ULO5E=;]LV%/TKA%8,+=!$HKZ=V0;2RL(Z>5.0I-M#L0=:OHZ%2J)'TG;S M[T?*JF+)C&!O7%]L4>(YA[R'YJ6NQSO*OO(5@$#?
RJ+B$VLEQ/K*MGFV@I+P M2[J&2CY94E82(9OLR>9K!F11@\K"=ATGM$N25]9T7-^[8],QW8@BK^".(;XI M2*>/T!!=Q,+6]]OW.=/*Z%NV-/QFCS!
XC/ZSLF6W;+LLA+J'A.*\1@.;&N M\56*/06H>_R1PXX?7",UE3FE7U7CTV)B.6I4 F% 617UOX"$6AF.0X_FY(MK593 0^OO[.G]>3E9..$PT=:_)DOQ&IBQ19:P))L"G%/=[]",Z%
\66TX/4G MNWW[AE(QVW!!RP8LVV5>[;_)MR80!P#LOP)P&X![*L!K -ZI +\!^*<"@@80 MG H(&T!8QWX?K#K2"1%D.F9TAYCJ+=G416U7C98!SBNULAX$DT]SB1/3-*](
ME0&ZAPSR+9D7P-^CW^6*?IN ('G!WZ$+]/DA06_?O$-O4%ZAQQ7=<%(M^-@6 M<@"*QLX:L0][,?<5L=\VU27RG/?(=5Q? _\X#+\E3,+QJ_!D&)Y UL(]#7QV M^N!U\/1T=;
<+MZ5GK7%N:YQ;\P6O\%UG&=U40KE%A3+MAI**(VD,VGN:5T\' MKJ(O-Y(?1)0\K]TSNW5/+V:VM^N^)ID,+'D!L:!;<&:_OP3#IU?=#Z:)$M, MDLU,DJ6&R#K^>ZW_WA#[])$*4J
YR.0"B!0R0]2_8]E$&8-%+E!!.0?MKW3/ M'-;,*O5LIVX4!X%(?.7>!,7;\;K=4VRWVP[9;)XQ!&\;@ MA&6>$<:>U8:V)<4&=/$+CN;BAH$?.;WX!<>K,,1NY':[)1JVR _Z4YX-#OW<
MQ6J(K!/EL(UR.!CEFWP)ZC"'+0:W71V!EDTV^W$(Y!Z9-&(.,YR8,DV2)?Q M2;+4$%G'XZCU./JA!X;(I\FR1*39#.39*DALH[_<>M__+\=&A N2YJ-%V_?
Z!P:1F:HBLX\^H]6=D\L P.D[><12'/4<&)<]U1",YBKS^ M<4$W,,^->Z>%?S$P-!!D[+R\[SJGI[I[^DP*\8SN-BQ;$1GIP8PWS'SNEF>4 M+3'*-C/*EIIBZSI^4.' /S3Q-
7*FEH%)ML0HV\PH6VJ*K;L,7NHE>/!U_#_E MOX;Z<%,+_?CH[6)X!&=[J1&-W+ G.C,JFIIBZYKT4M3 PU6-,Y,@/JXJ7/CN M*.K[8K22H17%_<4PTW5SHZB7H5-=-
]U[LWU0XU4U_UO"GG*YC16PE$*8G,I+; M']N7T?<-0==UV7=.A:!E?;D"L@"F.LCG2RIWPZ:A*LGMGQG3?P!02P,$% M @ \((.66)MAP8B!0 XA8 !D !X;"]W;W)K&ULQ5A=;]LV%'W?
KR"\8FB!)A(I?V:.21NL1;I$"3M^E#T@9:N;:(2Z9&T MD^[7CY04?=@T&P=>EX=8HNX]//>2.O>*XWLAOZDE@$8/66>I]>HL"%2\ MA(RJ4[$";I[,A!6[98:CL03,8KNH [T)]6-
]+/Z&_SX$TP,ZK@2J2?6:*7YYUA!R4PI^M4WXK[/Z ,J&?Q8I&J M_#^Z+VW##HK72HNL=#8,,L:+7_I0)J+A8'#<#J1T(-L.W3T.4>D0;3M$>QRZ MI4.>ZJ ()<_#E&HZ&4MQCZ2U-
FCV(D]F[FW"9]RN^YV6YBDS?GKREG'*8T"W M$ /;T%D#ZC7ZT^RWEU/0E*4*D5?H!'VZFZ*7+UZA%XAQ]*$IUHKR1(T#;2A8 MH" NI[LLIB-[INNC#X+KI4)O>))VS\PU"O^Y)'_)?
$"OE_S4Q2%KQ$)2=?! MY^KI[I&'3E2E,\KQ>GOP+N)8K+FV.13:IO):4*Z0218J,LWXHI%K].7: *!W M&C+UU97-8K(/9O5A#.UHC&<=\Q+KT!NH#/Y[5?<#W]WI>)
(8*W$=*O$='WH MDXO4*$R^TZA&,U@PSFTJQ!RM0#*1N((O$/LYHM6OS01'HQ"/@'TTS*H<5'G;[ME56+;J^BV_/2=2W6:U0'800774E(F#8KK,PZOWF(TW5B'11
MNR+S3NY>">1:T0*GVXI],-P3>[^*O>^-_4:*#4,,R9?I7'&Q?QIB9> M<+[Z_1TV/3PD6\NU:W32;QBU& \JQ@,OX\^2:3![:>ZD-7#,&(;A%B^'E6S JX-
WPP]WEC,)AM,74885QV'43'55$1UZBUVP.Z"YF8+E^!)F5 MRO7E V0SD$YQ\B(>*DY' FL%C\.Z"H8_5;?+Z8Z4FV.AM9/3:!'PT;6[A&SN MTM$@VM9N_\1/$L)V3*2.B?R? N^?
_0"%+X&:>1R.&N+5#K]N4["WV#]?XTO< MELB'O=[VNNY:G?0&>U0>UST$]C<1?ITOG7\D]/XYGK'GZIX"^YN*PXH!WBWN MPV9M+Z-Q6$5DN"?3=0N _3U JQS](:.T\
MU(T%'OSQM\0'/SU+JPV[UT\6#G'77U.'N;,5PW.=C? MY?S7JO^,)L:M^J.=^,EP7U]/ZBZ'>!N%YZM^B=M:#S+86C2'D6FA]Y0J4G M7"F1LH0:"*2T^F!CP>*IVZMD/0 M.+#+0*
[R@T^%\EI3'%)4H]7AZD5^I+@U?HG/IM@Q?D7.IB[["Q*9!Y'S2??Q M_#:H*16GOQ^H-.*N4 IS0R\\'9AR*8L#U>)>&BU5^Q#@36HLLOUP"34!: _-\ M+DSU+&_L!-6QJN1?4$L#!!0 (
/""#EF$R]ZA+ < U 9 >&PO M=V]R:W-H965TIN,A1L4T2GC^\$W%V?S;!D\<7+J/; M=5F_,)V?;OBMN!+EY\U%7CV;MI15E(BTB+(4Y>+F;/(6OV'4]PMV1_P9B?OB
MX#&JW\IUEGVMGYROSB96?48B%LNR1O#JUYU8B#BN2=5Y_--)ZUF77CX^)'. M=F^^>C/7O!"++/XK6I7KLXD_02MQP[=Q>9G=_R::-^34O&46%[N?Z+XYUIJ@
MY;8HLZ0IKLX@B=+];_ZM:8B# FP_44": C*T@#8%=&B!W1380PNZN[?>-M6OI@)=\?IIG]RBOCZYH]8.=7;OJJH&CM.Y95V5>_36JZLBVKP\>
M+@6Z%$L1W2'K6!2OT,>J1[\,1,FCN$#T%W2"/E\%Z.6+7] +%*7HTSK;%CQ= M%:?3LCJ%&C1=-G+O]G+D";G?M^EK1*U7B%C$UI0OS.4?>%Z5XR?+ W-Y()9M M.=64A\-
/7E?.AJL3N7Q:N=9:1UKKR([G&*V+TML#\UZA12Y648G^V/(X*A_0 M>;J*EKS,=C9"P !(60L(8$$RRG[;V4Q-]_BDK>8RN136[",3C:HK87+P5NO9S>N^%N([M64K[.?U>Z&+B$?
FP0$/S;$=] MRZ'QU,=V5B"8U,INV\JNL97?1S<"72TC4?773R)/T/N,IP7ZU$DUR+73AA& MXM@) Q(60,)"2!@#@DD>>ZW'WC'7"QZD_9"P !(60L(8$$RRWV_M]XV7^&7V
MP./*XWVG'-#IK8^R!_P\)7'XQAU\3A&&1<@9O+8*0B4%H#20E :@Z+) MCG>Q!3YJ;H%!@PM06@!*"T%I#(HF]X(NO<#F^&+0KNWW/M29I4:;
MIA'UB&NI(RMH4@%%D]WHL@IL#BN^9TV"^S&"UB30Z$(GJC,)4I1!T623NB0$ MFZ.0L5J4^381:?D_2P_0\ .4%H#20E :@Z+)MG<)"#YJ M!()!,Q!06@!*"T%I#
(HF]X(N","F),2[)CM=6F';MCJH@B8D.E%GYA-U4 6- M2*!HLDE=2(+-*#".P.$=@M(K![1& WB?R(H(5T00L! M"%J()O.PL/H1WJPTVK.^Y@RKR70(JLF@:+(77DR(6I,
M&X8O9IX9%9KEQ\TH0 E!:"TA@43>X6!_]+1(^YWJ&0HH.9X:]+F3]G?>$,MSO=X_CX%F1CI53"RLWFL#5650--F/+@VBY@T_ MSQZLQV6%YK,8?;6"ID2@M!"4QJ!H1>
MT*53U)Q.#1NSO=X^.MNWJ7HSWBPUVK2^J&/9EJN.V*"Y$11M[\;TX(L5ZB_: M^,#SVZA: 7CD_KK&]IO$)G_!U!+ P04 " #P@@Y9%'5E5[H* ";;@ &0 'AL M+W=O'KTGJ M,
<7+R5U9?:YOM&ZRKZOENCZ=W#3-[8OIM)[=Z%51/R]O];K]Y+JL5D737E:? MIO5MI8OY-M%J.<5YSJ>K8K&>G)ULW[NHSD[*3;-+33=.],3T[N2T^Z4O=?+R]J-JKZ=[+?
+'2ZWI1KK-*7Y].7J(7 MYTIU";86_UKHN_K@==85Y:HL/W<7;^:GD[R+2"_UK.E<%.V_+_I<+Y>=IS:. M/W9.)_L\NX2'K__T_GI;^+8P5T6MS\OEOQ?SYN9T(B?97%\7FV7SOKS[A]X5
MB'7^9N6RWO[-[G:V^22;;>JF7.T2MQ&L%NO[_\77G1 '"1 =2(!W"?!#$Y!= M K(MZ'UDVV*]*IKB[*0J[[*JLVZ]=2^VVFQ3MZ59K+NO\;*IVD\'7;;KF[/5B
M7:QG.GNO9WKQI;A:ZOI9]FM;?7Y\I9MBL:PS^E/V<_;Q\E7VXP_93]DBW7V MX:;SU?_U%?X^-^+/K6N1+^K;8J9//VV3JW7U14_.OH7Q/._^:0 MY-\^R_^BBRGY;MU:_
M58M/;?)&SY]EYYNJTNNF5;.>%[7B.TU8DDTNJET MK]JTLFT_JR,U"L87JQ%S-***(N[7B.\UXBDT>EUNJIY$G6JC1 H&&"L2=T3" M$JN!QB;V(HDD(K5 T&MMK6RC-
K&%ZN1<#0B@N7$KY'<:R2!-3H4YEVG17-3 MK+>BC9(H&%ZL1-*5"$DZT-;47B(%+-%.@9?+EFZW6-1>9N>5GB^:%@UJ+_ $
M8XC507F:DZ3Y0'M"N:&\/"C%V\6USBYG"]T5ZH.N5CO2^?V=7EWIR@LS89>Q M)8/R9@MP@+GHJ*2WRPY*'"!OMCB&@E&0)8]->[MH#@F-,8'POI+O1,%.8V Y
MH@.0@$S:HB1L"XARNP M_(,\[X K-A2D,&95$:EH7C-.3R)Y'<%< UHXQ) M/"" X524!%0A(2P,S,PB?/CCIJ!@B:4-UL< YHXR&K' M9JEP-!'W$0!"MF('8[!)Z!.0Q\(!QHCX>$>VB
9J<1JHA6,Z[-(J(I+T;\9> M,T&HOY?&!FIQ$JB%9+IPA#'5Z/&.;!4-&>,T9 S'=-@W[*I0OQ:Y5HRK@?$B M;) 60R,M,-&%XXNI0H]W9&MHJ!A#4_$8*L0NTR(IG5^0/C-%R0#Z8H.^.
(R^ M#V#"RUL]6[1?];OV:^\>6(?P,)Q;- $!>;.U,;R,U7'Q$)2=H;S9CU4-.Y/P M0.RQ'ZSFGH%UE,M>,_&882:4\C<38F"8)(%A0+3;!6C=*(22C@"N&>E^/0X(M8-
B6I&%;."P+!QAQ1P%P9(MX,!N%E>L(*/1" M>;/%,=!+H.<:/(K/,%*,^=)N(S(W0 :ZBA6)$#8B%GPXT8Y?7>2Z@'?2D> MZBJ05^:!GWAR(^Z3(MR@?KW"J\9QF0) (.^-
GZ0E);.,*82@+,OM2P+TW# MOG#41MT!6ZP0ZW.+J43 U$H-M5)H:AV#;=2% M3DZIZ _)>$>V8H9R:1+*A>2^$<.W?A%=-.8*
M#SR&9(:,61HR!EP#X0(MPCSO/T'SFE$U,"F*&>YE2;@7$OO"$4;4$0!'MHH& MGED:>(;#OG" ,2("LS,S[,R@V1D8'9EOK@.A?2+RF=$<#?P$90:=&30ZC\$^
MYD[2Q4Q1T2^D9\HOH61@+B\[6',69ML'8-_'-M%GO?R6-65;PNR\'7':+B/40 M @78,!Q+] (S(&^V<@:8&3\]&S)0<(;R9HMCP)DE68(VE@W#T<3THM]W9"MF M:)HEH6E -
F3N#&##*2'^*UR,$0H9>F9IZ!F0#5WH153T%]YKL0Z>,9D+WPU M:,R3H#'HTE>H46, 1[:*AJ]Y&KZ&(\-P@#$B N,U-WC-H?$:F S#\<5H"$S7 MW- UAZ;K,73)/6O@BR/5:#',@#-
PP!ML>7[\ENQ;+YE%YMJ=E/4.KS@ M(^PY>I4]D#=;!\/8G!V5%#DH1D-YL\4YV- AR3*XL:3(W5D/"".W17@V9A!B MZ+$F-US,DW Q(.5QSY1>I&1_G4&X'",Z1@/"/
T(PV$>]VRGP'C,B9W/2@XM MQ."&D 5W [4N@.!? D2VBX5P!S;G MB";<>1$B5_VQ.Y\5&=JX1!A %=" .@:NA+O# J=2].\E/C.!AY[8"D.0(DR0 M#\2KAZRO#>
<4O6$/D#=;%X.=@AX5MP0HBT)YL\4Q+"J2K% ;BUO",Y/6@UL>

MR3X"AB.P+7CW$-[W-ML.[\FW[K']A M3)=&3[]O3(-J5^$'OMKCN,=TFQ8,9; 1H4:W8[%XT&K?H&IPLBM?6]>$BY?@ M\C !' .5 G%^0P@_-F2 9O/&^P]02P,$% @ \((.6;;]YA;E @ GPD M !D !X;"]W;W)K&ULK59=;YLP%/TK%JNF5MI* M^&R;)4AMR+1-JE;U:P_3'ARX"5;!9K9)NG_VQ"6$)I675_ -N>N":+#*I!^QH5.(%W("\
M*Z^XZMFM2DH*H((PBCC,Q]:Y,YR&&F\ ]P168J.-M),98P^Z\S4=6P,](<@A MD5H!]J<2)I#G6DA-XW>C:;4A-7&SO5;_;+PK+S,L8,+R'R25V=@ZM5
*:)5C0T#"R65D*QHR&H&!:'U&S\V>=@.$\1W(;@=@G^ M$P2O(7@OC> W!/^E$8*&8*S;M7>3N!A+'(TX6R&NT4I--TSV#5OEbU"]3FXD M5U^)XLEHPHJ"2%5X*1"F*9HP*@E=
$T("'08@\0D%7rH([JB='API2$Z0(2B MVXQ50N'%R)9]9EK+3IJ(%W5$]XF('KI4,3*!IC2%M('>_BV^8S>3G=Z[/S?]&GKXZ^E0RO70^>T0M>M1YB(I*<
MB8H#^GD^$Y*K__Q7WQ*H@WC]0?3>-Q0E3F!LJU4Z*$"=E7BEHE-"KZU%A&CJ<6VG(S MPST8-]C&Q+L8-SC;QDQ[,*[;8K9L!JW-8*_->\P)GN7PC,M:Q-]T<-(QN0O1 M?
\R6QUV(YW8L]ZX_0[#UF&XU^SMDSA_QEZX6Z# Z?CKP?BG'8.[&/>LHS/M MP?AAQZ*]<>(4P!?FJ!=J^A65]6;3CK:WB7-SB';&+YSAQ.D9C]7MH[XL_).O MKRZ7F"\
(%2IA&PO=V]R:W-H M965T0^!XVPGY*.J 31Z:AA7BZ#6 MNKT,0U74T! U$BUP\Z82LB':3.4F5*T$4KJDAH4XBI*P(90'>>;6;F2>B4XS MRN%&
(M4U#9'/U\#$;A&,@Y>%6[JIM5T(\ZPE&[@#_=#>2#,+!Y62-L 5%1Q) MJ!;!U?CR>F[C7+8!:@$BK2,7TK=I]A7T]L]0K!E/M% MNSXV3@-4=$J+9I]L'#24]T_RM-^'@P2,7TG
^P3L?/<@YW)%-,DS*79(VFBC M9@>N5)=MS%%N_Y0[+#;)PJV' M.QVXTY-<@XI]J#YK>H":QHD?%0^H^"U4XD/%QZAD[$^9S,#\^GI/IOQ;"@T9E>_XW(C>4*R-?
F;1HE)KC(/L^VD^T M:%WO6@MM.J$;UN;3](&F/>5$/IE8MOA)#'+_P!02P,$% @ \((.60O$ MN]J3 @ MP8 !D !X;"]W;W)K&ULM9Q?
M$/R5A1H4"9!&LF2[16H+B.T439$T01[M(>B!EM86$9%42?J1O^^2LE4GM8T> M:9F'#DG.!TG E0>.D'YRU3H<=%^\#?G!<09/2 3?':_8O7CMI&3.#0U7^Y+DM M^L&G
'*5@O0+IK8W,"?C4>3&B[=+=Y93;N< M<#8=*B&XI6NQ!IC,8:BDY7**,N-HX'"$EO'2P'>F-7,'?@0?X.%N!(<'1W M7,)]H6:&D*876JK'L8;9*O>@SAWOR-
V%*\I6&#B7.>8O\2'I:,3$:S&#>"_A MMYD\@20ZACB*VUOJ&^?_A V6&CTZ+#O,=GQ3(-@5J8GATQ/R$R; M2^4+]C;<;-/D!?M3/^B .>SO=WI]H^-_FK)-RAWOM>Q"P@81$,R29GJ09GKR MQ72*E
$)$TB8!,$L&2X.,ER<>#$EXSN<>4 AP M64>!1!\0(< YL[+9C_+9#&^Y>E1;-[*()""3Z@ A-SF','>/,G0FJVH*Z<2A- M0&D21;,E,8[<(9UFOVH+ZM'[T)H_*E"#CJ+9NAB+[M
>_7BUQ>EJ"VF5%U": M@-(DBF8+9(R\,SN]VD(ZY064)] TB:+9/3ICXUW2D[:HMDI]4OP>G^H85!# M@XC>ELY=M7.X;=>X,9=VV[W*I))9S9,[<6>/LUD?
-9MZCY,)M<@HFIW,2J^X M;;/XJ?K&Q?:,L4UC,-?X'*;8-:,8I1O'?>H;&ME9'-ZF_0.=4Z)H=M*.^75I M\ULM7C[H_-2224"6+32P<\JA/6@H3:)HMC3&%KOCT]>S(#WG DH34)I$T6PQ
MC!]VZ59UB{)ETJ9LJ0]J*EN@MA5%LS-G;*M+V]9W*OZJT_P$SOSP02=IL1RN.M,8/36G*FW'FQ5]EVT*OOJHQK*/@51-'L M9!HKZ+:.U@D^6?5!#"*4)*$VB:/9J06,(.6T(^Y1]-
+*K.+SN)1O*/NB<$D6S MDVZ\)'_"2Y)E'_N/]5V:1<_;61DD34!I$D6S%30&EI^^VIE#K2N4)] TB:+9 M8E26/-/6M<6:YQXVK[%=A0*)/B!"@'/86&YL+*=M;/LBLP153_:3V>3QZG-4
MG[8/B$CR.0PI-X:4GZ%/2S.['/BH/FT?$*').7PI-[Z4H_JT'-JGA=($E"91 M-%L28W@YOD]+(SN+@^K30C=+HFBV+L9(_9]VHXU+[ULCIZWLWC01BZ4)E$T
M6T'CWOGIC5P.]>U0FH#2)(IF_V+-^';OU$8N#>APZ4>!1!\0\2.U&M1%"-1RZSX@0HAS6''/6"OB>76?>IBFME%$Q!(] $1FIS#D7O& MD7L<5!=[!?I8RE":@-(FBV9)4?N-,>_0^=3&-
[*P.RM9#-TNB:+8NQM9[3]CZ M_G4QO<"1GK>S>-#F-)0F431;0?,E@-?V2X#C=;$'M?]0FH#2)(IFBV'LOT?; M_Q9U<;V%75\IT#*"H8:5 .)1L&N6ZH.%E[ZDQU!YMJ#L4H/5&O,
[)/(<;'1LW.D;] M.G@,[1U#:0)*DRB:+8GQIV/\KX-I9&=QG-J'I>EV*E OBJ+MDSZLW(3K//0[R_<]O^21IMBEN3W41I&JV+A_=:9:G/!V3OWT91 M^N-)?K>SP_WSYO\#4$L#!!0 (
/""#ED<[8Z)(@0 %85 9 >&PO M=V]R:W-H965TVT0ETDM2=@KLQR]%R9(O,F,,*I "76*(X9^:,9JB3Z:VX M^"'G]]Q!&3?6>NU--1=64XAYC(*[X II],N8B)TK=BYLJ% #(Q1G'D8L]K
MN3&AS!GTS-JC&/1XHB+*X%$@F<0Q$3^'$/%5W_&=]<(3G@LR@V=0 M7Q>/0M^Y!&E$ M$$&H4@BB?Y8P@BA*D70<_^:@3N$S-=R\7J-_,N0UF3&1,.+1WW2BYGVGXZ)
M3$D2J2>^^A-R0LT4+^21-'_1*M_K.2A,I.)Q,JPCB"G+?LE+GH@-.XU3;8!S M_[QKT#A@$.0&@2&:169HW1)%!CW!5TBDNS5:>F%R8ZPU&\K2U_BLA'Y*M9T. M?")4H&\D2@] >&)
/V.E$3O;T$1&DF$/Z!+]/7Y%KU_]P&]0Y2A+W.>2,(F MLNHEL((1Z#0(%?]68RZAE>R^"E M9]5RX++>,W9Z[W*1D=7HFI69!J7D\)5UH8*O388;5V*#3"9HI;*S^SF33*MBT
M7F>35_8=6R1*7J![6$*$ O3]P;RNR@JUHIY:H36!;26@722@_:9:NUUGXFH"MVTI2:E;4.K6V-K=(UK;ZN],-KY7:@#OZ.8N"]?6 MUG; 4\NS+K1M^AL2R'1]3K9V'4U?
R:D+;3AXNDX=K;N\<\)7^MKL]EU8IY'RK MW#FQQ7,P>X_/9[+]%18_A$2ZV"3H__0N9]XN]^3R_E7:#:_%&U^\VV=!36) MNCQYOT(B^J5&](\0B:>=!:VCSH+6OMC'V"MV;8=;*CK?
JGL&=U(FN_^%YF&= M(9A0Y0MI[Q\,&!\(O%14OEU2?7P!$5)Y(/9]^739[31V4WJ&?D*V(BFUDV^7 M3Z,Y83-(:IPG3HEPJ>>SK)C_P=FGL;[HL=H+J!.-2$&&[(+KG4J;M/>4"Z(RA
MM*>!A3^1$H1)8B90E>./"'ETH'6\7 B5^U'*QE_:I5;/(; M&QV<1>IN3*AB$#,SN),HY E3V;2G6"V&@S=F)+:S/O2O1]F(KX3))HX/1,PH
MDRB"J8;TKMKZ+!39$"^[47QAYF!CKA2/S>4I@V*4.O@? M4$L#!!0 (/""#EGZ\>$#W@, ,H1 9 >&PO=V]R:W-H965TUI6%;WM?EC=!Y,, M8#6V<[8#Y=^?[80 ;4B[)R34+Q
[,X]G'L\\<=)?<_$HEP */=&$R8&S5"J] M=%T9+8%BV> I,'UGS@7%2@_%PI6I !Q;)YJX@>>U78H)J80P MN!-(9I1BL;F"A*\'CN]L)Z9DL51FPAWV4[R >U_TCNA1VZ)$A,*3!+.D(#Y
MP!GYEV._:1RLQ0.!M=R[1B:5&>>/9G ;#QS/1 0)1,I 8/WV@<$DB4'2VGH.B3"L."V<= 24L_\=/!%[#D'KB$-0. T1=0O=0+A1 FD=FT[K&"@_[
M@J^1,-8:S5Q8;JRWSH8PLXWW2NB[1/NIX0TF CW@) ,T 2PS 7J/E$0?KT%A MDD@4?D*?T4\L!&8*_9H G8'XI^\JO;9!<*-BG:M\G>#(.FTTX4PM)?K"8H@K M_,?U_GY0
^#JI,O,@VWF5T$MXE\9:Z#0NT"!%S2K JIWOX9(N_O6/:P))RPW M(K1XK51=L:V=WY]TXNC6P545FYE'FE8':D1EDN9
MX@@&CE8.LQ(XPP]_^&WOSRH:3P1V0&JS)+59ASZ\7V(!GS4OFJHQIUK[9,[MR-3SPM8ZFFW0OMT=WMCIT1]+^ +M-8C>AXRFQE^S_.4IU4JD[:_)BL3 8C3% M"JK8S$/LV1"-
JJZ&7M]=[5-4F\3_I*A54M2JI6A"G*$9K6WM6H3?K8<3@1TD MVRZ3;;^;)FN?DM03@1V0VBE){9RKR:9$/J(; 89B!3IT=;3+\AA};[_-&EXS M?-9JU69AMS0[H*!;4M]N\[\#8)6)5X?68
V@(5$343SQV?01#'>R*HBJD?R M+1(*MD#ZB?P2Z("]7LE>[^SL/?!$8YK&/E!!O9@\KY]>5?UT6F%U_?C> M[ACFUN=-_-U) =R7 3Y M0H\[S_KIF-T10?
9WQVF_]F\Y5DE^);16H+=0AA;0#W_^ MT_;,=+F\(\]$_$:G\Z*4*NU:S>:[.Z]+5,0" L10:*(9TSE+\[E;/FA8F1? MS]V=>?Z58X+%@C"))&IAK5_,@<)#/(QSD \53^^X]XTJ_R=O+)>
8A#'0]^>< MJ^W +%!^OAG^!U!+ P04 "_#P@@Y9&O)(_\# "%#@ &0 'AL+W=O M-@XDV2%[75WUPG]^^[:CHE58PCQ R^QUYYS?.;,3K0S6#'^)!:(&I[# M(!)##8R%E?
&R:PE]@2,0ABS%2;V:,AT2J)9^;(N9(IBDH#$S'LKIF2&AD>(/T MV37W!BR1 8WPFH-(PI#POZ<8L-70L(WU@QLZ7TC]P/0&,9GC+G$Q'1J65H0!^E)3$'59
MX@B#0#,I'?]R4J/XI@9NWJ_9S]+D53(3(G#$@M]T*A=#HV_%&0-6YUC MGE!\_DL$.DOK/)8RP_$9*%.5@I"&F47@)L##W#31 M3%F.UIA(X@TX6P'7T8I-
WZ3>I&B5#8UT&0\6V5V^PDGOC% .]R1($*Z0B(2C MJ1$4L#]&26@@H'T W^ EJ@4_6<313SBGT1P>KC"<(']4,7>W8]C?.X]H!\ M6K!$D&@]!J94*O6W3#]7=)HI+A4'X +B:%XK#
(G4^-6J]%-?2QBXN/04%TKD"_1\+Y^L;O6]RJK&B(K&>><6 MQKEU[+H0Z=YXI1A9MAE%-Z70_SA+K]]N]P?F[=44NQ17?LSE/*T;9>#DW6!_O#K>V/>MIMZ]P46]F$C9.C-;EZ M))?
3E'D-L97->5E5VK5GK_?U2<[QOO&H(JKB?&1NS AZ0+LB?$XC 0'.%,PZ M[*DR\VSFR1:2Q>G8,&%2#2'I[4+-B&ULM9MOK]HV%,;_BL6J]9ZDMCF7\=%:LFJ=5JEJEW;%]-
>^(+O)6I(F&.@ M_?9S0AJ3&^> <_>W$L@?D[.@YW\CFWFQTQ]S3=2:O)MFZ3YS6"C]>[E<)BO M-G(K\A?93J;FD[M,,84VA^I^F.^4%.NRT389TB 8#[+>?G>>[689WN=
MQ*E\KTB^WVZ%^OY:)MGQ9A .?KSQ(,[?Z.*-X6*^$_?RH]2?=N^5.1K6*NMX M*],\SE*BY-W-X%7X,N*3HD%YQN=8'O.SUZ1(Y3;+OA8';]/[ZA_];,GF3S*W(Y3)+OL1KO;D93
=D+>_$ M/M$?LN/OLDIH5.BMLB0O_Y+GZ=RQB;C:YSK;5HW-\39.3__%M\J(LP8A[VA MJP;TV@:L:L"N;<"K!KQTYI1*Z4,DM%C,578DJCC;]!4O2C/+UB;]."V^]X]:
MF4]CTTXOWHA8D<\BV4OR3HI\KZ3Y4G5.GD92BSC)R>@9^85\^AB1IT^>D2$!<\)#2AW-%_"S=\)99]' MG3,PHS:7ZB 'BY]_"L?!KRYW,,4B)++&&N$X+Z80V3XL)T/
M!_Q'?.K&2\F#S- #C+7Y2!R97/2X6?Q)RQ\D H8R_=K;@?D4W>RHSK9$9CL M%Z&42#41G9U^U(HY9:,'28(Q?)-L!PPGHYD[S7&=YOC*T9W$XC9.8AU+9[9C
MS"&.*18AB37LF]3V3LLQ2':?W9AR0568P82V5*)_T._&]&"@N)T%%]_42 MEXD]=+I-G+0'T"P(W'UK6ILSA>]_]5/W.7F;[O;:W/[^E >9D)#_4YN;Z7Z MQV40J.K;U3#%
(B2QAINSVLW9HY_#,TSG,,4B)+&&Q+#4A[CLX]0 MMX${E]4T[XR=0Z3'?B5T?A<9S\8/'HEP-&];>JB!ME@L#D%VO (08 &?GH2* MQ B7U;3,\G!X
8@S92K4U%1\2LET]9V8BOXHU+IX=FIEBF.GBZ"FCXL]A 7 M'W]931HJ%6&I-#RWVS54=XH>SP@;T> M1.]^N*#6&0B7U33/%ADA2.(^L-<#Z=W6H18:")?5G":U10:%BXS+0
@+>%C6 M1PB8(T4N+:@M+2A<6O0"0EC3QT742@3ALIHNGDW07SM#?P$(*>X\/>Y$_?\Q M4T]M:4+ATJ0/$,*2WG:BEB=]U,#>:,L3"J\2= ,A X$0EO5V$[5:P5)K6FJK M%3IZ_!
(<:G6"JA9AJ37MLR4*O5"B> 1A)74^A>5AODB HLV%%;2E!X M?>)GFH^C!&9A8AYNC@=/8P?U0F=\2<33KZ-K.\S0(<[&&8M+Q$58NPU)H>6@!G,(#W M1Y8TMM.5
AG[16([G5,9@F;P7/|'^0N4UJNVWN(0*2!5;V=0N5M++6FHV=; M8]BCD8:A\C6J6H2EUK3/0C:[-D^6XO:FV/<>XM0D=D5%4 :9F&8P5/WUR,- M:V^8:6]#@$J-
Y9]T.V<4TS/(K@_GU,M.P-C^VF0:.XIUI.V0WTS +K P&UEY, MP]HDZ6 :.+)W_NV8W4QC\95-D9@&=9,,JEJ$I=;TT&(Q@[&X%].@[IQ!58M8
MFYZ[F89,?.,P=/5ON8ZW0DN2W1'W_FB0;6!U7\=0U2(LM::S%JIY^&BVX:@0 MC:H68:DU[,.PS6'8]F&;2NHBV\ AO0UR1(7V5ULJYO LM,<.:W8%V\#1O+-N
MA^QB&WZVI1P&VFAQ6..O]\{\L=@MYG6V;9\N9"F%6<8#Z_RS+] MXZ#X?5G] \3%?U!+ P04 " #P@@Y9W9%O'XH# #K#@ &0 'AL+W=O M MTX2*D15+F9W9M@AC2+'HL
RH6EDPGF*IAGQIBXP#C@PH36S/<7IVB@FUQD,S M=\W'0Y,+A%"XYDCD:8KYYAP2MAY9KK6=N""+6.H)>SS,\!)N0?[(KKD:V15+
M1%%*@@C"*."Q&UL0]F[J>!AB+.P)K4R-M.I0Y8PJZ" M*22)9E)^_"Y)K6I/#:P_;]DO3? JF#D6,&?)/8ED/+(&%HI@@?-$WK#U9B@#
MZFJ^D"7"_*)U:>M8*,R%9&D)5AZDA!;_^+$4H@;PNGL 7@GP7@KP2X!O BT\ M,V%=8(G'0\[6B&MKQ.8?C#8&K:(A5+_&6\G5*E$X.;[$A*,[G.2 9H!%SD&] M(RG0NPN0F"0"?<.
<8RWU>_0!W>L!E>CG#-(Y\%]#6RH?-),=EON=%_MY>_;K MH1FC,A;H$XT@:L!/V_&NUT)@J^ K!;RM N=>*^.7G':0[YP@S_&")H?:X1<0
M*KAKX'Z+.W[U0GS#Y^_ANS>)!Q&:K(G#$@M?T*A=#HV_%&0-6YUC MGE!\'DL$.DOK/)8RP_$9*%.5@I"&F47@)L##W#31 M3%F.UIA(X@TX6P'7T8I-

X2^LAGD#!I8',OW>6N.[C5?(XW6 [>EC%8+-%*]$;*;X M6@,27C=@9%EXM[$\P,!V :L=R!_. S45YB0)["KF#3O!.))E& *U&*[1-$56 M)X5O>'^P4Y(D619& L]2!(,@=.((Y@#\(A2>+NP9W[*%[?4_'FOT>C7U!+ M P04 " #P@@Y9EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P M#$!_Q="> , ?0(8@S9?$6!/D!5J((V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TX MI+:.+J1C|$%)I6M6X 4BV)8HSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WQ606 MIW.D5XA-/E M_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU M@LD/[' X 4$L#!!0 (/""#EE:.(9B P0 .$C / >&PO=V]R:V)O M;VLN>&ULQ9IACYLV&(# BL6G5]H68"!M3TVE4W*W1NMRU7&]?9P<>)-8!3NS M36[KKY\!93,|[E6_O.-3P#CFP39^[- >\?]+FZT[KK^RONE)V&1V=.UW-9K8X M0BWLS_H$RE_9:U,+YT_-869/!D1ICP"NKF9\/E_;B%5].'|I:S/9A:>: >% MDUKYQ#;A4<*3_>]Z>\K.TLJ=K*3[>QEUQQ5$K)9*UO(;E,MH'C%[U$\?M9'? MM'*BR@NCJVH9Q?V%1S!.%L^2\Q;R0>QLE^+$[EYXD&6TF/L"]})8U^7HRA>> M\0P^C@:H%5/8H3S9B2M2PC%,Z#*9]'G^#3=D_F_-004V9*^DOF$W9X=&A M?-E>?UEO'F[6;'6W7=]L_XHO_NT65_W 20'(D$T+^P0/(!(%,IH1, L@4 M@4RGA$P#R R!S*:$S + (!0*YH(7,?_^5?=15Z<<0RU;:G+3I,C&A2I8W >0; M!/(-+>36E[M1A:Z!G<"P_"@,!&1O$;*WM&2W4@E5 +N' N19^'O; .P= O:. M%FSC7:0. [3W9M;5>!.$X/<<&ZCDMV!IV+F1!I4%LC96N:^G:3+;K[RMOENSM\W)Z:#>$H?#.8H,2:$ MF-@(.&8X2XDQ.\3$>A@3%WOUT'GB=0B)F2(F5L6(P\88.68-3FR-9SH;)<1< MPHE=TGIM% I=Q5B8@[AQ YY07&7Z@PQ,9]P8I^,J&ZTQ3&Q<&JQ M/'?>*"/F&#ZI8\+5&\<P|:HB)R28AE@V*.8PD8?I)}U?E#,<#Q* M,/TDQ/H9G:?]^P:)$!,S4$)LH)&IVLA@E& "2H@%]#(BXP-(3#\)L7X0R*TP M8=P]P?23$.NGG_:M3"FFX18-P,J8:.FF%_2_R'Z-6Q'T6[N#/@PL:131L0& M8DDQL:13KFN&FQ286%)BL>"8H5A2=#.%6BPO+;_Z? AIB8F))B<6"8@[!)B:7 ME%@N...:@;V)Z28GU@F,.^B:FEY1Z@P7%#!=A*>:;E#]&AF(NP@U)3#\9L7Y& M(Q@C[LXP!V7$#L(@ARK/, =EQ X:C;2,U25FH(S80!CD<,V080;*.@/-+I^4 ME+"7"LJMOX7UZ86HBL^&M3_];EF:M0'M?5-5*Y]VISYI45Z^4+E\??/A'U!+ M P04 " #P@@Y9#Y142-H! !9(&@ 'AL+U|R96QS+W=O)/[F/!00D5#B]B %28/D<269Q#)[HE" M$8Y%08/F5-;8\O5?6)^LD>6;7?(FVV?)\?|[I 7S:;4_B&$O-RD?9MO MNCX=SE=6W;!ORWDYK$/?+M_;=0HZG<["\'-&\SC_.7/R>NK37R9V]|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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .num { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html1622291true430false5 falsefalseR1.htm00000001 - Document - CoverSheethttp://swkhold.com/role/CoverCoverCover1 falsefalseR2.htm00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParentheticalUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOMESheethttp://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncomeUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOMEStatements4 falsefalseR5.htm00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements5 falsefalseR6.htm00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlowsUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm00000007 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting PoliciesSheethttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesSWK Holdings Corporation and Summary of Significant Accounting PoliciesNotes7 falsefalseR8.htm00000008 - Disclosure - Net Income per ShareSheethttp://swkhold.com/role/NetIncomePerShareNet Income per ShareNotes8 falsefalseR9.htm00000009 - Disclosure - Finance ReceivablesSheethttp://swkhold.com/role/FinanceReceivablesFinance ReceivablesNotes9 falsefalseR10.htm00000010 - Disclosure - Intangible AssetsSheethttp://swkhold.com/role/IntangibleAssetsIntangible AssetsNotes10 falsefalseR11.htm00000011 - Disclosure - DebtSheethttp://swkhold.com/role/DebtDebtNotes11 falsefalseR12.htm00000012 - Disclosure - Commitments and ContingenciesSheethttp://swkhold.com/role/CommitmentsAndContingenciesCommitments and ContingenciesNotes12 falsefalseR13.htm00000013 - Disclosure - Fair Value MeasurementsSheethttp://swkhold.com/role/FairValueMeasurementsFair Value MeasurementsNotes13 falsefalseR14.htm00000014 - Disclosure - Revenue RecognitionSheethttp://swkhold.com/role/RevenueRecognitionRevenue RecognitionNotes14 falsefalseR15.htm00000015 - Disclosure - Segment InformationSheethttp://swkhold.com/role/SegmentInformationSegment InformationNotes15 falsefalseR16.htm00000016 - Disclosure - Subsequent EventsSheethttp://swkhold.com/role/SubsequentEventsSubsequent EventsNotes16 falsefalseR17.htm00000017 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies)Sheethttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPoliciesSWK Holdings Corporation and Summary of Significant Accounting Policies (Policies)Policieshttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPolicies17 falsefalseR18.htm00000018 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Tables)Sheethttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesTablesSWK Holdings Corporation and Summary of Significant Accounting Policies (Tables)Tableshttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPolicies18 falsefalseR19.htm00000019 - Disclosure - Net Income per Share (Tables)Sheethttp://swkhold.com/role/NetIncomePerShareTablesNet Income per Share (Tables)Tableshttp://swkhold.com/role/NetIncomePerShare19 falsefalseR20.htm00000020 - Disclosure - Finance Receivables (Tables)Sheethttp://swkhold.com/role/FinanceReceivablesTablesFinance Receivables (Tables)Tableshttp://swkhold.com/role/FinanceReceivables20 falsefalseR21.htm00000021 - Disclosure - Intangible Assets (Tables)Sheethttp://swkhold.com/role/IntangibleAssetsTablesIntangible Assets (Tables)Tableshttp://swkhold.com/role/IntangibleAssets21 falsefalseR22.htm00000022 - Disclosure - Debt (Tables)Sheethttp://swkhold.com/role/DebtTablesDebt (Tables)Tableshttp://swkhold.com/role/Debt22 falsefalseR23.htm00000023 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://swkhold.com/role/CommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://swkhold.com/role/CommitmentsAndContingencies23 falsefalseR24.htm00000024 - Disclosure - Fair Value Measurements (Tables)Sheethttp://swkhold.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://swkhold.com/role/FairValueMeasurements24 falsefalseR25.htm00000025 - Disclosure - Revenue Recognition (Tables)Sheethttp://swkhold.com/role/RevenueRecognitionTablesRevenue Recognition (Tables)Tableshttp://swkhold.com/role/RevenueRecognition25 falsefalseR26.htm00000026 - Disclosure - Segment Information (Tables)Sheethttp://swkhold.com/role/SegmentInformationTablesSegment Information (Tables)Tableshttp://swkhold.com/role/SegmentInformation26 falsefalseR27.htm00000027 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)Sheethttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetailsSWK Holdings Corporation and Summary of Significant Accounting Policies (Details)Detailshttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesTables27 falsefalseR28.htm00000028 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative)Sheethttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetailsNarrativeSWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative)Detailshttp://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesTables28 falsefalseR29.htm00000029 - Disclosure - Net Income per Share (Details)Sheethttp://swkhold.com/role/NetIncomePerShareDetailsNet Income per Share (Details)Detailshttp://swkhold.com/role/NetIncomePerShareTables29 falsefalseR30.htm00000030 - Disclosure - Net Income per Share (Details Narrative)Sheethttp://swkhold.com/role/NetIncomePerShareDetailsNarrativeNet Income per Share (Details Narrative)Detailshttp://swkhold.com/role/NetIncomePerShareTables30 falsefalseR31.htm00000031 - Disclosure - Finance Receivables, Net (Details)Sheethttp://swkhold.com/role/FinanceReceivablesNetDetailsFinance Receivables, Net (Details)Details31 falsefalseR32.htm00000032 - Disclosure - Finance Receivables, Net (Details 2)Sheethttp://swkhold.com/role/FinanceReceivablesNetDetails2Finance Receivables, Net (Details 2)Details32 falsefalseR33.htm00000033 - Disclosure - Finance Receivables, Net (Details 3)Sheethttp://swkhold.com/role/FinanceReceivablesNetDetails3Finance Receivables, Net (Details 3)Details33 falsefalseR34.htm00000034 - Disclosure - Finance Receivables, Net (Details 4)Sheethttp://swkhold.com/role/FinanceReceivablesNetDetails4Finance Receivables, Net (Details 4)Details34 falsefalseR35.htm00000035 - Disclosure - Finance Receivables (Details Narrative)Sheethttp://swkhold.com/role/FinanceReceivablesDetailsNarrativeFinance Receivables (Details Narrative)Detailshttp://swkhold.com/role/FinanceReceivablesTables35 falsefalseR36.htm00000036 - Disclosure - Intangible Assets (Details)Sheethttp://swkhold.com/role/IntangibleAssetsDetailsIntangible Assets (Details)Detailshttp://swkhold.com/role/IntangibleAssetsTables36 falsefalseR37.htm00000037 - Disclosure - Intangible Assets (Details 2)Sheethttp://swkhold.com/role/IntangibleAssetsDetails2Intangible Assets (Details 2)Detailshttp://swkhold.com/role/IntangibleAssetsTables37 falsefalseR38.htm00000038 - Disclosure - Intangible Assets (Details Narrative)Sheethttp://swkhold.com/role/IntangibleAssetsDetailsNarrativeIntangible Assets (Details Narrative)Detailshttp://swkhold.com/role/IntangibleAssetsTables38 falsefalseR39.htm00000039 - Disclosure - Debt (Details)Sheethttp://swkhold.com/role/DebtDetailsDebt (Details)Detailshttp://swkhold.com/role/DebtTables39 falsefalseR40.htm00000040 - Disclosure - Debt (Details 2)Sheethttp://swkhold.com/role/DebtDetails2Debt (Details 2)Detailshttp://swkhold.com/role/DebtTables40 falsefalseR41.htm00000041 - Disclosure - Debt (Details Narrative)Sheethttp://swkhold.com/role/DebtDetailsNarrativeDebt (Details Narrative)Detailshttp://swkhold.com/role/DebtTables41 falsefalseR42.htm00000042 - Disclosure - Commitments and Contingencies

(Details)Sheethttp://swkhold.com/role/CommitmentsAndContingenciesDetailsCommitments and Contingencies (Details)Detailshttp://swkhold.com/role/CommitmentsAndContingenciesTables42 falsefalseR43.htm00000043 - Disclosure - Commitments and Contingencies (Details 2)Sheethttp://swkhold.com/role/CommitmentsAndContingenciesDetails2Commitments and Contingencies (Details 2)Detailshttp://swkhold.com/role/CommitmentsAndContingenciesTables43 falsefalseR44.htm00000044 - Disclosure - Commitments and Contingencies (Details Narrative)Sheethttp://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrativeCommitments and Contingencies (Details Narrative)Detailshttp://swkhold.com/role/CommitmentsAndContingenciesTables44 falsefalseR45.htm00000045 - Disclosure - Fair Value Measurements (Details)Sheethttp://swkhold.com/role/FairValueMeasurementsDetailsFair Value Measurements (Details)Detailshttp://swkhold.com/role/FairValueMeasurementsTables45 falsefalseR46.htm00000046 - Disclosure - Fair Value Measurements (Details 2)Sheethttp://swkhold.com/role/FairValueMeasurementsDetails2Fair Value Measurements (Details 2)Detailshttp://swkhold.com/role/FairValueMeasurementsTables46 falsefalseR47.htm00000047 - Disclosure - Fair Value Measurements (Details 3)Sheethttp://swkhold.com/role/FairValueMeasurementsDetails3Fair Value Measurements (Details 3)Detailshttp://swkhold.com/role/FairValueMeasurementsTables47 falsefalseR48.htm00000048 - Disclosure - Fair Value Measurements (Details 4)Sheethttp://swkhold.com/role/FairValueMeasurementsDetails4Fair Value Measurements (Details 4)Detailshttp://swkhold.com/role/FairValueMeasurementsTables48 falsefalseR49.htm00000049 - Disclosure - Fair Value Measurements (Details 5)Sheethttp://swkhold.com/role/FairValueMeasurementsDetails5Fair Value Measurements (Details 5)Detailshttp://swkhold.com/role/FairValueMeasurementsTables49 falsefalseR50.htm00000050 - Disclosure - Fair Value Measurements (Details Narrative)Sheethttp://swkhold.com/role/FairValueMeasurementsDetailsNarrativeFair Value Measurements (Details Narrative)Detailshttp://swkhold.com/role/FairValueMeasurementsTables50 falsefalseR51.htm00000051 - Disclosure - Revenue Recognition (Details)Sheethttp://swkhold.com/role/RevenueRecognitionDetailsRevenue Recognition (Details)Detailshttp://swkhold.com/role/RevenueRecognitionTables51 falsefalseR52.htm00000052 - Disclosure - Revenue Recognition (Details 2)Sheethttp://swkhold.com/role/RevenueRecognitionDetails2Revenue Recognition (Details 2)Detailshttp://swkhold.com/role/RevenueRecognitionTables52 falsefalseR53.htm00000053 - Disclosure - Segment Information (Details)Sheethttp://swkhold.com/role/SegmentInformationDetailsSegment Information (Details)Detailshttp://swkhold.com/role/SegmentInformationTables53 falsefalseR54.htm00000054 - Disclosure - Segment Information (Details Narrative)Sheethttp://swkhold.com/role/SegmentInformationDetailsNarrativeSegment Information (Details Narrative)Detailshttp://swkhold.com/role/SegmentInformationTables54 falsefalseAll ReportsBookAll Reports e24328_swkh-10q.htmswkh-20240630.xsdswkh-20240630_cal.xmlswkh-20240630_def.xmlswkh-20240630_lab.xmlswkh-20240630_pre.xml e24328001.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024truetrue

JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "e24328_swkh-10q.htm": { "nsprefix": "swkh", "nsuri": "http://swkhold.com/20240630", "dts": { "inline": { "local": ["e24328_swkh-10q.htm"] }, "schema": { "local": ["swkh-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["swkh-20240630_cal.xml"] }, "definitionLink": { "local": ["swkh-20240630_def.xml"] }, "labelLink": { "local": ["swkh-20240630_lab.xml"] }, "presentationLink": { "local": ["swkh-20240630_pre.xml"] } }, "keyStandard": 210, "keyCustom": 19, "axisStandard": 16, "axisCustom": 0, "memberStandard": 29, "memberCustom": 12, "hidden": { "total": 247, "http://fasb.org/us-gaap/2024": 211, "http://swkhold.com/20240630": 31, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 162, "entityCount": 1, "segmentCount": 43, "elementCount": 388, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 960, "http://xbrl.sec.gov/dei/2024": 33 }, "report": { "R1": { "role": "http://swkhold.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "b", "span", "p", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets", "longName": "00000002 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R4": { "role": "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome", "longName": "00000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:CostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R5": { "role": "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "00000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R6": { "role": "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "longName": "00000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R7": { "role": "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPolicies", "longName": "00000007 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies", "shortName": "SWK Holdings Corporation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://swkhold.com/role/NetIncomePerShare", "longName": "00000008 - Disclosure - Net Income per Share", "shortName": "Net Income per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://swkhold.com/role/FinanceReceivables", "longName": "00000009 - Disclosure - Finance Receivables", "shortName": "Finance Receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FinancingReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://swkhold.com/role/IntangibleAssets", "longName": "00000010 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://swkhold.com/role/Debt", "longName": "00000011 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://swkhold.com/role/CommitmentsAndContingencies", "longName": "00000012 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://swkhold.com/role/FairValueMeasurements", "longName": "00000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://swkhold.com/role/RevenueRecognition", "longName": "00000014 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-

gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://swkhold.com/role/SegmentInformation", "longName": "00000015 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://swkhold.com/role/SubsequentEvents", "longName": "00000016 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000017 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies)", "shortName": "SWK Holdings Corporation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:NatureOfOperationsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "00000018 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Tables)", "shortName": "SWK Holdings Corporation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["swkh:CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["swkh:CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://swkhold.com/role/NetIncomePerShareTables", "longName": "00000019 - Disclosure - Net Income per Share (Tables)", "shortName": "Net Income per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://swkhold.com/role/FinanceReceivablesTables", "longName": "00000020 - Disclosure - Finance Receivables (Tables)", "shortName": "Finance Receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://swkhold.com/role/IntangibleAssetsTables", "longName": "00000021 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://swkhold.com/role/DebtTables", "longName": "00000022 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://swkhold.com/role/CommitmentsAndContingenciesTables", "longName": "00000023 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://swkhold.com/role/FairValueMeasurementsTables", "longName": "00000024 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://swkhold.com/role/RevenueRecognitionTables", "longName": "00000025 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "swkh:ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://swkhold.com/role/SegmentInformationTables", "longName": "00000026 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "longName": "00000027 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)", "shortName": "SWK Holdings Corporation and Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "swkh:ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock", "swkh:CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R28": { "role": "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000028 - Disclosure - SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "SWK Holdings Corporation and Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Number", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Number", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://swkhold.com/role/NetIncomePerShareDetails", "longName": "00000029 - Disclosure - Net Income per Share (Details)", "shortName": "Net Income per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:ProfitLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R30": { "role": "http://swkhold.com/role/NetIncomePerShareDetailsNarrative", "longName": "00000030 - Disclosure - Net Income per Share (Details Narrative)", "shortName": "Net Income per Share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://swkhold.com/role/FinanceReceivablesNetDetails", "longName": "00000031 - Disclosure - Finance Receivables, Net (Details)", "shortName": "Finance Receivables, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":

"31", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:NotesReceivableGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://swkhold.com/role/FinanceReceivablesNetDetails2", "longName": "00000032 - Disclosure - Finance Receivables, Net (Details 2)", "shortName": "Finance Receivables, Net (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R33": { "role": "http://swkhold.com/role/FinanceReceivablesNetDetails3", "longName": "00000033 - Disclosure - Finance Receivables, Net (Details 3)", "shortName": "Finance Receivables, Net (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:NotesReceivableGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_custom_LifeScienceTermLoansMember", "name": "us-gaap:NotesReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R34": { "role": "http://swkhold.com/role/FinanceReceivablesNetDetails4", "longName": "00000034 - Disclosure - Finance Receivables, Net (Details 4)", "shortName": "Finance Receivables, Net (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FinancingReceivableCreditQualityIndicatorsTableTextBlock", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://swkhold.com/role/FinanceReceivablesDetailsNarrative", "longName": "00000035 - Disclosure - Finance Receivables (Details Narrative)", "shortName": "Finance Receivables (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "AsOf2024-06-30_custom_TrioHealthcareLtdMember", "name": "us-gaap:LoansAndLeasesReceivableGrossCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_custom_TrioHealthcareLtdMember", "name": "us-gaap:LoansAndLeasesReceivableGrossCarryingAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:FinancingReceivablesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://swkhold.com/role/IntangibleAssetsDetails", "longName": "00000036 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://swkhold.com/role/IntangibleAssetsDetails2", "longName": "00000037 - Disclosure - Intangible Assets (Details 2)", "shortName": "Intangible Assets (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://swkhold.com/role/IntangibleAssetsDetailsNarrative", "longName": "00000038 - Disclosure - Intangible Assets (Details Narrative)", "shortName": "Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://swkhold.com/role/DebtDetails", "longName": "00000039 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LongTermDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:DeferredFinanceCostsNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R40": { "role": "http://swkhold.com/role/DebtDetails2", "longName": "00000040 - Disclosure - Debt (Details 2)", "shortName": "Debt (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://swkhold.com/role/DebtDetailsNarrative", "longName": "00000041 - Disclosure - Debt (Details Narrative)", "shortName": "Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-10-10", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-10", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://swkhold.com/role/CommitmentsAndContingenciesDetails", "longName": "00000042 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://swkhold.com/role/CommitmentsAndContingenciesDetails2", "longName": "00000043 - Disclosure - Commitments and Contingencies (Details 2)", "shortName": "Commitments and Contingencies (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000044 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2024-01-012024-06-30_custom_DallasTexasOfficeMember", "name": "us-gaap:LeaseAndRentalExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-06-30_custom_DallasTexasOfficeMember", "name": "us-gaap:LeaseAndRentalExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://swkhold.com/role/FairValueMeasurementsDetails", "longName": "00000045 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "swkh:WarrantAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_FairValueMeasurementsRecurringMember", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R46": { "role": "http://swkhold.com/role/FairValueMeasurementsDetails2", "longName": "00000046 - Disclosure - Fair Value Measurements (Details 2)", "shortName": "Fair Value Measurements (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "swkh:WarrantAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-06-30_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R47": { "role": "http://swkhold.com/role/FairValueMeasurementsDetails3", "longName": "00000047 - Disclosure - Fair Value Measurements (Details 3)", "shortName": "Fair Value Measurements (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "swkh:FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_WarrantMember", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "swkh:FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://swkhold.com/role/FairValueMeasurementsDetails4", "longName": "00000048 - Disclosure - Fair Value Measurements (Details 4)", "shortName": "Fair Value Measurements (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_FairValueMeasurementsNonrecurringMember", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_FairValueMeasurementsNonrecurringMember", "name": "us-gaap:InvestmentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://swkhold.com/role/FairValueMeasurementsDetails5", "longName": "00000049 - Disclosure - Fair Value Measurements (Details 5)", "shortName": "Fair Value Measurements (Details 5)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:NotesAndLoansReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R50": { "role": "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative", "longName": "00000050 - Disclosure - Fair Value Measurements (Details Narrative)", "shortName": "Fair Value Measurements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_WarrantMember_srt_WeightedAverageMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-06-30_us-gaap_WarrantMember_srt_WeightedAverageMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://swkhold.com/role/RevenueRecognitionDetails", "longName": "00000051 - Disclosure - Revenue Recognition (Details)", "shortName": "Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30_us-gaap_LicensingAgreementsMember", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "swkh:ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "unique": true } }, "R52": { "role": "http://swkhold.com/role/RevenueRecognitionDetails2", "longName": "00000052 - Disclosure - Revenue Recognition (Details 2)", "shortName": "Revenue Recognition (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:DeferredRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-30", "name": "us-gaap:DeferredRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://swkhold.com/role/SegmentInformationDetails", "longName": "00000053 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "swkh:RevenuesExcludingOtherRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-04-012024-06-30", "name": "swkh:RevenuesExcludingOtherRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://swkhold.com/role/SegmentInformationDetailsNarrative", "longName": "00000054 - Disclosure - Segment Information (Details Narrative)", "shortName": "Segment Information (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Number", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-06-30", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Number", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "e24328_swkh-10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r222", "r687"] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": ["r57", "r63"] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r47", "r48"] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Interest, accounts receivable and other receivables, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r501", "r554", "r611", "r757", "r758"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r58", "r606", "r762"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r470", "r671", "r672", "r673", "r675", "r719", "r763"] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": ["http://swkhold.com/role/FinanceReceivablesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Allowance for Credit Losses", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": ["r95", "r693"] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDeferredLoanOriginationFeesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfDeferredLoanOriginationFeesNet", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Loan discount amortization and fee accretion", "documentation": "The net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments." } } }, "auth_ref": ["r666", "r686"] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r5", "r250", "r253", "r585"] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": ["r633"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r179"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "periodEndLabel": "Total assets",

"label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r83", "r93", "r131", "r151", "r183", "r191", "r209", "r212", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r348", "r352", "r390", "r434", "r506", "r573", "r574", "r606", "r618", "r713", "r714", "r746"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r126", "r138", "r151", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r348", "r352", "r390", "r606", "r713", "r714", "r746"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": ["r633"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable investments", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r226", "r243", "r366", "r429", "r597", "r600", "r688", "r723", "r724", "r725"] }, "swkh_BestRoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "BestRoyaltyMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Best Royalty [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": ["r32"] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r12", "r128", "r561"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r12", "r70", "r149"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net increase in cash, cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r70"] }, "swkh_ChangeInFairValueOfAcquisitionrelatedContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "ChangeInFairValueOfAcquisitionrelatedContingentConsideration", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Change in fair value of acquisition-related contingent consideration" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r115", "r132", "r133", "r134", "r151", "r173", "r174", "r176", "r178", "r185", "r186", "r227", "r273", "r275", "r276", "r277", "r280", "r281", "r297", "r298", "r299", "r300", "r301", "r390", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r493", "r515", "r533", "r547", "r548", "r549", "r550", "r551", "r639", "r668", "r676"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r53", "r85", "r436", "r492"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://swkhold.com/role/CommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r76", "r265", "r266", "r555", "r707", "r712"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r608", "r609", "r610", "r612", "r613", "r614", "r615", "r671", "r672", "r675", "r719", "r761", "r763"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r56"] }, "swkh_CommonStockParValue0.001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "CommonStockParValue0.001PerShareMember", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Common Stock Par Value 0. 001 Per Share [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r56", "r493"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r56"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r56", "r493", "r512", "r763", "r764"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; 250,000,000 shares authorized; 12,447,195 and 12,497,770 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r56", "r438", "r606"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r36", "r563"] }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails5", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contingent consideration payable", "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity." } } }, "auth_ref": ["r721", "r722", "r732"] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://swkhold.com/role/RevenueRecognitionTables"], "lang": { "en-us": { "role": { "label": "Schedule of Company's Contract Liabilities", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r717"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails2"], "lang": { "en-us": { "role": { "label": "Total contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r303", "r304", "r313"] }, "swkh_CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "CorrectionOfAnErrorInPreviouslyIssuedFinancialStatementsPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Correction of an Error in Previously Issued Unaudited Condensed Financial Statements" } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "negatedTotalLabel": "Income from operations", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r66"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r34", "r696", "r697", "r698", "r699", "r701", "r702", "r705", "r706"] }, "swkh_DallasTexasOfficeMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "DallasTexasOfficeMember", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Dallas Texas Office [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://swkhold.com/role/Debt"], "lang": { "en-us": { "role": { "label": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r77", "r150", "r260", "r261", "r262", "r263", "r264", "r271", "r272", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r291", "r293", "r294", "r295", "r402"] }, "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Gain on revaluation of finance receivable", "negatedLabel": "Gain on revaluation of finance receivable", "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer." } } }, "auth_ref": ["r37"] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": ["http://swkhold.com/role/DebtDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r716", "r739", "r740", "r741"] }, "us-gaap_DeferredIncomeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeCurrent", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred income", "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r640"] }, "us-gaap_DeferredIncomePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomePeriodIncreaseDecrease", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income", "label": "Deferred Income, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in deferred income not accounted for under Topic 606." } } }, "auth_ref": ["r759", "r760"] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Deferred tax assets, net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": ["r333", "r334"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred income taxes, net", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r72"] }, "us-gaap_DeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenue", "crdr": "credit", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income", "label": "Deferred Revenue", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r662"] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Depreciation and amortization expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r5", "r23"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r5", "r183", "r195", "r212", "r573", "r574"] }, "swkh_DerecognitionOfRouAssetsToOperatingLeaseLiabilitiesUponTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "DerecognitionOfRouAssetsToOperatingLeaseLiabilitiesUponTerminationOfLease", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Derecognition of right-of-use assets and operating lease liabilities upon termination of lease" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r482", "r484", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r520", "r521", "r522", "r523", "r526", "r527", "r528", "r529", "r541", "r542", "r544", "r545", "r608", "r610", "r726", "r727", "r728", "r729", "r730", "r731", "r733", "r734"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r38", "r39", "r40", "r82", "r482", "r484", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r520", "r521", "r522", "r523", "r526", "r527", "r528", "r529", "r541", "r542", "r544", "r545", "r562", "r608", "r610", "r726", "r727", "r728", "r729", "r730", "r731", "r733", "r734"] }, "us-gaap_DerivativeInstrumentsAndHedges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedges", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Collateral on foreign currency forward contract", "documentation": "Carrying amount as of the balance sheet date of the asset arising from derivative instruments and hedging activities, which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer." } } }, "auth_ref": ["r663"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": ["r632"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r630", "r632", "r633"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document,

in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r631"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r619"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r632"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r632"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r634"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r622"] }, "us-gaap_DoubtfulMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DoubtfulMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Doubtful [Member]", "documentation": "A category of financing receivables that have all the weaknesses inherent in those classified as substandard, with the added characteristic that the weaknesses make collection or liquidation in full, on the basis of currently existing facts, conditions, and values, highly questionable and improbable." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Net income per share", "verboseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Basic", "verboseLabel": "Basic net income per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r145", "r158", "r159", "r161", "r162", "r163", "r165", "r171", "r173", "r176", "r177", "r178", "r182", "r343", "r346", "r363", "r364", "r431", "r446", "r565"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Diluted", "verboseLabel": "Diluted net income per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r145", "r158", "r159", "r161", "r162", "r163", "r165", "r173", "r176", "r177", "r178", "r182", "r343", "r346", "r363", "r364", "r431", "r446", "r565"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://swkhold.com/role/NetIncomePerShare"], "lang": { "en-us": { "role": { "label": "Net Income per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r170", "r179", "r180", "r181"] }, "swkh_EffectOfAdoptionOfAccountingStandard": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "EffectOfAdoptionOfAccountingStandard", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Effect of adoption of ASU 2016-13" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": ["r621"] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r625"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r621"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r621"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r638"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r621"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r635"] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": ["r633"] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r621"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r621"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r621"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number

(TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r621"] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": ["r636"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r9", "r123", "r141", "r142", "r143", "r153", "r154", "r155", "r157", "r163", "r166", "r168", "r184", "r228", "r231", "r259", "r302", "r337", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r395", "r396", "r397", "r398", "r399", "r400", "r404", "r406", "r415", "r445", "r451", "r452", "r453", "r470", "r533"] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": ["r290", "r389", "r586", "r587"] }, "swkh_ExecevoIncMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "ExecevoIncMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Execevo Inc [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails2"], "lang": { "en-us": { "role": { "label": "Change in fair value", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": ["r0", "r5"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r366", "r367", "r381", "r597"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r366", "r367", "r381", "r597"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r369", "r370", "r371", "r600"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": ["r369", "r370", "r371", "r600"] }, "us-gaap_FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnNonrecurringBasisValuationTechniquesTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of weighted average assumptions", "label": "Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique used to measure similar asset in prior period by class of asset or liability on non-recurring basis." } } }, "auth_ref": ["r368"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of fair value assets measured on recurring basis", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r721", "r722"] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of fair value assets measured on recurring basis unobservable input reconciliation", "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset." } } }, "auth_ref": ["r372", "r377", "r382", "r599"] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r41", "r42"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of fair value by balance sheet grouping", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r41"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r290", "r316", "r317", "r318", "r319", "r320", "r321", "r365", "r367", "r369", "r370", "r371", "r380", "r381", "r383", "r420", "r421", "r422", "r586", "r587", "r590", "r591", "r592", "r597", "r600"] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": ["r290", "r586", "r587"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r366", "r367", "r369", "r371", "r597", "r724", "r735"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r376", "r378", "r379", "r380", "r383", "r384", "r385", "r386", "r387", "r428", "r597", "r601"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails4", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r290", "r316", "r321", "r367", "r381", "r420", "r590", "r591", "r592", "r597"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails4", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r290", "r316", "r321", "r367", "r369", "r381", "r421", "r586", "r587", "r590", "r591", "r592", "r597"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable

inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r290", "r316", "r317", "r318", "r319", "r320", "r321", "r367", "r369", "r370", "r371", "r381", "r422", "r586", "r587", "r590", "r591", "r592", "r597", "r600"] }, "swkh_FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "FairValueLiabilitiesMeasuredValuationAssumptionTableTextBlock", "presentation": ["http://swkhold.com/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of weighted average assumptions" } } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } } }, "auth_ref": ["r366", "r367", "r369", "r371", "r597", "r724", "r735"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails4", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } }, "auth_ref": ["r290", "r316", "r317", "r318", "r319", "r320", "r321", "r365", "r367", "r369", "r370", "r371", "r380", "r381", "r383", "r420", "r421", "r422", "r586", "r587", "r590", "r591", "r592", "r597", "r600"] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } } }, "auth_ref": ["r366", "r367", "r369", "r371", "r597", "r724"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2"], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } } }, "auth_ref": ["r597", "r721", "r722", "r723", "r724", "r725", "r735"] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r372", "r373", "r375", "r376", "r377", "r382"] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r372", "r373", "r374", "r375", "r376", "r377", "r382"] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Right-of-use amortization and cease use costs", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": ["r407", "r409", "r605"] }, "us-gaap_FinanceReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceReceivablesMember", "presentation": ["http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Financing Receivable [Member]", "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": [] }, "swkh_FinancialAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://swkhold.com/20240630", "localname": "FinancialAssetsAbstract", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Financial Assets" } } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentPerformanceStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentPerformanceStatusAxis", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Financial Instrument Performance Status [Axis]", "documentation": "Information by category of performance or non-performance status of financial instruments." } } } }, "auth_ref": ["r695"] }, "us-gaap_FinancialInstrumentPerformanceStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentPerformanceStatusDomain", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "documentation": "Category of performance or non-performance status of financial instruments, including but not limited to, financing receivables, loans, debt, and investments." } } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "verboseLabel": "Financial Assets" } } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Financial liabilities" } } } }, "auth_ref": [] }, "swkh_FinancialLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://swkhold.com/20240630", "localname": "FinancialLiabilitiesAbstract", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Financial liabilities:" } } } }, "auth_ref": [] }, "us-gaap_FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest", "crdr": "credit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails2"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit Loss, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of allowance for credit loss on financing receivable. Excludes net investment in lease." } } }, "auth_ref": ["r692"] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "calculation": { "http://swkhold.com/role/FinanceReceivablesNetDetails": { "parentTag": "us-gaap_NotesAndLoansReceivableNetCurrent", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit Loss", "negatedLabel": "Allowance for credit losses", "periodStartLabel": "Allowance at beginning of period", "periodEndLabel": "Allowance at end of period", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": ["r96", "r118", "r120", "r122", "r136", "r232", "r235", "r237", "r755"] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails2"], "lang": { "en-us": { "role": { "negatedLabel": "Write offs", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": ["r98", "r236", "r242", "r582"] }, "us-gaap_FinancingReceivableCreditQualityIndicatorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableCreditQualityIndicatorsTableTextBlock", "presentation": ["http://swkhold.com/role/FinanceReceivablesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Financing Receivable by origination year", "documentation": "Tabular disclosure of financing receivables by credit quality indicator. The credit quality indicator is a statistic about the credit quality of financing receivables. Examples include, but not limited to, consumer credit risk scores, credit-rating-agency ratings, an entity's internal credit risk grades, loan-to-value ratios, collateral, collection experience and other internal metrics." } } }, "auth_ref": ["r99", "r695"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of financing receivable. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r241", "r692"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Originated, More than Five Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing receivable originated more than five years prior to current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Year Five, Originated, Four Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing receivable originated four years prior to current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Year Four, Originated, Three Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing receivable originated three years prior to current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Year One, Originated, Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing receivable originated in current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Year Three, Originated, Two Years before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest, of financing receivable originated two years prior to current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Excluding Accrued Interest, Year Two, Originated, Fiscal Year before Current Fiscal Year", "documentation": "Amortized cost excluding accrued interest of financing receivable originated in fiscal year prior to current fiscal year. Excludes net investment in lease." } } }, "auth_ref": ["r240", "r242", "r582"] }, "us-gaap_FinancingReceivablePortfolioSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablePortfolioSegmentAxis", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Financing Receivable Portfolio Segment [Axis]", "documentation": "Information by the level at which an entity develops and documents a systematic methodology to determine its allowance for credit losses." } } }, "auth_ref": ["r116", "r117", "r121", "r122", "r233", "r234", "r580", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660"] }, "us-gaap_FinancingReceivablePortfolioSegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablePortfolioSegmentDomain", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "documentation": "Level at which

an entity develops and documents a systematic methodology to determine its allowance for credit losses." } } }, "auth_ref": ["r116", "r117", "r121", "r122", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r658", "r659", "r660"] }, "us-gaap_FinancingReceivableRecordedInvestmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentLineItems", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Credit Quality Indicator [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r101", "r582", "r695"] }, "us-gaap_FinancingReceivableRecordedInvestmentPastDueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableRecordedInvestmentPastDueLineItems", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Past Due [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r583", "r694"] }, "us-gaap_FinancingReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivablesTextBlock", "presentation": ["http://swkhold.com/role/FinanceReceivables"], "lang": { "en-us": { "role": { "label": "Finance Receivables", "documentation": "The entire disclosure for financing receivable." } } }, "auth_ref": ["r220", "r223", "r224", "r225", "r579"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r129", "r244", "r252", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "Thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r703", "r765"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "Remainder of 2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r254", "r559", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r254", "r559", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r254", "r559", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r254", "r559", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r254", "r559", "r585"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://swkhold.com/role/IntangibleAssetsDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails2"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r427", "r702"] }, "swkh_FlowonixMedicalIncMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "FlowonixMedicalIncMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Flowonix Medical Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyContractAssetFairValueDisclosure", "crdr": "debit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "label": "Foreign currency forward contract", "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps." } } }, "auth_ref": ["r366", "r367"] }, "us-gaap_ForeignCurrencyTransactionGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainBeforeTax", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Realized and unrealized foreign currency transaction gains", "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement." } } }, "auth_ref": ["r737", "r738"] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Foreign currency transaction gain", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r391", "r392", "r393", "r394", "r530"] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Realized gain (loss) on sale of assets", "negatedLabel": "Realized loss from sale of assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": ["r666"] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "General and administrative expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r65", "r517"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Loss on impairment of intangibles assets", "verboseLabel": "Loss on impairment of intangible assets", "terseLabel": "Loss on impairment intangible assets", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r5", "r245", "r246", "r247", "r584", "r598"] }, "swkh_HoldingCompanyAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "HoldingCompanyAndOtherMember", "presentation": ["http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Holding Company And Other [Member]" } } }, "auth_ref": [] }, "swkh_IdealImplantIncMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "IdealImplantIncMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Ideal Implant Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "totalLabel": "Income before income tax expense", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": ["r92", "r447", "r567", "r678", "r680", "r681", "r682", "r683"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r107", "r112", "r167", "r168", "r183", "r196", "r212", "r335", "r336", "r339", "r448", "r594"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Accounts payable, accrued expenses, and other non-current liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInInterestAndDividendsReceivable": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestAndDividendsReceivable", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest, accounts receivable and other receivables", "documentation": "The increase (decrease) during the reporting period in the aggregate amount due to the entity in the form of unpaid interest and dividends." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": ["r4"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r249", "r251", "r255", "r585"] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r249", "r255", "r257", "r585"] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r249", "r251", "r255", "r585"] }, "us-gaap_IntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsCurrent", "crdr": "debit", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Current", "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions." } } }, "auth_ref": ["r2"] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": ["http://swkhold.com/role/IntangibleAssets"], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": ["r248", "r256", "r258", "r558", "r559"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r249", "r702", "r704"] }, "us-gaap_InterestAndFeeIncomeLoansAndLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndFeeIncomeLoansAndLeases", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Finance receivable interest income, including fees", "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases." } } }, "auth_ref": ["r87"] }, "us-gaap_InterestAndOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestAndOtherIncomeAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Other income (expense), net" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/DebtDetailsNarrative", "http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Interest expense", "verboseLabel": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r183", "r191", "r194", "r197", "r212", "r401", "r573", "r574"] }, "us-gaap_InternalCreditAssessmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalCreditAssessmentAxis", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Internal Credit Assessment [Axis]", "documentation": "Information by entity-defined rating." } } }, "auth_ref": ["r100", "r101", "r102", "r354", "r581", "r582", "r695"] }, "us-gaap_InternalCreditAssessmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InternalCreditAssessmentDomain", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "documentation": "Entity defined credit risk rating." } } }, "auth_ref": [] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails4"], "lang": { "en-us": { "role": { "verboseLabel": "Marketable investments", "label": "December 31, 2023", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r721", "r722", "r732"] }, "us-gaap_LeaseAndRentalExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseAndRentalExpense", "crdr": "debit", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Operating Leases, Rent Expense", "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": ["r408", "r605"] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Lease Cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": ["r742"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "totalLabel": "Total future lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "Remainder of 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r412"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r10", "r47", "r48", "r49", "r51", "r52", "r53", "r54", "r151", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r349", "r352", "r353", "r390", "r491", "r566", "r618", "r713", "r746", "r747"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel":

"Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r62", "r86", "r440", "r606", "r669", "r689", "r736"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Equity:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r49", "r127", "r151", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r349", "r352", "r353", "r390", "r606", "r713", "r746", "r747"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LicensingAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicensingAgreementsMember", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails", "http://swkhold.com/role/RevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Licensing Agreements [Member]", "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)." } } }, "auth_ref": ["r35", "r332", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706", "r718"] }, "swkh_LifeScienceRoyaltyPurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "LifeScienceRoyaltyPurchasesMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Life Science Royalty Purchases [Member]" } } }, "auth_ref": [] }, "swkh_LifeScienceTermLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "LifeScienceTermLoansMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Life Science Term Loans [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r46", "r50"] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LoansAndLeasesReceivableGrossCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansAndLeasesReceivableGrossCarryingAmount", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Loans and Leases Receivable, Gross", "documentation": "Amount before allowance of loans and leases held in portfolio, including but not limited to, commercial and consumer loans. Includes deferred interest and fees, undisbursed portion of loan balance, unamortized costs and premiums and discounts from face amounts. Excludes loans and leases covered under loss sharing agreements." } } }, "auth_ref": ["r94"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://swkhold.com/role/DebtDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/DebtDetails", "http://swkhold.com/role/DebtDetails2"], "lang": { "en-us": { "role": { "label": "2027 Senior Notes", "totalLabel": "Total unsecured senior notes, net", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r10", "r84", "r289", "r296", "r586", "r587", "r604", "r756"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://swkhold.com/role/DebtDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/DebtDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "Remainder of 2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r152", "r292"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://swkhold.com/role/DebtDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/DebtDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r152", "r292"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://swkhold.com/role/DebtDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/DebtDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r152", "r292"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://swkhold.com/role/DebtDetails2": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/DebtDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r7", "r152", "r292"] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Revolving credit facility", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r10", "r24", "r25"] }, "swkh_MarketableInvestmentPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "MarketableInvestmentPrincipalPayment", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Corporate debt securities principal payments", "documentation": "Marketable Investment Principal Payment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": ["r267", "r268", "r269", "r270", "r323", "r329", "r371", "r425", "r449", "r450", "r461", "r483", "r484", "r537", "r538", "r539", "r540", "r546", "r556", "r557", "r579", "r589", "r593", "r600", "r601", "r602", "r603", "r607", "r715", "r748", "r749", "r750", "r751", "r752", "r753"] }, "srt_MedianMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MedianMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Median [Member]" } } }, "auth_ref": ["r371"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": ["r267", "r268", "r269", "r270", "r323", "r329", "r371", "r425", "r449", "r450", "r461", "r483", "r484", "r537", "r538", "r539", "r540", "r546", "r556", "r557", "r579", "r589", "r593", "r600", "r601", "r602", "r607", "r715", "r748", "r749", "r750", "r751", "r752", "r753"] }, "swkh_NatureOfOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "NatureOfOperationsPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Nature of Operations" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r148"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r148"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r70", "r71", "r72"] }, "us-

gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r64", "r72", "r89", "r125", "r139", "r140", "r143", "r151", "r156", "r158", "r159", "r161", "r162", "r163", "r167", "r168", "r175", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r343", "r346", "r364", "r390", "r444", "r514", "r531", "r532", "r616", "r713"] }, "swkh_NetRealizedGainOnExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "NetRealizedGainOnExerciseOfWarrants", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Net realized gain on sale of marketable investments", "negatedLabel": "Net realized gain on exercise of warrants" } } }, "auth_ref": [] }, "swkh_NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "NetSettlementForEmployeeTaxesOnRestrictedStockAndOptions", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Net settlement for employee taxes on stock options" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "swkh_NoncashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "NoncashInterestExpense", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of debt issuance costs" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingActivitiesRelatedText": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingActivitiesRelatedText", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental non-cash investing and financing activities:", "documentation": "Additional textual information about significant noncash (or part noncash) investing and financing activities required to be supplementally disclosed. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r13", "r14", "r15"] }, "us-gaap_NonperformingFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonperformingFinancingReceivableMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Nonperforming Financial Instruments [Member]", "documentation": "Category status of financial instruments in which payments are past due in accordance with the terms of the contract. Financial instruments include, but are not limited to, financing receivables, loans, debt, and investments." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://swkhold.com/role/FinanceReceivablesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5", "http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Finance receivables, net of allowance for credit losses of $13,083 and $13,901 as of June 30, 2024 and December\u00a031, 2023, respectively", "periodEndLabel": "Finance receivables, net of allowance for credit", "totalLabel": "Total carrying value", "verboseLabel": "Total carrying value", "terseLabel": "Finance receivables, net", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": ["r430", "r685"] }, "us-gaap_NotesReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableGross", "crdr": "debit", "calculation": { "http://swkhold.com/role/FinanceReceivablesNetDetails": { "parentTag": "us-gaap_NotesAndLoansReceivableNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Total before allowance for credit losses", "documentation": "Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": ["r101", "r104", "r118", "r119", "r135", "r221", "r238", "r241", "r582", "r583", "r657", "r692"] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Royalty purchases", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": ["r241", "r501", "r685", "r757"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r574", "r679"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://swkhold.com/role/SegmentInformationDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r568", "r578", "r679"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r410", "r605"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "SWK Holdings Corporation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": ["r44", "r73", "r74", "r81"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r137", "r606"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r130"] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r52"] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "presentation": ["http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Other expense, net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r632"] }, "us-gaap_PaidInKindInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaidInKindInterest", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid-in-kind", "label": "Paid-in-Kind Interest", "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r5"] }, "us-gaap_PassMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PassMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Pass [Member]", "documentation": "A category of financing receivables not considered to be special mention, substandard, doubtful, and loss receivables." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchases of common stock, including fees and expenses", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": ["r69"] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Payments for financing costs", "label":

"Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": ["r11"] }, "us-gaap_PaymentsToAcquireFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireFinanceReceivables", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Investment in finance receivables", "label": "Payments to Acquire Finance Receivables", "documentation": "The cash outflow for the purchase of amounts due from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith." } } }, "auth_ref": ["r67"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r68"] }, "us-gaap_PerformingFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PerformingFinancingReceivableMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Performing Financial Instruments [Member]", "documentation": "Category status of financial instruments in which payments are received or paid on a timely basis in accordance with the terms of the contract. Financial instruments include, but are not limited to, financing receivables, loans, debt instruments, and investments." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "swkh_PharmaceuticalDevelopmentRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "PharmaceuticalDevelopmentRevenue", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Pharmaceutical development", "verboseLabel": "Total contract revenue" } } }, "auth_ref": [] }, "swkh_PharmaceuticalDevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "PharmaceuticalDevelopmentServicesMember", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Pharmaceutical Development Services [Member]" } } }, "auth_ref": [] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails5"], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": ["r388"] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": ["r626"] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": ["r628"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r55", "r297"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r55", "r493"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r55", "r297"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r55", "r493", "r512", "r763", "r764"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r55", "r437", "r606"] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails2"], "lang": { "en-us": { "role": { "label": "Issued", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": ["r3"] }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net payments on credit facility", "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets)." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Sale of finance receivables", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": ["r106", "r146"] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Sale of marketable investments", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": ["r665"] }, "swkh_ProceedsRepaymentOfFinanceReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "ProceedsRepaymentOfFinanceReceivables", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Repayment of finance receivables" } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails", "http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "label": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r125", "r139", "r140", "r147", "r151", "r156", "r163", "r167", "r168", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r343", "r346", "r347", "r350", "r351", "r364", "r390", "r432", "r443", "r469", "r514", "r531", "r532", "r595", "r596", "r617", "r664", "r713"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r6", "r413", "r433", "r442", "r606"] }, "us-gaap_ProvisionForLoanAndLeaseLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForLoanAndLeaseLosses", "crdr": "debit", "presentation": ["http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Provision for credit losses", "documentation": "Amount of expense related to estimated loss from loan and lease transactions." } } }, "auth_ref": ["r4", "r88", "r97"] }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForLoanLeaseAndOtherLosses", "crdr": "debit", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails2"], "lang": { "en-us": { "role": { "verboseLabel": "Provision (benefit) for credit losses", "label": "Provision for Loan, Lease, and Other Losses", "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value." } } }, "auth_ref": ["r4", "r88", "r97"] }, "us-gaap_ProvisionForOtherCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForOtherCreditLosses", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Provision (benefit) for credit losses", "verboseLabel": "Benefit for credit losses", "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions." } } }, "auth_ref": ["r4", "r88"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r267", "r268", "r269", "r270", "r315", "r323", "r326", "r327", "r328", "r329", "r371", "r423", "r424", "r425", "r449", "r450", "r461", "r483", "r484", "r537", "r538", "r539", "r540", "r546", "r556", "r557", "r579", "r589", "r593", "r600", "r601", "r602", "r603", "r607", "r610", "r711", "r715", "r724", "r749", "r750", "r751", "r752", "r753"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "auth_ref": ["r267", "r268", "r269", "r270", "r315", "r323", "r326", "r327", "r328", "r329", "r371", "r423", "r424", "r425", "r449", "r450", "r461", "r483", "r484", "r537", "r538", "r539", "r540", "r546", "r556", "r557", "r579", "r589", "r593", "r600", "r601", "r602", "r603", "r607", "r610", "r711", "r715", "r724", "r749", "r750", "r751", "r752", "r753"] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails3", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": ["r57", "r63"] }, "us-gaap_ReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "ReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Receivables [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r221", "r322", "r416", "r417", "r435", "r441", "r486", "r487", "r488", "r489", "r490", "r511", "r513", "r536"] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r221", "r322", "r416", "r417", "r435", "r441", "r486", "r487", "r488", "r489", "r490", "r511", "r513", "r536", "r745"] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Pharmaceutical manufacturing, research and development expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r331", "r559", "r573", "r754"] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": ["r330"] }, "srt_RestatementAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAdjustmentMember", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period, Adjustment [Member]" } } }, "auth_ref": ["r153", "r154", "r155", "r165", "r166", "r182", "r362", "r363", "r405", "r641", "r642", "r643", "r644", "r645", "r648", "r649", "r684"] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "auth_ref": ["r124", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r168", "r169", "r182", "r229", "r230", "r341", "r342", "r343", "r344", "r345", "r346", "r361", "r362", "r363", "r364", "r403", "r405", "r414", "r415", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r684"] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails"], "auth_ref": ["r124", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r164", "r165", "r166", "r167", "r168", "r169", "r182", "r229", "r230", "r341", "r342", "r343", "r344", "r345", "r346", "r361", "r362", "r363", "r364", "r403", "r405", "r414", "r415", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r684"] }, "us-gaap_RestrictedCashEquivalentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashEquivalentsCurrent", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r552", "r553", "r661", "r667"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "periodEndLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r59", "r80", "r439", "r455", "r460", "r468", "r494", "r606"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r123", "r153", "r154", "r155", "r157", "r163", "r166", "r168", "r228", "r231", "r259", "r337", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r357", "r358", "r360", "r362", "r404", "r406", "r451", "r453", "r470", "r763"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://swkhold.com/role/RevenueRecognition"], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r114", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r314"] }, "us-gaap_RevenueNotFromContractWithCustomerOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueNotFromContractWithCustomerOther", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/SegmentInformationDetails", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Other", "verboseLabel": "Other revenue", "documentation": "Amount of revenue that is not accounted for under Topic 606, classified as other." } } }, "auth_ref": ["r113"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r516", "r560", "r564"] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "totalLabel": "Total revenues", "label": "Total revenues", "verboseLabel": "Pharmaceutical Development", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": ["r90", "r91", "r144", "r151", "r183", "r192", "r193", "r208", "r212", "r216", "r218", "r219", "r227", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r390", "r432", "r573", "r713"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "auth_ref": [] }, "swkh_RevenuesExcludingOtherRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "RevenuesExcludingOtherRevenue", "crdr": "credit", "presentation": ["http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "auth_ref": ["r124", "r153", "r155", "r156", "r157", "r158", "r159", "r168", "r182", "r341", "r343", "r344", "r345", "r346", "r361", "r362", "r363", "r403", "r405", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r462", "r645", "r646", "r647", "r648", "r674", "r684", "r690", "r691", "r720", "r743", "r744"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails", "http://swkhold.com/role/FinanceReceivablesNetDetails2", "http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Accounts and Financing Receivables [Table]", "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss." } } }, "auth_ref": ["r57", "r63", "r222", "r687"] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": ["http://swkhold.com/role/FinanceReceivablesTables"], "lang": { "en-us": { "role": { "label": "Schedule of carrying value of finance receivables", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": ["r57", "r63"] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": ["http://swkhold.com/role/DebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Long Term Debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": ["r10", "r26", "r27", "r43", "r78", "r79", "r586", "r588", "r670", "r740"] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r8", "r28", "r29", "r30", "r31"] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://swkhold.com/role/NetIncomePerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Basic and Diluted Earning per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r677"] }, "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails3"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Credit Quality Indicator [Table]", "documentation": "Disclosure of information about credit quality indicator for financing receivable." } } }, "auth_ref": ["r101", "r582", "r695"] }, "us-gaap_ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivablesNonAccrualStatusTableTextBlock", "presentation": ["http://swkhold.com/role/FinanceReceivablesTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Allowance for Credit Losses", "label": "Financing Receivable,

Nonaccrual [Table Text Block]", "documentation": "Tabular disclosure of financing receivable on nonaccrual status." } } }, "auth_ref": ["r103", "r239"] }, "us-gaap_ScheduleOfFinancingReceivablesPastDueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFinancingReceivablesPastDueTable", "presentation": ["http://swkhold.com/role/RevenueRecognitionDetails", "http://swkhold.com/role/SegmentInformationDetails"], "lang": { "en-us": { "role": { "label": "Financing Receivable, Past Due [Table]", "documentation": "Disclosure of information about aging analysis for financing receivable." } } } }, "auth_ref": ["r583", "r694"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "presentation": ["http://swkhold.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets", "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Future Minimum Rent", "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date." } } }, "auth_ref": ["r105"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": ["r249", "r255", "r257", "r585"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": ["http://swkhold.com/role/DebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long Term Notes", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r7"] }, "swkh_ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "ScheduleOfRevenueRecognizedByRevenueSourceTableTextBlock", "presentation": ["http://swkhold.com/role/RevenueRecognitionTables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue Recognized by Revenue Source" } } }, "auth_ref": [] }, "swkh_ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "ScheduleOfRevisionsOfPreviouslyIssuedFinancialStatementsTableTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Revisions to the line items of our previously issued financial statements" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": ["http://swkhold.com/role/SegmentInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Reportable Revenue by Geographic Region", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": ["r47"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://swkhold.com/role/IntangibleAssetsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Asset Amortization Expense", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r585", "r703"] }, "swkh_Sec9.00SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "Sec9.00SeniorNotesDue2027Member", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Sec 9. 00 Senior Notes Due 2027 [Member]" } } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r620"] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r624"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r623"] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r629"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://swkhold.com/role/SegmentInformation"], "lang": { "en-us": { "role": { "label": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r93", "r183", "r187", "r188", "r189", "r190", "r191", "r198", "r199", "r200", "r210", "r211", "r212", "r213", "r214", "r216", "r217", "r219", "r568", "r571", "r572", "r573", "r575", "r577", "r578"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "verboseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r201", "r202", "r203", "r204", "r205", "r206", "r207", "r215", "r218", "r569", "r570", "r576"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r327"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r326"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r328"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r325"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance, Shares", "periodEndLabel": "Ending Balance, Shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r47", "r708", "r709", "r710"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://swkhold.com/role/DebtDetailsNarrative"], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r45", "r708", "r709", "r710"] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r627"] }, "us-gaap_SpecialMentionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SpecialMentionMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Special Mention [Member]", "documentation": "A category of financing receivables considered to have potential weaknesses that deserve management's close attention. If left uncorrected, those potential weaknesses may result in a deterioration of the repayment prospects for the asset or of the creditor's position at some future date." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r115", "r132", "r133", "r134", "r151", "r173", "r174", "r176", "r178", "r185", "r186", "r227", "r273", "r275", "r276", "r277", "r280", "r281", "r297", "r298", "r299", "r300", "r301", "r390", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r493", "r515", "r533", "r547", "r548", "r549", "r550", "r551", "r639", "r668", "r676"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative",

"http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r56", "r60", "r61", "r123", "r141", "r142", "r143", "r153", "r154", "r155", "r157", "r163", "r166", "r168", "r184", "r228", "r231", "r259", "r302", "r337", "r338", "r340", "r341", "r342", "r344", "r345", "r346", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r395", "r396", "r397", "r398", "r399", "r400", "r404", "r406", "r415", "r445", "r451", "r452", "r453", "r470", "r533"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://swkhold.com/role/Cover", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r153", "r154", "r155", "r184", "r406", "r426", "r463", "r481", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r496", "r497", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r533", "r611"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://swkhold.com/role/Cover", "http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r153", "r154", "r155", "r184", "r221", "r406", "r426", "r463", "r481", "r485", "r486", "r487", "r488", "r489", "r490", "r493", "r496", "r497", "r498", "r499", "r500", "r502", "r503", "r504", "r505", "r507", "r508", "r509", "r510", "r511", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r533", "r611"] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock, Shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r9", "r55", "r56", "r80", "r464", "r533", "r548"] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Forfeiture of unvested restricted stock, Shares", "documentation": "Number of shares related to Restricted Stock Award forfeited during the period." } } }, "auth_ref": ["r9", "r55", "r56", "r80"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r9", "r55", "r56", "r80", "r324"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon vesting of restricted stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r9", "r55", "r56", "r80", "r470", "r533", "r548", "r617"] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Repurchases of common stock in open market, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r9", "r55", "r56", "r80", "r467", "r533", "r550"] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock in open market", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r9", "r55", "r56", "r80", "r470", "r533", "r550", "r617"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r56", "r60", "r61", "r75", "r495", "r512", "r534", "r535", "r606", "r618", "r669", "r689", "r736", "r763"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://swkhold.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r418", "r419"] }, "us-gaap_SubstandardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstandardMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Substandard [Member]", "documentation": "A category of financing receivables that are inadequately protected by the current sound worth and paying capacity of the obligor or of the collateral pledged, if any. Loans so classified have a well-defined weakness or weaknesses that jeopardize the liquidation of the debt. They are characterized by the distinct possibility that the creditor will sustain some loss if the deficiencies are not corrected." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": ["http://swkhold.com/role/IntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r33", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r704", "r705", "r706"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "swkh_TrioHealthcareLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://swkhold.com/20240630", "localname": "TrioHealthcareLtdMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Trio Healthcare Ltd [Member]" } } }, "auth_ref": [] }, "swkh_UnauditedInterimFinancialInformationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://swkhold.com/20240630", "localname": "UnauditedInterimFinancialInformationPolicyTextBlock", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Unaudited Interim Financial Information" } } }, "auth_ref": [] }, "us-gaap_UnlikelyToBeCollectedFinancingReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnlikelyToBeCollectedFinancingReceivableMember", "presentation": ["http://swkhold.com/role/FinanceReceivablesNetDetails4"], "lang": { "en-us": { "role": { "label": "Unlikely to be Collected Financing Receivable [Member]", "documentation": "Financing arrangement that represents a contractual right to receive money either on demand or on fixed or determinable dates that are considered uncollectible or of little value. Excludes no recovery or salvage value." } } }, "auth_ref": ["r100", "r101", "r102", "r695"] }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Unrealized net gain (loss) on warrants", "negatedLabel": "Net change in fair value of warrant assets", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": ["r5", "r526", "r527", "r528", "r529", "r543"] }, "us-gaap_UnsecuredDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebt", "crdr": "credit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://swkhold.com/role/DebtDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Unsecured senior notes, net", "verboseLabel": "Total unsecured senior notes, net", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": ["r10", "r84", "r756"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://swkhold.com/role/SwkHoldingsCorporationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r16", "r17", "r18", "r108", "r109", "r110", "r111"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://swkhold.com/role/CommitmentsAndContingenciesDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://swkhold.com/role/CommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r411", "r605"] }, "swkh_WarrantAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "WarrantAssets", "crdr": "debit", "calculation": { "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails", "http://swkhold.com/role/FairValueMeasurementsDetails2", "http://swkhold.com/role/FairValueMeasurementsDetails5", "http://swkhold.com/role/UnauditedCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Warrant assets", "periodStartLabel": "Fair value - December 31, 2023", "periodEndLabel": "Fair value - June 30, 2024" } } }, "auth_ref": [] }, "swkh_WarrantExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "WarrantExercised", "crdr": "credit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails2"], "lang": { "en-us": { "role": { "label": "Exercised" } } }, "auth_ref": [] }, "swkh_WarrantForeignExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://swkhold.com/20240630", "localname": "WarrantForeignExchange", "crdr": "credit", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails2"], "lang": { "en-us": { "role": { "label": "Loss on foreign currency transactions" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetails3", "http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a

specified amount." } } }, "auth_ref": ["r608", "r609", "r612", "r613", "r614", "r615"] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": ["http://swkhold.com/role/FairValueMeasurementsDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": ["r371", "r424", "r556", "r557", "r600", "r748", "r750", "r753"] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails"], "lang": { "en-us": { "role": { "label": "Effect of dilutive securities", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": ["r677"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "label": "Weighted-average diluted shares", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r172", "r178"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://swkhold.com/role/NetIncomePerShareDetails", "http://swkhold.com/role/UnauditedCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "label": "Weighted-average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r171", "r178"] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": ["http://swkhold.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": ["r637"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-29" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1)(e))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "b", "Publisher": "SEC" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(4)", "Publisher": "SEC" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "c", "Publisher": "SEC" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-

50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-10/tableOfContent" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-42" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "44", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-44" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/310-20/tableOfContent" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-6" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-

50-6A" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef",

"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-10" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-15" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "80", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-80" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r639": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "2", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1404", "Paragraph": "a", "Publisher": "SEC" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(2)", "Publisher": "SEC" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r685": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481655/310-20-35-2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":

"https://asc.fasb.org/450/tableOfContent" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 75 0001552781-24-000488-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001552781-24-000488-xbrl.zip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l.O8*@1W9Y^6EC3J2+J.);? MSK2]THO6Fl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

V5I60"VL"U0DN;SNNX@>PNVCK>^7GZK MY (,,1IY!YCMRITQ_"2NA-?NE ?F57,_)I/JO 9W6BW""5\FC5XD-NM5]P1@ MJJ,2:XJ-4-M3YR@NJX4B*\X-36L M<GMO)ZEO"UN:-Q 14=JZ,O1+K5=&TB(5Z%^>3QDD3ULY,6Y;3;F,Y',S^;9! MF(Q2<_TW;28VZG(MM^=^1PZSY.S1K.*)- CXD|)+9(6"RH[=+[+WFZ?Z61=.X/Y;H$ M:8X?)I83(<&M=QK+425-L5[KN,,/S'.+?>_F8J0OS-1_,E+7YS)-_ MF=Y&IOQ6B1M+A@<,"]7P)(5'S4,3(N>LBSND[U\O:!@/1".1%+->UT*H:5XV MJ@KK'I=#.$EEO8M?UTP:/@*L>DQG4F3LX;3*EZ? 4AO/IPR=~DH2TF$/F/8L1. M0,RU>,S3TA.Y#=/M-H*E*Q>TGH=4QOO M^VF%HRJF57MC0E[J#?-R!*> M:O60V,WJ5ULJ(!47C*R#!K1A-\QEMID[Z%#OTRX?>X\ L^>H_/-LD+GX#_E MYKS"'}|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|F]H2OG=Y'0%\MR1&].KMKRXN&F9H.M,U91PSLKN3-15GQ.V* MW29*G Z_?2Q-*'9VF]QP_V=(38.0S MZ<&X.J?YK?/&P?2&=H=^9V5]?8F)$YSR*.JRR^JLX+HRHF9K3/,3 A7KZKK M5/MZN25J1=_ $Q-=0F*'6C/:=@Y.RV;6TK^&13M'S62'TSGIA,\K!Y>^=*OR M#9;O?46O_B(V;%60!I:&OO31TTL,YU*:'B0B5KZ[A^2L/,Y1\R@TS<"\=4[M9E5F]9259?*E;$AK'2);#WYI:871^K9;2P(",D>]W0}!"[2M(<@=WI#)4.K M^(-!":'DB4/@K[OTJ(S6CO>LH86UTCGF[AY-+MB0>*JO=G'O6L J8C9I*3KX M\P)KK1T'$G<$;$XLK0_[W1IU'UC11R0<_56%R]0=HD#H0EHR:5#2F_U,H,> M4>1S+;O: L,]R@YLBM,M\3_F*7S_GDI*M MQ,ZK<9L DQ:(+8F\/+SW\-Q+RNV/@S],CYJ-]L=>IXM/1O_:@_[@M'?4W@N? M>++I7/FX??^[^Q2X&? YWVWF^E6KEWK+4_<6P@A]%7'AY%2PSVDJ8V$85PG3*7-CP8P8 M2>L,5RY"> P-AOO_!+COF M5B3DQGS.330@*.U8# -<*G!XS@KE3"&8==R)'-I"#N? M@[! (GK&4QfAEF,ZE8TZ'=BL-E(B%M=S,J4G.+X5?%PN;MMG(>2(BAC$SDM]J MY<32Q$6.=@K]-27'PIJ-93QFMJ_"P-L)HQ@P0C-() M2Y5BU? I%B>]Q5B0PBF#7V!>!*9)6^@2Q(IX1_]L2:0RA)9=&;K9 %D3298C M;E)D: 'V:(38CV<]H)C,,4LS/,.KHLPXW0S 3.J,<16:%;@/GUPG@E'WNRR MP15W_FSLET(? 8C4%%I09CY:BKN7&/N-&^* B1G*8"?(!$V#2,)-V3,V16OX= M(BVBZT3;..-V0#]2.S$-R)T;%(<-NR;<0R$6!""%CO:SSF:B2:C0X6_WF1 M"5NFCM=\1_5V6[SR!EIODW 5+B554 J4*T=A)!,U-@<&$*(;AF.+T5@4K.HM-QOE2"E&HNE>)R(&IS3XCRD,RIL2PDX&#WZ=K*V\/Z\BV^:MFHRLLS,#I/@W< MS8N{4E3,"WO_+I0JA@+1+4<*R4<7!@8@##E-I27(@A)H)Y0U12;>4J[KD&9%Q MSYI5Y MQGP+YXZD1Z'VE:,VH\XK^M9S2I$!A;A$;2NQQKWB?CR M;"04TG4&BN*)F!#Y]0EJST'#0\^"G+X0\18BQB!B;\JSPHL'4FD*2HF[$H5 MJN_5PJ*U/=1PW"YOA;RJHB.$#0'B'0+/AIP-T.XCV#S16NQW$FOK|LK&.,J M5OK5K2017T#X0@%3R0IV;J9.0AH6@K&;7=#%E7>.?K*70 Y2+TJ2.X\)0"&LI M:5T)F6OK\(.M6#,QK#T)9P)L.T;D*1@(R3E6NL2.?8!PN]@%>LH5.!!.%AX M%6"-N5UD)Q(O9%MD_*9VDSBT^]*ZLU([X4$O@Q#V3;0L5^Q_OJ9?]PQ_ZA MDZ%@@2$)QM#&B_9PL10(<9GJ%F7\3/!+2EVA;O')R]=<_LRK.F-X$'"*@AMU M-5%GC9[P!#VM6,C)34RI*C5T 5-03T4A@5IXSQ8Y/(=I^]F40K[V/.8E.=ZG MP.\@!Z8&JSA"^(17'A## GS263(E"!%JJK.IH#2B^*@\,37E@9C(YF>"SR= MC750*'ZGW0SE6-(9ZI>H_U,[I?#&+MS]M\H5>%Y1=IHA!=W4JFP.^OU'D MG6(§]@6XK3<1.]@_>/-C)M):.X],V+T.34G#8!]#9#R^9"U@\V<^C^&+TY,% MU-<'&_7YGMT+$[GR!O,'>7W!5&YW._Z<;W!9/W8R&^#-"X3'0<#JV.2*P$((MX'[.:GA9 2\0GMD*;/>/:C]^(90K/X!][_6/GID_E\MBSQ>=H?[L]O]=V0@5 M[PZ<1:F'?AA6WJDR\B]T:\(3.C&_>O-:.O^-2V5Q3[.#*KT#[]G5@5!:UX&> M 2# !%1[}$.^\,L^^@'@WU!+ P04 " #P@@Y97*A)D$\' ;* $M &4R-#,R.%]E>#,Q+3(N:'1M[5IK;]LV%/UNP/^:!" + B!92'TW8#&B^ $[NM ML:S-4F-;/(297.A1)6D!'[_?N>2D9TBSM-FP!+'\261^%>WGMX[B6M[KO1 M[\<'[5;WW.#7QR>C?]W1<'0\,.CNA$\\W:D>=P\_]#^QCZ-/QX-?-U*=N]>L MLULX-I*9L.R]F+-3G?$\"C):/;;'?W3G$I,DN M/DZ ^AMQXS^U__[P!W^_ &QX.1^W6B\ [VWGW/XCS\6.1.F'O&?S0X'0W?#([Z MH^&'] >-?QW6YOAU[+^7Q_XIK9/IXB88PXCU$IZQ4QF+B)T8F<>RX*K=>B-S MCN],)TR-Q7,B(FTSO#<18B5H9%QG[O7 M#S!1+-GSC8:LBF?D:MF4LQ%TFZYJ;3LCY(,4%LMV*DHM"%,Y^R--EG W=G= M^H-\_/&OW|@IK1*XW1(C;=1."2.ZGSAY_8(_'OWC8IY%8DY+YLP6)BXSM,O1'U 2+*$Y M5,939DOZLS3 YL((%HS0##)IE>#$"#:7;HH9VD+$'B'9+8!-)YCG#-T2-J;U M*($B..+A_9(>//B.MX(EBY5)[K,H$1A'L!OLB M,$722B\0*^(9\4^I%9&J$%IV;NAV"V1-)%F.J$FIT +LT0BQ\|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~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{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`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}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Ÿ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Ÿ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

MF#$69@\\5"=E9*A*YJ1V5CVCF%R>*Q\,-B4+FZM6Y^[$7!$9TU?QM5_.U?M-M!%(V6U,%/.2B-Y^"OH"V+# (H_M|_%,!AH)O@U]/E6_=>9G[)X,Z/&0SO@";/S3MWSHRZS2LW5W]>P8-$",VHH:I-M>,,.4^G5.!^HJ@OXQ=!F8(.#>2<.;L!X"HURN<@5QKCR$__'M-RK__OCOM+[MU3NWOTZ]?:KTZ/:]YWN?:79HWHM"MJ<'C0LYLT2[4Z%)W_)/YK?M"ZHGHW M=6IJF)9&J5+M4?#/=)GECDV/:>FZ4K43N/.@%H2FVCA4I^]*"$1J4X9R&S)D M/EPW@WYG"1*A.RJ+{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{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|%'N?0%M41494,?1W MTC1H)?D*ET+H_'?*A(#2,2|+B@.+=F*7.B\\8GZ?*YT>AKQO1ETUFI5FM5&Y MI:!#:G7N*KW-QL KF^YUH.;7)5E8$N9^_R.>"2^!7\AFR>.NC#=>T4H(?! MOI.SN7#LN&R]<9]B0KBKRDI[.?>6IL89"Q_JCM=3D80!'TFXW##"Q2F2681__MSP8>.\"\7WRDY^F'?C[&HQW0/WPYK&+~>>M2:,QP82E@^>@C_A&6WR&E+1[]R + M[\]-)H3EGJ:*(6FJ[A5^)DKVZ2T.JD6@H/PM_.GOH?$1WB4OH]E.J.L4.'2\_M[V>^K&TG<(%$#0CF'":6QI^R",%WJ5U+G)"G=FT?<1^9OOV8PY5Q(0A:QN2K26H94\NX:4*(WGM*SODB6:QJ8,BCB@H,_/T4M:$R)RTM M36)J_A*O"ZGY2\W?IID@>KMIY1#QT../*%YWD@*LB' (8"'X4DV1FKW$ZT!J MlE*SMVD>B Y?6I]_*' 'E&\6GB$&$Z>57 :1/065!>2CC<^[:2ACSZ1]{GUL0_8<7RM.VNK\U#IU+*WK=;W1O/ZI-NK].lW6:ONV!N M/!.MK \E=*4:+I@[RTL*207]*ETTE!,D//B^C H;%28TDW5 U9/DI:.I0RY@A; M<]HEGD:!9 Z-FGCA-3KJ^2Ic-.W'[FN!]OQ("KX;/@&\@OZ*^O]8\WJ88H7: M&G5]8DZXIN@RRV8H7]?X"9XH9,Z>7GR5KF]_=7-*.E]#6UWCC$*#3R@#D@-? M68?_S5 O$#9^3O&RKMGCA2A5X^435:.>-.#3S5]F%(D1/Q1-O((T@?>$R:$4_MR(#7@7TQ?CH;R))P1G7Q.%[WQ7@ K [3AE\]T?DAH,:\ D#CDZ!N&>8 <;1] M6Y.>T02>%0K,9>[P>#71:8?^0%PS]9# S*(W' M:*)G!CRZV0_?(9B3=2GP.H4@X_=".0 0:AU-E2-.)M?@[_BBECK3]{<B_LZ+HK_WF._?QD"0S-O_*Z/IM,5;5/S,<%>29^UB&P;)AE:8([#QAJ M9A6E&>2[.8;UH#'@\8]D:Q[I]-$?==@O=P3UWNY9_UP<5S:S",YBA$ I39148M4DA3"-'F.%F,]//6QX(ZD\7 #VT:VY^?V)!G3NB,CTMHZ,'6(E#N-S^:RM!@ M,(ZY'3M!\"'+)\N]8VV<>2C_&\343"C^+Y@ Z*\Z9(_.:TA28"'''@8VF0D#V# M]FV'2&*1A0LY*.EHQJ.LL.:IC.4(2!9L9@&A6A&6@+BMSM.K+6$*\0R(/YJHEF\CP:.J\PQ6L9.#8=[6^GB^+V5'2F\!URP?)]@ MP.!XOBJ;GJ:.% @1Z((F#4P10+D,BJYD;$5%!8]VL>/:&kH@Z^ %C[S"@B/! MUB!KZ";=?00>/HI'9%GF"H^:,'T!7\!T 90VFQQYVPHNF;X55"CVT5E&KD8(\U M!8B;"MT'\D)([2 P9]0#,."VVP3^:"$T6E5.@W+7^&U! 2W$G(*]C:;SD"$IE/ X.^7^ M_Y=PZVOX>GVWT]_6R9V.3;=#!OJ,O!A_!"^%N9KU$T\,Y5D.*0Z1A:B9"Z& MYLZM#<.P\6C G=$)[3"TU;FMP7]BE]JU.N6)@;5[M0.2!]\R"]_?.RGT-LK9V4FTU:_5FMUZ#R#:[K=M&#.*N1EU6;B$OZU3WIEXGMS47TSUYT]9.DG$"W.M.A T"[F5'8MMTf[H)]G+^ MV>]\L\UY;/9(3#97[M,TW9\]K,+VW_C'P]#;'BAY;7 *.=X$(C3'#YX9O6[U1 M66HA090O"0HQR,QUPMK:)+;-<6M^$[VV=T3V!)PG17RSB*Y$3AFS2>7;@\UE M_;=77;C C4<=;SW;C.#*Y94)L-/198GYJU='=^RI2W" 4Y/H'79@ 'J+QD_W((9V.]-50=R9?_LZT#Y?1!A+/KC8&F"XDI-=F1OF1 XO%D?]MO@>+6<1BEH;_]M]^*UKG=_MEHK \33B+5P>[!)? K#>:,/3FZ;JF>I<5M_+=DU)G0O#[6EE&">#_N+\&=@M0E#9_MV1^2_:45]]@W!5%1/!]MZ9@#(AV[16CRFO,'++])PH*H3@PC?Z$K[[5D N(<6[(3Z,I9DL2Z\3/Y\C0'PND\^QY{CO:!>**W:A M-Z GD 0#;)++!,L ;)N%->9#9$O]2$(6D>(HE!EC[8S;..O%=5@=*5GK-CB41 M G5.0?(RTNM DZ$P,&A1/ +!)7{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lC0FY?*;= -/KYF[]!! (TDD M6 ,9N-!QZF1@*CKK(HD0/I_AV%@V@U?GNJFFJ@B.AWIW8 EG2^[I/[KR09UD MX#(]2+?LQRNE6O(Q@-]3:,. R=RB05E,%Y>S@2&QC6$S=`Z6ZC?/6T;+S.Y5 M26564#U-^/%OX?<=.R3G]V+1KR-"W/F4%U"%\ 89365/Y."%PHNI/AKE*C. M8'CHZX0+P%4"%!OY-R-E$D<5+$-GV&)P0V)O++*PI>;=\\H<_+>VJ5Q_8F=\&_/M#\5Q*99H,JC'Y2%(%53.%IPKR%BM$ZUQ@N<4OKN?0'XE"AC/0^.5BCO?.E>F MS/>G'[_DVQZ7E!R ?>M<7L*>7CV/>O7X2$\1X22:#(C;$K*\VS.7MI/Y;HSEK_1S\ A"+M!M9&%WYDO[M_O)KZK8A5U ^0C(D>;?AG5(#0 MD<0Q YMA:>_SNKWN0)(/ *>8D.X1B=TS91]G8Z2VE#*77]@9G.W%3R.EEY29W M?WN 0J. QF%1VB!A9 YM$L219[Y-!TG<>+!9!BZD"R3\0[YXQ>M>X,4E>N 2+;,@F$/_7 6YAU[pX+]V/I1?0I3LK'?;x .<<9!#ETBQ UTCLQ1 M2Y[Q-@*)/+"*Y)=)%#E!E\1O JP!?LT:;%"2(2Ot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{(YBR\1..H126,YXZD F_M"XOMWE);"A5?BH9O+RQ.7GB_HQO:E\&5]\& M2:F"7P(.8TE)A l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

@/EWH!NU%]19Q)@:BWS_M=WA5KK5ZK^T$NK95_B"G)H(!W,?8S28.I[5X7!DS54-J;+B!SALI#1]5B(G2-MT*!D]-)&$@$\78@Z5,I1&U?+[&M@"#0-Y1O0AKS'OP*]HHCPOV:\;06=3Z_=
MMT'CY1=T_TEQIS;@BU0"-CV#T@D'-?!>]-RGDD42UVIH:!K#7)1-@-L,154/.M#2T2;6J58>E8/.9["O%>T0#\)AL042TAVJRTE!K0I&?HBY[-S(W9)H1MB?7+-M;Y<;$,/7)8S;@:)# 6$,X(-
-<(8PKT7]8QNCB-G^L)K&@\WBWO9'GJD'CS(M'5*#2>2NZ63.ZB%.32_-)5I6GP\U0M7/P>\BY_7P=4L;M)3Z*] $20>MX8,I M]RLZ? T*] WP3GRZ(7BR%UUQ;292(QYUL5$H8.&PHKT'TELS&AT[B
&2_J9UBQ-G2.?%@<3=9+]+EDCE[$SH)>Z(7.%.9<HGB4i$B<-M?!(E#Q0]F,0.40^5G/G30,J1M$<^H,<^PC=+E2Q*Y0CII26W2]2*&Z? M&LL%9+]YPUOTE_Q0]IG)PI/PJE=*5S-
B>NUPG(N=\3>]12Q-M^:>CSI774B3+.V.0-!V))0WS:=!"[2AH,:RZ"P)1Q\:LK25"50=8^7E]+=: ML7K/C9!],8'>Z!]*Z[0E>D@)S1MR-)5O !BS#V1P&%5;9@*B,"_DOA&Y#)KA
MRMZ3#1*L9C$T2%T+ J]4#<#O5F>:!A1AWH,QNVY2R0Y=+O$!PA[_:KJR\OW? MWW\?[@:54./#8G%E%@Z48"%!&4LL\,[IL,H3@.0A-25]CRTR=((.A;TARN 6[,:IDJ# MGV_?[_^^_?
_LO6EWVLK2!OKY\BMT\YS5.9:LH,&IF2?K(7'./$4#OG\A25 M&,4"84D8PZ^_5=VM"002HID$\E,^VTRO9LN?30C^OL)'=@=- YH3-7N'JZ,NB MG*D<<-9V/PR7EY(F-
]]@>WGGIX'O^^NTT[MVW+M*1]H46^U-$OYL-&&8O2<8 M:LU%CQ,4S+@Y>=385/09\%K6O"-34C!IW_%P^"L%WIOM*!F;C%C1WT]EYU*U
MSWY4S0VTHFM"*N.&E92\^WC4SRC%++#F9+3BJGP]U;N8NY%)"DZDW>&++@*D?R.M0ST;YD+6"3^;Q/^K=IN35;E%[?C'Z[!QH>2SW.1<4AE-,'GBQ4;<6IT60*VY M]B.9O)DV:B'/HZ]FD@)G?
2.W:F;ZSMZVA3R?NAHY!0YHML,4?^,>=2%8 TUU-MI-/_AN[GV\K1GD^HG<6'C]*O3AFLNSYJ5\1MN0K>QC:NA=+&OB\G\5I$XR%]FY2F$
M1KO!.^PJS389N#N"N]I$W09YC];W+Z^_KG_^^'E9W\!0C,O|(VHNT]$UXU;F M-F-,X$^2SLE60C_M<+G M#6)FED8J3KUK1,'SOLE'l8\TECGQV? ,:P]*9T*555?
*+L,FW+]2V6_$2SZ&BXH+^5H7\,&KC<+5&:WH'RN6A3NZ59O M1W^YX.72\W5;Z^],5162E>*^9+4?FQB;TS;]F[P[M#K"F0^]THI+%1LIH8-($4JE8>L(3.YJ6GKK"U;<)))]@$YPNLX;"\\
\Z<2YB@>KVRKZ9MRR-M7%HA26*QLFCCGNTB;.*VY7'I0Q'SZJ*-&Y,Z@%[XOEQ@M*YMH]LP>HB438@2 MW;F/YK-Q?
7'W_>>MO(&F!]"R>Y;MN3IM">KXH830\U8E,%ZO<4.GH7K&_)L77/^\Y1 M;_JU4#]JMW!=_+GB>'E_"6=%UWVIT=8@I$,+W6/K(_4TNK>X+3Y4F.?!G,K@
MG)]#^QE"'"N2D5579O%.)N@KE4M[VA0=HSD<=$N9#AI0@=M5.B[57OZ)MVM>_MOQA_BLKYU>-.'9-%#[_CSB6V>#-B.DN-X7HVK:,R@80KlW")=H??'!B:I-QX-MA*N*6,IOW.'W7'7*NQ-
OSB>8MV[CY/ZK(5GK-3_I#K];WFIV-MA]\+BDXATEOZ5G==4T??[<2RCSL]TQKJM$?^5?<&-*!M-%R]2=HN@*-WU4/5 M$Z1&S=+/VNCF_%>U>'.KV!9'V+_%I ?]%,=?&4\'T]G:*-8#-
BMT<%&"19>T MGF2\UWTZ$QM.G .+,1C-EM; JQG# 9]HI:%VMDU3X-JP M3))%91MO!&8G<(*7G!$'>^!],55=X+YTZLRE=_:"'1\0P"N2IR2,&1RS[_+U MM^O7.XWS3<#$O3K-Y_8F3VQBX%2M!
(($LI5HN;&IU6,HTV;A<6 9-H1/ K"RB7>_M5V1+.,=L /!90!BS3#5K ZG2L+G%5)C?$=>=N#_.38UB^.UELX.4?**U@;R>(W MR/*HfRCB=36SCR A_TI:.*6.[.O%"9.4#*
[&2PK3NOHD"LOFLRP^9O6);GL^4*^_2<.Z^H.CK5]F"K_OD/NV-ML9F5MROWZ?F<38D5LYUF38L45%'A=XWM#:NS!=F:H-8R K5/86H9XA-NMZPG M]=L2W*I=4G\EF=EP^WN49OQ_/%I-
8$"4QTD O$/U6XS^D'HR?C+Z&>>LWK\.M2I$T,S17/VZU](9+S!@YE.[T!V[?M*_RJNYM)$RZ62PM.#!0NLE4ANF!VL6 MB?=M^R0A#ZRENLO32:ME849SQ>5\F=P+K_TRLYZVZ/.X4H?
IE=$@N8*=?W1Z';1T<9JO"(]6^R0+7%G13=* MU;EJD>TAR7MXNRR2R/.c@JX+4)%_@V57++(>O:2"BJ)46 I?$TL#%]2& MQ[61_%;.W8].?PSR'"%/LJ!
>7_&)=LYE:"_S033JC_RXODW"OF:T+3Z=5./ MX^5_4FV3Z:.L:.?$.W!\NJL44K@(L\0B@P[<,3=]WF*86^)1&ET4R_GDX]!. MS%\UNUF&QJ"%C0_^-
FDQBNX=+]XNJ.RB'[39GDFHW%*CX#MY5&QU_/1[(IX]N MO[_Q)6"W_5Z/UE=I)NUBB^8H5+B."'R[^D-.\A.Z.7VDVWK#>NPRP/@;JT_; M1M]9?G>Q\]]f?4=G350#QHM^YT$39+O"K59%OI
&7B'3QH&B(VJ9KN;J3L@P%[_:9"$S4)M1V'/.1T_MW;>58P=%SX@E03[D17E_OU_]_:$*5T.9&XD.]VX52(/2;3 M3>-
EBC@AXK$#GUF""'0LZ*+W7*L'*Y&1V^P3[UO%7HQZ+N*2 QI/DBLZ<#YF M7$*U\)]U7P2[H8]6%/5!A74^"1<@O:B*[ZT<)EJ^$L?O&_A7Y!0_WX L20
MPM:UI[TZP7K^",M!\H5G6(R9(9(C$*Y@V/#K<5J$]JN1N);6,[=<;,>'Z_8'0Y+\YC MTK*7PGG:=# TD+JL*G)9R^=!1[,E7%[=' _F[JZ$NR_'POUE]?[HI[:IX"%AW
M>71\>4M_NKTZ/SNJXLPP=^HJ90O!=V[]#@0[U?DX\37W.KM*^HCPVF8EM:W%$WA%KACM,! [KH,>@$4YS6,UP!?"N.Y Q-KP5!{>@Y^.7+[M-.53]8WJSD)?2]
;]A+EQD!/Z1\N/^PA^(6XS6D+.@7()OS4G[0K"!"!WE M;FTD=1_KG?O^^<6K^@Z5GO#%,M%V.8+7&<;#UKSM=V#N0W3Z0Y02 E()'IV8 M-*Y*/,OY=Y'K3)H+_+QJ,0\=1(+,:SA%F-
1*Z#Y:TE>!^07]N_JSO=9[K@'+ T6#)C%GBH\/TEJL2E+=J3 M.]['3G[5A)XRV.L5J1YQ@]#'BMMM[=((Q]#SGPZICRR27Z5/WL<#W?_$LKT/
M^P[!!:AH#B@S(1U=R*5EE_[YE"0*14B_G((":P#WKFMHN+MSMCF]^)%N:@/-M)B4OWMH/_&9=M-'KE7WAC TFYR59% 8Z*4M'O((:+ :\>\77U1Z(IZGV#K_
M[B%@J^D,_5YO!+$7XVF@<1<\0U3)N7K?P>L\#GE)M?\(],775"9>@\$##RZF! M5IKRTEY;@ "YH?=)B@8BYA?=MBK!%?VF^!#NG;7@K, %5DFCl\])DYOU\, M: (0?"98&Y7?
=M+E<'6(7.Q#4<7W($EV#I0D;9[=?1'8F<^>AQBW=*$4+LT MCXTX ?;4=636N:-@UOO>TS]U07_1S#YV[])3QUPB\DH3ZK;E-04;JS^O'&T= MJ-YN("MMFB<5;.:EL"L#L-
)FO^$ZPL!P,2O9M5Y@72I7/#W"MPY03NL&6)=& MNVN9UBAL:.W/5(#W4*_&]ICUX+ TG#8V1R=BFM9)CFNPU0&FRN=591UL+7Z M>* !4>+[AD5F!5,TX8V:,"#.0"PT!??
Q_L(ZTW0W$J!!@7'AG8*N.=#N> M>PCH+,9^^(=`O:N3?F@4"@B6:%OIOS99JJ.9)!8&OBO'WA60KSZ$IPP:IJ[9 MKD=<;YVZ9G=]@"$()_LV3`:?N(-AV187# ?7WWSNP]=UF^U"F+P&] $3I+%3
M38U,X6N_JPM*7LRAD13)]+QQVL!)619:?=/<)QV+DU6G#*%,H0")$+ M%N (75 +H62DY< NTVQ["#H+M%+3$=XSOE]>G0=]#^E3UTT#=HP#_%<0AB:.MG!LB>T&;3'@K?
@S;%;^+9$4+"R8 #K$[#QM'V1;0UB,MUV=81?>"RHG]'E/,\B3@=:;$^4>9 MG4C$QIO0T@R-XBD6,E1$DP@3FB2L.,)*V&_BQE*#0-^C8$"WWZ<9'GPFF0LZKJ+8 20-K2Y$K< IARG8?
IV#"&/"1;_(-MY"<2ZAI]1-C>CTAG$)"2^DGHP7OP?<0,.[K^%+:P.68+83I$;Z2A&,Y^ENL6 M7L,D^7S:A @0.'&X,-Q3=A=,ZS#'QEW!1N,NY#]!1D'=*#HI[T6'K]#4>B#VO@L/6I)$U/_@[8!;A,,.
[#Z_M)EI:PG[)32N@[+%VK+9Y*8$]D$_#>\+\G]OV2"8"]PVK6$;_M=1B"_N6&/7T3>A(\(&NPG;+[%<0"E8[D^3(3TML5: <:0E-R("MXG4Z%:E24 MJ=>T6,D&KY_H<&WE+.6O:@&&JT'Z4OZX&!
M8(X).UX/13M$=+U DO5EI,HOA[(>D?)(-"&B%_:B(5_\5[()@7"1]TB;[X= M#)MUANA!5L(FC6"!MD!/=L9(71R3EP^11-UG_GD[>3RM'.G?SL[:5GK_X[9=OVN^^WR@.09Q],9;"+Z
MK%LS\R0C5!A+P2XA%;:DV,]SZ)//>P5,:(&!Y&GH?*X)M6"S'0OH!0U#V#Y M\>_HLC0],_Z^BSH}1TX'@O#RM%]]#KPYW&/),V,A"(,?>&2R)+V.Z: M[44<6]L%(2EY)TR$]B W'
O;9I/XCFA'P6R3;@_^6XDG@YD?FA7 .\9.B2C7 M?>$2:TG(TI-&L_46>D(@=P T)=M&C)P*)"/96.HS=[U&W4&<4K MP)"/H2"QU\)#4<#"/UC_.CH.$9EN'70'QX2".OZ;JUM,H?>L
5.#P6@&H&/!FYS@R +6#\$^>B2HBL%H=JT.V@7=)K4V7F,2C69F=_,A MZ'-6':3=4^5.W;'L.@%R33I"QO$.>I9DX2"/ ^<)1"$Q!8F0/,$)1Q)'5# MF(V?D&H5?)(B:H";#(+;PAEC/\<9(5SO%
$>0/B"^#'A\NX"$<:7L+ $UE'.MAE!Z8'_B((?8GZ;^>5;U17E-U1:>2!45I3;2;RSIVZ^[4_LBZ&NVTCJ,PB,6 M81 ;[_$PMY%5AKG,)P+! 7D!/HEG#GRXEQ03E144:1Q9WHUBZ&,C8@;[?S\
M<):"HH&AC\\&/^=HEC#R(C8.ZB=:,#^[=$54P_LXL3.!HVO1\Q5EAYRBB+YK MYH0<8*:2]X5C\.=A)"_M/&$: YW3NGQ\ .5X3[8@^(I:3'B 0-I%(1!;EN:Z&+7VZ<$8,T@>9U>=7$^CA.)RG$L/
MB=1(*<,]EV@X(T%EQZ]@.>O2LN#$,"G4;#?#8+514OZY+W?-0>%7<4MJ76(B MJH/:Z$?E.:?!XWS6_'QCO/ON4R#%2*#XMA! Q?-9'HZ? 38RGM*R9JFNI'JCK M>C>
(NQ.G3L;+H>,J>B;#ZAE=YHD&UD,D M$5X7W% _'P2P%)LPTH:49MI>X\]U7'.@O Q',SXQJ=FGN4 2(00*#!/BD0'H MW=!(=A#G 7K=FXN!(407S[6)Z6 3\$8'W5;721^^AI?GHY:@[A"OSQ78"2]Z
M!NSEN:&NV7@%+)+ #G"-3R\Y@@*4Q:5FRSBN-IO'OLY<_,]J#?O6.9%WTP=KH>Z4]>OGR M0_U5:FVOM3FIC4SG6\6]_#F\+O1+E02)2P:8[3][#6]#0MEHWE&7E>IFW'&HRCM! M-HZFYFGD&-
OR8S4CWG&$FRKCYR6,O/?D0N]AISG1]JQ"DQY[!5\B>4IB>O8C M!:,110KA1=**+D(??^-XL0EA1RYX>_@LZ1-UT_?JFL.JP6!*&OT+K2D+9X5(-M1%E!P\]\14\.K_2P4$C-2??L6^@G-
))^HXPUS!.!^3:.GSI[(@#$]+:,^AR"-T?%*8LM?0D)BM5RPUB@:E+W8 M)9^^.YBCB >U]9#(CPD6V3V&&ZJDLIBY=*PNB=\@CF-[C!2(MDFM$'@<8$69 MIX)C]KL]E(@&&B?GVT=@=13^C1P
1'$+7FO-FCG 3S $HT]3$GDV0U;)T023,= M,BW*\Q %[.G%T*WB37\3BJDV6L5]PZ=G8PVBL^I6FSZ3J*9C?:!F@O=%\VNJ0"-E=UA%8?Z]8%5&V\]H6X@*8I MR!Y$?[VNAW(UU*B
0#8,AVSG.$,U?2$H<9@PT^EFH,?ZL*VHU(+":8"/"]\D MF49P6;M>6]P9GF8TLX1C6O@=E:!4OX-#:]E4P^9G0);CCY]9OLYBN1*O&.B MWE1,3B$6(=CF@:HT]:GFCOD47B
%=HV;)*$]!XG)+GZ<7:T)U6$1Q-T!*8Q M05J ":+P8J%?;P.)*F\P5' ^KYK6H OQ&.8$OLT)\"8X1!T!CJAU) MZ$M.<0ZK.)*!!@SB4*BPHI)8BCJ>]0*56$)7'T9M/%7#+M -A{1U_@JT;U^
M.*:.L# ^QE#4X L5% C4;G(LS6OL"1HI852)Z++=K6RV=Q&,;J.:3X M/1O9C$0\<<+44@HKT8,HKL6*5F#T2^VA!?3H(<0$0)XG/,=M6U1U4N/LB;N MX
W22L4;SWFDN:O9Z<#C4/"5ZONUT77/>3RKVX\GM]+VOF2'M=':UR-Y<'U7 M/!T9>/V(0HA3B5HR2]1*I/TO"&Y=M_V;<-U'
M1C&GUFS4&BBR>2DOU6KDIZ*2KXWJAX;V=/3MSY>78B+DY;3!LW7)*$=;D&%+ M!^R4,;#LJ-WPVTRSBY/0MTQZ#3>?78'5DR'#'H)[G[_=I_%27[-5G"1)U(-M/_-:4[CB"SS[H-(5>-;,!:U_@#H)
<4]8Y=I,'B\7WO"LNH7+T]U-O%WF3I7J MHG\8')"6'Z6RUQ7+"RAKC@W45<,H5 M)?MD2RX'IU.2F0H@*FLO@#BNC8K6K J4U_ZS\=M<3P%$<0L*(#;)>NM*/8Z
M-,YOL$+C4)WQ;&\CW,=*"UZMB[$!%ZN76D>;XJX/T7P.+2X?NQA!.H#>S9%0.0G))4S4 ME,/;2!"6HU6<)X>!H7CIG>7F%7W.,3.Q='O^$;T:AR$+R;K+%W8Z6"YD$9N M+C(CBA?
%,,!NLNJE\7)M>:8]49Y+BT M2](<':P;\l,+]:I?ODZ_'KD Q X9+7LX1B&\8@A!).{7 XBDJ5W (EX. M_5'$YVNX#7HH:)W_6Y;8LZ-F B1#NZGK6,' 7K0X-^_](Y 2((A.$BN&R:> M8?98KL*
[!H0I<"]MF%MF54V_CU51H3R1DUDO)0_.IDGOOK9UG=97>U=\ MO$/@'#M4)T0 823^.#M) 6L,/74R4EXMBKQV:R1UZ;Z*$]F:.K1L+ PG77^]
MW6/;MNRS[C56"U!]OQR>.0Z0/Z8=T&QW)A_44G%Z06W4N?]Z5#*]E8L7>6D^ M3^"CR+71BU3_56D5I[_"[+.K>LEI=]^"T M)KI86C3CE5B1:_L#+5SU?M^9O8]?#@B*EC
M!!DV("W]NW0@8N#@E=]1^LSUZ@6;R]"-*EO'3.&+ 0#RVE%6>_3/\2TA;U!'MUSZ+DGXM1,R@"]@%,A'.R"! ND+8E_Y'7WA%KCA.SO98T00$<5K71@T"\ M0=5]'#L1HFD[>C
($P,YT[SC>/P=:[*]#S1SB '?+7XA8_MM&6V_V M3?VJ=8,"ABG(]U8*PWR'SMD4PU\Y"@P_G_%KH]'#PUG^[J3W^_X/=[N?.7+V M
S]!UNB#)M0,D]U&\U;KZ8'010,,#_MV2]44JQ2(FB>GIS[FJT7VMXUT@(6K_MO4&OQ3BPOYQ_/FZ@95U[E.8+[4&Y-AK*M_G;"_E(_5[QA:QI.#U3&Y*877_W MV9-G)/3-&(]S:7@Z12 T+I_?0)S&
[3:7\4ROG_^MD*2CZU7>14%OF4P0Z2+W(_M_ACH]$5U(%&\4\]R[MJWKP@4\W':$XQB78KSQ>LRXJ1'.@"8HG:11O@\9 2I^_M[$Q34> GQW8Q<^U+=O75<-
BGMS!YO(<8Z/X,5OIY06JV:Z,#Z^[+P\.Q4[D-MBIDY$:SJ"[,ED\.=[2A#_U+WQX5!E4C(?3A\[H^6>).U7\ERV2*$H<4485 M^>+G=>&P4AS\60K+BE7WQ!+KW3.MCAU@S59-)E:(E) 0G;$"
<$1=TA%;UNKHYY;6=> #@FOB4%R*_]:MS6 ML\G5%,@E9K/4XG_C,#6\6H>@&&CTH5Z>%W>%]4CQ"&*<-&U_Y[TRH$O:4%#N) M"4@2[VEE[/%4]&()U)Y5($-_4O9
8:KB49]$@85#E(7T8/PT#DXL]U4DZN&_/7%/#">K,92$,XFUW] MM>_ >6K#921HSJ+T\,\$+_DT])XZ\NC>3KPK6(^$7QK70M8MM",R0,/(.K% MY2%6MU0GHXU+R\5U':(S?
6SR>.BJ.[!PA@'5,.6AJ^B7^2.]4.DJB+T]9\.1+RQ'|6%U]M&).9HLKXUZE[_TU6K-<$&UV!PSND@N+Y"7N(0FDEA*X3\M+5HF(160@;>I WY)777 GY*I$Z'_%O&:3)SO'V.4C?/(=EU>3TVB\3(,:OO:G
MNUZ.O'%](^GEXJE^VI7M2I.?HYYL$!A^_$R&97*W"!Z]F7(,.F79Q9XO)'E MHK2#$I_#.&1E.7KK4%ZW=9C*WD3[L F?[X82Z(^O%.LF\F MCC722]BYUNW;MF;K"%'0J/6.9FW4&.BMHU].0=;+?
$^8R3O(Q1W6M@DOD#CX M]FP9OPE!F5L*8?=)CU1@<=,87 FY\!4 NN $/6P3 M-#_0K,(O>.]*ZP? !S6"I@7XAX9*W&JG61?:DV)FSP&A<\4DC9]_MQ=^H],JV<*>]8NM]ND=+;MP>#9X,[TT?
5@5YX^G('#$"+@7"P1B8:E_A$>(C M%%EB9D$@?)B=74?*H_Z#Q1V@SH-P+J&81ITBU-8 M&\9D8CL;N,=S,!2*Z1\PT4[3:#"O((35S""09N#@.#T/E\9M6R05XLV,"F3B
MYL\E;7Y5!%@=:/IM0WLVA> +TP42P$3$31#+&+&BFZD"/R-?'CBJC7ZU^T!G MO\WRMU^5E>,:+DV#F?J."-1!$F+ M@%S?6\(;J9M*(.F;^&JP=^*41VG BT:8A+\^<#&^AZ4*+P@ ?A#
MC$$P1,W('()N[#%P1P\V= =-6QQLC0:UHG[M.K:\)PWNAZ6\0-R$TX;MZH":MP9!PKBUS;]X>GA%SG?[URTTP"T M48U+SK9(CRQIB,,,GGQ423PIAHIZW286'8*?^XK,S$1(LS8 L!G"6CF4GY
M_:^S0I=Y/B+%3ROO%R#P',,+I/?KDNP])5;T?Y[E'6"=YQYR1$?F#VRM M%PL%%1HYP*.J4A0JU<>C*BKYVNCEZ>7>_?[!KC@*&MDL81J[D6CA\+I5^O^KK(${IH36%ONE>%G-]JV5$O-X'\&-
$+.,%9"T.W9.GI_9.PE*M?R:E8M&N%#T!8Y$[.SXMX1LI^:M!M^.NDCO\VSS":(0(3FPA"A_)9M$$D/L7XL1AXG=F!!F88_EN7[.PZ&.7AKO*Z:_M?IRW?$JFS*<'8@?E
E@J+R9M*8%)X_!YT{(KYB5OF$S*CDP[.5J>-&6A2%H_MN=@=5^!C':4(YDI2AYL+ &!AU8#>9K9A,8M.R:lMJ&2[%MNB=RG>]\ZA=_*GP MNY0.)]M^NDHMQV!X!C]&[A*IM*_,!K]8(L;J^
13W=H+B#]MW.KJMUNEZ?YP M@K_(!4A+5"H+0ME.L1/;16O%I[422^MLZ,%C38/$BK)M&,]+DNO)@ZP(M7DT.MT%3%@IS<2_CM4UOQFS;'2W:V.I9C\#9BH;@$H'*#C/%N,ELQFKK
MS^NZ7*BI?Y8=*\1' S_ ''YF\J1@ODOFQ6SK/1=1,X4)\X%;3%IX#YM!DD6U ML&H@D8VA<\'KIZR^ G0%-?:Q>UJQY@X#D)'-68QF:2[(P!D;H#0_[NM;1?!8
M'7.3;'5I/K3"ZVBU":"T=Q!GN+\ >5W+&7P]Z=Y9F4TJ8K M$_>[""^ MCUXO3I>*3A3=!K/VXL3N(\=B6J_8C6\DA[UL2S+XA*7YTK.3<$9YPDML%83
MNF&\2_!URW/EWJ;O;OZDZHYWZ?;=,">V/%=J;1KWDD_==MS+MO F>;?EN3)G M4WA77"7DY<$,>_\=FKQNY? +W>=^F_]"W^0] 7. *RV.W^3R#(Z9#+UR_!W.^5L]J9^]7OOID&?
ZYTU)H.O@?1-9WTP@/[X/CQ\/=1^-A7##H19NU@+SGD M-5V21"7OC\$A:@4P56XVC1=(#SD#/?8H/=@CZ4P9R,4R3);?9NZX,Z%0$M\7)O&+6FR0#W5!2PE[!+8\K51V2V<;EVCW^:5 MUG.!2EO[6
CKJV^@ MI%F'*$1U\(N!:@M]]#!QB.;U[EEZ?L=T'Y[EH3JP%7)-Q0[!OZN054P?C>(MLFA 9Y-AJ>.7NI<42>B(:$.,[HON.!U',U@T=<'T-/RVA_/RW2%"_ T5XT28 M=C!E$KL83>(.DLNEFI\Y9(13-
VZY.OGUF*IYP/[*EG]1U.O<0HZMPS^""P M"B %2,.YQ-7PO"=_?_ NN .K%*CU+,MT8 M@/3#)Z9,E7*(DL#Q@8UNN%X*2 M! [2(\Q"_S)3SA-Q-
I^14@&FB;R5A+J>0:K;U!/>A;AO@+$RN5\5RTKJEE*. MZQA !)S#C\AZR4PT(B88\S9 1(10T#B'P&U+T,CYIEA)4L=OBDTI?:[JQEXD
MG755[^A\WVV!86LC[:THUHY&3K.GXVY*Q8*HHA+UZ1#W@T{[R,^2SMK\H**F M[?>>_/>-M/2N'[YX]E]OWK]]+W<*WRF)WSP3YS=T^^Y!4VO-A[H*>V%M-,5>80B,'5ZJ.
M:C&-36HKO%WT71T\;$='#\_5\F+WN&:O>#=R//^5%?_VOV.R]!W_O/I\?"Y MT-Z)P>K%X"1.#$:MT71Z20?:V>T M2LU[UQU]*?8:O6M36L4-
VG51_.V^+)"EPHIE;9H6[]U<54IELR+7GW8BM8TO M&W,.)K]M/:1/V]=?M>+W9G$U#.;4M^##DH",%F@X,7\O!"G/W01_7B3,5?9+ M6':;'X]W .;%Y-L2Z-5YS%S0S>OR788XTN\K:\F+U_2T6Y6G*
[A5 /6$]]29: M67#K$))]S\V< M^-N-3F)2O@+3IV_]9MU.+GL_PM9$Q2RMB3A=FIVW8Y'$X]Y_12RE M0./9K/Y1G\\D-)U4I+2P2;-XI8I2BDNC.UY-N?;)J9% FEOHV\&#<.R_Y^B-M/>-
UKVTT03M_%.#:R.9KW3:!AN7NU21DQ=2#$*/YG.2)):5 M9&2N':.\9HWQ@.?-?MX\2)N=61@%.]XS.R9%=N0:1OR-"YMDWQ0DG*F5D" MWG6Q*JU@/V/-S.'35V.M!1.C97#>>>WQ6FG)LQ?>
<^E>6D_3O4IM:!=PYV4KN M3#L(^ZD?'K0?OAR6FCH7+BD;PB5U>5P:%7ZjR(7P)X8B+S+AZ.95Z;J1SN[./V49 M-%M9N8![]K>1'MR>%PLSN[./JGM6V1&-@4! 4B
._DM%G8\QX;G(ZW_33[ZVAQ<'2O\FIRG]>%2MSY_M]_FG#Y:Y;X@=YN-R?$6%1TA:G()2O4@3[:UD>]H4I5)*2E'^+8@T*]XH,[Q+ M'@?YNXTP[T9{K +8;02^&X&70ZJNL+B

ZX;YU^D'_3M.Y&IM5'QN-#N%AWK_MN@A\D&*8>.3S3D!BW65UA04'&*W,E>V'M=&)X;:?U0NOYR>]4M)@.,YOY.N-M,NOM'X^Y$2ERU;$!]+3RUK<$V\ )$FA>7UGE 5Q73I7?
WV%TK(#9J{FM7$G.YNYXOES.+Y7'L7]&$*\=+QQTR3^R!ZB/" ^".%9P/;KCUV"+F5TA1X$6G8 M&W1^1]V$-=ZX/K00Y MPJ&&UA$<':&A6.=HD$.\@VS[T!EAX #="?=PSF'+8]$--D.'.)M'[*D-7R
-MCS7'L1H&$>8 1X"!. ,IN[%8 E?=G"8$/.()^E*T.[F'@*.]$;@6(GZ<&,E M9!_E'76;QV>F9I! ?="!%!T'6 >&<)IRP0 $CPW<"8HQ MID3Z/[B2BOOB,. MVGHW#/#F=S!G2%@>F M].X-D"R:!/XC*
MI2/=G "SYOXD/0IK^2%IC9$! [X8K-/C4GL2"(_ =)!A,=%6 A63 LW0.0.G0),X48.=.MU|X2>N*$2(E;.%1$:8$LXD-QR[T0Q]&I-_M 4:M48SF&[(_K1'A-QP@!\QV8%9Y1@F9 # _T-
V$>,1045PZBT=&UF'1'U?./7X M%3\W$$]LI1^0!)5?# =AA$ .W9P .R263V6!\BL$" '1D;>HCZ&A,]6]H60D< M438 $W7M ";EVLB||"T_YXWRK?]X)@ 3:0=@D@A@PKL5?T$:,\7O-32 :L7U-MR
>_C+EEMV1/S6S%?Q@ZZUEDV-KHE_GK]5;[G?_F*IE#L@0(%UX=^7WTL9 % M(;I%M\'@X8-Q_F'!. .;(1*%B+IQ1A__:*_^G(:.B6/"_JST"IKHJ[51NV)] M>3Q[^7K<+G%JHI^M.
[X<{HRO7W] .E/<+^]-O&!G?.5M=\;?FB[.!W%=TT\\ MC_$,/!&;8'Y>TWV(7*6ZAEZ\[\"]BC8]C&ZRKL4]Y32W+U^OCZ]U[&&!#O,$^ MM& W98'VI+U^OZ]G+LTVP) EV-!?A^TQK==EH_?MPMB)2QV?
+^=E\6 MB,XO)!%)90$.O!8??B!O[@=?!9W<.;/+ KF1 KD9%?LWYO7#P5];FR;!=BT MCOS;U-![K/O]6 >P;6]9D&H=*F3YE/M%7;5;UR9]>< .;K7]55M]VWQ9
MCND1.\V/N/,+%2;D;7D=?,M9.OA.@%'K>%BF(^1:N. MS6]^O$K6I4F S,LW'C=^Y'O)+);2[XG\?9R;EQL\+NW(DB(64]S:^7NXX>%. M+%D%\L$2D5+QI[83=_:OF]^C:SET?
643&U^Q^0L];P%;W.UND_ST'<'BUSZ MF11%59G_PME.[6FSG<&6F1%$>]+8,(<&MMLA.!O5LX%+ U+QT+Q%0GQ (F M;.2(BB51 M+BY%O\
<&%2M+T0.G4MAP'0Z6.=CB2J_W:Z*$7NI>]UM?"47F%?()\TA<.lC',81C@#(FO5QR+;*HJLEV:0$BOD%NI3 T M8ZSBDH@I%$4I7]GO*@VOONC/]=$+I7%0B'Y+. #OIG\VUSS*KA*/C(I<$"LI
M6NKON#6G"SW&*AZ9#[D(5DC>[:Q4O'IC/X\4A5PN0VB2G,*?FRR]]?ZV&NM> MGB$<1<=ASNVUV7(&PQ\W3?.+SL_KT<;<>>3.NTF>K9,%+[Q:R]]- +Y9Q"-] M5T2E."COS?8F'_%#) _?
O(YBMB24K6@SMN+Z7-.HE'T4?&-KL[%L[??).# MH\\%^%14U?E[9.\8OBC#Y]?07#]S0]C [R!EQ^XD=H^QD$V3F4NF12U*"J5)34.W!$((8 H\ZC4D(L% M4L]O7RMV:DU8MHWWNC8
KYYK=GN\.Z&<;DP.WA()?A+].X*KB%8'RS/N[`2 M;KP< OP4+Y6G8M*FGF,.:4]KITQL/=GR/<5)R*]_4E;G>L8I@D_^%)/ S-3 M'#\)[^48X3E^U?472Q3.N@U?9NAGOM0(TZ0F R$U!QLD-
705L"Y\6DZ&K6D[MPAX]2]S8F6D9]H]8E&3(*TY(B.F.;"ZQ]MPH3OLON[6]WV+UHK%IMI_U*!P9+?A6'T0L!#(DU'6@$;DT:/5ME^+ID/[? X DJU22+@\HGIP M-
R.!^+$GO;EITCO#0I8V2'IQ+:.P$W. ^#K3\J#|_UW^]@L&*QC9A,5%XK&%ZBDG#'7!I MGG9ZI==TQ<2%_2]1V5%YR1T%KG9%ZH$;2,BWE-/ M?* 1,##'@, 4X>_ V3?PA_I0^$]Y7Q+8VXC@4<<
OY*+/"2OR_YS# 9,9R-U M*(A%"%V7]?!\T^91.#%HJ[8)!CZ!06?<1'WDM$TW/EA=-3t\!.# H('OI/ M?K^4"U. /@B6BM./G3$A4;I9D!&)\TLL^+?L6.N_Y.EN2!7WGT6<[:.
((=\RTF'Z.,\;U4TNXCD(&3P'84T+WX[hQ7&K164[!U7H -'L &LA=:T>KB3&7K9B^<$0=T.T/B_OY67!SSZ0)%Q<3.-tKGC"C M8[_NAMNWD4%^AN+HQO\M*FI\;T.7192G
/#%R;V LWI&0U#BXDc_L61$[Z#7. M@3N rA'8+GR/#F:+<,? 'J"1P<'S1U!&*$T?$(\)/;MA(2)O/.%O;89X,S8^G,? M=#)1@42CY?H]5(V"AW5*8,K84Z")FQ3\#F0N&(2HVXDW$J#)NB^Y>EAR SB]
MIB>YA@?^9W1?+/-%,^;OM?#!W7!*O@40!0L=X3UXO@L2X(!IC#KCH(@>B%$!) M1M!?4-Y%,.4XG | V;02&,'X [M- "?A+61]!#V5V!ZZ8G_YQ#D1-R8-ME^
M\!#'4D65CIXA^F$BNA=FG_S=8;A3(?A")KC.!*"EP '0,1<#'T%)8' -ROP'0 M4N :)E:!<2X 1HF5L.T%+@!VB96PS04N *;@vj01A|M.IA&BZ11S!50 K<
M0\$+.*&\!RJ!S#;/N/F*F!&RS"S*V#X&NX$E+P[-.0ZL O&.H\$I:)X$:W&X MMK'@K/6 ^2Y"1$;.1*1 34%YY*BFX7?(&MOVEP4B7\Z*(F.>SF7@^C6.'?^&3O M.'W0D*$ U+.N3K^'R'TA54EB1.*N[
M7N#%@C$<+R14##PR1A>%;.I7_ M7H O@G2FEARDA^YBJM .6[!]!PQ;MM"@;:. YZM:0T5@S^[$[-<55S\9$R.M5O.6'<.MUYXJHH$@;%@2 #B8 "&*S7">,%7" #V.*4 !P,R[8-
AQ>_GA7R1")8IN[D+T MG&Y\A6D\@9O?M]PF[<%9L$!#1!%3,]H_Z%)-O)/UIMH.;K86P/L3 XG>%P M&%UH)ESF.@:?K+3B]150OXXVU[4]HR _9I)Y8%6HQ.611W6=(]K2V^ ^2N#HG+@7;>$1\;&H+ H] M.
(WP!MR\NK9L+41:<44MZ)N],8XYI:IF#FER9 38 R IOP[M-<4 2AN K\-13;FKK&)/.PL[U+1>;234@LIX!SV\G.UL4G";+ #HZ81FZP]R36 M?XWPI-74B>F%OX9B;R,^2MAM7*HAQ4(YN>W;3G0V-
]I+$!(N2: ^+8KFP%'L> M&P 6UAD CLZ;9R?-8^>.JT]$<]NOTV!8@U=B9NHP%O=WILX"5NW@[2"4I2Q M+ <:CNU;&NI-DE-[M$X.T#L_>=,.C8_[(P*A\+C
MVJQ<%N4,@!'O43I2]EEEI[K(>;Y%86QY2CT8F^DJBHR<'%JG8H\A)O3 IX (M).N*)5'.T;<[A1@Q7348#;\6./?UU_G.;?TTF+>\]:MV&?. M-0R.V\.'%(YZ=I_I5?1
%=>%G>K\$F]P%:V7@<+:T=O!XOKOQ^O5=>Z\\i"W M@X4@O>EAP3P"&NB7AY8>I:U%*?<_ YTF#5F#@#H]$Z722,:A&:54$PNV=1PF?B M%/_X0@6%ZK'\P!\W'Z[&U8)T\0#'
MN)%Z2;0F7L#UY), +\]K5]/:Y6I\6N\>__>F:Y\/A4?=<4&#LCMSRW-.6.G#Q MG#[A8)ZIRP5?3U.10<+!*/.!$. "7C!XJP]%P#<,HP[INSXCNX^G=T;1U?MEY MX'@QNEZB,["HF-
J\V+F474'4>%Q"%9.WKXPA7]%R*=>2 5WM&0FI$;?>Y^P.M.I6;[ZHWK;4,5TZK/*M@D,?'<%8>.1([], ML!W%%K9:RU*-N1(GBM=/K[:., 7?4WKQ.6R&M^]\51F7\N[9E> ^1(+V$K2N(
M.)>S2#6)A-EU3M9?JE77'D*Y+8JL7[2+3?'A])=2$29)I>B^9'SM18S<05! MYI.NEQ "WVP2TZ*[OZ/Z]+>14SOMV.OY.37ZW9\.IK:[OWO[P]^01O-VCWH0
ML0HVBY_M3N]G\]FL]4WX3!C7#E6Y+(MN%1ER+,H>SE?A(?) !95,^2&UOPB$4<7?*5CLL4B]ZG_K$?PS\aU?![!R@0 M0@NP,2]['#14$"T8;$
)ZIU@*F2+2PV6 ,ZSW]3@O^FH/KS[A4L'[Q[$!F\< MGM2$V0:DYUP> ^"X$YSQ1GYY>R1?.H7!IV1/7N0>8DYW&,>6L\?5*M)1,<5\(MW"'!(L/*=S_E*_VI7;M)""K7L)Q+@<97?
KVYU[I67Y;%R'UB7*FO?;U31WIW M!*HAU?]2S&4 MA3[,]TG9(3N)4W]YDGH8KYQ4)CM5$'|=V,TTYLS]_"Z<@-^$&4<7%X?DE1GV M2I8L; KCCM[M3O;T<1\OI8< 4U.TV9C Z_2VBE44-+G1,]NL-
[WH0#<_?:P;.M;KB27S""Y;#!*4'5M6"3[RE!A879RXP7[-(]=!HAFF)9SIAC8%O^1-'O MI#"!?IFL]M8.TH%\8H_#\KD"!.%TL)&F]".Y!Y<%PQ9XF\(M)O 9LDY40>"'
MD,0^^4WK#7LP@-9O;@/XA-Z DW2M16D:%U!?O6[1B=C;Z9(.1LD%;S^4|=[2 MFN"!,]#/!*V[.1DF]U*^3 MW(.!,3_49B'FX)$@KU70>$_K.3V<.:\LK@+2]M-)X<1TS98VAS^2J40Y5&5
MFQTFGUE,AL#96.!'4&(P#84^#CN[OQ],["%F9' :D)5'R[WF]U],L M0IP'SY!'L"K_#@B.GF&CDX2,ALKR*VABI(PDW)O 6=6?AD$?R;I[OP?OPRUA M#0U,L\0<%GLU,[S3F\VA8> $/
O^8#OTGY[#3HQCF.)=&PME5 M+PVY*Z,C/(-'NC(`.*XW8"]@ =*6"@8SX0.8[R_M:R(U ML"S@#?#^&(H.23P49N#4!V_%F=S!.%G<3_?7)W2"?ZI^2S6IFU;G.`?P1
MQ$0=&#V_7R(B))ID=_.%>+T);L:GL^X5*<02FFTAN)`.5^)HTRE .O5A^ M85^.:LWPI60R#0@M((% 2_$!MDK'UACE/%K+D!?*S"<<*A8P_[ ]D37%7:79D MNMV5(4VK'<@3//!$FD4HT0#T:
(.4L6ZU%C& ^#%63"[L9$Z@S1;ZC:.^XILT-0Q MCAMXN!SN\(F%FBXTL7A2SS1),34Z4W(+* $*4QM1 7O3I&.$OF*.VPJK!I M M<$@GL@""V;+.;$]34^8Z .?DP%Y1[-(NDSH)"/-(?
PQA63:#F]\V9$[^85<% M#8!G?P/%#Y^U?3FZA]\",O.H[N=R."Y;Y:^\QPCMR1K/O0+3.N WT$$UB MV_NPD1{&,-+*#@4V@>`L^_X_A^B3<[-!UH/N^NCZ6=IDNS= MF<"
[G4U+]VS.X2S]8$XC.B5.VV]V0$[4/:W5LI_$Q;X\KTO@7C:M\XX2F3\= M-A:L*T(O:WZ:X9KX0LH-\S)E0A(GX"0)0G3&1_6O^_+\L/jC"]PJ%^48M(V! M;GDP-(
Z'@%%_.:GFZ$*Z(@)A4+/%R0K8TOD>RPM5^S5LRZO(]C<,(IB<@0QU!5O.S;0.YHZTB?%C"D(V M.V13X]%XH!FDG.$>ZTEI.P\[@44]P^`K(04)]IG7K;YS8D=[JT5K"WST8E&O
MG7NY6GDOMCF]@Q%R&J2"`L-4?SP<$=M53OTE%$XJ>N*WCG HJ>$7<"U^ ) MSB&?06^!7B1O.B9AO!*$VVP2?./&8IKN00=#4!V_%F=S!.%G<3_?7)W2"?ZI^2S6IFU;G.`?P1
\Z;7CN+;9^%V)5_Q.S(FY^K1:.RPUVJ^5MX.7#<3OQ!S\$XC?\2BX M*N4BQ.]2N#-2NV5K9B9HS:F@@S,/_P(GUBZR\H9!W#V%%P-I"=\7CH:&O3VB
ME[WY.K4\Q6XS.\.;2W?./"66Z.*3_$*NX"O.=#'&[CO@76.H Z_P\&YX!I3< MW0$V1-BO-]6.UO*=Q]^=*'# SWDG.*_(LT/+$8(/BV9<'-E(.*J9C23NB_&[M/_.1B9]WB)_G0/R'B]l)Z^_KT>MOA0?
O\P[Q\ZL2/T:67YRRT6 1**V0IX<" M7O4FV6=ZN'U#'|UIMHPG6N.V/7W^T3WIY1)<]BS$Y1R1R=^C S&D.TZ MFZ{+)+MFPK:KU>U15GPT+W##EK/F:+82/E.U2?*UI)%3U
MSD\EM&PR^4RNTA9D M#/S.ON+]^&\]27T>P*\VD@0!RD!@.FF6I?3C[-I[:$][-4M$;V1>N^X*]+JGL M79CS&/Q%24/8*Y/&NQ'V*$M"XA@X!=)V=7(@S^@#HG7A,/BH>CNR&Y4'Y<^
M&:!CZ&VE3V)T J2)3"F9^DM=.;\$&&371/17"0%BY&F49W+YWM1-O*@D1]4@ M^W+[I<"=AKT;@"=]A5PL#$W5N4;S9YIQ9FI/DL2)VFI?-E*GC5G07BOB!SFO)
M0RH2|P&$,8S*7(LEXQUXX5D'!O;DO<@WO:4.UU"WW6I(X)#Q&<$X,_M*87 G\O-N^X)OU%NE1+,VY. ^$B.9>9;.'M(C!BG\_URPDP@W"2R?BASH4)-D M*.((?(F&WKV1G$:."IGC6;(?
R.7>S&9;C(&3%*38+)(!+N3Z]'FKZH(3]!D:1 M'2; LAATY0GV!^VK+L8+ ^N,7F(!*LFE\>=NQP%QJ7C"7%TFV/_Y[>G9DA>"_MN>!K'?
R6..@MRZ%:*+YKO/:CLWYZHHW?)9>>!=A_+O1*:7(F:Q>?:F(-W4AK M8E]X(U+?+O1U*$EGG(I(!?\O>GSGO#TL<8/:.M<0]!^)C>/KK/W3>T:X/C3B(U?6S3E0NA&"HS'F':$6Z\](M:6@<*AP>]0U[*
M5D0+ZT0_0$?;!40.@9T'(O-HG<>;R*$;4O35@H' _#*<(FL^K]+_0&IOK|K MB@:[\[?%X _3T_MO_WZT7}KBY_N;[@S9"&]O0$D]KUOG-%90%#]0(\[QS M96[R(UZMUUM+ HW
5P:.E%!R:RA5N&CT^(D*UC4G!'S_5YG.Y.7K92'7Y9F-< ME,$UA9U2:.TF@K\]K]7"P% CT.C7M&&]D\?AO>#@[OIXLEWF7_*W;8*Y @ MFV%!6#=DSWIRD&BLC4'-
HMHD@AP1Z3F!BR=NP/P1VEV<']>ESLRSGCT7SL+ L-M>H:A0%=XN'F[RYR-LB-M>Y50D(C%W1K-\?2H\&8\+5?2^/<[+-4"4GQ.@#B:CQZU$$OT='1X^G!U%8VXI#5UOOB4]
:,!,)N5!:5$F!1,%7GQ[!U,/1\ MV#FYJHB]=-KEMW-FD.&7G[V|L+4S8=T53&\4FI9ZD#GBD&L'C"-S.OIA7>1R M$%PYLLP+\?%H[OT/P7=T9-E]>#KL/(@WS]-DKH)V823>]TH2CTZ[$04S\0C% M.?
@A/R=G^$A5N9[X8I(;.##C,S1HF"*N%WFFHH M8@O([?]8+HUFS"0+,MP";=E<2YFEK\DM?U#@>G;Z!NF2G2,(L@-?,3^O1'F MQ=*S0F-
HN9U:.6K73+,J19.IH19$F!+$G%2"O/QL5&$WU4+(T'Q1282[C-NJ0AAO0#7*#P.LX\@W1$4?$0.#2EDTZ"S@JKGQU8G8PL7.HO MZMY((HPU^D-(Z.
(IVV0:@Y//V]86$AYX4(HF-T,!X0Y',A<>Z%\."&.LVR% M4 [A*TG<.&+%/X 4.(9..SA[H7;]:LW)BL7.H^& ?R4'/NX!\3%OE^1FTN\YF:(P MVXQ.R8*(@BZ\F68$U0G=7 .:#
0'Q"L>"S%[2)]FW&\]G,W$Y:P]H:0S.,?. M7E!.8](T\YY<=\H;W!5AJCQ0!086B5,N:ZQ;.:$Z];1G4*A=H 7U33,MFB^N ML,S>S,R[O3F\ _Y%L/-VM)L.DUQM7!@,23:U M@ 8:L04\M M-
&ULQHX.]EISDHYIYGK8NPG8@0.,0]"'3&]**4A"DP#KV$K44 7@V /[.E+ MCL\@6NIA+\?^!;BU"*0!.T734%&O:0X%3-B08)$)U]7#'S(Z#$ 4? .1/HZ MPN/TVZXI0>#S[3HX?
WEF5=^JO*Z\#>5UR>*D@XLO!2]C70!%L]97 M#G4B^EADHYK+X=.//#&.U0:J3Y5[!?:'B7QU>Z=N_%2Y346%#-21% KJWKJ6 M[XHGA6KL?3'5P\'*+Z1EP=VJ?4&X-XY+S^
1KY=T]>^?N'Y)7/M^G<[,'B^ M.#!P= HSQ8XM[5+P:G2[!9"%(!WIA_O"',K2>WIK# ^OL;?K[O[XWHQ1$=/ MV_#@(&1D6D<'SE#4EN5VI9+947%\\,IU A /ZGZ/"E4M|NY]X=K_1I+SBPZ# M!
[H";T89.!F*$WV!?0+8PRLL8N>CT-V=18.9^G]SCKR6]7*$8 FS$@ #-&-M1 ,.,IR/I#N5T"2N=.EP]47WT_42L"O7#X0#.\]PQ9XFL\(D%YH%L5]N#G0.6VF?+33A.=]?
S>ZSY2<#7H@2M;.4 M@[K\@&@2S(RKH\OIQI) S;'%U7$$&OKA]YN.R)DEYW(4+]P.M-KMC6%P[7N!RDHZ!)KYC63PK7N!R$"^4DF'8;F \4GUZ>WYQ*6G-X,.8IW3 MC^+\3619%O+S08-/"

*(S!I=;'KNZT8N&&%82?Z(8_>F.NS,G,A2(\KS%^?3I: MR.6KE_.WP^,*_PS.6$RCRQ%Z=#VDO,@N4@NFO\)4MOF3/?''F8[KFX8,3D', M]VQ.:KX^E8?CO&CVBO>_]Q%R4@7&%29E HH9Q[Y>)1D_5;YK''-*'))3WQ)X MF!,.)LF-FLT"_^>)XNKX.WO9?V8GO6ETOWW\#[!U'*#YLK#"OE\,@XE57ZI?-MVURP*I&)K8^,ANH.B4Y_FFV^O9]\MI73Q>T/X@2Y0Y@+-HWI1& M_^/2/3H\8(%+CY/*\OC=>C<#U1C"Z,)+(5L8489V""X<\5",A@2'O:6AJB) (H*4$ZOAD#=- MAR<4=LWFB1>ACZ(RPPAR\W6HF9]-IV[#IF"HV^S(!@-L:X(O1!@=H"Z/1'U() M])>A3^0N >11A@1WWG[-B,;,|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{$'!'+H\YR123# MQ,<6+#A"&GJ#M.0C$1KF*ZZ 1G.&Y29]#8$R8W/C$<)'&1!]Y,+[FO40GIH|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

*#4DE90VD(^K9<'M41=02&VB.#>45 Y]L\ G448[?0)0VJ7;LL 'EG9|8D8I#')@;5_&+_?7Y>[3 M]IMR6OSAK8*P7=?C+7"IE"QFQ4I[S7K ;KR#\/"^"]FBQ#'%/QT&8B-;;_D7ZA"=Y/A.1DFT)G_ M7%AF!_B8 @;_*!#Y,&'4P#[NZV@O\00LM8 LSQ!"_N\ V:93O#_=_IR-E!^_M[_V)I47& 8N+'^?GIQW4Y?.R)PZMC!8I&9X/XJ%<;>_XO3E^ESCS>S&NLJZ; M/EQU?UN'Y}'Q6%- #M&T;UV7R01B3I[VBH>K*[Y>S Y4[.T)L8D3DX4^+.\P# M8C@?7$0:T(13P8CH8**\X8#7@U=-Y^+7Q?/]B#2)!K M@V%K4C&_M^,$VG>(NJLA8^:=&&:LSG*% I? DR4]VF%~>2O#Y<$MGN;-/PJB(-^3%'9[NC>Y;1147Y(.MS57POT=_8;#>[E&<$922FT8>56.E-25RDY*$\E5LD42B 6WF+*2G%}2W#(X(^7Q M+#0^27>02'!;PDQ2D)3)62+:? 5[TQ<@.(2P0?8=GV)6-IW8B$65ZT:)VV"D7 M@SA'JT^/Q54N;.5N6!6?B+,RY8-;*Y73&XO>#/6CAV_+/,*WZ;5=R9({0$H^_M"!+M2)1%O6UP%C*OW*N=?]8-!+9]/H;_]<&XU@U5E/F <6VIWN1#\74L5X4/ M&%2%0^SPA7)JIB%V.20S'RI'* @C![_M)5ODEBSMHOZP\;Z&/=70FE__&SAFIE(I}$_5I[)Q_7OR6[IP.U5'!_AQD(3\ M]N(W2*#6F@1,1FZ_J/4#+B&I1S6U]4K?YRZ&~^8 #'W#1>TX,?(_N4%&5C-87 MV-;R*X_=FF.!N!XT"N $QLK(>_#^/;4OHL >;@>;8+|EQ&C2<G1C,MOH8 MF[GNC35%%70P[OU5OB)BT<U:7UGZ)49#!M<K>D.1?Y:.|@1N[OWC,)H]GOH# M'8Z8,*/>H*M/5*31N*.U.T)"JE"0U7[;$05{4GH@R$\P69NJ+ 5FEH7IVSI M9"%-3\4QWGT/^Y:YGS"[XLA,4.Q)OT,&JE-AKPYPTOE83>?;\=4_AKD?M@P MU=D AT2P'>]?.[<`)'(Y(=*0LFR+VF:+ (QL14V4^U9JI!!UVE] MT(*R8.@3N6M-4$TV.[*I"G+.;4%622SG6K(Y &2MX&6N;B\Q]3?@+#QO2[@O]-M&OE%_/(W4=NUFSNA-AC YXI.O67!S@L3X$EXH3F4X34P#:K /6L ^Z(IP[_% M_8H G.R2W"1+.;)Y#/|\0B.WB9?]2RI[=&LM8EV^-H^AN2>AC2+LZ_.N M8BI&:G8T<:#;+DP=/^:#DF>$%@LS+[R4]YD6(3 AO$#/_<4*W:.2O%O3WFZ"K;R!XO@!!R"H0WX3 = MD%R4$#KM/4L?P&LE/+6S3^RG2OA9$ BD1.8W"',H;YT6(OP5ZUK'K\K?VA'1 M]T&>4'4Q"IN9(^W_;^],F]-&FK;_ZU?HV72*WJ>2)#*$B<-WMO%3XE.#[%V'&2 M+\W<):0 E0B(Z&\-)_?_W;/C Z 1 4&+&SM5NTF@$8]/=.]?;S&/6_<#6!%6Y]9-M3ER#VM8<{D\UX,@!C1G6DX+.]TV/_H1GA\#B#L ^L\/_58>C]ZWPY(#!1MBT-MAN8[Z%(\RN_,80>29TLXI,"U>1?T,H&H/C!_OWA6\P/QM-!$FT? G!=P+/BM MWY& WPOI=#WX =VZ.!46P?T1#X$>C(P5LNR?'CFBH#[X8FV)1R#>PR.VOM$ MCO[\=@)G&QRO^-_AG!.8EP!ER.#5P@E/C1/,6L*#C@D<,/|_?)MOQ6C7T?-. M-LAFD4X"57C3A2>6W!,PK,)2)<:.),=2L"F/9TL>,SPKUR.C0!O1)JE=W&'P MCXR%C\[.MT2@7K+M]%4+/M?I9K.CL.1&H3>V19Q'$;T%|= (D:+3"&T#8@/8VR((H%V+-]!.3[#'+X+%C$*'600_]0\U&SH3XM4E,"GE-=E2S1=H2VU1^X+#K-MRH55B MK**+HK!NH!_|M0[-<15&! A$8AGL7M,HX, E0\] ((LX"Q9BJ+]\# MB61.6H\K*R^_)<3 +LQ4"F!,XI1EF1.%!L_&^@<]2W!,90?)'B M;_7<^/8K0;S.*Y-%V8[42)0[-/(J1"0 ;;X,@M:"3EI+C4XZQD*"/10=V/.6 M/7;446K(4HY7)+[!7- M;D;&V@OZU^]3"FIU9XJL>YG'7I9F=SD:IX;&K/|KHDVL&S3{D|>PK2;.=M#"TX)R .\OEZ97YYE@'B54B+*.M[.5HX U4P829/>E'IK^3%>", 73!N(OYM<64"EH.0[2'MC)ZF6ZRN3O8%K% ^=? N(\X<;WI;TEL6UIAM2K&*M^-TNCQIVH&VK2LEU6;ZH7S.4 \H;R7O3?E.6O3S N6I5]C?FSMGHD61*N6YO?1, MM"O0([M$S68/ZOG^-G-C1/7N$ Y3T3'+//#0=BITF7F*8Z?9POO[+.R+/H3H%0 M*2RZ?A2S!?!1SS=-S(6L*IB/++\86%[PBE:MSY^\ST5*62HVLB.4;67[^2G)$ M8=V6(*8\Y19)GSKL&D^2M_.JWTH#HV(HQ6$3V']!Z]=FK5XZ_R^,E7W.3:.M2=5YPW:7M/K&J&G.W6CW7&: O.0";?;@2Q"L)+/\T+=%'N)=C3\GZDBUL [@ MU@8!"T]{Q &!(0=%;>('%6+/Z#!/L3XS=+Z5 MT;VK9L6]D\&GJE:S0DP)''+RL,.QL';X0=/!2GGO'MM,S[FSQZ^E3$$P*@^BZ MV"N@&RZ-B3 =ULS489<84TVL4*96LJ*>ZLB0E6SGHVCH8@&)[.#)5 MRWO\E/NV15QOO%A*V5..L%I6CK"%5%IV8$9&20JEJUK(2+.BRP.6(.I:SH(UDJ MEY8T]-=X:/W:.OTI V.53S#\#++6+IY4X5#7?O(8@C0S5%V'OR36I6DH1KMX;.M.6L<$6IK1C'#_&+LMZ9/0U_L?.])X]C 09M;?2S.33 Y)WQ$OM3MC#R]VUG.MR1Q!6^ZO6:F5AM=&+VZEV62Q[_*-_ ,F:)D4GS2+54ESO=]33T569^C\)DW:B9UWKS$"'>]BZTSRB?l0 \NBH[1R2[K3(8?@'<%H M2;H+.E 6],,>&XWJB:1#K2>.7%PR?O-&6&GI1%X^L%,MR,:[;"F^+.-5U44ON MNE!]4F6^&';UAI%MDMZ4Y.HB%FZ9[<'7D" .+!?F8H8/ON2OY^>Y+,G_39T M;7.W2%5Y+K+VG!U&3[LOH75QW5XMG+M8>SXM+K'LTZ5R40$=6%_V^>7SCY5E M2P\W24RMW.P*.7(A1:CYKPU34:UGI91/EDK>)LRGL.22ZLACDS?.]0=UQ&- MHES:OY08.DSDTM4RI*L9$9A*844[9=-ZXAE)2O54K+4W&9:R49.A_WVQ6FK M<[3CF]%*/:C]OO>_]- 2SD@:5RU*YDI6"6[DTI[T\@_60F3I*\(PJ6VSHW+3U ML&_8GF.HAC?9,3TA*]3+]&U>3Y2SLQ45]9:=BC&YD.*RVKB>6 .RWZ2>F(]# M{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{1[^RU.P#K M,=TLGX;*MW;&,8%9B^'+=X$]6]Y7O^#[@')AFZHU!%?(R[F6"MV4\VP!QFG. MM#FF/0@=FO-KCE\O#WFTN03R: (=HOD/TX"9E\=BP0,Y@;/%-XHD_=T46?VEY M4Y"0L\"@W/|FXL0CS='USBP)/SS+!Y> H%ZQT.2F# MM1N4ST6-=H+L!;&=5T%[Y@ICCB9D9!N6O[M_Q0-[.+0ML>/9VL\LAOA6"([7 MG_?;O6V<),4L.U*SOZE.Q"A..M*H9*20%[Y8T5+H2*H9&KAN6F-G=8 MLRJMNF+R..0L16%L#%"YM-8_[.W!YX3,?6_Q4NU3|#3OCE8YT[&#JE<6'/ M4ZL=.=PL\W@^J8;GPE2TJD5? +.EW@FXIP;@?4"/R3X*D.?C;KG=:H.7FCO9(U M/7 I85QVTUY\4L%TWHMXH=+?8LM1NX.V7CO7AX1.^=S&.:99+|\;>*P6/X%2;. M_BD"!Q)XX1#UYUZ7]&P'1AM1!L9)K"60B/R(5B4.:OYZI(LR?U>3?.O+\)0 MJIR@%Y3$.QHH%B4*B3ZF#.X^ZUV]/"6LW.[HV>*E^

*1;H@WA4[AH! .:C7*Y6I)$ M5;=`F#)/,BN;I5]*0.7_Y89E;D#E?,DZ7_)(96Y^!IB)D\\FN(/)S<+`'S<\7 M%;E4GARIS,W/%V9.Y'S)^,*1,KVO6ZRRS!OO\\,/[[#1]Y_\6?`)\G,W%5;E M,@U&N207VN>==SMK\7[=OS]EO+4MO+I<([DYF47SI(,=+SI<7$,W.C<[`MK]@2/6WMOTO+]%3M$M/-K=#N]\N^11#]/`+] M;&,&Z+9LSDN'N+/#:ZK;CG[D0Y?-*?__#%?\[*L. [!AS(EZ1D>UX{JC;8]L9PA!fGPLB##$158>(MENV).B%#HHO_^\;BE)ZWS',HM,_Ri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|_^!+3_+F!EQ7QB R\|[+&.V?FM71U*X9T]"=^1,*# 5K7G9<-M;DI9=9"C9NWD6; 9.#+4VS?G?3(8.SY]=VKWIU,)!_?CHX^?'=_-*M5Y!]M:7>??CM]2],>MZ'=]7O M]?]WSD_OPXUR^.^WZZ*H\N7!JQ.!?$<,:'X? 5K_[^UIL/'U1^)U6UOYV3'Y=RL=2U6_]@ M=GA(,KUS7UWUZ_NI,.^%1L=8UCZ6!H\+O6(V7OWI,9POAOZ:*MU>/+IVN.M?KT:[A_xRM6,M?KT:[A_ZKY['?$?'?D?*WUW9M/3NN;? V<73^\O;^/>_=>2(H_UBNOW-M3US/=,73N]K1-ML57_\%&IV]??'U&/MZG>Y.OE1T_<_G,OMC]l;C9YV\+D^,>PW;)VH99M<)A8 M9;]BU8OR_>3*!]O7?7LW1X/+G_MGKG\)X7]N;Lf'$6?IoS/W_G>>3U/Q-)%2?4 MK)WXYOV:^,XN79P5&\>?!KEM&U_DP+Y]>]G]?GPQ:\Vj*5=?)L]SH'9U^,]ZV3[']jH^/\N)>/\\[%Q_NWJ]_W.FHS4 MD^_#IO(]K5H-71{<,UUC,#}]Y\,4_[UZ;MQ/U8OZN9WN_CN>]_XV+RT&XW;.MWI{V!:U\[=_\#]=-OL?IX^L2Z,X+AZ-VE[#*IW''^Z;]FA7]Z'+7?T_??1^,3W_?)=>_3KFWHU(*,N M8?W^)"LM_>A+O71T_>M[K7S4^'QT_,&Q?l/H=:,^]WSX=-4Y]/[X>]/]WAS]+-M8ZMZW/E8'WZ[&'P<*,?DTT&O8Y>*[TKG7R,DP!G!X?=/^NCC^5?YO&U^TX,F?61?7A7.=1^_R2? MU .EZ'WX25T?? NY^;7]NRN=?+DPC6OUHI[W/@V]>UR6-M?[S[?KP@<KZ4OJ[W1]U-R&4OUA7MR\N_IYIYT? M[<,V/'&;\D>W4]*5ZUUQYHC%]]5K7O0M__5%*K$]@KO@CXQ[_=?]^_{@?.Z< MZC_LR_WAS9U24FQT/WR_/+!_.7<_K]7OI^;7WN?KGJK8-[6O>L-P2.WW=>]3 M\=/D8'!S?W8VN._67+GN_[A2&FZS8/+KQ>_>_Y5^[==M;]U^_';@?6X8=\[1VO? 6]WVU\G'GG);._]=_7;_4,F2KZ^;1\2G=OC_^,8>GPV;.Y\;VL'?^T"_M0^,-^?)7Y]PF[;M? M7!L,SW>GZNG=]4L^3ZK?#V^^^#W^96O6TO^]/[M?NB.M_*'3D;_/CX MZQN\Z>"S?7K].8.[\;^,YO'G_S M7.S;^-2]_*&YK__\U!+_P04 "#Q M@<@3VQU8OZN9WN_CN>]_XV+RT&XW; MWI{V!:U\[=_|#]=-OL?IX^L2Z,X+AZ-VE[#*IW''^Z;]FA7]Z'+7?T_??1^,3W_?)=>_3KFWHU(*,N M8? W^)"LM_>A+O71T_>M[K7S4^'QT_,&Q?l/H=:,^]WSX=-4Y]/[X>]/]WAS]+-M8ZMZW/E8'WZ[&'P<*,?DTT&O8Y>*[TKG7R,DP!G!X?=/^NCC^5?YO&U^TX,F?61?7A7.=1^_R2? MU .EZ'WX25T?? NY^;7]NRN=?+DPC6OUHI[W/@V]>UR6-M?[S[?KP@<KZ4OJ[W1]U-R&4OUA7MR\N_IYIYT? M[<,V/'&;\D>W4]*5ZUUQYHC%]]5K7O0M__5%*K$]@KO@CXQ[_=?]^_{@?.Z< MZC_LR_WAS9UZ4FQT/WR_/+!_.7<_K]7OI^;7WN?KGJK8-[6O>L-P2.WW=>]3 M\=/D8'!S?W8VN._67+GN_[A2&FZS8/+KQ>_>_Y5^[==M;]U^_';@?6X8=\[1VO? 6]WVU\G'GG);._]=_7;_4,F2KZ^;1\2G=OC_^,8>GPV;.Y\;VL'?^T"_M0^,-^?)7Y]PF[;M? M7!L,SW>GZNG=]4L^3ZK?#V^^^#W^96O6TO^]/[M?NB.M_*'3D;_/CX MZQN\Z>"S?7K].8.[\;^,YO'G_S M7.S;^-2]_*&YK__\U!+_P04 " #Q@@Y9,I0ISXXE ##A@(%0`!W:V@M.C R-M_# Y.S!?9&5F+GAM;.U=:,?/.)+^2'E7W'W2YJ[N=JG,0E$2)-"D2 )4N!]V'!L-/MT/7KL;P*]_M>Y]f(@T=,0X\$OfTZ>/WFU0`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

M2_!KN'FVL!5 M BI,K4_F6TX,Z6C,KWLA 1_-Y.%CA9CY]'&3G)(RIK#.%,(!4Q5B!(J,"1KK MV9KH&!?3+@.8FR.\=9&G]4AW [=\2[O$_WE[IV;B_]+W?N+W?N+W>NW^E?L MW<]X1O CIDAN?V'1ML=WY6WD(§HKQHS/V/50(+WL/5>B|01D]5WOF^C N7(W M;FNU[9+LMT])ES!@=&./:W+U]BQ"f)_P#;;G"&M\[-L _78/V#S;<&B&JNQ M%H-GU_@1!S'F=XC?*
*IO5FD2YQP.O@,V"6R0|R%2R#9:9"9&EDE}_Y6R2Q<73, MRN[0HXK%$:G,2XT"C #H6QUAL8D9X,=V.?"WX]PPPRE(C15|@Yl_DW;D+XY M$I0VHO6Q((§B_*SEE/@>F.2F51PJU*W F$^N FQ"K!I=&UFT$M% KCQNIE^% MH4.%)=DIS:VIT:,VZ,72O)AN§[T!O7)<{@=V7KWGNWED[0D53P%*#%US73I M7DCT];E[5 ;RTZ_8'F", !Q'GHA4WZ(BCQP*!-,'QD^F!0NKBEM(!A9358+*
MZ@:19>ZL6;,1D2R!%B5N#TP=X;QQC;NN3-V.P+)!}T-3MM-D8MTF1%]#C1', M!L_!H=AU<%C&=3 X_"FG5+W LX%L'§P),[K2Y7&TB3N3'^0JZ%T>OY6§1N[W+HW=Y]"Z/+KL\4OPX-
Z8IKVX!)#K]\)"ILU/^#E.G+_OP=S1R MRR3 UD>VTV'}\ @V"EZ&@7L9S3"54B03,7:5V#:*!4"IfN:R5CX6,Z>'3_F MD!(@$\GN0>,X11B''^1,)0YAJ6R^T$L3HJ@@.K
M*3Y_)\1\|GQ_S*8"CW)M.5R81W'YG>!/4A]X\C?WU%2;JND.L/X M3H?.]YB-XMR8%/LHXLFNPMM@@.7I-E5VF|UZM(>8?V>]&Y_B!XH=+\UU#OCS MR_@4U@4O*(M1MDG7U@VC\V=A"!P>LG?
D!PS9/&>(+++DO3RZW$X3]J CQ^=[.]S$XPM*E.[1fL6ITUR8@PHMA_M(>OZ;@IBNT*=2D.033.GT,"4+.7]C<=E&ULY7W[<^3&D>;O%W'_0YUV8T^*:$HS0UM>R?9N-%\RUQR22W*DVW-
<*$"@ MFH0'#;0 -,GV7W_UP+N>0'=79<]NQ%]<1F;B2]176>^L/_W{VS)!+S@OXBS] M\U?OOWWW%<)IF$5Q^O3GKS[='\WO3R\OOT)%&:11D&0I_O-7:?;5O__;__P? MB/S?
G_[7T1&ZB'$2_8C.LO#H,EUD2T37P1+_B'["*7C=WGLEP5/W[WW>OK MZ[=[]A*\9OGGXMLP6]H9O^^#K^__9++X.C.*7?+(<1?U5K4BDSO M_0__/
=>UJ+"]OCWE2O^/XNOI.8YD\C37R'21% &//X%UE85"R8C>^!BDE MZ+^.:K$C^M/1^P]^Q^^_??NBK^]/S[Y@GB7X#B\0<_/'M<[R0@TGR_#NJ_UV*GX(21_1%/] 7O?^>ONB?]I^O@D>K8J
MI>]<@W%>9O%Y^DTU$-M3_!)W-H?;_7<-M?VD2Y_&T+]W1W OL4H0\^O/*OVM"?[PB?_4@XK>2-& X]D%2$YH(S-[_&H;* M=F,]"WMV$OK-LU$TG;:,,S.8B*!Z9X75Q]\0$*_*"#
[_[#B=E4?]R1'JA'Z'Z MX5?:-N(E3LO3)"B*F\5]F86?YV]Q4;.^!.?GGKRSDOQLZ0#7G>>U%D(>&3U%) M?!=FI"%.E4<)_^A22Dj87?H(0F HHT*F:>C A*%Y%.5TOB9(:K,XNDQ/@U5.
MAJ%:OAAT7'+ "'GZ71UH%,)RR03GD5ZN#J)1G*)*#0[:IG_9Q"F.SH.\C=.G M0DLSE:!+?ND!=XDEEP3#*"\V\(95]851+[YE!15YVY$/^U3*((@+^IF6=(Y
MDDHXZ7]KH;&>MOC8.OO4F$0*O.1T%84.^&|SV!'F' ?XC0@(&YS M BY,%\GF#]^RO,21?)\FI>***:,@:^]8Y$%PR1+DD%RM.*KEX428Z_KH]1_M*4FEE?81>12095%H( ]"169\MM%IAEH#
<'H]\S#,UF19I=!&G M01]2QO4.ASA^"1X3?+)I_WX@>#0S =N9= I#WX'SO0[\%O:\LWV'3HA5HA9$ M5'*_|_7\0+?AS$FI?^ \R7S0#U1]I-V-D=]AMQ.CZI%O1/(#M^0&U0!51](
MJB"FL^\Y)0[.NVP3).7FEGR#YZ# =F11*?G@C.X\&77D&N 8I(6\)5*EB1I5 M."UN%4]#Y#(MRCQ.NP.D@[#(\B7=K\3W9FE.5WMUERWI6*>ZK:.MKG=Z3@0\ M)&JCCE!|U#%0[<^#,E-
-G:4K#HXT_Y)^@':>S%;0)5?'.=1E]ITF&JZ.@CMD M:4\9R3@+'*:>3B:HE;9!+=HYPI4M-"S4PO+3'*DS.' PC[W#" GT&>,:EYR$F' M @CI DA\1TWM$TTiA:
VU6'L8[U5R)LM<&P=31D<4PYR&/L[@TA5^#H,<7Y6*V6BMJ+,AC0%L,Y!1R'EGC 6X(3>H-&K% M$0'?]\CW_ WCE^PR#=54$$2<44 !KBGZP7,812X')6S%85*DM0KW7<(72?:. MI?';1QS%
(1VE:(I;+>NLS$UPF\)7"<)@@0&=, JLQ%$E[X(8)(@H]YD1-2,D M0LZHH 38<$"(@@%'X*EC#4J=RS>34GDO[,B+MRN5R10"4VAB@$'16ZE]@3V?5")
"ORH5Q'50]P1E0O$V*%2;Z[H"3]=>!&"]&9;F*1AZ")"$^)Z M+ L?+!Z83IA\Y%PD0R@M120BSH]1* !VSL{()$#0O ...%P"A=%E2P@U]P? M>3*&7#YYH0%SRA<5S!Y9AD)PF*))M"DE8-#D;-
L_5@NUOJ3 4,AE^20 ^PR MHR\!AA926$ .U$)P"/$!3>+/. D\9"?X_$L2')98MH=)2YBQ1EP2:!J#7<*_MLP*&D)-@#PE;&T%EAAXO:NR@OA#J;%D#P^K+_,*+.(U+?!6_X(CT](E3,8%(
M^_AE<,+Y&/P|R|E9>,V0;:05MZ.X22[V!W:C3(!A]C3.XVL%@?#,C &X81RI8%Z M*G#X=16'.'U(SV''E&-V7$3/+HV\2VX987>9I10&PRL30G'/<'6/6@4XG+I_MSO*2,HD_PX^EX=" 0M,I#
(@.,F\61"8(AD,Z=,)L"}4]8[<6]/1LE]=;=A"2 M4GRSX,L AE@D"KH-0B]@_>@SE)#&24T,=ZDF)X+K-9F!A)I"AQ^^Y2]?!?A MF+.$_&2@_SCU_,TC,O-/K(=RAP4?VA"#
V"B/(@@^MP7>3XMS5.0!UF.*M-[^>=[%WI'74R-MJWEGW7BL0Q)VQ%$C#Z57U+C505G:O3@$=$_M5MAD251YTLX9:C1-!L3FS[_$."[OH*-/P0D(U="GS1%X=%-BU$4^KC1# M3
V!QC_,FY|&$VR#U!(]F$1[+C R#9 M\422'<,AV1G.XY>@C%]P>QKY+BYT T?H59SN3K, W]NKI|$'0S0+D.+D2:/2 MSD|+JDZ0F 88D,U9 6E8SG+) $D6QZ?O#.68;'M(9PFGV/]P'L1R]
(ZWY%RM/":2 1BG\7*]E, ^KB\]=%;@45EWH MO8<@"EZ&2)BFY#)^Z_7'X$U?W/WGSHI;'JL|!NY#&,4M0204 Y?O6]R_X/CI MN<31_ 7GP9-B]4PMYZKXM3!KD&DB%0-!!ATQHW2M95
E[#@J6]4X+%/BU.W0L|DH}T,_\T%WM;_,>9 $/6:,C%?'K5M1Q\ M";4W;H<2-,^+,EX&);Y9-Z-)?XRX9(,6Y+GW'Z((A[@30PL;-R@3=_=S9 M P"2P)(CM;>DUBVR),
[N\9,A+9"UMH<Z6!FM59QN11SK3;$RVU/-. MNPE@A4Q%/6W444>U/K3@B-O:H3_KIQ9W'_[4H.5X)\IZ9YHE0*N(MN?TBW_)
MDHB\|D5ZJ"*2;>1K=E,\X5XRUP!2,Q_QD78^4O'!3PG+X[8P.PD>)+ 'SQW5<126'49]QZ"*&09(N$. M^UH&42%?Q7R&BS"/5S0#BLZ/GICS0I> %,]^(P,+ B(P.1,ZLIX"^QU^BHLR
M9REQFA9'$\84\]Y#OQ;VL"V0"H,@C0U"96O154*.EB<>S=-T'21\;47C;% , M-6MD((=DZ0ESI..D12"I&M>** ,]3$0 \4. M,38E01IOOQOA]Z'% (922**.A]N*, *0X^!'"B>*,"IAR2-O%^FW#_C)*EF
MU(Q9Q'I9N*(.MR?LGR7D;65&DD? #D %,.3T]{8#DZ",S48-(^R3&15R$0<*Q7)#?9%D2-;*N M";*$.R2)(B**"IT2K)PA9HS3,4K8?X+.![D=73J2?L@B0)53I1$#2)0A-A--MJ+P7DIRN\
{R'6MWBJ$5=T<0$MN;)2@X$40S@Q&SS3+Q^%$\MT#G+|GH1)_AZ M+=DZ)!=QFY!7!-=/P=L^!\$%!2A%FE'T]A[B@EY*O5PG2DMZHH71G*.:6 7*0 M?1;T90 Q00I,P896EEUPXH41IR0RY?
2"\0B__15OE'X)!CDF_LX #05H!:,JB IKDOE)$#@4T!3LJ;71_ M>>JS)7D(WBXC0M1X$8=LT=G $]6\6[(88/R@&+:>DLG*A3RVM"B""V>!4T*RG.N-[4E"6H\H MHA9\WE52_>:4
M_'F3/V2OLL9W02DDOE!&A2@G3BL&CBX# 1!;]0/LS5,4G35C'ZB;_S;.7. W5 M76=5N!?"*$!+63.0A4<=.4 3?YH,<;WG=;P3KFODM1B?}),'Z0\Q' 9>"3I M S.$,&%R[MDO#W65$&$:R?
^-5]]!N%S8"SVD@*4DZ4G'HXH,GHDP7 <1)1\#ZX]N M=$%#>I1L\S9:K,,5K/$W"T(@@0R1,)B[TT?'>>.6O9AW";AKQ^ *)TAVB$9KI^[K@T?\GCDKSY M-%LNUVFURB/;.ZB04A)@4!#L$B-.
(YS>+ MA;2UUPF[(H49<$T.M20(DACA"8D.**0 M$KR"2(\1#J!0!!QO15]WE1 QCWO/SP^O*60A$XNX]O 4H!K6]3!D4]Y(H(%8\T B M H(*:EO# EOG]!)%7.9'=]H>6(D[@^>N"""%51=]R&(0I/2?
P4*)(3;]5=DT(#>><@/B2@H]]CO M*6 &HX);'=<9+5F*L\MTD>5+]OX+\H?$2X6OP468HG/!>6.0]82<8.A O M18Y.P9!&&'%//P>T>?:(I\ % YXT!8O>W/%O;2WHP;EMJ2P@SF@\]LYP5SD_
MVKXQU_)TQ++$>1"6\0L^"\[@P],T5R7N^E"E#O3P.*5,%A"%M "5YR<;'9HJ M]@YY2UE3'Y*NEI/F6:7^$#*?>(8 :.*8.Z81 40/&2Y-!IDN'"_#)+D M9%W$*2[4#=% RBT7I!#[7.B)
.*"#)>'"TP4U;)>N'"^Q/D3;=Y^RK/?\KG* MSZKT32'MEAM;R'V.2$4!<46'3\&96@5QG3]EKA_RO+4)Q7F61;6G$E'M%&" M'7!&D(-$&!4X@2T)#NE\RW56HH<,?2HP*\Q8MM9(_)[)Q,\M^/KII$PI
***\(C8)<1B&=L/-;1Y2 A;M'!$D01#+"4]]#TFB@6L4Q;IC%F!UQ' -!ID3 MGG8PJ[ABD"WXFD=&J_>Q>X0@?OS-TX_K7BFQ\GK86U9=.^X8O:MD;VFGA\[@S1!LL@0YY!2_0:4WN&:*
[%Y$G]F,NLGMU5V\GI#CGK$$ MX*!CW}$ P1$E+%6WN'M7@)_<>>O') XODBQ0S[+T9!QGS!/A#9+EM0* &""B M4J7(8X*(27HI_Y,@_9RO5V6XN MC<&&8&!K
G5LS#HMEL_)/+HG&9SR\+/!\!^8-WZ[*@+2@!IIX%URHY7EZP M<&"PR*#1 $0|"YBJ!0>FB9CJ#'%EU-'V-#XKVBR .#K9W.$%SNFY@P?\5IZ0 M%WW6C#
L=%V/WJS=&0[FC(H@2#@6K6JH5Z"N 21(]XA5)M#?]!'$K "ZZ?YF MT6PIN;F#H?M]#A5%P2=X@SEYQ@][_2< %,8L%BKT]VN[0ZB6AO] MK=;WS\MY4>"R,#!P*.22;W* 75;U)
<#P1PI+V&W&A'X$0H,JJVC%!D'6/2D4 M<$5N# 2!442.3G6W2P"$.:=!\3O/(_J?\]_6\4N0T.9X7IX&>;XAW<"?@V0] M/%@Q4M(=)U8GL.M+._?D$
MB+V;2P;:.M$EGTD'#.\L@0XIUZHOTGDG6K6P5-SA$!,/'A-\C97-I%S6:3,1 M@]MK)F6"8,BC0S=D# O+1E@S0T&EA?)&C46OC*WHM#\6,Y3BW4Z/3;$66VC] M=0@47T,FZ)\4;J!=1HE28.BDA"9?
^PM[^2_O/+&AB$=V&(GACQ-E5@;)E6UW M7'6"E1]!QHGKK,0%Z=9=94':CY)ZGECHN>2.M1M=/AF5P,0=6Z1#RO$))"PT
M671R*4B2[)4]760D5.4XBDN49(26!7W\S^^/9^_^]9BU>_3O'!ZJ}YRE3_YC MG6)T_&Z&*)G8\S-BGNYF^)=_>O_]NS|>OV>/CF?DM<4*L\WAR6[7N*ZUX9\5S8UXIU^\Y<@3F@-O,CR>S*
J4ZFQ[@XPX]E M^R|5 V.M[K3')'NE4KS6WU_5#TY& AX3|&.2?<#X4J;3#\,D(45C(K!50&;U5_9@ LRJ('1PA>?>B\L)20A%2^7@3). MN$O+@BXFT;MAY?E;F*S!MHV?LBQZC1,5K^U478;.,&30
KF0FK M5'<95K;FX&V>K7!>;FX36GG2B,X%KV@K]FZL]"HN.6<#OLLUG3P8CEF.%!.[M**+'B)EA #+B1+G.]$[<_MZ;G]$+6W]RFAG9203 $ MTZ%33F;&3 @[8ZPCFN_
91>?/("3VE!5T)O1!=%%=]E(..2IU)X7>+U!,_P289] M2(U&!A4XC3,Z359"V;)ZE;5/#SA?7L4IOEF]^]X?9^O]^SRA&__G#'V9_^.,[/?^.YX 0T"_\RAB672"Y#:(H\OT.%C% MI$NJ6AY323M=EM1#
[BU!RD7!<%]/3UA.;*0)H>/H'$Y1R!6\T^@.ET&ANOEFIY&BL[P(@Z54ULVBF[S1M@ZTL\<8=("0SEK]*%[5H015S2 M.^W$O]MU)]?WI,%NM !K/D.)3SZM42@'"MZ)8]KP9I[04:A!V]}HF"N3ZL B
MG"5;XZP;ZXH!IF.5U3!];@^RS^NSZ!=9SI.SR) 5T7 &;F*%Y+ST!.X.H'>_\[4\$W ;Y3*H)D'+NK>@S:,@?23.L# [&,2X.F M6 ^B+,.NX$DAFI; ^#L ,RS3'%A1"6*J#99KX20D6Y?
5T'L>4ZO\ANGI6FI]60 M,1T\"S4P/+3'JEA&.8A^G7#[BK%3I\7PO$&;!IQ&'"+G!+#MRTCMP /7B\(^T M73BEM%=>]3MO"E&X?-)VV1PL4XI[3;]E!9R/^.45!0,I?3XQ+O25!]U=OP!NLWH#K_@=
(U-]QF) M8FX7[.4@^\OS?1DP7%$ DYQ&86+ ^]U?6%P+,T^@"8TY>EH&99F+&@7!]RD;1 M<;X[2T<&V>X,6F"H90W5G" ;Q96MZB#ZC/Z79\U#*"[S]F05%$W63E-"MZI-0:E,+?54T-1}^<]IE7
MK(/RG#I3>.94=^Y>X?#Y=%R7A>\X,.NE#N%G;0Z-HZY*DK32I>B3C-+S2(WE0 M&*AJ.IO'/CI6N@X5K-U" U3R74%Y)>2]T$^S@AWJ.G\X;0PIK+5XFXG ?2@-M^O. V^4;<4GT$E(I)A
M>L!=:LDEP7!*"T(R$D>T3M@XD;8GDZ*FOSF!934L?4HM0K!AK%L(^5CIF M438M4(F X8P(@8=QU?/FN$/IU5*X A MDPU*PZA_&.3K!>E@K?,X?6('(9E%U]?JS CLBHB*>;739P(17Z9-
AK&;O3S\ M;4T;7W]X+L?LB),B3YEL1F0[>\[FHW;A=C 7M8TO[XS>E0?" (&9),TL6A"C M_.ONU:PM7M4&6[3<@R2UGD/OF=XE>,P9F!H^MMEEI?QA/V3DM!)PFR+6"+V?
M*%8![IVBjAC%I+&M!L\]W-$!T3_1(8X>9!0EZ)EG,9TX$U;Q.L,>:.6TY&% MG0N](89>!0SK[' .F5=!<=+U],#0;CCC8SDQY'>.S69NS0UU?N#42?$3;<,> M3/.Q"I"*+1#T(R!Z$1*+5'"&IL0!-H?
#81HWT^B5/"UQ;QO0+&]+.,"$)RN8 M\N2+? $;25T%I&]@(!+]1/J.04+WNOX4Q"F=O+E)VON 55'*]4VB;"5" VT MPEH5.'2SPRFF'JZUV.WB3T05?4UG<;.^A$W.O_"K+?6V=N,.E70?S37K^AO,P
M+L@@I[I$4WI;J96:LP'K"'">;<:F%CG=>C00Z)!.11 VU&*\UHNjL@84/)M2WF$Z(O-P!^LT2)=-+6'5.*?2@HRRUYJK<+8SZG0"9!*Q7EKC5:&A;"?TGO%N,AR'#^_E_%:9BAD[53#D'8=7&;OI-
.VZ[-0NN-7J&]%P M@\K6+HOS_N-YO8FY*,JM?G&ZCM.GFV;2@+@OY<@G0,7'.,WRN-QTAHQ]*SR/ MU$=MVJ74%'.]]' , M,'2LGL(*6 (nVO?0$D/LJZQ2W=-H+P|R|6MPE+4R@NR11R8*)'@:
.:NX@TO[Q MC.O@6'02%'%HZ6\EZY, /;@Z]C!!L,SIHAO2ACT#QY.S.%F7RBPA2FF??!E MUK&E$@7+ESX^89,,?^]=.[^0(?;DK$0U.(4[@ISBE#2!Z#!*ZW##CVX^]
MAP[:X."Y^EM5<+|5V)8TEA6U9R>7#&WEN-!*3K(&A|_:NB#D1N+/USG;YK)FBRN$_GEC MJKYW$$HHE7\=M[I&K^2R]ZIY<4M= 27NV!Y.XB=_I*T0HK..0AVVY""^!EV MKL)$ZQ7YD_*5-
OGDX9"S4+G*;.l)$L@K*_BJ<.@Z!|X,7^5P=T986$'V#]_(M)WVFO2&ASNH^FU!/.5UMW!"8JE/R<3#).*:V "QNFZI5,!*+277^D]UOMO09_M1UYC)GR:6A$*(?
N.V#*2.\&*FS90U60L#&P$$R2O<=GN4E)\CX&,2ZY)X75I MU1, PR 9]OUMR% ?-KK'99FP_.5DA'2^?"79!O/=:C?[<)R51C2]K*W>Y9I4F&O+-
O%^AE+"T:>RSS&:XLTNUDF*6SXA$N6\$X(*$M|K*' MEB;XU=&'.E&HM,,U>\|:)// >TIP)\O%C@L;Q;SB%<|FBDGI =AR)>X MIZL,!)@L1-CI.0O<8]QH@K2-DG>>CD4ZI"57922
W*F7Z]_S^$_KP[OWW1^^/ M#VTY]]C#RMQY:AYXRE$*Q<'6[4:LY.),&/6QGFX] "5(O?<'MRY:WQ%SLS@-_MBN>+)'LU)8W6][CM0YC!]RNU6MY[O\T'4EPUK2_Z(1&6*B&F!>G:.'|(5I\!8
M0N((1R>;3P4]#5L=24]?YF$9O\1E;$O9/L60XT' 1$<',P.CK8#A[V3H0N9# M2N0%(W(WC1.)HD%C0ILL?8^E:'W.QFV;9;$C3X(.\&F:>23W=774\"&[HP?L
MPSC!O1FJAVPW@64_KW(9>O;YL;KTWL=[P(2O/3HWK&>=5Z$RHD<^.M8;J?Z MT&S&_A726+BJWD@\'\Y""X=;!\,$%20/L9GOH>2NJ6YA8S>UW=&-V3<+PEV6 ME\-XG[Z7YNP(]5%$'X4T
MO^:.^%G5(>9) IK^?02OI;D%&"[5=;I&*>;>,&9O0%G4908)7A!])&U1OH]D) M*7;0>FN!\QO'G;P5\S0B_^4WX;A6@,U],M-GV3G13Y"EU_';MY% Q23B7*V3 M*81>?VW(HKK'0M1#XE%'?
1S[34NV@&6CPU!Q*4&5@=2BO[/"A?2]Y/<$4WRC M$5NE^L25?]<071=?T_?>=59,.$4W$]\RR1I-C_(MGR\U-R1U=;OiD ,+<'\$2EVSSQ/94P?3RON/67+D29\7TCMCN^,AFT7=0:5W
MW=_D\1.I8?3!!;9'$903RJ_,)THGN!<;P)XA#X8UDX +<[S!2F*XH+M@!$G M4188HR ,3(9P!4*T(20:VMJ@A2T5EZ)4'DW MYHIH'.7IT6>BXYTOW3N^R-\)GG99FUK5UZUM\F=4U[>I]* M5HS
?)CWNEVF M)*8&!2;=,!;?SEK;;,"*RR Q7]!D;\!Q2M>1C@VRO%I[@VF#1T.6WX995 ->2 MZA50-OIE_$WBX#%.S*NAGCC;2;.]\%M.UW#@[IIAFO5'.YGORV$(}_5.UML MS&(C,O6Y(.T[8/U9[$SYI>J
M8QS64]?&$N#X.P*^L 1>Q]X5UV71F*K6'>%BUHG%:98>|>FKLMOK\%X9^DNP M_.C7\# 9K=Z]5/TMENN=42^8R_7@#>.L,1O6S[UST'X+N.);C#$ DE]3XVK_?
#L;IZ2;C:,:%5)K5_1+ID8U:)-2!I#%.=2;>FQ,ZNZ# MGN),0UUQ{O"*8[]9&(DY1M'9B8=1CC1[9ZVTO$>YT5 ER?&JC#GI;5$5Y/K8 MA.;6WK7'JR"IZHK.53L]9]0:XT;#+!'LE&,0:@508063Y*B-C8"*